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ABBREVIATIONS 
 
List of abbreviations used throughout the text in alphabetic order: 
 
AF Autofluorescence 
AFB Autofluorescence bronchoscopy 
ALA Aminolaevulinic acid 
AMD Age-related Macula Degeneration 
CCD Charge-Coupled Device 
CIS Carcinoma in situ 
CT Computed Tomography 
CXR Chest X-ray 
DAFE Diagnostic AutoFluorescence Endoscopy 
DV Digital Video 
ENT Ear-nose-throat 
FAD Flavin Adenine Dinucleotide (oxidised form) 
FD Fluorescence detection 
FWHM Full width half-maximum 
GI Gastro-intestinal (tract) 
h-ALA 5- hexylester-aminolaevulinic acid  
HPD Haematoporphyrin Derivative 
MRI Magnetic resonance imaging 
NADH Nicotinamide adenine dinucleotide (reduced form) 
NADPH Nicotinamide adenine dinucleotide phosphate (reduced form) 
NPV Negative Predictive Value 
NSCLC Non-small cell lung carcinoma 
PDT Photodynamic therapy 
PEA Photodynamic endometrial ablation 
PET Positron emission tomography 
PpIX Protoporphyrin IX 
PAL Phase Altenating Line (video norm) 
PPV Positive Predictive Value 
PS Photosensitiser 
RGB Red/Green/Blue (video signal) 
SCC Squamous cell carcinoma 
SCLC Small-cell lung carcinoma 
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ABSTRACT 
The aim of this thesis is to optimise and gain fundamental information on two applications of 
photomedicine using fluorescence imaging and spectrofluorometry: (1) the detection of early 
bronchial cancer by autofluorescence imaging and (2) the endometrial ablation by 
photodynamic therapy (PDT) based on the use of Protoporphyrin IX (PpIX).  
Fluorescence imaging and spectroscopy require a fluorochrome localised within the tissue. 
The fluorochrome can either be endogenous (naturally synthesised in the body), endogenously 
induced (synthesised in the body from an administered drug), or exogenous (synthesised 
outside the body). This thesis concentrates on the clinical applications of the endogenous and 
an exogenously induced fluorochrome (PpIX). Therefore, this work has been divided into two 
parts according to the type of fluorochromes. 
The numerous endogenous fluorochromes occur naturally. They are collectively responsible 
for the fluorescence properties of biological tissues. This tissue’s intrinsic fluorescence is also 
referred to as autofluorescence (AF). The AF of bronchial tissues, change when they become 
dysplastic or neoplastic. Early neoplastic or dysplastic lesions show an overall decrease in the 
AF intensity as well as a distorsion of the spectral shape. Endoscopic imaging devices rely on 
this principle to detect early neoplastic lesions in the tracheo-bronchial tree. 
The first part of this thesis describes our efforts to improve the performance of AFB and to 
gather insight into the mechanisms at the origin of the AF contrast in the bronchi. For this 
purpose, we conducted a number of clinical and ex vivo studies using imaging and 
spectrofluorometry. Our initial clinical imaging study revealed that the detection of a red 
background image instead of the red AF image increased the lesion-to-healthy tissue contrast 
by a factor of 2. This improvement has been implemented in an AFB device that is currently 
commercialised by the Richard Wolf Endoskope GmbH. In a seperate clinical imaging study 
we investigated the influence of the excitation wavelength on the AF contrast. Using a 
narrowband (6 nm FWHM) excitation around 410 nm resulted in a 1.5 times higher lesion-to-
healthy tissue intensity contrast than observed with a comparable broadband (80 nm FWHM) 
excitation. A supplemental study showed that short wavelength blue backscattered light 
around 430 nm has the potential to discriminate true positive lesions (i.e. early neoplastic 
lesions detected positive with the AFB system) from false positive lesions (i.e. benign tissue 
changes detected positive with the AFB system). 
A spectrofluorometric ex vivo study was performed to gain insight on the mechanisms at the 
origin of these contrasts. Five principal mechanisms are discussed, namely changes of: (1) the 
fluorochrome's concentration, (2) the fluorochrome's metabolic status, (3) the fluorochrome's 
physico-chemical microenvironment, (4) the tissue architecture such as thickening of the 
epithelium, and (5) the concentration of light absorbing chromophores such as haemoglobin. 
We measured formalin fixed human bronchial tissue samples with an optical fibre based 
spectrofluorometer. The formalin fixed bronchial tissue samples showed a general decrease of 
the AF of early lesions compared to the healthy tissues. However, no distortion of the lesions' 
AF spectra with respect to that of the healthy tissues was observed. These results were 
confirmed by imaging of the tissue samples with our AFB system. 
The observations from these ex vivo studies together with results obtained in clinics with our 
imaging system lead us to conclude that the AF contrast can be attributed to a combined effect 
induced by: (1) changes in the architecture of superficial tissues and (2) the concentration and 
spatial distribution of haemoglobin in the submucosa.  
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Furthermore, we investigated inter-patient variations of the bronchial AF to estimate their 
impact on the spectral/photonic design of AFB systems. An endoscopic reference with tissue-
like optical and spectral properties was designed for this purpose. Surprisingly, the AF 
intensities in spectroscopy of the human bronchi showed only minor (< 30 %) variations from 
one individual to another. 
The exogenously induced fluorochrome Protoporphyrin IX (PpIX) is synthesised from 5-
aminolaevulinic acid (5-ALA) in the haeme biosynthetic pathway. PpIX is widely used in 
PDT and fluoresence detection for both malignant and benign, lesions. The second part of this 
thesis deals with the pharmacokinetics of 5-ALA induced PpIX in the endometrium. The final 
goal of this study was the optimisation of the treatment protocol for photodynamic 
endometrial ablation to treat menorrhagia and hypermenorrhea. The PpIX build-up in the 
human endometrium was measured in vivo by spectrofluorometry following intra-uterine 
instillation of 5-ALA. An intra-uterine optical-fibre based probe was designed for this 
purpose. The PpIX pharmacokinetics showed important inter-patient and intra-patient 
variations regarding the time interval between the drug instillation and the maximal PpIX 
fluorescence. Indeed, we have found that this time interval ranges between 0.5 and 5 hours. 
The maximal measured PpIX fluorescence intensities varied by one order of magnitude from 
one patient to another. Finally, no correlation was found between the characteristics of the 
PpIX build-up and the patient's hormonal status. 
Keywords:  
aminolevulinic acid, autofluorescence bronchoscopy, backscattered blue-violet light, 
backscattered red light, bronchial cancer, cancer, Carcinoma in situ, clinical study, contrast 
mechanism, DAFE, diagnostic autofluorescence endoscopy, dysplasia, endoscopy, imaging, 
in vivo, inter-patient variations, intra-patient variations, intra-uterine optical probe, PDT, 
pharmacokinetics, photodetection, photodynamic endometrial ablation, photodynamic 
therapy, photomedicine, Protoporphyrin IX; spectrofluorometry, tissue fluorescence, tissue 
optics
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RÉSUMÉ 
L’objectif de cette thèse est d’optimiser et d’approfondir deux applications de photomédecine 
faisant usage de l’imagerie et de la spectroscopie de fluorescence : (1) la détection précoce du 
cancer bronchique par imagerie d’autofluorescence et (2) l’ablation de l’endomètre par 
thérapie photodynamique (PDT) avec l’usage de la protoporphyrine IX (PpIX). 
L’imagerie et la spectroscopie de fluorescence requièrent un fluorochrome contenu dans le 
tissu. Le fluorochrome est dit endogène (synthétisé naturellement par le corps), induit de 
façon endogène (synthétisé par le corps découlant d’une drogue administrée), ou exogène 
(synthétisé hors du corps). Le sujet de cette thèse est consacré aux applications cliniques des 
fluorochromes endogènes et induit de façon endogène (PpIX). Dès lors, ce rapport de thèse 
est divisé en deux parties distinctes selon le type de fluorochrome. 
De nombreux fluorochromes endogènes sont présents naturellement. Collectivement, ils 
contribuent aux propriétés de fluorescence des tissus biologiques. Cette fluorescence 
intrinsèque des tissus est souvent appelée autofluorescence (AF). L’AF du tissu bronchique 
change lorsqu’il devient néoplasique ou dysplasique. On observe sur toutes les lésions 
néoplasiques et dysplasiques une forte décroissance de l’intensité d’AF, ainsi qu’une 
distorsion de la forme spectrale. Ce principe est utilisé dans les appareils d’imagerie 
endoscopique pour détecter des lésions néoplasiques dans l’arbre trachéo-bronchique. 
L’objectif de la première partie de cette thèse était d’améliorer la performance de la 
bronchoscopie en autofluorescence (AFB) et de découvrir les mécanismes prévalant à 
l’avènement de ces contrastes dans les bronches. Pour cela, nous avons conduit plusieurs 
études cliniques et ex vivo, faisant usage de l’imagerie et de la spectrofluorométrie. Plusieurs 
études cliniques utilisant l’imagerie font partie intégrante de ce travail de thèse. Dans la 
première, nous avons établi que la détection d’une image formé par le rouge rétro-diffusé, en 
lieu et place d’une image rouge d’AF, permet d’améliorer le contraste d’un facteur 2. Ce 
dispositif a été implémenté dans l’appareil d’AFB, actuellement commercialisé par Richard 
Wolf Endoskope GmbH. Dans la deuxième, nous avons étudié l’influence de la lumière 
excitatrice sur le contraste d’AF. Pour cela, nous avons utilisé une excitation à bande étroite 
centrée à 410nm et obtenu un contraste lésion-tissu sain 1.5 fois supérieur à celui obtenu avec 
une excitation à bande large. La troisième étude montra que le bleu à courtes longueurs 
d’onde (430nm) rétro-diffusé pouvait différencier les lésions vraies-positives (càd. lésions 
néoplasiques précoces détectées avec l’AFB) des lésions fausses-positives (càd. changements 
bénins des tissus détectés avec l’AFB). 
Une étude spectrofluorométrique ex vivo fut réalisée pour comprendre les mécanismes à 
l’origine des contrastes. Cinq mécanismes principaux seront discutés : (1) la concentration des 
fluorochromes (2) l’état métabolique des fluorochromes (3) le micro-environnement physico-
chimique des fluorochromes (4) la structure du tissu (par ex. l’épaississement de l’épithélium) 
et (5) la concentration des chromophores absorbants, comme l’hémoglobine. Nous avons 
mesuré des échantillons de tissus bronchiques fixés en formaline avec un spectrofluoromètre à 
fibre optique. Ces échantillons ont généralement montré une décroissance de l’AF des lésions 
précoces en comparaison avec le tissu sain. Pourtant, aucune distorsion ne fut observée entre 
le spectre d’AF sur les lésions et celui des tissus sains. Ces résultats furent confirmés par 
l’imagerie des ces échantillons tissulaires avec notre appareil AFB. 
Les observations de ces études ex vivo, combinées aux résultats obtenus en clinique avec 
notre système d’imagerie, nous amènent à conclure que le contraste d’autofluorescence peut 
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être attribué à un effet combiné induit par (1) la structure architecturale des tissus superficiels, 
ainsi que (2) la distribution spatiale et la concentration de l’hémoglobine dans la sous-
muqueuse. 
En outre, nous avons étudié les variations inter-patients de l’AF bronchique pour estimer leur 
impact sur le design du système AFB. Une référence endoscopique dont les propriétés 
optiques et spectrales étaient proches de celles du tissu fut construite dans ce but. A notre 
étonnement, l’intensité et la spectroscopie d’AF a montré uniquement de faibles variations 
(<30%) d’un individu à l’autre. 
La protoporphyrine IX (PpIX), fluorochrome induit de façon endogène, est synthétisée à 
partir de l’acide 5-aminolévulinique (5-ALA) dans la chaîne de biosynthèse de l’hème. PpIX 
est largement utilisé pour la PDT et la détection de fluorescence des lésions malignes et 
bénignes. La deuxième partie de cette thèse traite de l’étude pharmacocinétique de la PpIX 
dérivée de 5-ALA dans l’endomètre. L’objectif de cette étude était l’optimisation du protocole 
de traitement pour l’ablation photodynamique de l’endomètre pour le traitement de la 
ménorragie et de l’hyperménorrhée. La hausse de la concentration de PpIX dans l’endomètre 
humain après l’instillation intra-utérine de 5-ALA fut mesurée in vivo par 
spectrofluorométrie. Une sonde optique intra-utérine à fibre optique fut construite 
spécialement pour cette étude. La pharmacocinétique de la PpIX montra d’importantes 
variations intra- et inter-patients quant aux différences dans la durée entre l’instillation et le 
maximum de fluorescence dû à la PpIX. En effet, nous avons trouvé que cette durée pouvait 
varier entre 0.5 et 5 heures. L’intensité maximale de la fluorescence due à la PpIX variait d’un 
ordre de grandeur d’une patiente à l’autre. En définitive, aucune corrélation n’a été trouvée 
entre les facteurs de croissance de la PpIX et le statut hormonal des patientes. 
Mots-clés: 
Acide aminolévulinic, bronchoscopie en autofluorescence, lumière bleu-violet rétrodiffusée, 
lulmière rouge rétrodiffusée, cancer bronchique, cancer, carcinome in situ, étude clinique, 
mécanisme du contraste, DAFE, endoscopie diagnostique en autofluorescence, dysplasie, 
endoscopie, imagerie, in vivo, variations inter-patients, variations intra-patients, sonde optique 
intra-uterine, PDT, pharmacocinétique, photodétection, ablation photodynamique de 
l'endomètre, thérapie photodynamique, photo-médecine, Protoporphyrine IX, 
spectrofluorométrie, fluorescence de tissu, optique du tissu 
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Chapter 1  
Introduction to 
Photomedicine 
hotobiology deals with the effects of light on biological tissues. Its study domain 
encompasses a diversity of physiological processes from circadian rhythms, plant 
growth (photosynthesis) and animal vision, to sunburn and cancer. Some interactions of 
light with tissue originate from endogenous physico-chemical conditions while others follow 
administration of photoactive agents. In this report, we will focus on the reactions between 
light and biological tissues related to the emission of fluorescence and/or the generation of 
cytotoxic agents in biological tissues. In medicine, fluorescence and fluorescence related 
photochemical reactions of biological tissues avail for therapeutic and diagnostic purposes. 
Medical diagnosis using the fluorescence from biological tissue is referred to as fluorescence 
diagnosis (FD). The treatment of neoplasia and non-neoplastic diseases using the light 
induced photochemical reactions after application of a photosensitising agent is called 
photodynamic therapy (PDT).  
The first part of this chapter gives an introduction to the physical basics of fluorescence and 
an overview of the optical properties of biological tissues. The second part concentrates on 
tissue optics, and the characteristics of endogenous and exogenous fluorescence of biological 
tissues and its clinical applications. Moreover, the physicochemical basics for PDT are 
defined. Physical and chemical features of FD will be discussed separately in Chapter 3 of 
this thesis. 
P
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1.1 Physical Aspects of Fluorescence 
Luminescence is the emission of electromagnetic radiation, especially light, from an 
electronically excited system. Luminescence could be considered a cold light source, as the 
emission of light occurs at temperatures far below that required for incandescence. Physically 
speaking, luminescence occurs during transitions of a physical system, i.e. atoms or 
molecules, from its electronically excited states to its ground state under emission of light. 
Depending on the mechanisms leading the system to its excited state, the light emitting 
phenomenon is named chemoluminescence, bioluminescence, electroluminescence, 
cathodoluminescence, and photoluminescence. Other forms of luminescence such as 
radioluminescence, triboluminescence, and thermoluminescence will not be discussed here. 
Chemoluminescence, found for example in "glow-in-the-dark" plastic tubes, results from 
excitation by chemical reactions. In bioluminescence, the excitation energy is provided by 
biochemical, mainly enzymatical, reactions in living organisms. Examples for 
bioluminescence are the glow of fireflies (lampyridae) and sea plankton (Dinoflagellat 
noctiluca) observed in summer nights. Electroluminescence is activated by electrical current. 
It is the origin of the light emission in neon fluorescence tubes, LEDs (light emitting diodes), 
auroras (polar lights) and lightening. A special form is cathodoluminescence originating from 
excitation with accelerated electrons, as is the case in television and computer cathod ray tube 
(CRT) screens. Photoluminescence is the luminescence from systems excited with ultraviolet 
(UV), visible (VIS) or infrared (IR) light. Examples for photoluminescence are watch hands 
or (emergency) signs that glow in the dark. Essentially, photoluminescence can be divided 
into two categories, depending on the nature of the system's excited state: fluorescence and 
phosphorescence. Fluorescence is the emission resulting from the decay of an excited singlet 
state, while phosphorescence is the emission resulting from the decay of an excited triplet 
state. Molecules showing fluorescence and phosphorescence behaviour are also called 
fluorochromes or fluorophores. 
The various molecular processes which can occur in excited states are frequently illustrated in 
a Jablonski diagram depicted in Figure 1.1. In such diagrams, the energy levels of a molecule 
are shown as horizontal lines on a vertical, schematic energy scale. Transitions between the 
energy levels are depicted by vertical arrows. The diagram in Figure 1.1 shows the singlet 
ground (S0), first (S1) and second (S2) excited electronic singlet states of a molecule, as well 
as the first excited triplet state (T1). On each of these electronic levels, the molecule can exist 
in a number of vibrational sublevels, which themselves consist of different rotational 
sublevels. The latter are not shown in the figure for the sake of readability. The total intrinsic 
energy of a molecule state is the sum of the electronic, vibrational, and rotational 
contributions. The ground state, i.e. the most stable energy configuration, is typically a singlet 
state (S0). 
Excitation occurs when an electron in the S0 ground state absorbs energy, typically in the 
form of light and is transferred to one of its higher energetic states. These transitions occur in 
about 10-15 s. The excited states are short living and decay rapidly. Three principal decay 
mechanisms are possible: (1) the non-radiative decay (vibrational relaxation and internal 
conversion (IC)), (2) the radiative decay, and (3) the intersystem crossing (ISC). 
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Figure 1.1 Jablonski diagram. The diagram show the singlet ground state(S0), the first and second excited 
singlet states (S1 and S2), and the first excited triplet state (T1) of a molecule. The thick lines depict the 
thermically equilibrated electronical states, while the thin lines illustrate the different vibrational levels. 
Transitions between the energetic levels are depicted by vertical arrows. The molecule is referred to one of its 
excited singlet states by the absorption of light. If the final state is a higher vibrational one, the molecule will 
rapidly (< 10-12 s) relax to the vibrational ground state (“vibrational relaxation”). Internal conversion (IC) is 
the non-radiative transition from a higher electronical state to a lower one. Fluorescence is the radiative 
transition of a molecule from a higher electronical singlet state to its ground state S0. Typically, these transitions 
occur within 10-9 s. Intersystem crossing (ISC) describes the transition between the excited singlet state of a 
molecule and its triplet state. Transitions between a molecule’s triplet and singlet state are quantum 
mechanically forbidden and long-living (∼ 10-3 s). The emission of light resulting from this transition is called 
phosphorescence. 
1.1.1 The non-radiative decays and internal conversion (IC) 
Following light absorption the fluorochrome molecule is usually excited to a higher 
vibrational level of the first or the second excited singlet state (see arrow "Absorption" in 
Figure 1.1). With few rare exceptions, the molecule rapidly (< 10-12 s) relaxes to a thermally 
equilibrated state, i.e. to the lowest energy vibrational level of S1. Vibrational relaxation 
processes occur between different vibrational levels of a given electronic state. They are 
illustrated with narrow-stretched wavy arrows in the Figure 1.1. Internal conversion takes 
place between the different excited electronic states, but also between the excited singlet and 
triplet states and the singlet ground state. The internal conversions are illustrated as wide-
stretched wavy arrows in the Jablonski diagram. 
1.1.2 The radiative decay 
The molecule in the vibrational ground level of S1 then returns to its electronical ground state 
S0. The energy difference between the higher energetic S1 state and the ground state is 
compensated by the emission of light - the fluorescence. In the excited singlet state, the 
electron is paired, i.e. of opposite spin direction, to the electron in the ground state. Thus, a 
return to the ground state is quantum mechanically allowed and occurs within a short period 
of time. The average decay time between excitation and return to the ground state, also 
referred to as “fluorescence lifetime”, is in the order of 10-9 s. 
1.1.3 The intersystem crossing 
Molecules in the excited S1 state can also undergo transition to the first excited triplet state T1. 
This transition, also referred to as intersystem crossing (ISC), is associated with a spin 
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conversion, i.e. a "flip" in the spin direction. Consequently, the electron in the excited triplet 
state is unpaired with the electron in the S0 state. According to the selection rules of quantum 
mechanics, transition between the T1 and the S0 states are forbidden. Relaxation from the 
excited T1 state to the S0 ground state with emission of light is named phosphorescence. 
Typical phosphorescence lifetimes are in the order of 10-3 s, thus much longer than 
fluorescence lifetimes. Apart from the mechanisms listed above, several other interactions like 
quenching (see below) and energy transfer can lead to the decay of a molecule's excited state. 
A fluorochrome is spectrally characterised by two spectra, namely excitation and emission, 
defined as follows: The excitation spectrum is the wavelength distribution of the excitation 
light absorbed by the fluorochrome. An emission spectrum is the wavelength distribution of 
the emission light measured with a fixed excitation wavelength. It is typically presented  
as a plot of the emitted fluorescence intensity versus the wavelength [nm] or the 
wavenumber [cm-1]. The fluorescence emission and absorption spectra in this work will be 
plotted as a function of the wavelength [nm]. 
The Jablonski diagram in Figure 1.1 shows that the absorption energy is typically higher than 
the emission energy. Consequently, a fluorescence emission occurs at longer wavelengths or 
lower energies than excitation. This phenomenon is referred to as "Stokes’ shift" (Sir George 
G. Stokes, 1852). This is due to the rapid decay to the lowest vibrational level of the S1 state. 
Furthermore, fluorochromes generally decay to higher vibrational levels of S0. This results in 
further loss of excitation energy by thermalisation of the excess vibrational energy. Solvant 
effects, excited-state reactions, formation of complexes, and energy transfer are also causes of 
the Stokes’ shift. 
One fundamental property of fluorescence is that the shape of the emission spectrum is 
generally independent of the excitation wavelength. This is known as Vavilov-Kasha's rule. 
This phenomenon can be understood in the context of the non-radiative decays. Absorption of 
high energetic photons will excite the fluorochrome to higher electronic and vibrational 
levels. However, the excess energy is rapidly dissipated by vibrational relaxation and internal 
conversion to the lowest vibrational level of S1. As internal conversion generally occurs in 
10-12 s or less, while fluorescence lifetimes are in the order of 10-9 s. Therefore, dissipation of 
the higher excited states to the lowest S1 state is generally complete on fluorescence emission. 
Consequently, the fluorochrome's emission spectrum usually reflects the S1 → S0 transition 
independent of the initial excitation. 
Another important correlation between a fluorochrome's excitation and emission spectra is 
expressed in the mirror image rule. Indeed, most fluorochromes show mirror image symmetry 
between their fluorescence emission spectrum and their S0 → S1 absorption spectrum. This is 
due to the fact that vibrational levels are equally spaced in S0 and S1. Since excitation occurs 
within about 10-15 s, the position of the nuclei is fixed and the transitions are said to be 
vertical. This is called the Franck-Condon principle. In other words, if a particular transition 
probability between vibrational levels (e.g. the 0 and the 2nd) is most likely in absorption, the 
reciprocal transition is also most probable in emission. The mirror image rule and the Frank 
Condon principle are illustrated in Figure 1.1. However, it is needless to say that there are 
numerous exceptions to the rule, too. 
One of the most important properties of a fluorochrome is its quantum yield. It describes the 
number of photons emitted relative to the number of absorbed photons. Consequently, 
fluorochromes with large quantum yields display the brightest emissions. Rhodamines are an 
example of fluorochrome with quantum yields approaching unity. The quantum yield and the 
Chapter 1 – Introduction to Photomedecine 
5 
fluorescence lifetime generally determine the intensity of the flurorescence emitted by an 
"ideal" fluorochrome. 
 
Figure 1.2 Mirror image rule and Frank Condon principle. The absorption and fluorescence emission spectra 
of numerous fluorochromes show a mirror symmetry (left image). The Frank Condon principle (right image), 
states, that fluorescence transitions are “vertical”, i.e. occur without geometrical changes of the nuclei. 
Consequently, if the probability for transition between a state A and B (here 0 and 2) is largest for absorption, 
the reciprocal transition is also most probable in emission. (adapted from [2]) 
Quenching describes the decrease of fluorescence intensity through a wide variety of 
processes. Collisional quenching is the deactivation of the excited-state fluorochrome after 
contact with some other molecules in its environment. These molecules are called quenchers. 
Another form of quenching is the formation of non-fluorescent fluorochrome-quencher 
complexes. This process is called static quenching. Other factors of quenching are related to 
the absorption of incident excitation light by quenchers or the fluorochrome itself. 
1.2 Tissue Optics 
The application of light in medical science as a diagnostic or therapeutic tool demands 
knowledge of the interactions of light with biological tissues and structures. The principal 
effects that may interfere with the propagation of light incident to matter are reflection and 
refraction, absorption, and scattering. The way light propagation is altered by matter depends 
on the optical properties of the matter. The parameters characterising the optical properties of 
biological tissues are listed in Table 1.1. In the following section, we will give a brief 
overview of the optical parameters of biological tissue. The absorption coefficient μa, the 
scattering coefficient μs, the index of refraction n and the phase function Φ are referred to as 
the fundamental or "microscopic" optical parameters. The absorption and scattering 
coefficients, μa and μs, are the probability of absorption and scattering occurring per unit 
pathlength. 
The index of refraction n is defined as the ratio of light velocity in a vacuum to its velocity in 
the tissue. In tissue optics, the microscopic parameters are usually measured using samples 
sufficiently thin to minimise contributions from multiple diffusions.  
The phase function Φ(s', s) describes the probability density of a photon to be scattered from 
direction s' in the direction s. The other microscopic parameters listed in Table 1.1 can all be 
deduced from the three fundamental ones. The total extinction coefficient μt is given by 
 μt = μa + μs Eq. 1.1  
It describes the inverse of the mean free optical path (Lt) of incident photons in turbid media. 
The optical albedo a is defined by the ratio a=μs/μt. For a=0, attenuation is exclusively due to 
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absorption, whereas in the case of a=1 only scattering occurs. The distribution of scattering in 
turbid media is described by the anisotropy factor g. In terms of the phase function Φ(s’, s), g 
corresponds to the mean cosinus of the scattering angle. A value of g=1 denotes purely 
forward scattering, g=-1 purely backward scattering and g=0 isotropic scattering. For most 
biological tissues g ranges from 0.7 to 0.99 [4], indicating that photons are preferably 
scattered in the forward direction. The effective scattering coefficient 
 μs' = μs *(1-g) Eq. 1.2 
takes into account this anisotropy of scattering for biological tissue. All optical coefficients, 
except g, are generally presented in [mm-1]. The anisotropy factor and the albedo are 
dimensionless. 
The macroscopic parameters, μeff, d, R, and T, listed in the lower part of table 1 are generally 
measured from thick tissue samples. The microscopic parameters can be evaluated from the 
macroscopic ones using theoretical models for light propagation. The effective attenuation 
coefficient μeff is the inverse of the effective penetration depth d of light into tissue. The latter 
is the depth at which the incident spatial irradiance has decreased to by 1/e in the tissue. The 
relation between μeff and the microscopic parameters μa and μs' can be derived from photon 
transport theory:  
Fundamental microscopic parameters 
μa  Absorption coefficient [mm-1] 
μs  Scattering coefficient [mm-1] 
n  Refraction index  
Φ(s, s')  Phase function  
    
Dependent microscopic parameters 
μ t = μ a + μs  Total extinction coefficient [mm-1] 
Lt = μt-1 Free optical path length [mm] 
a = μs/μ t Albedo  
g ∫− ⋅Φ⋅= 11 dss)1,s()a21(  Anisotropy factor  
μs' =(1-g)* μs Reduced scattering coefficient [mm-1] 
    
Macroscopic parameters 
μeff )'(3 saa μ+μ⋅μ=  
Effective attenuation 
 coefficient 
[mm-1] 
d =1/μeff Efffective penetration depth [mm] 
R  Diffuse reflectance  
T  Diffuse transmittance  
Table 1.1 Tissue optical parameters. The fundamental optical parameters are the absorption coefficient (μa), the 
scattering coefficient (μs) , the refraction index n, and the phase function (Φ). The other parameters can be 
deduced from these parameters 
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 )'(3 saaeff μμμμ +⋅=  Eq. 1.3 [4]. 
The diffuse reflectance R represents the ratio of the relative spatial irradiance reflected by the 
tissue relative to the spatial irradiance reflected by a white reflectance standard. In the case of 
diffuse transmission, the transmitted spatial irradiance is computed relative to a 100% 
transmission standard. 
Absorption plays an important role in photomedical applications. The major light absorbing 
molecules in mammalian tissues are oxy- and deoxyhaemoglobin, melanin, myoglobin and 
water. The absorption spectra of these molecules are shown in Figure 1.3. We can observe a 
lower absorption between 600 nm and 1000 nm. This spectral region is called the "therapeutic 
window". Here, tissue scattering predominates over absorption and the light penetration depth 
into the tissue is high. Some optical properties of human bronchial tissue are reported in 
Chapter 3 of this thesis. 
 
Figure 1.3 Principal absorbers in biological tissue. Apart from water, melanin and haemoglobin in its 
oxygenised (HbO2) and de-oxygenised (Hb, not shown) form are the most important absorbers of light in tissue. 
Their absorption is lower in the wavelength range between 600 nm and 1000 nm. This region is referred to as 
the therapeutic window. (adapted from [1]) 
 
1.3 Introduction to tissue characterisation by Fluorescence 
The fundamental principle of tissue characterisation or cancer detection by fluorescence is to 
exploit the optical contrast, either intrinsic (autofluorescence) or induced (exogenous or 
exogenously induced), between the lesion and its surrounding healthy tissue. The contrast 
may be generated from the fluorescence brightness, spectral shape, lifetime or a combination 
of them. Detection of these differences is generally performed by spectroscopic measurements 
(space or time-resolved) or by imaging. Excitation of the tissue AF may be done in two 
distinct ways. In the first, the excitation light delivery fibre or fibre bundle is placed in direct 
contact with the tissue, while in the second, essentially used for imaging, a larger surface area 
of the tissue illuminated. Each approach has advantages and limitations. With point contact, 
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pressure on the tissue may alter the local blood content and so distort the spectrum. Spectral 
distorsions may also arise in large area illumination due to inhomogeneities in the tissue 
optical absorption and/or scattering. With non-contact excitation the detected signal intensity 
depends on the variable source-tissue surface distance. For spectroscopy the fluorescence 
emission may be collected via the same fibre as used for light delivery or by one or more 
separate fibres. Separate delivery and collection optics are required for imaging. Imaging 
detectors are generally based on intensified charge-coupled device (CCD) cameras. Most 
point spectroscopy devices detect the fluorescence signal by (intensified) photodiode arrays or 
CCD based detectors. 
1.3.1 Historical aspects of fluorescence detection 
The diagnostic potential of fluorescence from biological tissue was first described by Stubel 
in 1911. Stubel investigated the native fluorescence (autofluorescence) of animal tissue under 
illumination with UV light [5] In 1924 the French Policard observed the red fluorescence 
from porphyrins when examing tumour lesions with light from a Wood lamp [6]. Indeed, 
Policard observed the endogenous porphyrins in tumour tissue. Several years later, the 
Germans Auler and Banzer first described the localisation and fluorescence of exogenously 
administered porphyrins in malignant tumours [7]. Several studies have been reported on the 
exogenous application of HpD, porphyrins and porphyrin precursors for the detection of 
neoplastic and non-neoplatic lesions in different organs. In the 1960's and 1970's fluorescence 
detection using haeamatoporphyrin derivatives was performed by several groups to detect 
neoplasia on the cervix [8, 9], oesophagus, rectum, bronchi [10, 11] and the head and neck 
sphere (mouth, pharynx, larynx)[12]. 
In the 1980s, Alfano et al. [13] and Yang et al. [14] performed pioneering work in the field of 
autofluorescence spectroscopy of neoplastic and non-neoplastic tissues in humans and 
animals. Nowadays spectroscopy and imaging of the tissue autofluorescence is used as a 
diagnostic tool in several medical specialities including head and neck (ENT), bronchology, 
urology and gynaecology. 
The fluorochromes responsible for the tissue fluorescence can be classified in two categories: 
(1) the tissue endogenous fluorescence, referred to as autofluorescence (AF), and  
(2) fluorescence from exogenous or endogenously induced fluorochromes (induced 
fluorescence). While AF is essentially used for diagnostic purposes, exogenous or 
endogenously induced fluorochromes are used for both diagnosis and therapy.  
1.3.2 Autofluorescence 
Autofluorescence of biological tissues results from endogenous fluorescing molecules 
(fluorochromes). Almost all biological tissues emit fluorescence when excited at appropriate 
wavelength in the UV or visible spectral range. A biological tissue is made up of a complex 
matrix of fluorescing and non-fluorescing molecules. The mixture of the different 
fluorescence emission spectra combined with the tissue optical properties like scattering and 
absorption makes the AF spectrum of a biological tissue broad and structurless. The main 
fluorochromes in human tissue are listed in Table 1.2, together with various absorption and 
emission maxima extracted from literature. The Figure 1.4 and Figure 1.5 show the 
fluorescence absorption and emission spectra of various tissue fluorochromes (adapted from 
[15]). It can easily be seen, that the absorption maxima of endogenous fluorochromes 
predominately lay in the UV and the blue-violet visible wavelength range. Most endogenous 
fluorochromes are involved in cellular metabolic processes or are associated with the 
structural matrix of the tissues [16]. They can be classified in four groups, namely the 
aromatic amino acids and proteins, the pyridine nucleotides, the flavins, and the porphyrins. 
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The only proteins exhibiting fluorescence are those containing the aromatic amino acids 
tryptophan, tyronsine, and phenylalanine. The excitation maxima for those molecules all lay 
in the UV wavelength region below 295 nm [17]. Maximal fluorescence emission occurs 
between 280 nm and 350 nm. Their fluorescence properties are strongly affected by 
environmental factors [17]. 
The principal fluorescing proteins are collagen and elastin, both of which are involved in the 
structural matrix of numerous tissues. Their fluorescence stems from cross-links between their 
composing amino-acids [16]. Elastin is a flexible protein found in connective tissues. 
 
 
Figure 1.4 Absorption spectra of endogenous fluorochromes (adapted from [3]). 
 
 
Figure 1.5 Emission spectra of endogenous fluorochromes (adapted from [3]). 
Chapter 1 – Introduction to Photomedecine 
 
10 
 
Table 1.2 Fluorescence properties of principal endogenous fluorochromes. 
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The absorption and emission maxima of its crosslinked forms are around 325 nm and 400 nm 
[16]. Powdered elastin has absorption maxima at 350 nm, 410 nm and 450 nm, with 
corresponding peak fluorescence emissions at 420 nm, 500 nm, and 520 nm [16]. Collagen 
has an inextensible fibrous structure and is the main protein in connective tissue. Cartilage, 
ligaments and tendons as well as bones and teeth are mainly composed of collagen. The 
absorption maximum of collagen fibres is around 325 nm with a maximal fluorescence 
emission around 400 nm [18]. Measurements of powdered bovine collagen show additional 
absorption and emission maxima pairs at 280 nm and 310 nm, 265 nm and 385 nm, and 450 
nm and 530 nm [16]. 
Flavins and pyridine nucleotides are strong electron acceptors and play an important role in 
cellular energy metabolism. Flavin adenine dinucleotide (FAD) is the major flavin-related 
electron carrier. Its oxidised form (FAD) is fluorescent, while its reduced form (FADH2) is 
not. The fluorescence excitation maximum of FAD lies around 450 nm and the emission 
maximum around 530 nm [16, 17]. Other important flavin derivatives in biological tissue 
include flavin mononucleotide (FMN) and riboflavin (Vitamin B2).  
The other main electron acceptors are nicotinamide adenine dinucleotide (NAD) and 
nicotinamide adenine dinucleotide phosphate (NAD(P)). Both molecules emit fluorescence in 
their reduced forms, NADH and NAD(P)H. Fluorescence excitation and emission maxima 
can be found around 340 nm and 450 nm, respectively. Protein-binding drastically changes 
the fluorescence excitation and emission maxima and can increase the quantum yield by a 
factor of 4 [16]. 
Most porphyrins are synthesised in mammals from 5-aminolevulinic acid, as will be described 
in Section 1.3.3. The main molecule of the porphyrin family is heme, the precursor of 
haemoglobin, the oxygen-carrying red blood chromophore. Even if heme itself does not 
fluoresce, most porphyrins do. Their excitation maxima lay around 400 nm and the emission 
maximum around 635 nm. The fluorescence intensities strongly depend on the pH of the 
molecule’s environment. 
Other molecules being involved in the AF of biological tissues are pyridoxine (Vitamine B6), 
retinol (Vitamin A) and lipopigments (pigments associated with lipid oxidation products, 
found in aging and various pathologic processes), among others. The interested reader will 
refer to the review of [16] and the Handbook of Biomedical Optics [15] for more information.  
Autofluorescence spectroscopy and imaging have been widely investigated and are used for 
diagnosis of lesions in the bronchus [19-22], bladder [23, 24], head and neck [25], oesophagus 
[26-28], skin [29, 30] and uterine cervix [31-33]. A detailed review of the applications of 
fluorescence spectroscopy and imaging for oncological applications was published by 
Wagnières et al. [15]. 
1.3.3 Endogenously induced fluorescence 
Exogenous or exogenously induced flurochromes are used for both diagnostic and therapeutic 
purposes. As most of those fluorochromes also have phototoxic properties, they are referred to 
as photosensitisers (PS). 
Endogenously induced fluorochromes are not directly administered to the patient but 
endogenously generated from a precurser applied either topically or systemically to the 
patient. The most widely used endogenously induced fluorochrome in PDT and fluorescence 
detection is Protoporphyrin IX (PpIX). PpIX belong to the group of phorphyrins which which 
play an important role in the formation of key biomolecules like haemoglobin, myoglobin, 
Chapter 1 – Introduction to Photomedecine 
 
12 
and cytochromes. It is synthesised within the biosynthesis cycle of haem, depicted in Figure 
1.6. The PpIX precursor is delta- or 5-aminolaevulinic acid (5-ALA) or one of its derivatives. 
The initial step in this process is the condensation of glycine and succinyl coenzyme A 
(succinyl CoA) to 5-aminolaevulinic acid (5-ALA) in the mitochondrion. 5-ALA production 
is regulated by haem in a negative feedback mechanism, i.e. the presence of haem in the cell 
inhibits the production of 5-ALA. The 5-ALA molecule passes into the cytoplasm where it 
undergoes several chemical reactions regulated by various enzymes to produce the so-called 
corproporphyrinogen III. The latter re-enters the mitochondrion and is converted to 
protoporphyrinogen IX and finally to the phototoxic Pp IX. The last step is the chelation of an 
iron ion into the porphyrin ring, resulting in the non-fluorescent haem molecule. This 
chelation is enabled by the ferrochelatase. The haem molecule is then further transformed to 
haemoglobin. 
 
Figure 1.6 The biosynthesis of haem 
 
Exogenously administered 5-ALA (or one of its derivatives) fools the negative feedback 
mechanism of haem production. Thus, the external application of 5-ALA can lead to a 
temporary accumulation of PpIX. The amount of accumulated PpIX depends on the cell type 
or pathology. For instance, neoplastic cells show a higher accumulation of PpIX after 
administration of exogenous 5-ALA than healthy ones. The resulting fluorescence intensity 
contrast between healthy tissues and lesions is used in ALA-induced PpIX fluorescence 
detection of dysplasia and early neoplasia. An advantage of ALA-based PDT or fluorescence 
detection relativ to AF detection is that the spectral properties of PpIX are known (Figure 
1.7). PpIX may be excited at several wavelengths between 405 nm and 632 nm, resulting in a 
typical red emission in the 625nm-725 nm region. It should be noted, that PpIX is an effective 
photosensitiser and was initially used for this purpose. ALA-induced PpIX fluorescence 
detection has been used for various cancerous and non-cancerous conditions. We should 
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mention the urinary bladder [34-39], endometriosis [40, 41], ovarian carcinoma metastases 
[42, 43], and Barrett’s oesophagus [44, 45]. 
 
Figure 1.7 Excitation and emission spectra of PpIX. 
 
1.3.4 Exogenous fluorochromes 
Most exogenously administered fluorochromes currently being investigated for clinical 
applications have been developed primarily as PS for PDT (see Table 1.3). Most compounds 
have been designed with specific PDT characteristics, such as strong absorption at longer red 
wavelengths and high triplet state quantum yield (see Chapter 1.4.4). These properties are not 
necessarily optimal for fluorescence detection. Indeed, the selectivity of these photosensitisers 
has generally been rather poor for detection of pre-neoplastic and early cancerous lesions. 
There are distinct advantages in the use of exogenous fluorochromes, if these can be made 
with sufficient target selectivity. In particular, the photophysical properties and, in principle, 
also the pharmacokinetic properties can be selected and are known. Lastly, and importantly, 
the fluorescence signal intensity can be much larger than autofluoresence. This may simplify 
the instrumentation and reduce costs. The use of exogenous fluorochromes purely for 
detection raises potential safety and toxicity concerns. In addition, selection of the optimal 
time delay after administration is complicated by the fact that the fluorescence brightness and 
contrasts often do not peak at the same time in different tissues. For PDT treatment 
monitoring, photosensitiser fluorescence can play a significant role in localisation and 
defining the lesion margins for light targeting, in assessing the effective therapeutic dose 
delivered by measuring the fluorescence intensity and/or photobleaching and in evaluating the 
post-treatment tissue response. Several groups have developed non- or weakly phototoxic 
fluorochromes for in vivo spectroscopy and imaging. Such drugs could improve tumour 
detection and demarcation in cases when concomitant PDT is not intended. One example for 
this type of fluorochromes which is already available clinically is fluorescein. 
1.4 Photodynamic Therapy 
PDT is widely used for the treatment of early cancers and pre-neoplasia of the oesophagus 
[46], the lung [47-50], and the head and neck sphere [48], among others. Moreover, PDT has 
been investigated for the treatment of non-malignant cellular changes, such as age-related 
macular degeneration (AMD) [51-54], actinic-keratosis [55-57], and gynecological disorders 
(endometriosis) [40, 42, 43]. 
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1.4.1 Basic principles 
Generally speaking, PDT is the treatment of a disease with  the help of a photosensitiser 
activated by light in the presence of oxygen. The photosensitiser is administered either 
topically or systemically to the patient (Figure 1.8). Following administration, the 
photosensitiser will begin to accumulate in the tissue. The time delay between administration 
and optimal therapeutic concentration of the PS is specific for each PS and each type of tissue. 
The tissue is then irradiated with visible light of appropriate wavelength at sub-thermal 
irradiance (typically one hundred mW/cm2). The ideal wavelength corresponds to an 
absorption peak of the PS molecule. The light is absorbed by the PS, which activates 
molecular oxygen. The activated oxygen (principally singlet oxygen) causes irreversible 
damage to the target tissue. 
 
Figure 1.8 Principle of PDT. The photosensitiser (PS) is applied either topically or systematically 
(intravenously) to the patient. After a time delay specific for the PS and the application, the PS has accumulated 
in the target tissue. Irradiation is then performed with light of appropriate wavelength. The PS undergoes 
photochemical reactions with the target tissue, leading to apoptosis and necrosis. 
Photosensitisation may start with the production of a triplet state (T1) of the sensitiser. The 
notation of the PS triplet state may also be written as 3PS, instead of T1; here we use the 
3PS 
notation. Likewise, we write 0PS instead of S0. As shown in the Jablonski diagram (Figure 
1.1), 3PS is formed from 0PS after photon absorption and ISC. There are two chemical 
mechanisms of photosensitisation: Type I reactions and Type II reactions (Figure 1.9): In the 
Type I reactions the 3PS undergoes either electron transfer reactions with a substrate molecule 
(M) or hydrogen atom transfer. If enough molecular oxygen (O2) is present it can lead to 
highly reactive oxygen-containing species like hydrogen peroxide (H2O2), superoxide radical 
anion (O2
•-) and the hydroxyl radical (OH•). The reactive intermediates can then react rapidly 
with a multitude of biomolecules, potentially leading to tissue destructions. Type II reactions 
require O2 in the first step. Because of its long lifetime, 
3PS survives long enough for the 
molecular O2 in the tissue to collide with it. During collision, energy may be transferred, with 
the formation of excited molecular singlet oxygen 1O2. This process is efficient as the energy 
transfer is spin allowed, because the ground state of molecular O2 is exceptionally a triplet 
state. In this process of creating 1O2 by collisional electronic energy transfer from 
3PS, singlet 
ground state 0PS, which can be absorb light again, is regenerated. Collisional energy transfer 
may also take place between 3PS and a substrate molecule, with the formation of a excited 
triplet state 3M. For complex and heterogenous living systems, the relative importance of 
Type I versus Type II reactions is hard to detemine. It appears that the Type II reactions 
generally predominate in the photodynamic process, while Type I reactions predominate only 
if O2 is depleted faster than it can diffuse to the region of PDT. 
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Figure 1.9 Photochemical reactions in PDT. Two different types of reactions, named Type I and Type II 
reactions, occur in the tissue when the photosensitiser is excited upon irradiation and transferred to its triplet 
state (3PS). The 3PS state then interacts with molecular oxygen (O2) and biomolecules (M) to produce highly 
celltoxic singlet oxygen (1O2) and radicals (O2
•, M•). 
 
1.4.2 Historical aspects 
The history of interactions between light and biological tissues as related to medical concerns 
can be traced back to the dawn of civilisation. Ancient Indian medical literature (1500 BC) 
describes a treatment of non-pigmented skin areas by applying seed of a plant called 
“Bavachee” followed by light exposure. The plant was identified with Psoralea corylifolia 
that contains a photosensitising psoralen compound. Similar treatments for skin diseases such 
as psoriasis, vitiligo and cancer are described in early Buddhist and Chinese literature and are 
reported to have been used in ancient Egypt. Around 400 BC, the Greek physician 
Hippocrates already prescribed sunbathing for both medical and psychological purposes. This 
treatment called heliotherapy is still practised nowadays. Nevertheless, it was not before the 
18th century that fluorescence and the interactions of fluorescing substances in biological 
tissue for diagnostic and therapeutic purposes were systematically investigated. 
Anecdotically, the first scientific report of light induced reactions in biological tissue after 
application of a "drug" was published in a rather "non-medical" field. In the Tarentine region 
in Italy, only black sheep were breed, as white ones became ill after grazing. Indeed, the 
grazing animals ingested plants belonging to the hypericum family (e.g. St. John's wort) 
containing the photosensitiser hypericin [58]. This correlation between food intake, sunlight 
exposure and skin sensitivity of the grazing animals was made at the end of the 19th century. 
The first scientific reports on photosensitisation were given by Dammann (1883) and Weding 
(1887). They observed that animals eating buckwheat in the sunlight developed bubble-
forming rashes on non-pigmented skin areas. 
The biological photosensitisation using chemical substances was discovered by Oscar Raab in 
1900, when studying the effects of acridine red on bacteria. The first reports of controlled 
"phototherapy" date from the Danish physician Niels Finsen (1901). He described the 
treatment of smallpox using red light and also used UV light to treat cutaneous tuberculosis. 
The term "photodynamic action" was introduced by the physician von Tappeiner in 1907 [59]. 
He performed treatment of skin cancer using topical eosin in combination with white light 
irradiation [60] and demonstrated the requirement of oxygen in photosensitising reactions 
[61]. 
Chapter 1 – Introduction to Photomedecine 
 
16 
The first report of endogenous porphyrin photosensitisation was given in 1913 by Meyer-
Betz. After injecting himself with 200 mg of a haemotoporphyrin derivative (HpD), Meyer-
Betz noted severe pain and swelling of body parts exposed to light. In 1911, Haussmann had 
reported on the effect of HpD and light exposure on cell culture and mice. Since then, 
haematoporphyrin dervatives and porphyrins have been used for diagnostic purposes over a 
long time period (see section below). In 1972, Diamond et al. [62] first proposed to use the 
phototoxic properties of porphyrins for the targeted treatment of neoplasia. Six years later, 
Dougherty published the first report on a large series of patients treated with PDT using HpD. 
Since then, several other photosensitising agents have been and are nowadays under 
investigation for the treatment and diagnosis of neoplastic and pre-neoplastic tissues in 
humans. 
1.4.3 Properties and major applications of photosensitisers 
Exogenous and exogenously induced fluorochromes for fluorescence diagnostics and/or 
photodynamic therapy have to fulfil a number of requirements that are often related to their 
application in photodynamic therapy. The principles of photodynamic therapy will be 
explained in the next section. The main features of a PS can be summarised as absorption, 
fluorescence, generation of singlet oxygen, photostability, and selectivity.  
Photosensitisers ideally have excitation maxima within the therapeutic window (600 nm - 
1200 nm). Biological tissues are most transparent in this wavelength region allowing high 
penetration depth. The latter is essential for the treatment of invasive tumoural lesions. 
Fluorescence detection does generally not require high penetration depth. Fluorochromes used 
for FD might therefore have shorter excitation wavelengths. However, excitation wavelengths 
below 390 nm are not recommended because potential mutagenic side effects can arise from 
UV irradiation. 
The formation of highly reactive singlet oxygen is fundamental for the cytotoxic effects in 
PDT (see section PDT below). Thus, effective photosensitisers have long living triplet states 
and a high quantum yield for singlet oxygen formation.  
Nearly all fluorochromes and chromophores undergo photodegeneration after intensive light 
irradiation, including changes in their molecular structure and fluorescence properties. This 
phenomenon is called photobleaching. The outcome of PDT and FD strongly depends on the 
concentration of the photosensitiser in the lesions to be treated/diagnosed. This requires either 
a high photostability or a high concentration of the fluorochrome or photosensitiser in the 
tissue. All fluorochromes used for FD or PDT have to be highly selective for the tissue or the 
lesion to be diagnosed/treated. More precisely, fluorochromes and photosensitisers in 
oncological applications must accumulate preferably in neoplastic lesions, while showing 
only low concentrations in healthy tissues.  
Additional requirements for photosensitisers and fluorochromes for FD include low dark 
toxicity and rapid clearance from the body after treatment/diagnosis. Dark toxicity is the 
cytotoxic potential without any activation of the fluorochrome with light. 
Many research groups concentrate their work on the design, synthesis and application of 
molecules for FD and PDT. Numerous photosensitisers and fluorochromes have already been 
investigated in pre-clinical and clinical studies. However, up to now, only a few of them have 
achieved approval by national and international drug authorities.  
Table 1.3 presents a short overview of current photosensitisers and precursors that have been 
approved for clinical PDT. Photofrin® is currently the most widely used photosensitiser for 
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PDT nowadays. It has is used for the photodynamic treatment of both, early and advanced, 
oesophageal [63-66] and bronchial cancers [63, 64], advanced bladder cancer [35, 37], early 
gastric cancer [67], and cervical dysplasia and early cancers. Visudyne® and Photopoint® are 
successfully used for the treatment of age-related macular degenenration (AMD) in patients 
with predominantly classic or small occult subfoveal choroidal neovascularisation [68]. 
Foscan® is applied for the photodynamic treatment of advanced oral cancers[69, 70]. Among 
the PpIX precursors, Levulan® and Metvix® have reached clinical approval for dermatologic 
applications. Both drugs are used for the photodynamic treatment of non-hyperkertotic actinic 
keratosis of the face and the scalp [71]. Furthermore, Metvix was approved for the treatment 
of basal cell carcinoma and Bowen’s disease. 
 Photosensitizer  Application Company 
Photofrin® Haematoporphyrin 
derivative (HpD) 
Esophageal Cancer (E+A) 
Lung Cancer (E+A) 
Bladder Cancer (A) 
Gastric Cancer (E) 
Cervical Cancer/ Dysp. (E) 
QLT / Axcan 
Visudyne® Benzoderivative 
monoacid ring A 
(BPDMA) 
Age-related macular degeneration 
in patients with predominantly 
classic or small occult subfoveal 
choroidal neovascularization 
QLT / Novartis 
Photopoint® Rostaporphin (SnET2) Idem Miravant 
E
xo
gn
eo
us
 P
S 
Foscan® Tetra(m-
hydroxyphenyl)chlorin 
(m-THPC) 
Oral carcinoma (A) Biolitec 
Levulan® 5-ALA Non-hyperkeratotic actinic 
keratoses of the face and scalp. 
DUSA 
P
re
cu
rs
or
s 
Metvix® Methyl-ester ALA (m-
ALA 
Basal cell carcinoma, actinic 
keratosis and Bowen's disease. 
Photocure 
Table 1.3 Frequently used photosensitisers used in clinical PDT nowadays. (A = advanced stage disease, 
E = early stage disease) 
 
Chapter 1 – Introduction to Photomedecine 
 
18 
1.5 References 
 
 
[1] J. L. Boulnois, "Photophysical processes in recent medical laser developments: A review," Lasers in Medical 
Science 1(1), 47-66 (1986) 
[2] J. R. Lakowicz, Principles of fluorescence spectroscopy, Kluwer Academic/Plenum Publishers, New York 
(1999). 
[3] G. Wagnieres, W. Star and B. Wilson, "In vivo fluorescence spectroscopy and imaging for oncological 
applications.," Photochem Photobiol 68(5), 603-632 (1998) 
[4] M. Niemz, Laser-Tissue Interactions, Springer, Berlin (1996). 
[5] H. Stübel, "Die Fluoreszenz tierischer Gewebe in ultraviolettem Licht," Pflügers Arch Physiol 142(1), 1-14 
(1911) 
[6] A. Policard, "Etudes sur les aspects offerts par des tumeurs experimentales examines a la lumiere de Wood " 
CR Soc Biol 91(1423-1424 (1924) 
[7] H. Auler and G. Banzer, "Untersuchungen über die Rolle der Porphyrine bei geschwulstkranken Menschen 
und Tieren," Z Krebsforschung 53(65-68 (1942) 
[8] R. L. Lipson, J. H. Pratt, E. J. Baldes and M. B. Dockerty, "Hematoporphyrine Derivative for Detection of 
Cervical Cancer," Obstet Gynecol 24(78-84 (1964) 
[9] M. J. Gray, R. Lipson, J. V. Maeck, L. Parker and D. Romeyn, "Use of hematoporphyrin derivative in 
detection and management of cervical cancer," Am J Obstet Gynecol 99(6), 766-771 (1967) 
[10] H. B. Gregorie, Jr., E. O. Horger, J. L. Ward, J. F. Green, T. Richards, H. C. Robertson, Jr. and T. B. 
Stevenson, "Hematoporphyrin-derivative fluorescence in malignant neoplasms," Ann Surg 167(6), 820-828 
(1968) 
[11] R. L. Lipson, E. J. Baldes and M. J. Gray, "Hematoporphyrin derivative for detection and management of 
cancer," Cancer 20(12), 2255-2257 (1967) 
[12] J. R. Leonard and W. L. Beck, "Hematoporphyrin fluorescence: an aid in diagnosis of malignant 
neoplasms," Laryngoscope 81(3), 365-372 (1971) 
[13] R. Alfano, D. Tata, J. Cordero, P. Tomashefsky, F. Longo and M. Alfano, "Laser induced fluorescence 
spectroscopy from native cancerous and normal tissue," Quantum Electronics, IEEE Journal of 20(12), 1507-
1511 (1984) 
[14] Y. L. Yang, Y. M. Ye, F. M. Li, Y. F. Li and P. Z. Ma, "Characteristic autofluorescence for cancer 
diagnosis and its origin," Lasers Surg Med 7(6), 528-532 (1987) 
[15] G. Wagnières, A. McWilliams and S. Lam, "Lung cancer imaging with fluorescence endoscopy," in 
Handbook of Biomedical Fluorescence, M.-A. Myceck and B. W. Pogue, pp. 361-396, Marcel Dekker, Inc. 
(2003). 
[16] R. Richards-Kortum and E. Sevick-Muraca, "Quantitative optical spectroscopy for tissue diagnosis," Annual 
Review of Physical Chemistry 47(1), 555-606 (1996) 
[17] O. Wolfbeis, "Fluorescence of organic natural products," in Molecular Luminiscence Spectroscopy, S. G. 
Schulmann, pp. 167-370, John Wiley and Sons, New York (1993). 
[18] L. Stryer, Biochemistry, W.H. Freeman and Company, New York (1995). 
Chapter 1 – Introduction to Photomedecine 
19 
[19] D. Goujon, M. Zellweger, A. Radu, G. P., B.-C. Weber, H. van den Bergh, P. Monnier and G. Wagnières, 
"In vivo autofluorescence imaging of early cancers in the human tracheobronchial tree with a spectrally 
optimized system," J Biomed Optics 8(1), 17-25 (2003) 
[20] S. Lam, T. Kennedy and M. Unger, "Localization of bronchial intraepitheloial neoplastic lesions by 
fluorescence bronchoscopy," Chest 113(3), 696-702 (1998) 
[21] S. Lam, C. MacAulay, J. C. leRiche and B. Palcic, "Detection and localization of early lung cancer by 
fluorescence bronchoscopy," Cancer Suppl. 89(11), 2468-2473 (2000) 
[22] K. Häußinger, F. Stanzel, M. Kohlhäufl, H. Becker, F. Herth, A. Kreuzer, B. Schmidt, J. Strausz, S. 
Cavaliere, K.-M. Müller, R.-M. Huber, U. Pichlmeier and C. T. Bolliger, "Autofluorescence bronchoscopy with 
white light bronchoscopy compared with white light bronchoscopy alone for the detection of precancerous 
lesions: A European randomised controlled multicentre trial," Thorax 60(6), 496-503 (2005) 
[23] M. Szygula, B. Wojciechowski, M. Adamek, A. Pietrusa, A. Kawczyk-Krupka, W. Cebula, W. Zieleznik, T. 
Biniszkiewicz, A. Sieron? and W. Duda, "Fluorescent diagnosis of urinary bladder cancer - A comparison of two 
diagnostic modalities," Photodiagnosis and Photodynamic Therapy 1(1), 23-26 (2004) 
[24] D. Zaak, H. Stepp, R. Baumgartner, P. Schneede, R. Waidelich, D. Frimberger, A. Hartmann, R. Knüchel, 
A. Hofstetter and A. Hohla, "Ultraviolet-excited (308 nm) autofluorescence for bladder cancer detection," 
Urology 60(6), 1029-1033 (2002) 
[25] R. Paczona, S. Temam, F. Janot, P. Marandas and B. Luboinski, "Autofluorescence videoendoscopy for 
photodiagnosis of head and neck squamous cell carcinoma," European Archives of Oto-Rhino-Laryngology 
260(10), 544-548 (2003) 
[26] J. J. G. H. M. Bergman, M. A. Kara, F. P. Peters, F. J. W. Ten Kate, S. J. Van Deventer and P. Fockens, 
"Endoscopic video autofluorescence imaging may improve the detection of early neoplasia in patients with 
Barrett's esophagus," Gastrointestinal Endoscopy 61(6), 679-685 (2005) 
[27] K. Niepsuj, G. Niepsuj, W. Cebula, W. Zielez?nik, M. Adamek, A. Sielan?czyk, J. Adamczyk, J. Kurek and 
A. Sieron?, "Autofluorescence endoscopy for detection of high-grade dysplasia in short-segment Barrett's 
esophagus," Gastrointestinal Endoscopy 58(5), 715-719 (2003) 
[28] R. S. DaCosta, B. C. Wilson and N. E. Marcon, "Spectroscopy and fluorescence in esophageal diseases," 
Best Practice and Research in Clinical Gastroenterology 20(1), 41-57 (2006) 
[29] L. Brancaleon, J. H. Tu, N. Kollias, G. Menaker, J. D. Fallon and A. J. Durkin, "In vivo fluorescence 
spectroscopy of nonmelanoma skin cancer," Photochemistry and Photobiology 73(2), 178-183 (2001) 
[30] L. H. Laiho, S. Pelet, T. M. Hancewicz, P. D. Kaplan and P. T. C. So, "Two-photon 3-D mapping of ex vivo 
human skin endogenous fluorescence species based on fluorescence emission spectra," Journal of Biomedical 
Optics 10(2), 1-10 (2005) 
[31] J. M. Benavides, S. Chang, S. Y. Park, R. Richards-Kortum, N. Mackinnon, C. MacAulay, A. Milbourne, 
A. Malpica and M. Follen, "Multispectral digital colposcopy for in vivo detection of cervical cancer," Optics 
Express 11(10), 1223-1236 (2003) 
[32] N. Ramanujam, M. F. Mitchell, A. Mehadevan, S. Warren, S. Thomsen, E. Silva and R. Richards-Kortum, 
"In vivo diagnosis of cervical intraepithelial neoplasia using 337-nm-excited laser-induced fluorescence," Proc. 
Natl. Acad. Sci USA 91(10193-10197 (1994) 
[33] H. Weingandt, H. Stepp, R. Baumgartner, J. Diebold, W. Xiang and P. Hillemanns, "Autofluorescence 
spectroscopy for the diagnosis of cervical intraepithelial neoplasia," BJOG: An International Journal of 
Obstetrics and Gynaecology 109(8), 947-951 (2002) 
[34] D. Zaak, E. Hungerhuber, P. Schneede, H. Stepp, D. Frimberger, S. Corvin, N. Schmeller, M. Kriegmair, A. 
Hofstetter and R. Knöchel, "Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions," 
Cancer 95(6), 1234-1238 (2002) 
Chapter 1 – Introduction to Photomedecine 
 
20 
[35] P. Jichlinski, "Photodynamic applications in superficial bladder cancer: Facts and hopes!," Journal of 
Environmental Pathology, Toxicology and Oncology 25(1-2), 441-451 (2006) 
[36] P. Jichlinski and H.-J. Leisinger, "Photodynamic therapy in superficial bladder cancer: Past, present and 
future," Urological Research 29(6), 396-405 (2001) 
[37] D. Jocham and T. Gaertner, "Photodynamic diagnosis and therapy in urology," Aktuelle Urologie 
31(SUPPL. 1), 87-91 (2000) 
[38] N. Lange, P. Jichlinski, M. Zellweger, M. Forrer, L. Guillou, P. Kucera, G. Wagnières and H. van den 
Bergh, "Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid 
hexylester-induced protoporphyrin IX: a pilot study," British Journal of Cancer 80(1/2), 185-193 (1999) 
[39] M. Kriegmair, D. Zaak, R. Knuechel, R. Baumgartner and A. Hofstetter, "5-Aminolevulinic acid-induced 
fluorescence endoscopy for the detection of lower urinary tract tumors," Urologia Internationalis 63(1), 27-31 
(1999) 
[40] E. Malik, A. Meyhofer-Malik, D. Trutenau, H. Diddens, W. Kupker and K. Diedrich, "Photodynamic 
diagnosis of endometriosis using 5-aminolevulinic acid - A pilot study[Pilotstudie zur photodynamischen 
diagnostik der endometriose mittels 5- aminolavulinsaure]," Geburtshilfe und Frauenheilkunde 58(8), 420-425 
(1998) 
[41] P. Hillemanns, H. Weingandt, H. Stepp, R. Baumgartner, W. Xiang and M. Korell, "Assessment of 5-
aminolevulinic acid-induced porphyrin fluorescence in patients with peritoneal endometriosis," American 
Journal of Obstetrics and Gynecology 183(1), 52-57 (2000) 
[42] M. Löning, W. Küpker, K. Diedrich, H. Diddens and G. Hüttmann, "Laparoscopic Fluorescence Detection 
of Ovarian Carcinoma Metastases Using 5-Aminolevulinic Acid-Induced Protoporphyrin IX," Cancer 100(8), 
1650-1656 (2004) 
[43] F. Lüdicke, L. Berclaz, T. Gabrecht, N. Lange, G. Wagnières, H. Van Den Bergh and A. L. Major, 
"Photodynamic diagnosis of ovarian cancer using hexaminolaevulinate: A preclinical study," British Journal of 
Cancer 88(11), 1780-1784 (2003) 
[44] C. Felley, P. Jornod, G. Dorta, T. Stepinac, N. Lange, T. Gabrecht, H. Van Den Bergh, G. Wagnières, C. 
Fontolliet, P. Grosjean, P. Monnier and G. VanMelle, "Endoscopic fluorescence detection of intraepithelial 
neoplasia in Barrett's esophagus after oral administration of aminolevulinic acid," Endoscopy 35(8), 663-668 
(2003) 
[45] S. Brand, T. D. Wang, K. T. Schomacker, J. M. Poneros, G. Y. Lauwers, C. C. Compton, M. C. Pedrosa and 
N. S. Nishioka, "Detection of high-grade dysplasia in Barrett's esophagus by spectroscopy measurement of 5-
aminolevulinic acid-induced protoporphyrin IX fluorescence," Gastrointestinal endoscopy 56(4), 479-487 
(2002) 
[46] A. Radu, G. Wagnieres, H. van den Bergh and P. Monnier, "Photodynamic therapy of early squamous cell 
cancers of the esophagus," Gastrointest Endosc Clin N Am 10(3), 439-460 (2000) 
[47] P. Monnier, M. Savary, C. Fontolliet, G. A. Wagnieres Chatelain, P. Cornaz, C. Depeursinge and H. Van 
den Bergh, "Photodetection and photodynamic therapy of 'early' squamous cell carcinomas of the pharynx, 
oesophagus and tracheo-bronchial tree," Lasers in Medical Science 5(2), 149-168 (1990) 
[48] A. Radu, P. Grosjean, P. Monnier, C. Fontolliet, G. Wagnieres, A. Woodtli and H. Van Den Bergh, 
"Photodynamic therapy for 101 early cancers of the upper aerodigestive tract, the esophagus, and the bronchi: A 
single-institution experience," Diagnostic and Therapeutic Endoscopy 5(3), 145-154 (1999) 
[49] H. Kato, K. Furukawa, M. Sato, T. Okunaka, Y. Kusunoki, M. Kawahara, M. Fukuoka, T. Miyazawa, T. 
Yana, K. Matsui, T. Shiraishi and H. Horinouchi, "Phase II clinical study of photodynamic therapy using mono-
L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung.," Lung Cancer 
42(1), 103-111 (2003) 
Chapter 1 – Introduction to Photomedecine 
21 
[50] T. G. Sutedja and P. E. Postmus, "Photodynamic therapy in lung cancer. A review," J Photochem Photobiol 
B 36(2), 199-204 (1996) 
[51] J. Wachtlin, A. Wehner, H. Heimann, M. H. Foerster and A. Stroux, "Photodynamic therapy with 
verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results 
including juxtafoveal and extrafoveal CNV," Graefe's Archive for Clinical and Experimental Ophthalmology 
243(5), 438-445 (2005) 
[52] H. Van den Bergh, "Photodynamic therapy of age-related macular degeneration: History and principles," 
Seminars in Ophthalmology 16(4), 181-200 (2001) 
[53] A. Gabel-Pfisterer, A. Wehner, H. Heimann, M. H. Foerster and J. Wachtlin, "Photodynamic therapy with 
verteporfin for recurrent choroidal neovascularisation following prior argon laser coagulation[Photodynamische 
therapie mit verteporfin bei rezidiven choroidaler neovaskularisationen (CNV) nach primärer 
argonlaserkoagulation]," Ophthalmologe 102(6), 592-596 (2005) 
[54] R. F. Spaide, J. Sorenson and L. Maranan, "Photodynamic therapy with verteporfin combined with 
intravitreal injection of triamcinolone acetonide for choroidal neovascularization," Ophthalmology 112(2), 301-
304 (2005) 
[55] S. Radakovic-Fijan, H. Hönigsmann and A. Tanew, "Photodynamic therapy for actinic keratoses and 
Bowen's disease 
[Photodynamische therapie bei aktinischen keratosen und morbus Bowen]," Aktuelle Dermatologie 31(5), 225-
232 (2005) 
[56] S. Collaud, N. Lange, A. Juzeniene and J. Moan, "On the selectivity of 5-aminolevulinic acid-induced 
protoporphyrin IX formation," Current Medicinal Chemistry - Anti-Cancer Agents 4(3), 301-316 (2004) 
[57] W. Bäumler, C. Abels and R. M. Szeimies, "Fluorescence diagnosis and photodynamic therapy in 
dermatology," Medical Laser Application 18(1), 47-56 (2003) 
[58] L. I. Grossweiner, The science of phototherapy: an introduction, Springer, Netherlands, Dordrecht (2005). 
[59] H. von Tappeiner and A. Jodlbauer, Die sensibilisierende Wirkung fluorescierender Substanzen: 
gesammelte Untersuchungen über die photodynamische Erscheinung., F.C.W. Vogel, Leipzig (1907). 
[60] H. von Tappeiner and A. Jensionek, "Therapeutische Versuche mit fluorescierenden Stoffen," Münch Med 
Wochenschr 47(2042-2044 (1903) 
[61] H. von Tappeiner and A. Jodlbauer, "Über Wirkung der photodynamischen (fluorieszierenden) Stoffe auf 
Protozoen und Enzyme," Dtsch Arch Klin Med 80(427 (1904) 
[62] I. Diamond, A. Mcdonagh, C. Wilson, S. Granelli, S. Nielsen and R. Jaenicke, "Photodynamische therapy 
of malignant tumours," The Lancet 300(7788), 1175-1177 (1972) 
[63] J. S. McCaughan Jr, "Photodynamic therapy of endobronchial and esophageal tumors: An overview," 
Journal of Clinical Laser Medicine and Surgery 14(5), 223-233 (1996) 
[64] P. Grosjean, P. Monnier, G. Wagnieres, H. Van Den Bergh and C. Fontolliet, "Clinical photodynamic 
therapy for superficial cancer in the oesophagus and the bronchi: 514 nm compared with 630 nm light irradiation 
after sensitization with Photofrin II," British Journal of Cancer 77(11), 1989-1995 (1998) 
[65] S. J. Tang and N. E. Marcon, "Photodynamic therapy in the esophagus," Photodiagnosis and Photodynamic 
Therapy 1(1), 65-74 (2004) 
[66] C. N. Foroulis and J. A. C. Thorpe, "Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or 
early cancer," European Journal of Cardio-thoracic Surgery 29(1), 30-34 (2006) 
[67] T. Nakamura, K. Shirakawa, T. Fujimori and A. Terano, "Photodynamic therapy in gastric cancer 
[Thérapie photodynamique dans le cancer gastrique]," Acta Endoscopica 33(4), 521-529 (2003) 
Chapter 1 – Introduction to Photomedecine 
 
22 
[68] J. I. Lim, "Photodynamic therapy for choroidal neovascular disease: Photosensitizers and clinical trials," 
Ophthalmology Clinics of North America 15(4), 473-478 (2002) 
[69] M. P. Copper, I. B. Tan, H. Oppelaar, M. C. Ruevekamp and F. A. Stewart, "Meta-
tetra(hydroxyphenyl)chlorin photodynamic therapy in early-stage squamous cell carcinoma of the head and 
neck," Archives of Otolaryngology - Head and Neck Surgery 129(7), 709-711 (2003) 
[70] C. Hopper, A. Kübler, H. Lewis, I. B. Tan, G. Putnam, T. Patrice, C. Beauvillain, J. Evensen, K. Butow, B. 
Smit, J. Brown, J. De Carpentier, J. Carruth, M. Dilkes, G. Kenyon, F. Roberts and N. Sudderick, "mTHPC-
mediated photodynamic therapy for early oral squamous cell carcinoma," International Journal of Cancer 
111(1), 138-146 (2004) 
[71] P. Babilas, S. Karrer, M. Landthaler, R. M. Szeimies and A. Sidoroff, "Photodynamic therapy in 
dermatology - An update," Photodermatology Photoimmunology and Photomedicine 21(3), 142-149 (2005) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PART I 
 
AUTOFLUORESCENCE FOR 
THE DIAGNOSIS OF 
EARLY (PRE-)NEOPLASTIC 
LESIONS IN THE TRACHEO-
BRONCHIAL TREE
 24 
 25 
Chapter 2  
Cancer basics 
he term “cancer” denominates the wide range of malignant tumours that are 
characterised by uncontrolled proliferation of cells, their invasion into other tissues and 
production of other cancerous foci (metastases) at distant sites of the body.  
2.1 Facts about Cancer 
In the western world, cancer is the second major cause of death, with cancer related deaths 
preceded only by heart disease [1, 2]. It is estimated that about 23% of all deaths in the United 
States can be attributed to cancer [2] and similar numbers are reported for Europe [1]. The 
following chapter will point out the principal features of cancer and give insight into why 
cancer is a disease that is so difficult to cure. 
The human body is an astonishing and puzzling system of cells that interact with each other 
through a complex chemical communication system. Each cell has unique features and 
occupies a specific place in the body, where it fulfils its obligations on behalf of the whole. In 
a healthy body the cells stay in the tissue of which they are a part and regulate their 
neighbours proliferation and apoptosis. Sometimes, some cells suddenly become deaf to the 
proliferation and apoptosis control mechanisms and start following their own timetable for 
reproduction: a tumour starts growing in the body. In many cases, the deregulated cells will 
overproliferate, but not invade healthy neighbouring tissue or spread to other body sites. 
These cells form the so-called benign tumours. But not all over-proliferating cells behave in a 
benign fashion. Their invasion of healthy tissue and the formation of metastasis is in fact what 
make cancer a lethal disease. 
T
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Figure 2.1 Illustration of the cell cycle clock. The cell clock is composed of an assembly of interacting proteins 
in the nucleus of a cell and is normally run by stimulatory and inhibitory pathways. The four stages of the cell 
cycle are depicted as G1, S, G2 and M. In the G1 phase the cell increases in size and prepares to copy the DNA. 
The copying and duplication of the genetic material occurs in the second stage, the synthesis S. During the 
following G2 period the cell prepares for mitosis that takes place in the final M stage. A crucial step occurs late 
in the G1 stage, marked as the restriction point R. Passage of R is only possible when a molecular “switch” is 
set from “off” to “on”. If the switch remains “off” the cell either enters the G0 rest stage or undergoes 
apoptosis. In cancer cells, the inhibitory effects of proteins blocking the R passage way are inactivated, allowing 
“unlimited” reproduction cycles for the cell. (adapted from [3]) 
All cells of a tumour descend from a common ancestral cell that at one point started running 
its own proliferation and production program. But what makes a cell become deaf to the 
general proliferation regulation process? All malignant transformations of a tumour cell arise 
from the accumulation of genetic mutations in the cell that affect the normal life cycle. A 
normal cell life cycle is often depicted as a so-called cell cycle clock (Figure 2.1). The clock 
is composed of four stages. In the first stage (G1) the cell increases in size and prepares to 
copy the DNA contained in its nucleus. The copying is performed in the synthesis (S) stage. 
In this phase, all the chromosomes of the cell are replicated and the cell then enters the G2 
stage. During this stage, the cell prepares for mitosis (M stage), where the mother cell divides 
into two daughter cells, each containing a complete set of chromosomes. The two daughter 
cells immediately enter G1 and will either follow the cell cycle clock or temporarily or 
permanently stop cycling. At the restriction point (R) which occurs in the late G1 phase, a 
molecular “switch” determines whether the cell continues the cell cycle, enters the G0 state 
(senescence), or undergoes apoptosis [3]. 
Two classes of genes play major roles in triggering cancer. The cycle clock is driven by a 
variety of stimulating and inhibiting proteins. Proto-oncogenes produce poteins that 
encourage the growth of the cell by relaying growth-simulating signals from outside the cell 
to its interior, whereas so called tumour suppressor genes produce protein products that block 
the signals that flow through the growth-stimulating circuit, therefore inhibiting growth. In 
normal cells, these proteins interact in a well-determined manner. But sometimes, some 
oncogenes acquire mutations that serve to activate protein production at the wrong time and 
force the cells to over-produce growth factors which then affect the surrounding cells.  
Normal cells transforming into cancer cells begin by stimulating themselves and ignoring 
inhibitory signals. Fortunately, the cells in the human body are equipped with a kind of 
backup protection system to halt runaway proliferation. One of these systems initiates cell 
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apoptosis, i.e. provokes the cell to commit suicide if some essential components are damaged 
or deregulated. Unfortunately, cancer cells develop additional genetic mutations which help 
them to evade apoptosis. Another protection system limits the number of cell reproduction 
cycles. For a human cell this number is typically limited to 50-60 doublings [3]. After this 
number of reproductions, the cell stops dividing and enters senescence. This control 
mechanism is based on a DNA segment at the end of each chromosome, called a telomere. 
Telomeres protect chromosomal ends from damage and shorten a bit every time chromosomes 
are replicated. When the telomere length reaches a threshold value, the cell loses its ability to 
divide. Sometimes cells bypass this step and continue dividing. In this case further shrinkage 
of the telomere will trigger crisis, i.e. sudden death of cells. Once more, cancer cells evade 
this mechanism by activation of a gene that codes for telomerase, i.e. the enzyme that 
systematically replaces telomere segments lost during a cell division and allows the cell to 
replicate an unlimited number of times. As a result, tumours stemming from such cells not 
only grow large, but due to their unlimited cell cycling ability, permanently accumulate more 
and more genetic mutations. 
As already mentioned above, overproliferation and cell immortality do not create the lethal 
character of cancer. The critical point that distinguishes malignant cancer from benign 
tumours is the formation of metastasis and the invasion of normal tissue. Normal cells remain 
in the tissue and part of the body they belong to for two reasons. In normal tissue, cells adhere 
to each other and to the extracellular matrix. This anchoring of the cells to their adjacent 
structures is controlled by so called area code molecules, located on the surface of every 
individual cell and the extracellular matrix. Cells in the human body only can survive when 
their area code where the cell is compatible with the code of the surrounding cells and the 
extracellular matrix. As a consequence normal cells leaving their cell structure will die within 
a short time by apoptosis. This property is called “anchorage dependence”. In cancer cells, 
some proteins produced by oncogenes trick the nucleus by making it seem that the cell is 
attached while in reality it is not. This makes cancer cells anchorage independent and allows 
them to migrate freely throughout the human body via the blood circulation system. Invasion 
of cancer cells to other tissues results from their ability to release metalloproteinases that 
dissolve extracellular matrices. This mechanism that cancer cells have in common with white 
blood cells, allows the cancer cell to penetrate from its original location into blood vessels and 
use the bloodstream to access other locations in the body. Thus far, we have discussed the 
basic properties of cancer cells that allow overproliferation, tissue invasion and metastasis.  
But how does tumourgenesis take place in a tissue? Carcinogenesis, i.e. the formation of a 
cancer, is normally a long-term process, lasting several years, even decades from the 
appearance of the first genetic change occurring in a single cell. Carcinomas are epithelial, or 
squamous cell cancers and are the most common malignancies in humans. Each cancer related 
detection and therapy method presented in this thesis is targeting carcinoma. Figure 2.2 
depicts the creation of a carcinoma emerging from a single mutated cell. Genetic mutation of 
a single cell within a normal population is at the origin of the growing tumour (1). As the 
mutated cell starts uncontrolled and permanent proliferation, a hyperplasia, defined as the 
overproduction of cells, is created (2). The hyperplastic cells still look normal. Nevertheless, 
after several years, the descendants of the ancestral cell usually undergo further genetic 
mutations and enter the next step of carcinogenesis, called dysplasia (3). In this state, the 
shape and orientation of the cells is altered and the cells continue to undergo new mutations, 
finally leading to a carcinoma in situ (CIS) (4). In this state the abnormalities in shape and 
orientation have increased, but the lesion has not yet penetrated any boundaries between 
tissues. In quite a number of cases the tumour remains in this state for several years until 
further genetic mutations provide the cancer cells with the potential to invade underlying  
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Figure 2.2 Schematic description of cancerogenesis in an epithelium. Cancer development begins when 
genetic mutations occur in a cell (orange) within a normal population, leading to an increased potential to 
proliferate (1). This altered cell and its descendents still look normal, but show an excessive reproduction rate 
leading to hyperplasia. After some time, one of these cells (pink) probably suffers another genetical mutation 
that further alters proliferation and cell growth (2). The offspring of this cell now shows abnormalities in shape 
and orientation in addition to an increased proliferation rate. This condition is called dysplasia. With some 
probability further mutation will occur in some of the dysplastic cells (purple) (3). The descendents of this cell 
become more abnormal in shape and growth, generally fully disrupting the epithelial cell structures. If the cell 
growth has not yet broken through any boundaries between tissues (for instance the basement membrane), it is 
called a carcinoma in situ (CIS). A CIS can persist in its localised state for years and may never spread further. 
However, some of the cells may acquire additional mutations (blue), that allow the abnormal cells to penetrate 
tissue borders and invade the underlying tissue (invasive carcinoma). At this time the cells may enter into the 
blood or lymphatic system. This enables the cells to establish new foci of abnormal cells (metastasis) throughout 
the body. The cell mass is now considered malignant (5). (adapted from [3]) 
 
tissue and blood vessels. The abnormal cells can now spread throughout the body. It has 
become an invasive cancer (5). In advanced stage dysplasia, the mutated cells already release 
messenger substances (principally the so-called vascular endothelial growth factors (VEGF)) 
supporting the growth of additional blood vessels in their vicinity. This sprouting of new 
blood vessels is called angiogenesis and is considered one major factor for the progression of 
a localised dysplasia or CIS towards invasive cancer.  
As already mentioned above, cancer is the second leading cause of death in the western world, 
superseded only by death from cardiovascular diseases. The lifetime probability of developing 
cancers in the United States is about 43% for men and 38 % for women [2]. The causes of 
cancers are numerous and it is not always possible to identify the origin of every tumour. 
Nevertheless, epidemiological studies suggest that the inhaled carcinogens (tobacco smoke, 
environmental air pollution), diet, ionising radiation (X-rays, radioactivity), solar irradiation 
(UV rays), as well as occupational factors (asbestos, aniline, benzidine) are the most 
significant contributers [4]. Among these the inhalation of tobacco smoke is the major 
carcinogenic factor and can be attributed to about 35% of all cancer deaths. Apart from lung 
and bronchial cancer (the most frequent cause of cancer deaths in the western world [1, 2]), 
carcinoma of the upper respiratory tract (larynx, pharynx), the oesophagus, the bladder and 
the kidney arise from exposure to this carcinogen as well. 
Figure 2.3 shows the development of age-standardized incidence and mortality rates for the 
most frequent cancers in the USA and some European countries for the year 2001. The most 
frequent cancers occurring in these populations are lung, prostate and colon cancers for men, 
and breast and colon cancers for women, respectively. 
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The poor prognosis for long-term survival of cancer patients is mainly due late detection of 
this disease. Most cancers are detected only at a late stage when symptoms appear. By this 
time, most tumours have already grown large, are invasive and have probably already 
metastasised. Cancer management is then difficult and the treatment of advanced stage 
cancers is generally associated with high morbidity and poor outcome. Early cancerous 
lesions are less likely to metastasise and easier to treat, but remain mostly asymptomatic and 
therefore not noticed by the patient. Moreover, their small size makes them difficult for a 
clinician to detect.  
 
Figure 2.3 Age-standardised cancer mortality rates in the USA and some European countries for the year 2001. 
The data were obtained from the WHO Cancer mortality statistics [5]. 
 
Cancer prevention and management should therefore include [2]: 
• Limited exposure to carcinogens or carcinogenic factors (tobacco smoke, ionising and 
UV radiation) 
• Changing unhealthy lifestyle patterns that promote cancer (diet, physical activity) / 
modification of health risk behaviours = preventing the occurrence of cancer (primary 
prevention) 
• Regular cancer screening of high-risk patients 
• Optimisation of early cancer detection methods = early detection of cancer through 
screening (secondary prevention) 
• Improvement of therapeutic methods  
2.2 Cancer Detection and Diagnosis  
While primary prevention campaigns such as tobacco prevention and cessation programs, 
dietary education campaigns and physical activity interventions aim to reduce the risk of an 
individual for developing cancer, secondary prevention focuses on the monitoring of high risk 
individuals for the presence or absence of cancer. There are three tools for cancer detection: 
Chapter 2 – Cancer Basics 
 
30 
screening, diagnosis testing and surveillance [2]. Screening depicts the early detection of 
cancer or pre-malignant disease in mostly asymptomatic high-risk persons. Diagnostic testing 
is the evaluation of patients with signs and symptoms associated with cancer, and focuses on 
the localisation and staging of the tumour. Surveillance depicts the follow-up screening for 
new evidence of cancer in patients who have already been diagnosed with or treated for 
cancer or pre-malignant disease.  
Regular and efficient cancer screening will increase the number of cancers that are found in 
an early stage. However, efficient screening is only feasible with low cost, rapid and 
minimally invasive cancer detection methods. This is the reason why the main body of 
research presented in this thesis focuses on fluorescence detection of early cancers. 
An efficient and powerful cancer detection and screening method must ideally fulfil the 
following criteria: 
• Allows for the detection of small tissue and cellular changes 
• Has a high sensitivity and a good specificity 
• Allows for the discovery of the presence of a disease as well as its localisation 
• Is easy and inexpensive to employ 
• Do, according to the medical precept “primum non nocere”, more good than harm  
(i.e. is as non- invasive as possible) 
 
At this point, it is be necessary to define some terms that will consistently appear in the 
context of medical detection and diagnosis. The quality of a detection method is described by 
its "sensitivity" and its "specificity", generally expressed in percentage [%]. The sensitivity of 
a detection or diagnostic method describes the probability that an individual having the 
disease is screened positive. The specificity of a detection or diagnostic method is the 
probability that an individual without the disease is screened negative. The detection and 
diagnosis of a disease in an individual having the disease is also referred to as a "true positive 
(TP)" result. In contrast to this, a positive detection or diagnosis in an individual without the 
disease is called a "false positive (FP)" result. If a detection method or diagnostic test 
identifies a healthy individual as not having the disease, this is referred to a "true negative 
(TN)" result. The failure of a detection method or diagnostic test to detect the disease in an ill 
individual, is called a "false negative (FN)" result. We can thus identify the sensitivity with 
the quotient of all TP results and the sum of the TP and FN results. The specificity 
corresponds to the quotient of the TN results and the sum of the FP and TN results. The 
sensitivity and specificity of a detection or diagnostic method is generally diametrical, i.e. a 
high sensitivity is often associated with a low specificity and vice versa. Two other 
parameters are frequently used to judge the quality of a detection or diagnostic method: the 
positive predictive value (PPV) and the negative predictive value (NPV). The PPV 
corresponds to the probability that an individual identified as positive for the disease really 
has the disease. Accordingly, the NPV is the probability that an individual identified as 
negative for the disease does not effectively have the disease. All abovementioned terms are 
summarised in Table 2.1 below. It should be noted that the sensitivity, the specificity and the 
NPV of a detection of diagnostic method are very difficult to assess since these parameters 
demand the knowledge of the number of true negative and false negative results. The 
determination of these parameters would require extensive sampling from putative healthy 
cell tissues. However, in the case of invasive sampling as with biopsies, such a procedure is 
often not defendable for medical and ethical reasons. 
The decision as to whether an individual is negative or positive for a disease is made by a 
diagnostic method referred to as “gold standard”. A gold standard in medicine is “a relatively 
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irrefutable standard that constitutes recognised and accepted evidence that a certain disease 
exists” [6]. In cancer diagnosis the gold standard is histopathology and cellular pathology. 
However, the objectivity and inerrability of histopathologic diagnosis, especially for early 
neoplastic pathologies, has been discussed in several scientific reports and reviews [6-10].  
 
Sensitivity (SENS) 
Probability that an individual with  
the disease is screened positive. TPFN
TP
+
 
Specificity (SPEC) 
Probability that an individual without  
the disease is screened negative. FPTN
TN
+
  
Positive Predictive Value 
(PPV) 
Probability that an individual with  
a positive screening result has the disease. TPFP
TP
+
 
Negative Predictive 
Value (NPV) 
Probability that an individual with  
a negative screening result  
does not have the disease. TPTN
TN
+
 
Table 2.1 Main parameters that describe the quality of a detection and diagnostic method. TP and FP depict 
the true and false positives, respectively. TN and FN represent the true and false negatives, respectively. 
Definitions of these latter parameters are given in the text. 
 
Significant interobserver variations in the histopathologic diagnosis have been reported for 
early neoplastic pathologies [6, 11-13]. This should be kept in mind when discussing the 
quality of a clinical diagnosis and detection technique. 
Numerous cancer detection methods have been developed during the past decades, and 
research and development is still carried forward. The common screening and detection 
methods for the most frequent cancers are listed in Table 2.1. 
 
Sampling 
of cells 
Tumour markers 
Imaging/  
Physical examination 
Colorectal cancer 
Fecal occult 
blood test 
 
Flexible sigmoidoscopy, 
Double-contrast barium enema, 
Colonoscopy 
Breast cancer  
BRCA1 and BCRA2 
mutations 
Mammography,  
Breast self-examination  
Prostate cancer  
PSA  
(prostate-specific antigen) 
Digital rectal examination 
Cervical cancer Pap Smear  Colposcopy 
Lung cancer Sputum cytology 
Immunohistochemistry  
(K-ras, p53 mutations) 
Bronchoscopy, Chest X-rays, 
spiral CT 
Oesophagus Sponge sampling  
Oesophagoscopy, Chest X-rays, 
CT, 
Table 2.2 Most frequently used cancer tests. Sampling of cells is one of the most frequently used and most 
inexpensive detection methods, but sensitivity remains limited. As well as the tumour marker analysis, cell 
sampling does not allow the localization of the lesion. This can only be accomplished with imaging methods. 
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The detection methods can be classified into 3 categories: cell sampling (occult blood test, 
Pap smear, sputum analysis), tumour marker analysis, and imaging techniques. It should be 
mentioned that the most popular diagnostic tests belong to the first two categories. In the 
course of recent developments in the field of genomics and proteomics these tests have been 
widely expanded and improved. Nevertheless, the number of false positives with most of 
these tests remains high. Moreover, common to all these tests is that they allow diagnosis of a 
disease, but not its localisation within the body. Among the abovementioned detection 
categories only the imaging techniques allow simultaneous detection and localisation. The 
most common imaging methods are endoscopy, ultrasound (US), X-rays, computed 
tomography (CT), positron-emission tomography (PET), and magnetic resonance imaging 
(MRI). All these methods have their advantages and drawbacks and no method is ideal for all 
cancers. More recent characterisation methods, among others under investigation are optical 
coherence tomography (OCT), high magnification/ resolution video endoscopy, narrow band 
imaging (NBI) and endoscopic (auto-)fluorescence detection. 
2.2.1 Cancer treatments 
The earliest and most widely used therapy of invasive cancer is surgery [4]. Surgical excision 
of cancerous lesions accounts for the largest number of cures if the cancerous tissue is 
completely removed. Surgery is indeed the sole initial treatment modality for over 50% of all 
patients with a localised cancer and for 40% of the patients with a regionally limited cancer 
[4]. Major shortcomings of surgery to treat cancer are (1) the need to remove large portions of 
healthy tissue to ensure the complete resection of the cancerous lesion and (2) the traumatic 
experience associated with a major operation. Moreover, incomplete resection of the 
cancerous lesions results in recurrence and metastasis. Recent computer aided imaging 
technologies have considerably improved image guided surgery [14], thus reducing surgery 
related morbidity and complications. However, the most crucial limitation is that surgery is 
not applicable to advanced stage cancers that have already metastasised within the body [15]. 
Radiation therapy is based on the irradiation of the cancer region with powerful x-rays or 
gamma rays from external or implanted sources. This radiation destroys biological cells either 
directly by inflicting genetic damage, or indirectly by inducing apoptosis. As healthy cells 
recover more easily from radiation than cancer cells, radiation therapy allows selective 
destruction of the cancerous lesion while the functionality of the surrounding healthy tissue is 
usually retained [15]. However, like surgery, radiation therapy sometimes fails to eradicate all 
cancer cells and is not suited for the treatment of metastasised disease.  
In the case of non-localised cancer and metastasis, chemotherapy, i.e. the systematic 
administration of anticancer drugs, are used. Most chemotherapeutic drugs interfere with the 
DNA replication process, thus preventing cell multiplication. Several malignancies, like 
leukemias, lymphomas and testicular cancer, show high cure rates with this treatment. 
However, most common cancers (breast, lung, colorectal, and prostate) can not be cured by 
chemotherapy alone. However, clinical studies have proven the benefit of chemotherapy in 
the framework of a cancer treatment program including surgery and/or radiotherapy (adjuvant 
chemotherapy) [15]. Hormone therapy is another kind of drug therapy that is quite effective 
for some cancers of breast and prostate [4, 16]. 
The increasing number of improved detection methods sensitive to microinvasive or low 
invasive lesions has highlighted the possibilities for less invasive therapies for these early 
stage cancers. PDT, under investigation for several decades, has proven a good alternative 
technique to treat endoscopically accessible early stage cancers.  
Chapter 2 – Cancer Basics 
33 
2.3 References 
 
 
[1] F. Levi, F. Lucchini, C. La Vecchia, E. Negri and F. Levi, "Trends in mortality from major cancers in the 
European Union, including acceding countries, in 2004," Cancer 101(1), 2843-2850 (2004) 
[2] S. J. Curry, T. Byers and M. Hewitt, Eds., Fulfilling the protential of cancer prevention and early detection, 
The National Academies Press, Washington, DC (2003). 
[3] R. A. Weinberg, "How cancer arises," Sci Am 275(3), 62-70 (1996) 
[4] R. Souhami and J. Tobias, Cancer and its management, Blackwell Science Ltd., Oxford (1998). 
[5] World Health Organisation (WHO), "WHO Data base," http://www-dep.iarc.fr, accessed on 23.03.2006 
[6] E. Foucar, "Do pathologists play dice? Uncertainty and early histopathological diagnosis of common 
malignancies," Histopathology 495-502 (1997) 
[7] A. D. Ramsay, "Errors in histopathology reporting: Detection and avoidance," Histopathology 481-490 
(1999) 
[8] D. Jenkins, E. Bentley and K. A. Fleming, "Evidence-based cellular pathology: a systematic framework for 
pathological diagnosis and clinical decisions," Curr Diag Patho 7(272-280 (2001) 
[9] S. S. Cross, "Grading and scoring in histopathology," Histopath 33(99-106 (1998) 
[10] E. R. Farmer, R. Gonin and M. P. Hanna, "Discordance in the histopathologic diagnosis of melanoma and 
melanocytic nevi between expert pathologists," Human Pathology 528-531 (1996) 
[11] F. T. Bosman, "Dysplasia classification: pathology in disgrace?," J Pathology 194(143-144 (2001) 
[12] P. S. Carter, J. P. Sheffield, N. Shepard, D. H. Melcher, D. Jenkins, P. Ewings, I. Talbot and J. M. A. 
Northover, "Interobserver variation in the rporting of the histopathological grading of anal intraepithelial 
neoplasia," J Clin Pathol 47(1032-1034 (1994) 
[13] A. G. Nicholson, L. J. Perry, P. M. Cury, P. Jackson, C. M. McCormick, B. Corrin and A. U. Wells, 
"Reproducibility of the WHO/IASLC grading system for pre-invasive squamous lesions of the bronchus: A 
study of inter-observer and intra-observer variation," Histopathology 202-208 (2001) 
[14] W. E. Grimson, R. Kikinis, F. A. Jolesz and P. M. Black, "Image-guided surgery," Sci Am 280(6), 62-69 
(1999) 
[15] S. Hellman and E. E. Vokes, "Advancing current treatments for cancer," Sci Am 275(3), 118-123 (1996) 
[16] K. M. Rau, H. Y. Kang, T. L. Cha, S. A. Miller and M. C. Hung, "The mechanisms and managements of 
hormone-therapy resistance in breast and prostate cancers," Endocr Relat Cancer 12(3), 511-532 (2005) 
 
 34 
 35 
Chapter 3  
Introduction to 
Bronchology 
3.1 Bronchial Anatomy and Histology 
The lungs are the site of external respiration, i.e. the junction between air and blood to be 
oxygenised and sent to the arteries. The blood carbon dioxide (CO2) resulting from the body’s 
internal respiration is released and replaced by oxygen (O2). The human thorax holds two 
lungs (right and left) that are subdivided into a total number of 5 lobes. There are three lobes 
in the right lung, namely the right upper lobe (RUL), the right middle lobe (RML) and the 
right lower lobe (RLL). The left lung shows a slightly different architecture than the right one 
due to the volume occupied by the heart in the left part of the thorax. There are only two 
lobes, namely the left upper lobe (LUL) and the left lower lobe (LLL) (Figure 3.1). The air-
conducting parts of the lungs are formed by the tubular system of bronchi, bronchioli, and 
alveoli (Figure 3.2). This so-called “tracheo-bronchial tree” starts with the trachea.  
The trachea divides into the two primary or extra-lobar bronchi. These primary bronchi 
further divide into the secondary or intra-lobar bronchi which on their part divide by irregular 
dichotomy into bronchi of decreasing size (segmental bronchi). The small bronchi subdivide 
into terminal and respiratory bronchioles and form the alveoli. The latter are responsible for 
the gas exchange between the air-conducting part and the lung blood circulation. The 
diameter of the trachea is typically 20 mm in adults. This diameter decreases to about 16 mm 
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for the primary bronchi, 11 mm for the intra-lobar bronchi, and is less than 8 mm for the 
segmental bronchi. The bronchioli have diameters smaller than 0.6 mm. The terminal alveoli 
are less than 0.3 mm in diameter [3]. Due to the decreasing size of the bronchial diameter, 
only the primary and secondary bronchi are accessible with conventional bronchoscope 
optics. The histology of the tracheo-bronchial tree is not uniform, but undergoes significant 
changes from the trachea to the alveoli. The principal histologic features of the trachea and 
the bronchoscopically accessible bronchi are given in the following sections.  
 
 
 
 
 
Figure 3.1 Lobar structure of the lung. The right lung 
consists of 3 lobes, namely the right upper lobe (RUL), the 
middle lobe (RML) and the right lower lobe (RLL). The left 
lung consists of the left upper lobe (LUL) and the left lower 
lobe (LLL). 
 
 
 
Figure 3.2 The tracheo-bronchial tree viewed from the trachea. The trachea divides into a right and a left main 
bronchus which further subdivide into the higher generation bronchi and bronchioli. The “B-numbers” give the 
official nomenclature of the bronchi. 
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3.1.1 The trachea 
The tracheal wall is supported by 15 to 20 horse-shoe shaped cartilaginous structures which 
open posteriorly. The posterior wall contains smooth muscle bundles. The inner lining of the 
trachea consists of 4 layers, namely the mucosa, the lamina propria (or tunica propria), the 
submucosa, and hyaline cartilage. The different layers are illustrated in Figure 3.3. The 
tracheal mucosa forms a ciliated pseudostratified columnar epithelium. A very prominent 
basement membrane separates the epithelium from the lamina propria. In contrast to the 
avascular epithelium, the lamina propria is highly vascularized and contains numerous elastic 
fibres and fine, densely packed collagen fibres. The elastic fibres are arranged in bundles that 
run along the longitudinal axis of the bronchial wall giving it a stripe-like morphology. The 
thin layer of the lamina propria separates the epithelium from the submucosa. The latter 
shows less elastic fibre and only loosely packed collagen fibres. The secretory portions of 
exocrine glands are located in this layer. C-shaped cartilage rings and the posterior 
fibromuscular wall are located subjacent to the submucosa. 
3.1.2 The bronchi 
The histological appearance of the extra-lobar, intra-lobar, and segmental bronchi is similar to 
that of the trachea. A photomicrograph of healthy broncial wall tissue is shown in Figure 3.4. 
The most superficial layer of the bronchi is formed by a ciliated pseudostratified columnar 
epithelium that lays on a thin lamina propria. The two tissues are separated by the thin 
basement membrane. In the extra-lobar and first segmentary bronchi the epithelial thickness is 
in the order of 40 μm - 60 μm. However, the thickness of the epithelium decreases with 
successive branching, becoming a simple ciliated epithelium close to the bronchioles.  
The lamina propria contains elastin and collagen fibres as well as blood vessels. The extra-
lobar bronchi, and the trachea alike, contain smooth muscles only on their posterior. In the 
intra-lobar bronchi, smooth muscles fibres are found right below the lamina propria. They are 
arranged helically in crisscrossing bundles around the bronchi. The muscle fibres become 
more prominent as one approaches the bronchioles. The arrangement and shape of the 
cartilage change significantly with successive branching. The cartilage rings found in the 
trachea and the extra-lobar bronchi make room for isolated plates or islands of cartilage in the 
intra-lobar and segmentary bronchi. It should be emphasized that the transition between the 
changing histologic appearances are gradual.  
The function of the conducting portion of the tracheo-bronchial tree, i.e. from the trachea 
down to the terminal bronchiles, is to modify the incoming air by heating, increasing its 
relative humidity, and purification from particles. Indeed, the proximity of the rich 
vascularisation of the airway walls heats the incoming air before reaching the respiratory 
 
 
Figure 3.3: Histology of the trachea. The
photomicrograph nicely shows the different tissue
layers in the trachea. The ciliated pseudostratified
columnar epithelium (respiratory epithelium) is
separated from the lamina propria (LP) by the
basement membrane. A portion of a cartilage ring
is visible in the submucasa (SM) (adapted from
[2]). 
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portion, i.e. the respiratory 
bronchioles and alveoli. 
Humidification and purification are 
achieved by the so-called 
"mucociliary escalator" which 
results from the interaction of the 
mucous and serous layers, and the 
cilia overlaying the epithelium. The 
serous layer mostly contains water 
and some proteins and is in 
immediate contact with the 
epithelium. A viscous mucous layer, 
formed of mucus secreted from cells 
and glands in the bronchial wall, is 
sitting on the serous layer. The 
mucous layer humidifies the air and 
traps particles. The mucous layer is 
continually refreshed as the cilia 
transport the mucous by 
synchronized motion towards the 
pharynx. In smokers, the number of 
ciliated cells in the epithelium is 
significantly reduced. Thus, the 
efficiency of the mucociliary 
escalator is reduced, resulting in 
irritations of the mucosa and an 
increased coughing reflex [4]. 
3.2 Bronchial Cancer 
Lung cancer is the most common cancer in the world with the highest incidence rates 
occuring in North America and Europe [5]. However, over the past few years, lung cancer 
incidence has dramatically increased in developing countries [6, 7]. The world maps in Figure 
3.5 illustrate the worldwide lung cancer incidence and mortality rates for men and women. 
The mortality rate for lung cancer in Europe exceeds that of all other most common cancers, 
including prostate, colorectal, stomach, bladder, and head and neck cancer, by a factor more 
than 2 [8]. In European women, only breast cancer is associated with a higher mortality rate 
[8]. The age-standardised lung cancer incidence and mortality rates in Europe are illustrated 
in Figure 3.6. According to the USA cancer statistics, it was estimated that about 172 570 new 
lung cancer cases would occur in 2005 and about 163 510 lung cancer patients would die of 
their disease [9] (the cancer statistics 2006 were unfortunately unavailable at the moment of 
editing).  
Malignant and non-malignant tumours in the lung can develop from all tissues in the bronchi 
and lung parenchyma. However, bronchial carcinoma represents about 90% to 95% of all 
malignant lung tumours [10]. About 60% - 70 % of these lesions are centrally located, i.e. 
accessible by bronchoscopic procedures [11, 12], and only 20%-30% are peripheral. The 
central bronchial lesions occur 25.6 % in the RUL, 13.3% in the RML, 15.4% in the RLL, 
30% in the LUL, and 15.7% in the LLL [10]. 
Figure 3.4 Normal bronchial histology. The mucosa (M)
consists of the ciliated respiratory epithelium and the lamina
propria (LP). Smooth muscle fibers and small blood vessels are
visible in the LP. The submucosa (SM) contains serous glands
and blood vessels. A portion of the hyaline cartilage is visible in
the lower part of the image. (adapted from [1]) 
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Figure 3.5 Lung cancer incidence and mortality maps. The maps show the worldwide incidence and mortality 
rates for men and women established in 2002. (Source IARC Globocan [13]]). 
 
               
Figure 3.6 Lung cancer incidence and mortality rates in Europe 2000. The data were adapted from [5]. 
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Among all central lesions, the squamous cell carcinoma (SCC) is the most frequent carcinoma 
type; its prevalence ranging between 29% [14] to 43% [12]. Other types of bronchial 
carcinoma are adenocarcinoma, large cell lung carcinoma, and small cell carcinoma (SCLC). 
This thesis work focuses on the detection of squamous cell carcinoma and its non-invasive 
pre-stages. 
It should be noted that over the past several years changes, in pattern of lung cancer were 
observed [12] with an increasing incidence of peripheral and adenocarcinoma [15, 16] 
principally due to changes in the smoking behaviour of individuals and cigarette design 
(filters, light tobacco cigarettes, profound inhalation) [17].  
The principal cause for bronchial carcinoma is inhalation of noxae. In western countries, 
tobacco smoke is considered the most significant noxive factor, being responsible for 85%- 
90% of all bronchial carcinoma [5]. Other factors are occupational exposure to inhalative 
carcinogens like asbestos, some metals (e.g., chromate, nickel, arsenic, cadmium), radon, and 
ionising radiation. However, these factors account for less than 9% of bronchial carcinoma 
[18, 19]. This is also true for environmental factors, principally air-pollution, which is 
estimated to be responsible for less than 5% of the cases [10]. 
Epidemiological studies show a clear dose-response relationship between lung cancer risk and 
the number of cigarettes smoked per day, the degree of inhalation, and the age at initiation of 
smoking [20, 21]. Occupational factors seem to be only secondary to the formation of 
bronchial cancer in smokers. A clinical AF bronchoscopy study on high risk patients by Paris 
et al. [11]showed that definite occupational respiratory exposure to carcinogens and active 
smoking were independently associated with the presence of high grade bronchial pre-
neoplastic lesions. In this study, 9% of all patients showed high grade dysplasia, whereas low 
grade dysplasias were detected in 45%. Similar data have been reported by Lam et al [22, 23]. 
The relative risk of lung cancer in men and women as related to their smoking habits is listed 
in Table 3.1.  
 
 SCLC/ SCC AdenoCa 
 Men Women Men Women 
Non-smoker: 1.0 1.0 1.0 1.0 
Ex-smoker: 16.2 3.8 3.5 1.1 
Current smoker 57.9 18.2 8.0 4.1 
Table 3.1 Relative risk of small cell carcinoma (SCLC), squamous cell carcinoma (SSC) and adenocarcinoma 
(AdenoCa) in the lung for men and women, depending on smoking habits (adapted from [5]). 
 
3.2.1 Carcinogenesis and staging of bronchial cancer 
Carcinogenesis is a multi-step process generally beginning with changes of the squamous 
epithelium under the effect of inhaled noxae. The individual steps were classified by the 
World Health Organisation (WHO) and the International Association for the Study of Lung 
Cancer I(ASLC) in the WHO/IASLC histological classification of pulmonary and pleural 
tumours that was revised in 1999 [Travis, WHO]. The steps of early cancerogenesis in the 
epithelium are defined as (1) reactive changes, (2) low squamous dysplasia (LGD), (3) high 
grade squamous dysplasia (HGD), (4) microinvasive carcinoma and (5) invasive carcinoma. 
Reactive changes include basal cell or gobelet cell hyperplasia and squamous metaplasia. 
Hyperplasia is characterised by increased proliferation of basal or gobelet cells, increasing the 
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number of cell layers in the epithelium to 3-10 [24]. In squamous metaplasia, the ciliated 
pseudostratified normal epithelium is replaced by a stratified cell structure of variable 
thickness [24]. Reactive changes frequently show spontaneous regression and are not 
considered as pre-neoplasia. However, reactive changes can turn into low grade squamous 
dysplasia. It comprises mild and moderate dysplasia. In mild dysplasia the microscopic 
architectural and cytological disturbance of the epithelium is minimal. The epithelial cells 
exhibit a mild increased in size and show pleomorphism. A continuous progression of 
maturation from the base to the luminal surface and variations in nuclei-cytoplasma (N/C) 
ratio are observed. More details on the microscopic features of squamous cell dysplasia and 
higher grade epithelial neoplasia are listed in Table 3.2. Moderate dysplasia is characterised 
by a moderate increase of the epithelial thickness with a superficial flattening of the cells. The 
N/C ratio is higher than in the mild dysplasia and mitosis can be detected in the lower third of 
the epithelium. The changes in the N/C ratios and mitosis are even more marked in high 
grade dysplasia. Cells are markedly increased in size and show strong pleomorphism. 
 
Abnormality Epithelial 
Thickness 
Cell size Maturation/Orientation Nuclei 
Mild dysplasia Mildly 
increased 
Mildly 
increased; Mild 
anisocytosis, 
pleomorphism 
Continuous progression of 
maturation from base to 
luminal surface; basilar zone 
expanded with cellular 
crowding in the lower third 
of the epithelium; superficial 
flattening of epithelial cells 
Mild increase of N/C 
ratio; inconspicuous or 
absent nucleoli; lower 
third of epithelium: 
nuclei vertically 
orientated; rare or 
absent mitosis 
Moderate 
dysplasia 
Moderately 
increased 
Mild increase; 
cells often small; 
pleomorphism 
Partial progression of 
maturation from base to 
luminal surface; expanded 
basilar zone; cellular 
crowding in 2 lower thirds of 
epithelium; superficial 
flattening of epithelial cells 
Moderate increase of 
N/C ratio; 
inconspicuous or 
absent nucleoli; nuclei 
vertically orientated in 
lower two thirds; signs 
of mitosis in lower 
third 
Severe 
dysplasia 
Markedly 
increased 
Markedly 
increased; 
pleomorphism 
Low progression from base 
to luminal surface; expanded 
basilar zone; cellular 
crowding into upper third; 
superficial flattening of 
epithelial cells; intermediate 
zone greatly attenuated 
High and variable N/C 
ratio; frequent and 
conspicuous nucleoli; 
vertically orientated 
nuclei in lower 2 
thirds; mitosis present 
in lower 2 thirds 
Carcinoma in 
situ 
may or may 
not be 
increased 
may be markedly 
increased; 
pleomorphism 
maturation: no progression of 
maturation from base to 
luminal surface; epithelium 
could be inverted with little 
change in appearance; 
expanded basilar zone with 
cellular crowding throughout 
epithelium; flattening only of 
the most superficial cells 
High and variable N/C 
ratio; inconspicuous 
nucleoli; no consistent 
orientation of nuclei 
relative to epithelial 
surface; mitosis visible 
throughout full 
thickness of epithelium 
Table 3.2 The revised WHO/IASLC grading system. The table lists the microscopic features of squamous 
dysplasia and carcinoma in situ (adapted from [25]) 
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There is little or no progression of maturation from the basement membrane to the luminal 
surface. High grade dysplasia comprises severe dysplasia and carcinoma in situ (CIS). It 
should be noted that several authors consider these two lesions to be identical. Low and high 
grade dysplasia are referred to as pre-neoplastic lesions. They are limited to the epithelium 
and do not break through or infiltrate the basement membrane. If the epithelial changes extend 
over the basement membrane and invade the subepithelial layers they are referred to as 
neoplasia. If the infiltration into the subepithelial layers is less than 3 mm, the lesion is 
considered a mircroinvasive carcinoma. Neoplasia that penetrate into deeper tissue layers are 
referred to as invasive carcinoma. Microphotographs showing the 5 principal WHO classes 
are shown in Figure 3.7. It should be noted that reactive, pre-neoplastic and neoplastic 
changes of the epithelium are often associated with inflammatory reactions in the bronchial 
mucosa and submucosa.  
The staging of invasive squamous cell carcinoma is described by the international system for 
staging of lung cancer. In this classification system, lung cancer stages are grouped according 
to their TNM (T- primary tumour, N - regional lymphnodes, and M - metastasis) anatomical 
subsets. Table 3.3 and Table 3.4 show an overview of the TNM descriptors and the stage 
grouping. 
 
 
Figure 3.7 H&E stained photomicrographs of the principal WHO classes: basal cell hyperplasia, metaplasia, 
mild dysplasia, moderate dysplasia, severe dysplasia, carcinoma in situ (CIS), microinvasive carcinoma and 
invasive squamous cell carcinoma (courtesy from S. Andrejevic-Blant, Institiure form Pathology, CHUV 
University Hospital, CH-Lausanne) 
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Table 3.3 The international TNM (primary tumour (T), regional lymphnodes (N) and distant metastasis (M)) 
descriptor system for the staging of lung cancer revised from 1997 (adapted from [26]). 
Stage TNM subset 
0 Carcinoma in situ 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T1 N1 M0 
IIB T2 N1 M0 
 T3 N0 M0 
IIIA T3 N1 M0 
 T1-3 N2 M0 
IIIB T4 N0-3 M0 
 T1-3 N3 M0 
IV any T any N M1 
Table 3.4 Stage Grouping. The table shows the international definition of the TNM subsets for lung cancer 
staging (adapted from [26]). 
3.3 Detection, Diagnosis and Treatment of bronchial 
Cancer: An overview 
Lung cancer curability and survival are functions of the disease stage at presentation [11]. The 
extremely high mortality rate of lung cancer is strongly related to the general late detection 
and diagnosis of the disease. Stage I and II lung cancers rarely cause symptoms and 
consequently, fewer than 25% of all lung cancer patients will present during the early stage of 
the disease [10]. Unfortunately, the potentially curative therapy for advanced stage lung 
cancers (stage III - IV) is often beyond the reach of physician's present capabilities [27]. 
Indeed, the overall 5-year survival rate for lung cancer is only 14%. This rate is about 25% - 
1% for stage III and IV lung cancer, but can reach 25% to 67% when the cancer is detected at 
an early stage (stage I or II) [28].  
Thus, efficient detection of early stage bronchial carcinoma is crucial for a successful 
therapeutic outcome and survival. This is particularly true for the detection of flat, small pre-
neoplastic lesions such as dysplasia and CIS, because those lesions have a high probability for 
growing into invasive lesions within a short period of time [29-31]. Clinical studies have 
Primary Tumour T 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour ≤ 3 cm in greatest dimension, no invasion more proximal than the lobar bronchus 
T2 
Tumour with any of the following features: > 3cm in greatest dimension; ≥ 2 cm distal to the 
carina; invading pleura; associated with atelectasis or local obstructive pneumonitis 
T3 
Tumour of any size directly invading any of the following: chest wall, diaphragm, midastinal 
pleura, parietal pericardium; or < 2 cm distal to the carina; or atelectasis or obstructive 
pneumonitis of entire lung 
T4 
Tumour of any size with invasion of mediastinal organs (e.g., heart, trachea, oesophagus, 
mediastinum) or vetebral body 
Regional Lymph Nodes (N) 
No regional lymph node metastasis 
Ipsilateral peribronchial and/or ipsilateral hilar lymph node meatastasis 
N0 
N1 
N2 Ipsilateral mediastinal and/or subcarinal lymph node metastasis 
N3 
Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or 
supraclavicular lymph nodes 
Distant Metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis present 
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shown that approximately 10% of moderate dysplasia and 19% to 83% of severe dysplasia 
will progress to invasive lesions [32, 33]. 
Monitoring the progression of pre-neoplasia to neoplasia is especially important in the context 
of the management and follow up (interval between control bronchoscopies, 
chemoprevention) of patients diagnosed with a primary cancer in the bronchi and/or in the 
ENT sphere. These patients are at high risk for secondary or second primary bronchial 
neoplasia 2[34-39].  
The incidence of second primary bronchial neoplasia for lung cancer patients ranges from 
0.5% to 10% [38]. Sixty percent (60%) of all second primary bronchial cancers are 
metachronous, i.e. occur with a time delayed response to the primary tumour, and 40% are 
synchronous. The prevalence of second primary bronchial neoplasia in head and neck cancer 
patients has been reported to be 7%- 32% [40, 41]. In a clinical AF bronchoscopy study, 
Venmans et al. [32] found pre-neoplastic central bronchial lesions in 25% of patients with a 
history of head and neck SCC. Long term studies on patients with secondary or second 
primary lung cancers showed that resection of early metachronous lesions improved the long-
term survival rate [38, 42]. However, most patients (68%) are asymptomatic at the time of 
diagnosis of the second primary cancer [42], which is frequently detected only "by accident" 
during a follow-up examination. Since secondary and second primary bronchial cancers may 
occur several years after the first cancer diagnosis [38], patients surviving treatment of a first 
primary carcinoma in the bronchi or the head and neck sphere require lifelong screening of 
second primary bronchial lesions [43]. Further high-risk populations that should be 
considered for screening for bronchial cancer include long-term survivors of small cell lung 
cancer, occupationally exposed groups, and subgroups of smokers (heavy smoker, family 
history of lung cancer)[44]. 
3.3.1 Detection of bronchial cancer 
The most common detection methods for lung cancer are sputum cytology, chest X-ray 
(CXR), computed tomography (CT), low-dose spiral CT, positron emission tomography 
(PET), magnetic resonance imaging (MRI) and white light or AF bronchoscopy.  
CXR has only a limited resolution and thus, has only poor sensitivity for the detection of early 
bronchial lesions.  
Low-dose CT is widely used for screening of high-risk patients. Its lung cancer detection rate 
is about 3-fold higher than with CXR. Several studies have shown that multi-detector spiral 
CT has a higher sensitivity to early and small sized lung cancer than CXR [27, 45].  
Spiral CT can detect lesions as small as 2-3mm in size [14], but at the price of a low 
specificity [46, 47]. Moreover, CT is not sensitive to superficial, pre- or microinvasive central 
lung cancers [45].  
PET with 18-fluorodeoxyglucose has to be considered as a diagnostic and staging tool, rather 
than a screening tool [48, 49]. Pastorino et al. demonstrated that the combined use of low-
dose spiral CT and PET improves the specificity of early stage lung cancer detection [50].  
Another screening tool widely used in high risk populations is the sputum analysis [51]. It has 
a high specificity especially for bronchial SCC, but only a limited sensitivity of 65% [51, 52]. 
It should be noted that this percentage is likely to be much smaller for dysplasie and 
squamous cell carcinoma. DNA analysis, automated quantitative cytometry and methylation 
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of the sputum samples have shown promising results to improve sensitivity [45]. Sputum 
analysis is the least encumbering and least costly of the detection methods mentioned so far, 
and can easily be used in wide range screening programmes. However, it does not allow 
localisation of the lesion within the tracheo-bronchial tree. Indeed, bronchoscopy is the only 
established method that allows detection and localisation of central bronchial lesions and 
parallel tissue sampling for histological diagnosis. 
Conventional white light bronchoscopy has a high sensitivity and specificity for early stage, 
invasive, central bronchial cancer, but is limited in the detection of small pre-neoplastic 
lesions. In the central airways, less than 40% of high grade dysplasia is detectable by 
conventional white light bronchoscopy [53, 54]. Autofluorescence bronchoscopy (AFB) has 
been introduced as a tool for the detection of flat pre-neoplastic central bronchial lesions. Its 
sensitivity for pre-invasive squamous lesions is about twice that of conventional white light 
bronchoscopy [22, 31, 55]. AFB will be discussed in Chapter 4 of this thesis in more detail. 
3.3.2 Treatment of bronchial cancer 
Surgery is the preferred curative therapy of localised non-small cell lung cancer (NSCLC) at 
stage III and below. Depending on the stage and the extent of the lesion, surgery is performed 
as pneumectomy (surgical removal of a lung), or lobectomy (surgical removal of a lobe). The 
overall 5-year survival rate for complete surgical resection of stage I and II NSCLC is about 
40% [56]. Limited resection such as segmentectomy or wedge resection reduce mortality and 
morbidity, but are associated with a 3 times higher local recurrence rate and a decrease in 5-
year survival [56].  
Post-operative radiotherapy and adjuvant or neoadjuvant chemotherapy can improve survival 
[57, 58]. However, about 30% of all patients with localised NSCLC ever undergo surgery due 
to presentation at an advanced stage, unresectability of the carcinoma, medical comorbidities, 
and advanced age [59]. In these cases, radiotherapy applied either alone or in combination 
with chemotherapy offers the only curative possibility. However, the mean 5-year survival 
rates for those treatments are below 27% for early stage (stage I and II) lung cancer [60] and 
around 10% for higher stage disease [61]. 
For localised pre-neoplasia, i.e. squamous dysplasia and CIS, (micro-)invasive carcinoma, and 
early stage bronchial carcinoma, minimal-invasive bronchoscopic therapies provide 
alternative treatment options [33, 62]. Most common therapies include PDT [63], 
endobronchial brachytherapy (EB) [64, 65], cryotherapy [66], argon plasma coagulation 
(APC) [67], lasertherapy with Nd:YAG laser and electrocautery [68]. The endoscopic 
treatment of early-stage bronchial cancer has been reviewed by Sheski [33] and Herth [62].  
PDT for the treatment of early stage bronchial cancer and pre-neoplastic endobronchial 
lesions has been widely investigated. Clinical studies have shown that the response rate of 
PDT is highest for CIS and microinvasive SCC sized < 1 cm. 5-year survival rates in patients 
treated with PDT for early stage bronchial carcinoma or bronchial pre-neoplasia vary between 
43% and 72% [Maziak, AnnThoracSurg]. The most common photosensitiser used for 
bronchial PDT is Photofrin® [69, 70], but clinical studies using m-THPC [71] and mono-L-
aspartyl chlorin e6 [72] have also been reported. In a 3-year follow up study Monnier et al. 
[69]and Savary et al. [71] reported a local recurrence rate after PDT for dysplasia and CIS 
inferior to 15%. However, the use of bronchoscopic therapies for the treatment of bronchial 
cancer demands accurate delineation and staging of the lesion, especially the determination of 
the lesion's infiltration into the bronchial mucosal layers and the exclusion of nodal spread 
[73]. 
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Chapter 4  
Autofluorescence 
Bronchoscopy 
s already mentioned in the preceding chapters, bronchoscopy is the only available 
clinical detection method that allows for the detection and localisation, as well as 
treatment of central bronchial pre-neoplasia and invasive carcinoma. Recent advances 
in the endoscopic video optical techniques have brought about significant improvements in 
sensitivity and specificity of white light (WL) bronchoscopy. The bronchoscpic detection of 
central bronchial lesions relies on the visual judgement of the bronchoscopist. Mucosal 
thickening, swelling or nodules are quite obvious during WL bronchoscopy, but mostly 
evident for invasive lesions only. Pre-neoplastic lesions have to be judged by more subtle 
alterations like redness, paleness, lack of luster, disrupture of mucosal folds or elastic fibre 
bundles, and vascular engorgement, among others [1]. Thus, correct judgement of small 
lesions strongly depends on the bronchoscopist’s accuracy and training. This is indeed one 
major limiting factor for the detection of bronchial pre-neoplasia by WL bronchoscopy. 
Autofluorescence bronchoscopy using blue-violet excitation light, on the other hand, has a 
higher sensitivity for flat pre-neoplastic lesions almost “independent” of the bronchoscopist’s 
experience. 
This chapter provides an overview of the historical development of autofluoresence 
bronchoscopy, the commercially available imaging systems, as well as the imaging system 
used for the clinical studies reported in this thesis work. 
A
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4.1 State of the Art of Autofluorescence Bronchoscopy  
Fluorescence imaging and spectroscopy are well established techniques for the 
characterisation of biological tissue and the detection of (pre-)neoplastic lesions (see 
Chapter 1). However, autofluorescence bronchoscopy as a diagnostic tool for endobronchial 
lesions, has only been investigated recently. 
Initial trials to detect early bronchial lesions using endoscopic fluorescence imaging were 
based on the administration of exogenous photosensitisers such as haematoporphyrin 
derivative (HpD) [2-4]. However, the photosensitisers used were not very selective for early 
bronchial tumours and were associated with long-lasting skin photosensitivity. Aiming to 
reduce skin photosensitivity, Lam et al. [5] performed fluorescence bronchoscopy studies 
with a stepwise reduction of the tumour marker dose. They found that good diagnostic 
accuracy for the detection of early lesions was achieved using the bronchial autofluorescence 
alone. First reports on the detection of early bronchial cancers using autofluorescence imaging 
date from 1991 [6]. Research that has since been conducted in this field, eventually lead to the 
development and commercialisation of different autofluorescence bronchoscopy (AFB) 
systems. 
4.2 Principle of Autofluorescence Bronchoscopy 
4.2.1 Spectroscopy of the bronchial autofluorescence 
In 2001, Zellweger et al. [7] conducted an extensive clinical study to quantify the 
autofluorescence spectra of healthy bronchial wall, and metaplastic and dysplastic bronchial 
lesions. The study showed a significant decrease in the autofluorescence intensity (intensity 
contrast) on the lesions compared to healthy bronchial tissues. These results are in agreement 
with an earlier study by Hung et al. [8] who examined in vivo AF spectra of normal and 
neoplastic bronchial tissue using different blue-violet excitation wavelengths. Zellweger et al. 
[7] demonstrated that this decrease was more pronounced in the green region (490 - 600 nm) 
of the emission spectrum than in the red one (600 nm – 800 nm). This results in a spectral 
difference (spectral contrast) between the autofluorescence of lesions and the surrounding 
healthy bronchial tissue. The origins of these differences will be discussed below. 
As demonstrated by Zellweger et al. in a second study [9], the intensity and spectral contrasts 
are most pronounced with excitation wavelengths between 400 and 480 nm with a peak 
around 405 nm (Figure 4.1). Examples of typical AF spectra of normal bronchial mucosa and 
pre-neoplastic bronchial lesions measured in vivo are shown in Figure 4.2. The AF was 
excited with blue-violet light at 405 nm wavelength (adapted from [9]). The figure clearly 
shows an AF intensity decrease in the spectra obtained from (1) normal bronchial wall, (2) 
reactive changes, and (3) pre-neoplastic lesions. The shape of the AF spectrum from reactive 
changes (metaplasia) is similar to the AF spectrum from healthy bronchial wall, but very 
different from the AF spectrum of pre-neoplastic lesions (dysplasia and CIS). In a recent 
publication, Tercelj et al. [10] mentioned similar results obtained with an integrated 
endoscopic imaging and spectroscopy system.  
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Figure 4.1 The green (450 nm – 600 nm) and red (above 600 nm) fluorescence intensity ratios between healthy 
bronchial mucosa and dysplastic lesions as a function of the AF excitation wavelength. The maximal intensity 
contrast was observed with a 405 nm excitation wavelength. The data were measured with a non-contact optical 
fibre based spectrofluorometer using a 405 nm wavelength for excitation. (adapted from [9]) 
 
Figure 4.2 Typical in vivo AF spectra from healthy bronchial mucosa, reactive changes and pre-neoplastic 
lesions (dysplasia and CIS). The spectra were measured with a non-contact optical fibre based 
spectrofluorometer using a 405 nm wavelength for excitation. These data were adapted from [9]. 
 
4.2.2 Origin of the bronchial autofluorescence contrast  
Even if the spectral AF properties of healthy mucosa and bronchial lesions have been studied 
by several authors (see above), not much is known about the mechanisms underlying the 
healthy/lesion contrast. However, several potential mechanisms are discussed in the literature 
and this issue is addressed in details in the following section. As pointed out in Chapter 1, the 
fluorescence originating from biological tissue depends on factors associated to: (1) the tissue 
optical properties and architecture and (2) the chemical properties and physical environment 
of the fluorochromes.  
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Consequently, the differences in the AF spectra between normal and abnormal tissues could 
be related to the changes of one or more of the following parameters: 
1) the intrinsic fluorochrome concentration , 
2) the metabolic status of the fluorochromes [11, 12] 
3)  the biochemical and biophysical microenvironment,  
4) the tissue architecture, such as mucosal thickening [13] or loss of the layered tissue 
structure, 
5) the wavelength-dependent light attenuation due to the concentration and distribution 
of (non-fluorescent) chromophores, particularly haemoglobin [13, 14] 
The latter two mechanisms are supposed to be most likely at the origin of the contrasts. The 
different mechanisms are presented below. 
(1) Changes in the intrinsic fluorochrome concentration 
The concentration and spatial distribution of fluorochromes play an important role in layered 
tissues like the bronchial mucosa. It has been shown that the subepithelial layers of the 
bronchial wall have a 10 times higher fluorescence yield than the superficial epithelium when 
excited with blue-violet light [13, 14]. It is supposed that the major contribution to the AF in 
the bronchi comes from elastin [15, 16]. However, the elastin concentration or it spatial 
distribution does not seem to be affected by carcinogenesis [14]. Collagen is another highly 
fluorescing fluorochrome in the bronchial tissues. It is supposed that the reduction in AF 
attributed to collagen at 390 nm in spectra of malignant tissues may be due to a tumour 
specific collagenase and the loss of collagen content [11]. However, it should be noted that 
Fisseler-Eckhoff et al.reported a marked increase in type-I and type-II collagen fibres in the 
lamina propria of bronchial dysplasia and CIS relative to healthy mucosa [17]. This is 
surprising, since fluorescence spectrofluorometry studies on bronchial tissue samples revealed 
no difference in the AF emission from lesions relative to healthy bronchial tissue [14] 
(2) Changes in the metabolic status of the fluorochromes 
NADH has been reported to be another dominant fluorochrome in bronchial tissue. Its 
fluorescence properties depend on the metabolic status of the molecule [11, 18]. 
(3) Changes in the biochemical and biophysical microenvironment 
Changes in the biochemical and biophysical microenvironment of the tissue, such as 
oxygenation or pH, may influence the fluorescence quantum yield, line widths and spectral 
peak position. Not much is known about the changes of NADH fluorescence during 
carcinogenesis in the bronchial mucosa and submucosa. However, the AF characteristics of 
NADH, among others, have been investigated in vitro. Pitts et al. [19] demonstrated a 
decrease in the fluorescence intensity of both NADH and flavins in carcinogen-transformed 
human bronchial epithelial cells compared to immortalised “normal” ones. This group 
reported that tryptophan was the dominant fluorochrome in these cells. No change in 
tryptophan fluorescence intensity was observed in the immortalised cells relative to the 
carcinogen-transformed cells. It should be noted that changes in the NADH fluorescence 
emission intensity have also been observed between normal and dysplasitc cervical tissue [20, 
21]. 
(4) Changes in the tissue architecture 
Thickening of the epithelium is discussed as one of the principal mechanisms for the contrast 
between normal and abnormal bronchial tissue [13]. Indeed, a thickened epithelium is more 
likely to absorb the blue excitation light and to re-absorb the AF originating from the 
subepithelial layers, affecting the measured fluorescence signal. 
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 (5) Changes in the wavelength-dependent light attenuation 
Changes in concentration and distribution of absorbing, non-fluorescing chromophores, 
particularly haemoglobin, in the tissue will further alter the tissue optical properties and the 
detected fluorescence signal. Scattering and absorption are wavelength dependent, and will 
affect both intensity and spectral composition of the AF signal. Recent research on 
angiogenesis and neovascularisation emphasise the role of haemoglobin in the AF contrast 
between normal and abnormal bronchial tissue. Haemoglobin is a non-fluorescing 
chromoprotein found in the red blood cells. It is responsible for the transport of oxygen and 
participates in the pH regulation process. When haemoglobin is bound to oxygen it is referred 
to as oxy-haemoglobin (HbO2), while its non-oxidised counterpart is referred to as deoxy-
haemoglobin (Hb). The absorption spectra of Hb and HbO2 are shown in Figure 4.3. Both 
spectra show a principal absorption maximum around 420 nm (415 nm for HbO2 and 435 nm 
for Hb) and a second maximum around 550 nm. Oxy-haemoglobin’s second maximum 
consists of two separated peaks at 540 nm and 575 nm. Thus, haemoglobin strongly absorbs 
the blue-violet AFB excitation wavelengths as well as it absorbs in the green part of the tissue 
AF spectrum.  
 
Figure 4.3 Absorption spectra of oxy- (Hb) and deoxy-haemoglobin (HbO2) (adapted from [22]). 
Carcinogenesis in the bronchial wall is associated with an increased growth of new blood 
vessels, called angiogenesis as reported by Fisseler-Eckhoff et al. [17, 23] and Fontanini et al. 
[24]. These groups investigated the micro-vessel density (MVD) in the tunica propria of 
normal, metaplastic, dysplastic and early cancerous human bronchial tissue. The 
morphometric findings reported by the two groups are summarised in Table 4.1. Both groups 
reported an increase in the MVD with increasing degrees of tissue degeneration. High grade 
dysplasia and CIS were found to have a 3 to 4 times higher MVD than normal tissue. In 
samples with advanced dysplasia, increased angiogenesis was found in the vicinity of the 
basement membrane. In a more recent work, Keith and co-workers [25] observed the presence 
of capillary blood vessels closely juxtaposed to and projecting into dysplastic squamous 
epithelium of bronchial biopsy specimens. The MVD in this so-called angiogenic squamous 
dysplasia (ASD) was increased in comparison with normal mucosa, but comparable to the 
MVD in other forms of dysplasia. Figure 4.4 illustrates the angiogenic squamous dysplasia 
and angiogensis in bronchial neoplasia. Shibuya et al. [26, 27]also reported an increase in 
MVD and the presence of ASD in bronchial pre-neoplasia and early cancerous lesions in a 
clinical in vivo study using a high magnification bronchoscope. All aforementioned changes 
in the vascularisation of dysplastic and early carcinomatous tissues are associated with an 
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increased blood (thus, haemoglobin) concentration in this type of tissue relative to normal 
tissue. Therefore, blood absorption is likely to play an important role in the AF contrast.  
Author Fisseler-Eckhoff et al. [17, 23] Fontanini et al. [28] 
Measured depth in tissue 
0.4 mm below the basement membrane in the 
lamina propria 
in the lamina propria 
(depth not specified) 
Measured Value Microvessel Density 
Vessel Cross section 
[10-4 mm2] 
Microvessel Density 
Healthy Bronchial Wall 33 mm-2 9.04 12 mm-2 
Chronic Inflammation 55 mm-2 14.4 - 
Acute Inflammation 43 mm-2 11.3 - 
Hyperplasia 40 mm-2 5.38 11 ± 5 mm-2 
Squamous cell Metaplasia 55 mm-2 15.3 11 ± 5 mm-2 
Mild Dysplasia 83 mm-2 2.95 13.5 mm-2 
Moderate Dysplasia - - 28 ± 20 mm-2 
Severe Dysplasia/ CIS 101 mm-2 9.08 56 ± 14 mm-2 
Invasive SCC 105 mm-2  7.61 77 ± 10 mm-2 
Table 4.1 Morphometric data for vascularisation of healthy and neoplastic bronchial mucosa, derived from 
Fisseler-Eckhoff [17, 23] and Fontanini [28]. Though the absolute values for the vessel density in the 
subepithelial layers of the bronchial wall are different, both reports show an increase in the vessel density with 
increasing grade of pre-neoplasia and neoplasia  
 
Figure 4.4 Photomicrographs of ASD (adapted form [25]). Image a) shows capillary tufts (arrows) projecting 
into the dysplastic squamous epithelium of the bronchial wall. The epithelium is thickened. Thickening of the 
basement membrane, as shown in image b) was frequently observed in ASD lesions. 
In Chapter 5 of this thesis, we present a number of studies aimed at investigating the potential 
mechanisms underlying the AF difference between normal and (pre-)neoplastic bronchial 
tissue and their origins.  
4.2.3 Optical properties of normal bronchial tissue 
The main optical parameters of normal bronchial epithelium and its subepithelial layers have 
been investigated by Qu et al. [14] and are summarised in Table 4.2 for blue-violet 
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wavelengths. The absorption and scattering coefficients, μa and μs, respectively, as well as the 
anisotropy factor g and the total reflectance R were derived from [14]. The effective 
attenuation coefficient μeff was computed according to (Eq 2.2) in Chapter 2.2. 
 Data measured by Qu et al. [14] Deduced data 
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[nm] [cm-1] [cm-1]   [cm-1] [cm-1] [cm-1] [μm] 
400 3.47 355.0 0.94 0.15 22.37 25.84 16.40 609.78 
410 3.30 350.0 0.94 0.13 21.70 25.00 15.73 635.64 
420 3.20 350.0 0.94 0.12 21.35 24.55 15.35 651.39 
430 3.03 339.0 0.94 0.13 20.68 23.71 14.68 681.18 
440 2.85 333.0 0.94 0.13 19.98 22.83 13.97 715.75 
450 2.67 328.0 0.94 0.12 19.68 22.35 13.38 747.39 
460 2.58 322.0 0.94 0.11 19.32 21.90 13.02 768.08 
E
pi
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470 2.23 317.0 0.94 0.11 19.02 21.25 11.92 838.70 
400 41.00 262.6 0.91 0.06 23.63 64.63 89.16 112.15 
410 30.50 259.9 0.91 0.07 22.87 53.37 69.88 143.10 
420 24.50 256.3 0.91 0.09 22.55 47.05 58.81 170.04 
430 12.50 253.7 0.91 0.13 21.82 34.32 35.87 278.75 
440 10.10 249.2 0.91 0.16 21.43 31.53 30.91 323.53 
450 7.60 249.0 0.92 0.19 20.67 28.27 25.39 393.91 
460 6.30 247.4 0.92 0.20 20.53 26.83 22.52 444.04 Su
be
pi
th
el
ia
l L
ay
er
s 
470 5.50 244.8 0.92 0.20 19.83 25.33 20.44 489.16 
Table 4.2 Optical properties of the bronchial epithelium and the subepithelial layers. The data for μa, μs, g and 
R were taken from [14]. The values for μ’s, μt, μeff and d are deduced from these data. 
 
Figure 4.5 Penetration depth of blue-violet light into the epithelium and the subepithelial layers of the 
bronchial wall as a function of the wavelength. These data were deduced from the optical properties measured 
by Qu et al. [14] as listed in Table 4.2. 
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The light penetration depth into tissue is given by d(λ)=1/μeff. Its values for wavelengths 
ranging between 400 nm and 470 nm are listed in Table 4.2. In addition, the light penetration 
depth into the epithelium and the subepithelial layers as a function of the wavelength is 
plotted in Figure 4.5. It can be see that the penetration depth in the epithelium exceeds the 
thickness of healthy epithelium (about 40 μm - 60 μm) and it is rather independent of the 
wavelength between 400 nm and 470 nm. However, the absorption in the submucosa is 
wavelength-dependent in this spectral range. It should be noted that the penetration depth is 
by a factor of about 4 (for shorter wavelengths) to 2 (for longer wavelengths) shorter in the 
submucosa than in the epithelium. 
4.3 Autofluorescence Bronchoscopy Instrumentation 
Technically speaking, autofluorescence imaging is based on the detection and visualisation of 
the spectral and/or intensity differences between the normal and (pre-)neoplastic tissue AF 
signals. In agreement with the observations from the spectrofluorometric studies reported by 
Zellweger et al. [7, 9], most AFB systems excite the AF with blue-violet light and detect the 
AF image in two spectral domains. 
Several endoscopic AF imaging systems have been developed [29] and are commercially 
available. Instruments from the following companies are currently on the market: the LIFE 
system by Xillix Technologies (Vancouver, BC, Canada), the SAFE system by Pentax 
(Tokyo, Japan), the D-Light system by Karl Storz GmbH (Tuttlingen, Germany) and the 
DAFE system by Richard Wolf GmbH (Knittlingen, Germany).  
The Xillix LIFE system was the first AFB imaging system to be commercialised. Originally 
based on a Helium-Cadmium laser (442 nm) for the blue-violet excitation and a separate 
white light source for WLB, the current system employs a compact filtered Xenon lamp for 
both AF excitation and WLB. The tissue AF is separated into two spectral components that 
are intensified and imaged on a CCD. According to Lam et al. [30] the two spectral regions of 
one of the first prototypes were situated at 500 nm - 575 nm (green) and superior to 625 nm 
(red). In the current system, the AF images show lesions as reddish brown zones on a greenish 
background. The LIFE system has been widely used in clinical studies and shows high 
sensitivity [29] in the detection of moderate dysplasia and CIS. 
The first SAFE system (SAFE-1000) also used a filtered Xenon (Xe) lamp for the AF 
excitation in the 420 nm - 480 nm region. In contrast to the Xillix system, the SAFE-1000 
only detect the AF in the green spectral domain (490 nm - 590 nm) by an intensified CCD 
camera. While the healthy tissue background appeared light green, the lesions appeared as 
dark green zones in the images. Few studies with this system have been published [31-34]. 
One drawback of the single-channel detection is the relatively high number of false positives, 
due to anatomically related shadows and mucus as reported by [31] and [33]. However, the 
most recent SAFE-3000 system, presented at the World Congress for Bronchoscopy in 
Barcelona in 2004, is based on the CCD tipped videobronchoscope technique. Unfortunately, 
not much is publicly known about the spectral excitation and detection characteristics of this 
system. The AF excitation is performed with a 408 nm laser diode with an output power of 
20-40 mW at the distal end of the bronchoscope [35]. The diode is integrated in the 
endoscopic WL source, which allows easy switching between AFB and WLB. A special 
feature of the SAFE-3000 system is the so called "twin-mode", in which the AF and the WL 
image are shown simultaneously on the same screen. 
Similar to the Xillix LIFE system, the Storz D-Light system uses a filtered Xe lamp for both 
WL illumination and blue-violet AF excitation (380 nm - 460 nm). The WL and the AF 
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images are acquired with a 3-CCD endoscopic video camera. The particularity of this system 
is the superposition of blue-violet excitation light on top of the AF image. Indeed, the long 
pass filter transmits about 1% of the backscattered excitation light through [36]. The latter 
creates a "constant" background image for the changing autofluorescence, making the 
abnormal tissue appear purple against a greenish-blue background. Nothing is publicly known 
about the spectral domains of detection or electronic signal treatment. In addition to the AF 
and WL mode, the system can also be used in the “ALA mode”, which is optimised for the 
detection of 5-aminolaevulinic acid (ALA) (or its derivatives) induced protoporphyrin IX 
(PpIX). However, the lower light sensitivity of the endoscopic camera compared to an 
intensified CCD requires frame integration to achieve satisfactory image brightness. The 
sensitivity and specificity of the Storz D-Light system had been subject to an extensive multi-
centre study published recently by Häussinger et al. [37]. The sensitivity of the D-Light 
system in combination with WLB for bronchial dysplasia and CIS was 82.3%, compared to 
57.9% for WLB alone. The corresponding values for the specificity were 62.1% and 58.4%, 
respectively. 
One of the first AFB systems spectrally optimised according to the empirical observations 
from spectrofluorometry was developed by our group in Lausanne, and later refined by the 
company Richard Wolf Endoskope GmbH in Knittlingen (Germany). A detailed description 
of the system can be found in the report by Goujon et al. [38]. The system is based on a 
filtered 300 W Xenon lamp that can be switched between conventional WL illumination and 
blue-violet AF excitation (390 nm - 460 nm) by a foot switch. The AF image is acquired with 
a single CCD. A green image (detection range 500 nm - 590 nm) and a red image (detection 
range 500 nm - 700 nm) of the bronchoscopic site are acquired simultaneously on the chip 
which is divided into two parts. The images are superposed and displayed in false colours on 
the monitor. The blue-violet excitation light is cut-off by a long pass filter. Conventional 
white light bronchoscopy can be performed with an additional standard colour camera clipped 
at an angle of 90° to the AF camera unit. A switchable mirror allows for easy changes 
between AF detection and white light bronchoscopy. Clinical studies performed with this 
system at the CHUV University Hospital in Lausanne have shown a high sensitivity of this 
system for bronchial pre-neoplasia and cancers, exceeding that of conventional white light 
bronchoscopy by a factor of 2.  
Since the first clinical studies reported by Goujon et al., numerous clinical and pre-clinical 
studies have been conducted to further improve the spectral design and thus the specificity 
and sensitivity of the AFB system. The studies presented in Chapter 5 of this thesis have led 
to several modifications to the system’s spectral design, namely the addition of backscattered 
red and blue-violet light. The features of the modified Richard Wolf AFB system currently 
commercialised by the Richard Wolf Company will be presented in the same chapter.  
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Chapter 5  
Comprehensive and 
Optimisation Studies 
of the 
Autofluorescence 
Bronchoscopy  
utofluorescence bronchoscopy (AFB) has been used in clinical examinations for 
about one decade. Several clinical studies have proven this technique to be a powerful 
tool for the detection of bronchial (pre-)neoplasia. As mentioned in the Chapter 4.3, 
the clinical study with the spectrally optimised Richard Wolf AFB prototype system has 
shown that the sensitivity of AFB is about twice as high as that obtained using conventional 
white light (WL) bronchoscopy [1]. Though the specificity was not assessed in this study, the 
number of false positive results was high. Similar conclusions have also been reported from 
clinical studies with other AFB systems [2]. Table 5.1 summarises sensitivity and sensibility 
A
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data reported in the literature for various clinical studies conducted with different AFB 
systems. In all studies, the sensitivity of AFB widely exceeds that of WL bronchoscopy, 
whereas the specificity remains limited and frequently far below that of white light 
bronchoscopy. Indeed, the high number of false positive results is a major shortcoming of 
current AFB systems. The majority of the false positive findings are due to tissue reactive 
changes, inflammation and bruised or bleeding mucosa. They generally result in unnecessary 
biopsies, a longer bronchoscopy procedure, and increased medical costs. However, it should 
borne in mind that the specificity, the sensitivity and the NPV of AFB are very difficult to 
determine, since they would require random biopsies in the whole tracheo-bronchial tree on 
negative appearing sites (see Chapter 2.2). Sometimes study reports misleadingly refer to the 
PPV value of a method as its sensitivity. This makes it difficult to compare sensitivity, 
specificity, and NPV values from different studies.  
Only few studies aiming to improve the sensitivity and specificity of AF imaging have been 
published up to now. Additional techniques can be combined with imaging to improve AFB 
performance. Intra-endoscopic optical spectroscopy has been reported recently by Bard et al. 
[3], Kusunoki et al. [4], Zeng et al. [5] and Tercelj et al. [6]. Bard’s and Kusunoki’s groups 
measured the autofluorescence and reflectance spectra during AFB. For this purpose, Bard et 
al. and Kusunoki et al. used a fibre-bundle inserted into the biopsy channel of the 
bronchofibroscope and put it in smooth contact with the mucosa. However, this procedure can 
bruise the mucosa and provoke bleeding. In contrast to this, Zeng et al. and Tercelj et al. used 
a non-contact measurement system based on a modified Xillix’s LIFE system with an 
integrated spectrometer unit. The AF and reflectance spectra were acquired from selected 
spots on the endoscopic sites. However, these techniques require additional equipment and 
prolong the bronchoscopic procedure [6]. They are still far from routine application and 
integration in commercial systems. 
A different approach to improve the specificity of AFB was presented by Goujon et al. [1] 
and Kusunoki et al. [4]. These groups employed off-line spectral image analysis and threshold 
algorithms to classify true and false positive results but, with limited success. Mathematical 
algorithms (multicomponent analysis, ratioing, etc.) to improve specificity have also been 
used in other fields of diagnostic AF spectroscopy and imaging, such as cervical intra-
epithelial neoplasia (CIN) [7, 8] or carcinoma of the ENT sphere [9-11]. 
In this thesis we aimed to improve the AFB sensitivity and specificity by optimising the 
spectral excitation and detection conditions of the imaging system. This approach was based 
on three statements: (1) The spectral AF contrast between healthy tissue and lesions results 
from a high intensity decrease in the green part of the AF spectrum and a much lower 
decrease in the red part of the AF spectrum. Consequently, the addition of red backscattered 
light as a background instead of the red AF may improve the spectral contrast and thus the 
sensitivity. (2) The intensity and spectral contrast are highest with a 405 nm excitation 
wavelength. Thus, the use of a narrow band excitation around 405 nm instead of a broadband 
excitation may improve the spectral and intensity contrast and therefore the sensitivity. (3) 
Bronchial lesions show distinct patterns of subepithelial angiogenesis (thus blood 
concentration and distribution) that are specific for each histopathologic class. Since the blue-
violet AFB excitation light is strongly absorbed by blood, the detection of blue backscattered 
light may take advantage of the histopathology specific absorption characteristics, and 
improve the specificity. 
However, optimisation of AFB systems requires a fundamental understanding and knowledge 
of the mechanisms responsible for the spectral and intensity AF contrasts between healthy and 
(pre-) neoplastic bronchial tissue. Except from the aforementioned studies of Qu [12, 13], 
Chapter 5 – Conprehensive and Optimisation Studies of the Autofluorescence Bronchoscopy 
65 
Zellweger [14, 15] and Hung [16], minimal research has been performed on this subject [17, 
18]. 
The following chapters present the results of the clinical and laboratory studies conducted 
within the framework of this thesis, as we investigate the mechanisms of the AF contrast to 
improve the sensitivity and specificity of AFB imaging. The reports of most of these studies 
have been published or submitted for publication. They are presented here as self-contained 
chapters and are briefly summarised in the following section. Additional information and 
results are presented in the appendices. 
Chapter 5.1 – Optimised AF bronchoscopy using additional backscattered red light 
The first clinical study presented here investigated the use of backscattered red light to 
improve the colour contrast between lesions and healthy tissues, and thus the quality of 
detection.  
The lesion-to-healthy colour contrast is defined as the ratio between the intensity levels in the 
green and the red channels on a lesion divided by the corresponding ratio on the healthy 
tissue. In other words, the colour contrast “C” is given by C= (R/G)lesion/(R/G)healthy. During 
AF bronchoscopy, a sharp decrease is observed in the green channel intensity on lesions 
relative to healthy tissues, whereas this decrease is less marked in the red channel. From their 
spectrofluorometric measurements, Zellweger et al. [Zellweger, ApplOptics] concluded that 
additional red light could improve the colour contrast in AFB. Indeed, red light added to the 
blue-violet excitation light creates a constant background in the image which allows the 
clinician to take full advantage of the decrease in the green channel.  
The main goal of the present study was to confirm these observations with a fluorescence 
imaging system.This study was conducted at the Centre for Pneumology and Thoracic 
Surgery, Lungenklinik, Hemer, Germany. An AFB system prototype was specially designed 
for this study by Richard Wolf Endoskope GmbH, Knittlingen, Germany. This chapter is an 
article submitted for publication in the Journal of Biomedical Optics. 
Chapter 5.2 – The Richard Wolf’s DAFE system 
The results of the study presented in Chapter 5.1 led the Richard Wolf Company to design a 
second generation AFB system named DAFE (Diagnostic AutoFluorescence Endoscopy). 
This system makes use of red backscattered light. The characteristics of this system are 
described in this chapter. 
Chapter 5.3 – Influence of the excitation wavelength bandwidth on the healthy-to-lesion 
contrast in AFB 
As in the study presented in Chapter 5.1, the clinical study presented here aimed to optimise 
the excitation light of AFB. According to the results from Zellweger et al. [15], the highest 
spectral contrast between healthy bronchial tissues and lesions is obtained using violet light at 
405nm for excitation. In a clinical imaging study, we compared the colour contrast obtained 
with a line-shaped excitation centred at 405nm and the broadband excitation of the DAFE 
system (430 nm, FWHM 40 nm). This approach provides information on the origin of the AF 
contrast. Preliminary results of this study were published in the SPIE Proceeding 5862 [19]. It 
has been rewritten and is presented as a single chapter. 
Chapter 5.4 - Blue-violet excited autofluorescence spectroscopy and imaging of normal and 
cancerous human bronchial tissue after formalin fixation 
This chapter presents a spectrofluorometric ex vivo study focussed on the understanding of the 
origins of the bronchial AF contrast. Since it would be ideal to have the possibility to perform 
spectrofluorometric measurements on human bronchial tissue samples fixed in formalin to 
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reduce the ethical and technical limitations generally associated with clinical measurements 
we assessed the AF changes observed between the in vivo and ex vivo conditions 
Spectrofluorometric ex vivo studies of bronchial tissue AF have already been reported by Qu 
et al. [13]. This study measured fresh or frozen tissue samples. Results reported in this study 
showed some contradictions to those obtained in other clinical studies [14, 15]. Therefore, the 
present study aimed to improve our understanding of the AF contrast mechanisms, and thus 
explain the differences observed between in vivo and ex vivo measurements. 
The fibre-based spectrofluorometer used in this study is described in detail in the second part 
of this thesis. This chapter corresponds to an article submitted for publication by 
Photochemistry and Photobiology. 
Chapter 5.5 - Improvement of the specificity of cancer detection by autoflorescence imaging 
in the tracheo-bronchial tree using backscattered violet light 
According to the results of the fundamental studies presented in chapter 5.3 and 5.4, tissue 
blood is very likely to play a key role in the AF contrast. The clinical imaging study presented 
in this chapter investigated the use of backscattered blue light to improve the specificity of 
AFB. As already mentioned in Chapter 4, tissue vascularisation is different for healthy tissue, 
inflammation, reactive changes, and (pre-)neoplasia. Hence, the absorption of blue-violet light 
will be different on inflammation and reactive changes compared to (pre-)neoplastic lesions. 
This study had two aims: 1) to investigate the potential of different blue-violet wavelengths to 
improve the differentiation between true positive (pre-) neoplastic lesions and false positive 
findings (inflammation and reactive changes), and 2) to implement the results in the DAFE 
system. These studies were performed using a linear variable band pass and high pass filter, 
respectively. The characteristics of the two filters and a custom-made filter holder are 
presented in the Appendix. The results from this study provide further information on the role 
of tissue blood in the AF contrast mechanism. The report on both studies was submitted to the 
Journal of Biomedical Optics. 
Chapter 5.6 - Design of an endoscopic optical reference to be used for autofluorescence 
bronchoscopy with the DAFE system  
and 
Chapter 5.7 - Autofluorescence bronchoscopy: Quantification of inter-patient tissue remitted 
light intensity variations 
The final two chapters present two studies aiming to quantify the intra- and inter-patient 
variations in the AF intensities and spectroscopy. Zellweger et al. [14] demonstrated in the 
above mentioned spectrofluorometric study that the intra-patient variations were significantly 
smaller than the inter-patient variations. 
These variations can negatively affect the image quality of AFB and the learning curve of the 
clinician. Moreover, the magnitude of theses variations will scale the dynamic range of future 
AFB systems accordingly. The quantification of the AF intensities with the DAFE imaging 
system is not trivial. As the DAFE imaging system deals with real time automatic control 
algorithms (see chapter 5.2.), quantification of the tissue AF requires the use of an optical 
standard (reference) allowing normalisation of the intensity levels. Such a reference should be 
used in the patient's bronchi during bronchoscopy. To allow normalisation, the reference must 
appear close to the bronchial tissue in the AFB image. 
In Chapter 5.6, the design and characterisation of a reference for AFB is presented. Chapter 
5.7 presents an initial clinical study aiming to quantify the inter-patient variations during AFB 
is reported. Both studies were submitted for publication and are presented in this form.  
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Table 5.1 Synoptic table showing the sensitivity and specificity values of AFB from clinical studies 
with different imaging systems 
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Abstract 
Autofluorescence bronchoscopy has been shown to be a highly sensitive tool for the detection 
of early endobronchial cancers. When excited with blue-violet light, early neoplasia in the 
bronchi tend to show a decrease of autofluorescence in the green region of the spectrum and a 
relatively smaller decrease in the red region of the spectrum. Superposing the green 
foreground image and the red background image creates the resultant autofluorescence image. 
The aim of this study was to investigate if the addition of backscattered red light to the tissue 
autofluorescence signal could improve the contrast between healthy and diseased tissue. We 
have performed a clinical study involving forty-one lung cancers using modified 
autofluorescence bronchoscopy systems. The lesions were examined sequentially with 
conventional violet autofluorescence excitation (430 nm ± 30 nm) and violet autofluorescence 
excitation plus backscattered red light (430 nm ± 40 nm plus 665 nm ± 15 nm). The contrast 
between neoplastic and healthy tissue was quantified with off-line image analysis. We 
observed a 2.7 times higher contrast when backscattered red light was added to the violet 
excitation. In addition, the image quality was improved in terms of the signal to noise ratio 
with this spectral design. 
Keywords 
Autofluorescence bronchoscopy; backscattered red light; sensitivity 
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Introduction 
Carcinoma of the bronchi is the most 
common cancer and cause of cancer deaths 
in the world, with the highest incidence 
rates occurring in North America and 
Europe [1-3]. Bronchial cancer has a poor 
prognosis, mainly due to its progressive 
nature and because most cancers are 
detected at an advanced stage [4]. 
Prognosis is much more favourable if the 
cancer is detected and treated early, if 
possible at the in situ stage [4-6]. 
Bronchoscopy is the only established 
method that allows detection, localization 
and definitive histological diagnosis of 
endobronchial lesions. Although the 
resolution of bronchoscopy is superior to 
that of chest radiography (CRX) and 
computed tomography (CT), conventional 
white light bronchoscopy (WLB) has 
important diagnostic limitations for 
detecting early cancerous and pre-
cancerous lesions. Sato et al. [7] have 
shown that for radiographically occult 
bronchial cancers in patients with positive 
sputum cytology, only about 30% of the 
lesions can be localized, with difficulty, by 
conventional bronchoscopy. It should be 
noted that the percentage of lesions missed 
during WLB is probably much larger since 
numerous radiographically occult lesions 
were not detected during this study. This 
important clinical problem is central to the 
extensive research efforts performed by 
numerous groups to develop patient 
screening and cancer detection methods [8, 
9]. 
One promising approach to detect 
bronchial pre-cancerous and early 
cancerous lesions during bronchoscopy is 
based on the imaging of the tissue 
autofluorescence [8, 10]. While 
conventional white light bronchoscopy 
(WLB) is based on the detection of 
minimal alterations in tissue surface 
structure, autofluorescence bronchoscopy 
(AFB) exploits the spectral and intensity 
contrast of the tissue autofluorescence 
existing between normal and pre-/early 
cancerous tissues. 
AFB works by capitalizing on the decrease 
in tissue autofluorescence intensity within 
the green spectral region for pre- and early 
cancerous lesions as compared to healthy 
tissue under violet excitation [8, 11, 12]. 
This decrease can be visualized by specific 
endoscopic imaging devices [13]. In most 
cases, due to the three dimensional 
geometry of the bronchi, a second 
background image is obtained in the red 
part of the spectrum, to perform a contrast 
enhancement procedure between the 
contrast bearing green and the non-contrast 
bearing red images. Several endoscopic 
fluorescence imaging systems (Xillix LIFE 
system [14], Pentax SAFE system [15], 
Storz D-Light system [16]) are based on 
this principle. 
Numerous clinical studies have 
demonstrated that AFB used in addition to 
conventional WLB significantly increases 
the number of detected lesions [8, 10, 14, 
17, 18] increasing the sensitivity by a 
factor 2. However, the higher sensitivity 
comes with a limited specificity [8, 19]. 
Moreover, it should be noted that most of 
the AFB systems are likely to be 
suboptimal since their spectral designs are 
not based on the results of comprehensive 
studies of specific tissue autofluorescence 
properties. One exception is the system 
developed and produced by Richard Wolf 
GmbH. This system emerged from a 
systematic and comprehensive clinical 
study of the autofluorescence spectroscopy 
of normal tissues, precancerous and early 
cancerous lesions of the mucous membrane 
lining the tracheo-bronchial tree [11, 20]. 
The group in Lausanne demonstrated that 
the highest contrasts between healthy and 
(pre-)neoplastic tissues are observed with 
excitation wavelengths around 405 nm. In 
addition, they observed that, at this 
excitation wavelength, a strong decrease of 
fluorescence intensity exists for these 
lesions in the green (below 590 nm) region 
of the spectrum, whereas this decrease is 
much smaller, but still present in the red 
part of the spectrum (beyond 590 nm). 
Typical spectra from healthy and 
dysplastic bronchial mucosa excited at 405 
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nm are shown in Figure 5.1.1. Since a 
small decrease is also observed in the red 
part of the AF spectrum, this group 
suggested a possible method to improve 
the performances of fluorescence 
bronchoscopy; use additional red 
backscattered light as a background instead 
of the red autofluorescence. According to 
Zellweger et al. [11], using an optimised 
amount of red backscattered light should 
increase the contrast between healthy and 
pre-/early neoplastic tissue by a factor 2. 
Moreover the background image created 
by the backscattered red light enhances the 
brightness and consequently the quality of 
the endoscopic images. Finally, the choice 
of backscattered red light appears to be a 
sensible spectral choice as it is minimally 
influenced by changes of tissue properties, 
textures and structures. It should be noted 
that a similar approach using backscattered 
red and near-infrared light was reported by 
Zeng [21] for autofluorescence imaging in 
the gastrointestinal tract. 
 
 
Figure 5.1.1 Autofluorescence spectra from normal 
(circles) bronchial tissue and dysplasia/ CIS 
(triangles) (adapted from[11]) These spectra were 
obtained using an excitation of 405 nm, FWHM= 
10 nm with an optical fiber based 
spectrofluorometer. The healthy tissue spectrum is 
dominated by a peak around 500 nm, i.e. in the 
green part of the spectrum, while the spectrum 
measured on dysplastic tissue shows equal 
intensities in the green and the red part of the 
visible spectrum. The dotted line separates the 
green, i.e. short- wavelength region and the red, i.e. 
long-wavelength region used to generate the 
foreground and background autofluorescence 
images, respectively. 
The impact of these spectral 
improvements, according to our 
knowledge, has not previously been 
assessed quantitatively with imaging 
systems. Therefore we have designed an 
endoscopic fluorescence imaging system 
that includes the features of violet 
excitation around 405 nm and offers the 
option to add red light to the excitation. 
This system was used for the clinical study 
reported here to confirm the results from 
Zellweger et al. [11] and to assess the 
potential of additional backscattered red 
light for improved contrast between 
healthy and (pre-)neoplastic tissue. 
Materials and Methods 
Instrumentation 
We used a modified endoscopic 
fluorescence imaging (EFI) system 
developed in collaboration with the 
company Richard Wolf Endoskope GmbH, 
Knittlingen, Germany. The system 
consisted of a modified endoscopic light 
source and a filtered 3 CCD RGB camera 
(5137 Combilight PDD and EFI 
5507camera). This experimental system 
offered the unique advantage of three 
different illumination/excitation modes that 
could be selected during the bronchoscopy 
using a simple foot switch. The light 
source contained an IR-filtered 300 W Xe 
lamp and was equipped with a flip-flop 
filter holder allowing for change between 
white light illumination for conventional 
endoscopy and two different violet light 
excitations for autofluorescence 
endoscopy. The two violet fluorescence 
excitation filters used in our study were: 1) 
a violet band pass filter (pure violet: "PV") 
with a transmission ≥ 95% between 395 
and 460 nm, and 2) a double band pass 
filter (violet plus red light:"V+R") with a 
transmission ≥ 90% between 390 to 470 
nm and a second weak (8%) transmission 
between 650 nm to 680 nm. The 
transmission spectra of these filters are 
shown in Figure 5.1.2. The slight spectral 
differences in the blue-violet bands were 
conditional of manufacturing, but do not 
affect the excitation properties. 
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Figure 5.1.2 Transmission spectra of the excitation filters. The transmission spectrum of the pure violet (VP) 
band pass filter is shown on the left. The graph on the right shows the transmission characteristics of the double 
band pass filter used for violet excitation in combination with the detection of the backscattered red light (V+R). 
Both filters transmit the same light energy 
though the transmission band of the V+R 
filter is slightly broader than that of the PV 
filter. This is due to the lower transmission 
of the V+R filter relative to the PV filter. 
Both filters were used alternately during 
the endoscopic exams. The illumination/ 
excitation light was transmitted from the 
light source to the endoscope via a liquid 
light guide (Type 4070.253, Richard Wolf 
GmbH, Knittlingen, Germany). 
As can be seen in Figure 5.1.3, the camera 
objective contained a 490 nm long pass 
filter that was optimised to reject all violet 
excitation light. A communication cable 
connected the camera controller and the 
light source. When the light source was 
used in the conventional white light mode 
the camera employed the standard video 
red, green and blue colour (RGB) mode. If 
the light source was used in one of the 
fluorescence excitation modes, the signal 
of the camera’s blue channel was 
suppressed. Consequently, images taken in 
the fluorescence mode contained only the 
red and green image colour information 
necessary to visualise the spectral contrast 
between healthy and pre-cancerous tissue, 
as described in the introduction. The 
gamma factor of the camera-video unit was 
0.71. 
The camera head was clipped to a flexible 
bronchofibrescope. Unlike conventional 
bronchofibrescopes, this device was 
equipped with illumination fibre bundles 
offering a high UV transmittance. The 
available total illumination power at the 
distal end of the bronchoscope was 
typically 120 mW with both excitation 
filters. This power was high enough to 
enable a real time detection of the 
autofluorescence/reflectance images in the 
entire tracheo-bronchial tree at the video 
frequency. In addition, this camera enabled 
the user to perform a “dual” automatic 
white/ colour balance as explained below. 
A block diagram of the system is shown in 
Figure 5.1.3. 
Study Design 
A total number of 41 patients were 
involved in this study which was 
performed at the Center for Pneumology 
and Thoracic Surgery in Hemer, Germany. 
The criteria for enrolment were: known or 
suspected carcinoma in the bronchi 
(standard diagnostic workup or pre-
therapeutic bronchoscopy), and/or 
resection of lung cancer (follow up 
bronchoscopy), and/or atypia in the sputum 
and/or abnormal X-ray findings as well as 
complaints of dyspnea or cough without 
suspect findings neither in sputum nor on 
X-ray. 
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Figure 5.1.3 Block diagram of the AF bronchoscopy system 
 
Patients who had received photosensitising 
agents like Photofrin®, those known or 
suspected of suffering from pneumonia, 
and those considered generally unsuitable 
for bronchoscopy such as patients with 
uncontrolled hypertension or bleeding 
disorders, were excluded from the study. 
All the AF bronchoscopies were performed 
according to the procedure approved by the 
local ethical committee of the Hemer 
Centre for Pneumology and Thoracic 
Surgery. All but three bronchoscopies were 
carried out under local anaesthesia. The 
procedure was performed in two stages. 
First, conventional white light 
bronchoscopy was performed with the 
standard equipment used at the Hemer 
Center (Olympus endoscopic white light 
source with Olympus fibre optics (Type 
BF 40 and BF1T40) or Olympus video 
endoscope (BF 160)). Then, the 
bronchoscope was changed in favour of the 
autofluorescence imaging system. 
Automatic white balancing (AWB) of the 
camera was always performed on a white 
cotton compress prior to endoscopy. 
Moreover an automatic colour balancing 
(ACB) was performed for each 
autofluorescence excitation mode on the 
healthy main carina of the patient just after 
insertion of the bronchofibrescope. This 
ACB allowed us to correct for the 
interpatient fluctuations in the tissue 
autofluorescence intensity, that were 
reported by Zellweger et al. [20]. 
Bronchoscopy was repeated first with the 
PV filter and then with the V+R filter. 
Tissue areas were classified as 
“suspicious” in the fluorescence mode 
when they exhibited a brownish or brown-
reddish colour with PV light excitation or a 
marked reddish colour under V+R 
excitation, respectively. 
All suspicious sites examined with the 
conventional WLB were then examined in 
the fluorescence mode and vice-versa. 
Since the principal aim of our study was to 
access the effect of additional 
backscattered red light on the 
tumour/tissue contrast, and not to 
investigate the sensitivity and specificity of 
the system, no random biopsies were 
taken. However, the endobronchial 
position and visual aspect of all abnormal 
findings were noted. Biopsy specimens or 
brushes were obtained from all sites 
suspicious either under WL or AF 
bronchoscopy. Whenever possible, 
biopsies were taken under fluorescence 
examination to guarantee a precise uptake 
of the specimens even on small areas. 
Biopsies were classified in a 3-class-
system with 9 histologic categories: 1) 
normal tissue, 2) reactive changes and 3) 
(pre-)neoplastic changes. Class 2 (reactive 
changes) included inflammation (code 2) 
as well as metaplasia (code 3). The class of 
(pre-)neoplastic changes (class 3) was 
subdivided into mild, moderate and severe 
dysplasia/carcinoma in situ (CIS), 
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squamous cell carcinoma, small cell 
carcinoma and adenocarcinoma, 
corresponding to the histologic categories 
4-9, respectively. Lesions classified as 
suspicious under fluorescence and 
attributed to the classes 1 and 2, 
(categories 1 to 3), were referred to as 
fluorescence false positive results (FP), 
whereas those in class 3 (categories 4 to 9), 
were referred to as fluorescence true 
positive results (TP). Our histopathologic 
classification system is shown in Table 
5.1.1. 
 Image Analysis 
All EFI examinations were recorded in real 
time on a Sony digital video-cassette 
recorder (Sony DSR-11, Sony, Japan). For 
analysis purpose the video material was 
sifted. One image per biopsied area and 
examination mode (white light, pure violet 
excitation and violet excitation plus 
additional red light) was digitised using the 
IEEE1394 interface of the videocassette 
recorder and a PCMCIA card 
(MovieCardBus, Aist MediaLab, 
Germany) in a portable computer. 
Digitisation was in the 24-bit RGB colour 
scheme. 
Image analysis was performed to quantify 
the red and green intensity ratios between 
lesions and the surrounding healthy tissue. 
The average intensity of the red and green 
pixels of the biopsied site (lesion), of a 
healthy tissue site next to the lesion 
(control), and of the surrounding 
presumably healthy tissue (reference) were 
computed with their standard deviations. 
All computed values were corrected for the 
gamma function of the camera system.  
The red and green intensity of a biopsied 
area was then divided respectively by the 
red and green intensities obtained from the 
surrounding healthy tissue in order to 
correct the recorded intensities for inter-
patient fluctuations and the colour balance 
of the camera. The corresponding ratios for 
the healthy tissue areas were computed in 
the same way. We computed the mean 
values and standard deviations for each 
histopathologic class.  
The true (TP) and false positive (FP) 
groups for each excitation method were 
compared by Student’s t-test, allowing a 
confidence interval (CI) of 95% for a 
significant difference between the two 
groups (TP and FP).
Category Histology Class 
G
ro
up
 
1 Healthy Normal 
2 Inflammation 
3 Metaplasia 
Reactive 
changes 
Fa
ls
e 
po
si
tiv
es
 
4 
Mild Dysplasia 
5 Moderate Dysplasia 
6 
Severe Dysplasia/ CIS 
7 
Epidermoid Carcinoma 
8 
Small Cell Carcinoma 
9 Adeno Carcinoma 
(Pre-)neoplastic 
changes 
T
ru
e 
po
si
tiv
es
 
Table 5.1.1 Histological code and related histopathologies 
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Results 
Patients and histopathology breakdown 
Among the 41 patients included in the 
study a total of 27 patients had at least one 
suspicious site (in the following called a  
positive case) whereas 14 patients showed 
no suspect bronchoscopic findings during  
conventional WLB nor AFB. In 4 cases of 
pre-therapeutic bronchoscopy the 
histopathology of the observed lesions was 
known from former examinations (the 
delay between the first WLB and the 
subsequent AFB was less than 8 weeks). In 
all other patients a biopsy was taken from 
each suspect site, resulting in a total 
number of 36 specimens.  
The histopathologic diagnoses for these 40 
positive cases were as follows: 15 normal 
tissue, 8 inflammation and metaplasia and 
17 (pre-)neoplastic changes (11 squamous 
cell carcinoma, 2 mild dysplasia, 1 
moderate dysplasia, 1 severe dysplasia, 1 
adenocarcinoma and 1 small cell 
carcinoma). 
In 23 of these positive cases, a direct 
comparison of PV excitation and V+R 
excitation AFB was performed on the same 
bronchial site. In 3 positive cases, only 
images recorded under pure violet light 
excitation were available, whereas in the 
remaining 14 positive cases only violet 
excitation plus backscattered red light 
could be applied. Since more positive cases 
were examined with the V+R filter than 
with the PV filter, we will only refer to 
positive cases examined with the V+R 
filter to discuss the visibility of AFB and 
conventional WL bronchoscopy. 
Assessment of the positive predictive value 
(PPV) of AFB and WLB 
All positive cases were, by definition, 
either visible with AFB and/or with 
conventional WLB. Whenever AFB was 
performed with the PV and the V+R filter 
in the same patient, tissue sites looking 
suspicious with the PV filter excitation 
were also suspicious with the V+R filter 
and vice versa. However the fluorescence 
contrast between the suspect site and the 
surrounding healthy tissue was always 
better with the V+R filter. Table 5.1.2 
shows the visibility of the 37 positive cases 
examined with the V+R filter according to 
their histopathologic status. These cases 
include 16 histopathologic  
positive lesions (i.e. categories 4-9) and 21 
histopathologic negative lesions (i.e. 
categories 1-3). Suspect sites as 
determined under WL examination were 
classified as “white light positive” (W+), 
excitation, were classified as “fluorescence 
Category  F+ and W+ F+ and W- F- and W+ 
  AFB: FP; WL: FP AFB: FP; WL: TN AFB: TN; WL: FP 
1 Healthy 10 3 1 
2 Inflammation 2 2 1 
3 Metaplasia 2 0 0 
  AFB: TP; WL: TP AFB: TP; WL: FN AFB: FN; WL: TP 
4 Mild Dysplasia 1 1 0 
5 Mild Dysplasia 1 0 0 
6 Severe Dysplasia/ CIS 2 1 0 
7 Squ Cell Ca 6 2 0 
8 Sm Cell Ca 1 0 0 
9 Adeno Ca 1 0 0 
Table 5.1.2: Visibility of positive cases examined with WL and by AFB. Visibility of the biopsied sites
considered suspicious under conventional white light illumination and/or with the V+R autofluorescence
excitation according to their histopathology. Visibility of the lesions using WL or AFB are labeled W+ and
F+, respectively. Cases invisible under WL and AFB are labeled W- and F-, respectively. 
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Figure 5.1.4 Mild dysplasia. The lesion on the spur is hardly suspicious with WLB, but appears as a sprawled 
brownish area with AFB using pure violet excitation light. When violet excitation plus additional backscattered 
red light is used the lesion appears as a marked reddish area on the greenish surrounding tissue. Moreover “3-
dimensional” perception is enhanced in the latter image. 
and those determined with the AF 
positive” (F+). Unsuspicious sites in WLB 
and AFB were labelled “white light 
negative” (W-), and “fluorescence 
negative” (F-), respectively. All 16 (pre-
)neoplastic lesions examined with AFB 
exhibited positive fluorescence. Among 
them, 12 (75%) were also visible under 
white light examination, and consequently, 
4 (25%) of the (pre-)neoplastic lesions 
were occult with conventional WLB. In 
addition, no lesion was visible during 
WLB and negative under fluorescence. 
Twenty-one (57%) of all cases showed no 
abnormalities in histopathology apart from 
inflammation and metaplasia, and were 
therefore considered as bronchoscopical 
false positives (FP). Nineteen (90%) of 
these FP cases showed positive 
fluorescence and 16 (76%) of the FP cases 
were considered suspicious during WL 
examination. Two of these latter 16 FP 
cases were incorrectly classified as 
suspicious by white light endoscopy only, 
but were not suspicious under 
fluorescence. Five of the bronchoscopical 
false positive cases were suspect under 
fluorescence only but not under white 
light. Theses results are summarized in 
Table 5.1.3. These results suggest that the 
sensitivity of AFB is better than the one of 
WLB. 
Illustrations of WLB and AFB imaging  
The following images show true positive 
lesions examined with WL, PV 
fluorescence excitation and V+R 
fluorescence excitation. 
Figure 5.1.4 shows a mild dysplasia 
presented by a 62-year-old male patient 
observed with conventional WLB and AFB 
with PV and V+R fluorescence excitation, 
respectively. This patient was known to 
suffer from a squamous cell carcinoma in 
the upper right bronchus and underwent 
pre-therapeutic bronchoscopy for treatment 
by photodynamic therapy. The images 
show the division between the middle and 
lower lobe. The spur was slightly 
suspicious with WLB due to thickening 
and reddening. Autofluorescence 
bronchoscopy exhibited a sprawled 
brownish area on the olive-green healthy 
tissue background under pure violet 
excitation. The same area is clearly visible 
as a bright red zone on a clear green 
background when backscattered red light is 
used in addition to the violet excitation. 
Table 5.1.3 Number of true (TP) and false positive 
(FP) as well as the true (TN) and false negative 
(FN) cases for WL and AFB with backscattered red 
light. 
These images illustrate the improved 
detectability and demarcation of the 
 TP FN FP TN 
AFB 16 0 19 2 
WL 12 4 16 5 
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extension of superficial bronchial lesions if 
AFB is used instead of WLB. Moreover 
the use of the V+R excitation filter clearly 
allows to generate much better images than 
the PV filter. In addition, the images 
obtained with the V+R excitation are much 
brighter and less noisy than their 
counterparts obtained with PV excitation 
only. This is due to an enhancement of the 
chromatic contrast between the lesion and 
the surrounding healthy tissue. 
Figure 5.1.5 illustrates the effect of 
backscattered red light on the background 
image in the red colour channel. The AF 
images from a case of severe dysplasia 
observed with PV and V+R excitation 
were seperated into their green (left image) 
and red (right image) channels respectively 
and are presented in greyscale. The lesion 
is visible as a dark, sharp circumscribed 
area on the base of the spur. In the case of 
PV excitation (Fig.5a) both the green and 
the red channel images show an intensity 
decrease on the site of the lesion. In the 
case of V+R excitation (Fig.5b) the red 
channel image exhibits a nearly 
homogenous intensity distribution, while 
the green channel image shows an intensity 
decrease on the site of the lesion. It should 
be noted that the spur was not classified as 
suspicious during WLB.  
Image analysis  
The mean normalized red-to-green ratios 
computed from image analysis of 
fluorescence positive areas and the 
fluorescence negative healthy reference 
zones are shown in Figure 5.1.6 for both 
fluorescence excitation modes. Their 
values and standard deviations are shown 
for the different histopathologic classes – 
normal tissue (squares), reactive changes 
(triangles) and (pre-)neoplastic changes 
(diamonds). The circles depict the mean 
ratios from the fluorescence negative 
healthy reference zones.  
 Figure 5.1.5a 
  Figure 5.1.5b 
Figure 5.1.5 Influence of the backscattered red light on the image background. These images present the same 
lesion as in Figure 5.1.4, but with the fluorescence images split into their green and red colour channels. They 
are presented in greyscale mode. Addition of backscattered red light to the violet fluorescence excitation light: 
(a) results in a nearly homogenous background in the red channel image. The corresponding image obtained 
with PV excitation (b) shows demarcated zones of decreased intensity, influencing the contrast between diseased 
and healthy tissue areas. 
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Figure 5.1.6 Mean values of normalized ratios for 
both pure violet and violet + red excitation. This 
graphic depicts the mean values of the normalized 
ratios  for pure violet excitation (data on the left) 
and violet excitation with backscattered red light 
(data on the right). The circles mark values for 
healthy and fluorescence negative tissue, squares 
mark healthy but fluorescence positive tissue, 
triangles mark reactive changes (inflammation and 
metaplasia) and  diamonds mark (pre-)neoplastic 
changes (dysplasia and carcinoma). The number of 
cases, n, is given for each histopathologic class. 
 
 
In the case of pure violet excitation the 
mean ratios were comparable for false 
positive normal (meannormal = 1.66 ± 0.39), 
reactive changes (meanreactive= 1.75 ± 0.12) 
and (pre-)neoplastic changes 
(meanneoplastic= 1.74 ± 0.43). It should be 
noted that the mean value of the 
normalized ratio for the fluorescence-
negative healthy reference zone was 
meanreference =1.03 ± 0.05. Adding 
backscattered red light to the violet 
excitation increased the corresponding 
mean values by a factor of about 2 for the 
normal and reactive changes classes 
(meannormal=3.65 ± 0.43, meanreactive= 4.04 
± 0.48). For the (pre-)neoplastic lesions 
this factor exceeded the value of 2.7 
(meanneoplastict for violet plus red = 4.93 ± 
2.25). The mean value of the normalized 
ratio for the fluorescence-negative healthy 
reference zone remained in the range of 1 
(meanreference= 1.10 ± 0.16). 
Discussion 
Autofluorescence bronchoscopy has 
proven to be an efficient and useful tool in 
the detection of pre-neoplastic lesions and 
early cancers in the bronchi. In this study 
we present an optimised AFB imaging 
system offering superior colour contrast 
between healthy tissue and lesions.  
One of the major problems the current 
commercially available AFB systems have 
to cope with is the poor image quality. This 
is due to the limited tissue 
autofluorescence intensity, combined with 
the limited light collection efficiency, 
throughput, and physical sensitivity of the 
imaging system [22]. Our system 
employed a filtered Xe-lamp light source 
in combination with a fiberscope specially 
designed for autofluorescence detection 
with an excitation wavelength around 405 
nm. Used in combination with a 3 CCD 
endoscopic colour camera we obtained 
noise-reduced fluorescence images at 
video frequency, i.e. about 25 frames per 
second, bright enough for a proper 
navigation in the tracheo-bronchial tree. 
This enabled the physician to perform the 
whole bronchoscopy in the 
autofluorescence mode instead of 
examining the bronchial tree in the 
conventional white light mode, switching 
to the autofluorescence mode only at 
specific sites. 
Another problem of autofluorescence 
imaging systems is how to take full 
advantage of the contrast between healthy 
and (pre-)neoplastic tissue fluorescence 
observed in spectroscopic measurements 
[20]. In the pure violet excitation mode the 
red (R) and green (G) autofluorescence 
images are mapped on the red and green 
video colour channel, respectively. The 
resulting R-G images delineate the 
fluorescence positive areas from the 
surrounding normal tissue, since the first 
exhibits a higher red-to-green fluorescence 
ratio than the latter. Pre-neoplastic and 
neoplastic tissue areas appear as brownish-
olive spots on the greenish background. 
Though the intensity contrast of lesions in 
these images is quite good, the colour 
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contrast is limited as the decrease of the 
autofluorescence intensity in the red part of 
the spectrum attenuates the contrast from 
the green part of the spectrum. 
Single channel detection of the green 
autofluorescence signal alone would 
alleviate this bias induced by the low 
decrease of the red fluorescence, resulting 
in a maximal contrast. But due to the tri-
dimensional geometry of the bronchi, both 
a background and a contrast bearing 
foreground image are necessary for an 
efficient distinction between healthy and 
abnormal tissue sites, for avoiding false 
positives resulting from geometry related 
shadowing. Such a background image can 
be created by backscattered light detected 
in one or several different colour channels. 
Profio [23] and Leonhard [16] reported the 
detection of a small amount of 
backscattered blue excitation light to 
optimize the quality of AF detection in the 
bronchi. Commercially available systems, 
such as the one proposed by the Karl Storz 
[16] company, are based on this principle. 
Since blue/violet light is strongly absorbed 
by haemoglobin, the use of this spectral 
domain to detect backscattered light 
generates much more structured images 
than using red light. Therefore, the use of 
blue/violet backscattered light helps to 
reveal the texture of the bronchi, but it is 
not ideal for correcting the 
autofluorescence images detected in the 
green spectral domain. 
Consequently, following the spectro-
fluorometric study of the bronchial 
autofluorescence performed by our group 
[11], we investigated the use of 
backscattered red light for the optimisation 
of our imaging system.  
We demonstrated in the study presented in 
this paper, that the combination of violet 
light induced tissue autofluorescence with 
backscattered red light increases the red-to-
green colour ratios between normal and 
(pre-)neoplastic tissue areas in the AFB 
images by a factor of about 2.8 compared 
to violet light induced fluorescence alone. 
This factor corresponds to the 
autofluorescence intensity ratio measured 
spectroscopically in the red part of the 
spectrum, i.e. between 600 and 800 nm 
between healthy and (pre-)neoplastic 
tissues by Zellweger et al. [11]. This 2-3 
fold increase of the red-to-green ratio is 
responsible for the improved chromatic 
contrast perceived in the V+R fluorescence 
images. Indeed, the bright red appearance 
of fluorescence positive lesions excited 
with violet light and backscattered red light 
are more easily perceived on the green 
background characteristic of healthy tissue 
than the brownish-olive coloured lesions 
observed under pure violet excitation. 
Moreover, the red background image 
created by the backscattered red light 
dramatically improves the signal to noise 
ratio, allowing better navigation and 
orientation for the endoscopist in the 
autofluorescence mode. In addition, the use 
of the V+R excitation filter strongly 
suggests an increase in specificity as 
indicated by Figure 5.1.6. Indeed, the 
overlap between the distribution of the 
normalized ratio measured in true positive 
and false positive sites is much smaller 
with the V+P filter than with the PV filter, 
indicating a more pronounced demarcation. 
Normal, inflammatory and 
dysplastic/carcinomatous fluorescence 
positive sites showed no significant 
differences in their normalized red-to-
green ratios under PV excitation (CI 95%). 
In the cases when additional backscattered 
red light was used, a significant difference 
could be observed between fluorescence 
positive, but histopathologically normal 
sites (false positives, FP) and true positive 
(TP) dysplasia and carcinoma (CI 99%). A 
much weaker, but significant (CI 80%) 
difference was observed between the ratios 
computed from inflammatory false positive 
sites and dysplasia/carcinoma excited with 
the V+R filter. The ratios computed from 
the healthy fluorescence-negative controls 
were all significantly different from the 
ratios computed from fluorescence true and 
false positive sites for the PV and V+R 
filter, respectively.  
This point is of crucial importance since 
the limited specificity has always been a 
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problem for autofluorescence detection 
systems [19]. Therefore, the results 
presented in this article indicate that the 
addition of backscattered red light provides 
an opportunity to better discriminate 
healthy tissue and fluorescence positive 
lesions. 
The issue of false positive tissue sites has 
already been reported by other authors 
using commercial systems based on violet 
autofluorescence excitation [24-27]. 
Several reasons may account for the high 
number of false positives. It is likely that 
some type of somehow atypical, but non-
cancerous tissues appear positive under 
AFB, including scar tissue [26], 
inflammation and bruised mucosa. Another 
source of false positives in clinical studies 
is related to the procedure of taking a 
biopsy. Whenever possible biopsies were 
taken under fluorescence light excitation to 
assure that the tissue sample was taken 
from the fluorescence positive area. 
Nevertheless, it cannot be excluded that a 
certain number of tissue samples were not 
taken from the fluorescence positive 
regions, but from neighboring non-
fluorescent tissue. Finally, histopathologic 
examination is deemed as the “gold 
standard” for comparison with 
bronchoscopic findings in nearly all 
clinical studies reporting on 
autofluorescence bronchoscopy. 
Nevertheless, some authors report on 
significant interobserver variability in 
histopathologic reporting [28, 29]. In a 
retrospective study of 343 bronchial tissue 
samples from AFB, Venmans et al. [29] 
revealed interobserver variability by a 
factor of 2 in the number of diagnosed pre-
invasive bronchial neoplasias. Thus, the 
interobserver variability in the histologic 
analysis of preinvasive bronchial neoplasia 
has an influence on the results of 
conventional as well as AF bronchoscopy. 
The tissue samples obtained in our study 
were analysed on a single view basis only, 
i.e. each biopsy was analysed by a single 
pathologist. It is therefore very likely that a 
certain number of AFB positive but 
histologically reported negative, i.e. AFB 
false positive cases are in reality AFB true 
positive results. This would dramatically 
change the values of sensitivity and PPV. 
Independent revision of the samples by 
two or more histopathologists might reduce 
such errors. The distribution of the 
normalized ratio for the healthy tissue is of 
particular interest in this context. Indeed, 
this distribution seems to be bimodal, the 
true negative sites being closely grouped 
around the value of one, whereas the 
normalized ratios of the false positive site 
are grouped at much larger values. This 
effect is particularly visible with the V+R 
excitation. It should be noted that the two 
sources of possible incorrect 
histopathologic assignations could explain 
the bimodal distribution of the ratios 
corresponding to the healthy tissues. 
Large interpatient fluctuations of the 
normalized red-to-green ratios within the 
histologic classes were observed with both 
excitation modes. These fluctuations were 
more marked when backscattered red light 
was added to the violet excitation. This is 
indeed a drawback of the method. A 
careful analysis of the origins of these 
variations will lead to a better 
understanding of this phenomenon. 
Interpatient fluctuations in the AF were 
reported from several spectrofluorometric 
studies in the bronchi [20] and in other 
organs [21, 30]. Since an important 
contribution to the fluctuations of the 
tissue autofluorescence intensity can be 
attributed to the inter- and intra-patient 
variations in fluorochrome concentrations 
and epithelium thickness, these 
fluctuations are more or less proportional 
in the green and red part of the spectrum 
(intrinsic fluctuations) [11, 20, 31]. 
However, this proportionality is no longer 
present if red backscattered light is 
detected instead of red autofluorescence. It 
should be noted that a similar phenomenon 
is present regarding the intensity of the 
excitation light available for the excitation 
of the fluorochromes. Indeed, our 
fluorescence imaging system uses an 
excitation band around 410 nm, 
corresponding to one absorption peak of 
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haemoglobin. The main alterations in the 
local intensity of violet light available for 
excitation of the tissue autofluorescence, 
are therefore related to the presence and 
extent of blood and blood containing 
structures, i.e. for instance, the density, 
size and depth of the blood vessels 
underlying the bronchial epithelium. These 
factors can vary markedly from one site to 
another. In the case of pure violet 
excitation both the green and the red 
autofluorescence images are detected. A 
decrease in the violet excitation light due 
to the above mentioned local blood 
containing structures, therefore results in a 
nearly proportional decrease in the green 
as well as in the red part of the spectrum. 
Consequently, in the case of pure violet 
excitation, the inter- and intrapatient 
variations of the red-to-green ratios are 
minimally influenced by the blood related 
fluctuations of the excitation light 
intensity. When backscattered red light is 
used in addition to the violet excitation, 
only the autofluorescence in the green 
image will be influenced by the absorption 
of the excitation light. However, since red 
light is less absorbed by haemoglobin than 
violet light, the resulting red backscattered 
image exhibits fewer variations due to the 
presence of blood. As a consequence the 
AFB image detected with violet excitation 
plus backscattered red is sensitive to both 
the intrinsic (fluorochrome concentration; 
variation of fluorescence yield, etc) and 
extrinsic (change of the tissue optical 
properties) fluctuations, leading to more 
pronounced inter- and intrapatient 
variations. 
This could have an effect on the learning 
curve of the physician using the different 
systems. Low variations in the computed 
normalized red-to-green colour ratios for 
fluorescence positive lesions indicate only 
small differences in the colour of lesions 
presented on the screen, while high 
variations in the normalized red-to-green 
ratios are associated with a wider range of 
colours that will indicate a lesion during 
AFB. In the first case, which corresponds 
to the PV excitation conditions in our 
study, it will be easier for the physician to 
identify “the” colour typical for a lesion. In 
the case of V+R excitation the physician 
will have to get used to a larger range of 
“colours” depicting lesions. This suggests 
that a physician will need ample 
experience before making accurate 
diagnoses when using the V+R system as 
compared to the PV system. Indeed, the 
improved colour contrast between diseased 
and undiseased tissue plus the increased 
signal-to-noise ratio of the V+R excitation, 
and resultant brighter images, overcome 
the drawback of a more difficult image 
interpretation. 
The enhanced chromatic contrast between 
a lesion and its healthy surrounding allows 
a precise demarcation of the lesion’s 
margins. This makes AFB an important 
tool, not only for diagnostic, but also for 
pre-therapeutic and pre-surgical 
bronchoscopy, where the determination of 
tumour margins is crucial for the 
planification and outcome of the treatment 
or surgery.  
In summary, the results presented in this 
work demonstrate that the additional 
detection of backscattered red light in 
violet light induced AFB, has the potential 
to significantly increase the chromatic 
contrast between healthy and abnormal 
bronchial tissues. Moreover, the additional 
light markedly reduces the signal to noise 
ratio, thus improving the image quality. 
This is of high interest for the development 
of future AFB systems. In the study 
presented here, each bronchoscopy was 
performed with fibreoptic endoscopes 
equipped with an endoscopic camera 
clipped to the endoscope’s eyepiece. 
However, the use of flexible 
videobronchoscopes has increased 
drastically in recent years. These CCD-
tipped endoscopes offer high light 
sensitivity, increased spatial resolution, 
low-weight, and easy handling. These 
features make them the tool of choice for 
most bronchologists. Videoendoscopy 
systems combining WL and AF detection 
are under development [32, 33]. Following 
the results presented in this work, the 
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implementation of the principle of the V+R 
autofluorescence detection should be 
considered in the development of such 
videoendoscopic system for the 
improvement of image quality. 
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5.2 The Richard Wolf’s DAFE system 
Following the results from the clinical study presented in the previous chapter, a second 
generation AFB system was designed in the context of a collaboration between the EPFL’s 
Photomedicine group and Richard Wolf Endoskope GmbH. It was commercialised as the 
DAFE (Diagnostic AutoFluorescence Endoscopy) system. The DAFE bronchoscopy system 
involves an excitation light source, a detection unit, and a video unit. A block diagram and a 
picture of the system are shown in Figure 5.2.1. It should be noted that some relevant and 
interesting features of the DAFE system are deliberately not given for confidentiality reasons. 
 
Figure 5.2.1 : Block diagram of the DAFE bronchoscopy system. 
5.2.1 The light source 
Like in the first generation AFB systems, the excitation unit of the DAFE system relies on a 
filtered endoscopic light source (LightProjector 5137) equipped with a 300 W UV- and IR 
filtered Xenon lamp. The light source is equipped with a 2-position flip-flop filter holder 
containing a metallic grid for white light emission and a band-pass filter for blue-violet light 
emission ("DAFE mode"). The filter position can rapidly be switched during bronchoscopy 
with the help of a foot pedal. White light emission ranges from 390 nm to 680 nm. The band-
pass filter for AF excitation has a high transmission band at 430nm (FWHM 80 nm) and a 
low transmission band at 680nm (FWHM 20nm). This second transmission band allows the 
addition of backscattered red light to the AFB images. The intensity of the red light added to 
the AFB image can be adjusted with a rotable interference filter located in the light path 
between the excitation filter and the light source output.  In clinical practice, the intensity of 
the detected backscattered red light is typically adjusted to be about 2/3 of the AF intensity 
emitted between 590 nm and 680 nm. In other words, the detected red signal intensity 
(assumed to be 100%) is composed of about 60% of tissue AF and 40% of the detected 
backscattered red light. 
The excitation light intensity can be adjusted by a rotating grid (with different holes size on its 
surface). The emission spectra of the light projector are shown in Figure 5.2.2 for the white 
light mode and in Figure 5.2.3 for the DAFE excitation. The inset in Figure 5.2.3 shows a 
magnification on the second red emission band of the DAFE excitation. The light from the 
light source is delivered to the endoscopic optics through a liquid light guide (Type 4070.253, 
Richard Wolf Endoscopes GmbH, Germany). This light guide was specially designed for AF 
Chapter 5.2 – The Richard Wolf’s DAFE system 
88 
endoscopy in the sense that its transmission in the blue-violet wavelength region is larger than 
for a conventional light guide. 
 
Figure 5.2.2 White light illumination spectrum of 
the DAFE light source. 
 
Figure 5.2.3 Blue-violet excitation spectrum of the 
DAFE light source. The insert zooms on the 
wavelength region corresponding to the red low 
transmission band around 680 nm. 
 
5.2.2 The camera system 
Both AF detection and conventional white light examinations are performed with a single 
endoscopic colour camera unit (type EndoCam 5506) composed of a 3CCD camera head and 
a dedicated camera controller. A dedicated C-mount zoom objective with an integrated 475 
nm LP filter ("emission filter") is mounted on the camera head. The spectral design of this 
filter was optimised to suppress all blue-violet excitation from the light entering the camera, 
whereas it transmits a part of the blue AF. Thus, the detected and displayed AF images are 
based on the complete set of colour information of the RGB space. The spectral design 
enables to visualise tissue structures that would be difficult to interpret if only one or two 
colour channels would be active. In the DAFE system, the three RGB components are 
displayed, allowing proper navigation in the tracheo-bronchial tree using the DAFE mode. 
Moreover, the chromatic aspect of the DAFE images is similari to that of conventional white 
light bronchoscopy images, which is much appreciated by many clinicians. The emission 
filter being integrated in the camera objective, the camera head can be plugged to 
conventional rigid or flexible bronchoscope optics. 
The image signal detected by the 3-CCD unit is converted into a PAL video signal by the 
camera controller. This video signal is delivered in the Y/C (S-video) and the composite 
formats. The bronchoscopic images are displayed on a CRT (Cathode Ray Tube) monitor. 
Y/C output was recorded on a digital video (DV) tape recorder (Sony DVCAM, type DSR-11, 
Sony Corp., Japan). Typical white light and AFB images obtained with this system are shown 
in the appendix. 
5.2.3 Image Analysis 
All quantitative analysis of DAFE image presented in this thesis were performed following 
the same protocol. The Y/C signal from the DAFE unit was recorded on the DV tape recorder. 
Video sequences were digitized via the IEEE 1394 ("Firewire") interface connecting the DV 
recorder and a PC. The process was driven by Adobe Premiere 6.5 (Adobe Systems 
Incorporated, USA), using the built-in Microsoft DV (PAL) format. Still images were 
exported in the "TIFF" format (Tagged Image File Format in the 24-bit RGB mode). This 
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encoding allows 8-bit quantification for each colour channel (RGB), resulting in 256 intensity 
levels per channel. 
The quantitative image analysis was performed with Adobe Photoshop 7.0 (Adobe Systems 
Incorporated, USA). Areas of interest on the image were selected and the intensity levels of 
the RGB colour channels were read out with the help of the histogram function. Attention was 
paid not to select saturated areas. 
A pseudo black mask is present around the circular endoscopic image to match the image size 
of a conventional rectangular (4:3) display. Signal intensity originating from the mask was 
averaged to quantify the electronic offset of the camera. The result was considered as a 
background to be systematically subtracted from all measurements. Depending on the 
camera's intensification settings, this background was up to 10% of the 8-bit quantification's 
dynamic range. Finally, it should be noted that, all intensity level values were corrected for 
the system's gamma factor (see below). 
5.2.4 Specific features of the DAFE system 
The DAFE Endocam 5506 is equipped with special functions to preprocess the detected raw 
input signal: automatic white balancing (AWB), gamma correction of the input signal, 
spectral crosstalk between the detection colour channels, automatic shutter function and 
automatic gain control (AGC).  
Most studies presented in this thesis are based on the quantitative analysis of the 
bronchoscopic images obtained with the DAFE system. Detailed knowledges and 
understanding of the system characteristics are therefore required to reliably assess 
quantitative study based on image analysis. In the following section, we will describe these 
features in details. 
Automatic white balancing 
The automatic white balancing (AWB) is used to adapt the camera response to the colour 
temperature of the illumination. Practically speaking, AWB is performed by pointing the 
camera to a white surface and activating the white balancing routine of the system. This 
routine measures the intensities detected in each colour channel and adjusts them until they 
correspond to a default value. In clinical practice, AWB is always performed on a white 
surface, such as a cotton compress, illuminated with the white light source of the DAFE unit 
before any medical examination. The AWB performed with the filtered DAFE camera 
deserves special attention. As the LP filter in the DAFE objective cuts off most blue-violet 
excitation wavelengths, only a low intensity is detected in the blue channel  when a white 
reference is observed. Consequently, AWB will lead to a maximum amplification of the 
detected blue channel signal. This results in rather high intensity levels in the blue channel of 
DAFE images, generating the impression of a "blue background noise" on the images. If the 
optical setup was modified during an examination (typically in the study presented in the 
Chapter 5.5.), a new AWB procedure was repeated before resuming the bronchoscopic 
examination. 
The Gamma factor 
The gamma factor in photography, video and computer graphics refers to a numerical 
parameter that describes the non-linearity of intensity reproduction of cathode ray tube (CRT) 
monitors. The relation (or transfer function) between the input voltage "V", i.e. the video 
signal intensity, and the light intensity reproduced on the CRT screen "L" follows a power 
function L=Vc,, where “c” is a constant parameter characterising the non-linear response . 
Accordingly, all camera raw signals "S" have to be corrected by the inverse transfer function 
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V= Sγ, with γ =1/c. Therefore, the exponent 1/c is the so called gamma factor of the camera. 
For conventional CRT monitors, c ranges from 2.2 to 2.6, and gamma will be 0.45.  
Figure 5.2.4 illustrates the transfer function defined by the international standard for high-
definition television (HDTV) (adapted from [1]). It is basically a power function with an 
exponent of 0.45, but has a toe slope of 4.5 for light intensity values below 0.018. Indeed, the 
slope of a power function at zero is infinite and limitation of the slope is necessary to limit the 
image noise in dark image regions. Transfer functions for other of video systems are very 
similar to the illustrated one. 
 
Figure 5.2.4  Illustration of the gamma correction in 
video. The graph shows a typical video transfer function 
for High Definition Television (HDTV). The transfer 
function is a power function with a linear slope of at 
low intensity values. The gamma factor in this example 
is 0.45 
 
 
Figure 5.2.5 The EIA grey scale 35 mm slide 
used for the determination of the DAFE 
system’s transfer function. 
Formally speaking, the gamma factor of a camera compensates the non-linearity of the CRT 
response, but in this thesis work the gamma factor isdefined as the overall transfer function of 
the whole video setup. This includes the transfer function of the camera, the conversion of the 
raw camera signal into the Y/C signal, then into the DV format, and finally the digitisation 
process of the still images. We determined the gamma factor of the Lausanne DAFE system 
using an EIA (Electronic Industries Alliance) grey scale (as shown in Figure 5.2.5) placed on 
a 35 mm quartz slide (Edmund Scientific, Germany). This scale provides two rows of nine 
rectangles, corresponding to of nine transmission values ranging from 3% to 60%. The slide 
background is opaque with a transmission of 0.1%. The transmission characteristics of the 
EIA grey scale slide are listed in Table 5.2.1. 
 Manufacturer Specifications Measured Value 
EIA Field Transmission [%] Tolerance Transmission [%] 
1 3 1.5 2.9 
2 10.125 2.7 10.27 
3 17.25 3.5 16.74 
4 24.375 4.1 22.99 
5 31.5 4.6 29.91 
6 38.625 5.10 35.93 
7 45.75 5.6 42.41 
8 52.875 6 49.78 
9 60 6.40 56.25 
Table 5.2.1 Transmission characteristics of EIA grey scale. 
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Variations smaller than 4% were observed between upper and lower rows. The slide was 
placed at one port of a 19 inches (about 48 cm) integrating sphere (Labsphere Inc., USA). 
White light from the DAFE light source was injected into the sphere through an other port in 
order to ensure homogenous illumination of the EIA scale. The DAFE camera head equipped 
with a conventional unfiltered objective was positioned behind the EIA scale. The 
camera/scale distance was adjusted to adapt the field of view to the whole slide. The camera 
was operated sequentially in the different AGC modes (see section below for more details on 
the AGC). The light intensity was tuned so that the detected signal from the EIA chart did not 
saturate the CCD. Video images of the EIA scale were recorded using the standard video 
recording chain. Digitisation and image analysis were performed following the standard 
procedure described above. 
Areas of identically sizes were selected on the images from each field of the EIA scale, and 
the RGB mean intensity levels were computed. All values were background-subtracted. The 
obtained RGB values from the nine transmission levels obtained with the AGC set to "low" 
are plotted in Figure 5.2.6. All transmission values were normalised to the maximal 
transmission of the EIA scale. The points were fitted by a γxaxf ⋅=)(  power function with 
the exponent corresponding to the system's gamma factor. The fitted power functions nicely 
superposed for all colour channels. The data and curve fits obtained with the AGC set to "off" 
and "high" perfectly align with those shown in Figure 5.2.6. The mean value of the gamma 
factor computed for the three colour channels and the three AGC settings was 0.64 ± 0.01. All 
intensity values in this thesis computed from DAFE images were corrected for this gamma 
factor. 
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Figure 5.2.6. Response of the DAFE system operated with the AGC set on “low”. The measured RGB intensity 
levels are reported vs. the normalised transmission of the EIA grey scale. The curve fits revealed a mean value 
of 0.64 for the gamma factors of the RGB channels. This factor is independent of the camera AGC settings. 
Spectral Crosstalk 
In a 3 CCD video camera, each of the image spectral components (usually red, green and blue 
or RGB) is detected by a separate CCD detector (see Appendix for more detailed 
information). The overlap of the spectral detection regions of the 3 separate colour channels is 
referred to as crosstalk. It is essential for a natural reproduction of the initial colours perceived 
from the object on the monitor. Nevertheless, the crosstalk will bias the results derived from 
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quantitative chromatic image analysis. Light of wavelengths within the crosstalk regions will 
be detected by both involved colour channels. 
The crosstalks of the DAFE camera were accessed by analysing the RGB components of a 
reference image excited with a monochromatic light source at different wavelengths. For this 
purpose, the white light source from the DAFE unit was filtered by a Zeiss quartz prism 
monochromator (Zeiss M4 QIII, Karl Zeiss, Germany) and projected on a matted glass plate. 
The monochromatic beam image on the glass plate was detected with the DAFE camera 
through 0° Hopkins telescope and recorded with the DV recorder. The monochromator was 
tuned from 400 nm to 660 nm in steps of 10 nm. Steps were reduced to 5 nm, within the 
potential crosstalk regions (480 nm - 530 nm and 570 nm - 610 nm),. 
Image digitisation and analysis was performed as described in the previous section. RGB 
intensity levels were corrected for the image background and the system's gamma factor. 
Figure 5.2.7 shows the intensity levels of the RGB channels. The values were obtained with 
the filtered DAFE objective mounted on the camera head. Values are thus presented for 
wavelengths longer than 470 nm only, and they were normalised with the B intensity level at 
480 nm. The following detection ranges for the colour channels were deduced from these 
measurements: 470 nm - 520 nm (blue), 490 nm - 590 nm (green), and 560 nm - 650 nm 
(red). When the camera is used with an unfiltered objective, the lower detection limit of the 
blue channel is 400 nm (data not shown). Two crosstalk regions were identified: between 490 
nm and 520 nm for the B and G channels, and between 560 nm and 590 nm for the G and R 
channels. Assuming that an incoming light (100%) is distributed between two channels, the 
resulting reflectance of the intensitiy detected by both channels are shown in Figure 5.2.8 (B 
and G) and Figure 5.2.9 (G and R). It can easily be seen that the crosstalk area between B and 
G is larger than between G and R. This is likely to be due to the high intensification of the 
blue channel resulting from the AWB process performed with the filtered objective. 
The crosstalk effect has to be taken into account when performing chromatic analysis of the 
DAFE images. 
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Figure 5.2.7 Colour channel response of the DAFE camera. All intensity levels were normalised relativ to the 
maximal value in the blue channel. It should be noted that the automatic white balancing was performed with the 
filtered DAFE objective, resulting in a strong amplification of the blue channel signal. The crosstalk between 
these channels is significant. 
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Automatic shutter control and automatic gain control 
The intensity of the light collected by the endoscopes’ objective vary dramatically because of 
the tube-like anatomy and changing dimensions of the bronchi. Moreover, the 
autofluorescence emission from the bronchial tissue is by 3 to 4 orders of magnitude smaller 
than the signal obtained during white light reflectance bronchoscopy [2-4]. Consequently, the 
DAFE system is equipped with two independent intensity control circuits to compensate the 
image brightness fluctuations, namely the automatic shutter control and the automatic gain 
control (AGC). 
The camera controller automatically adjusts the brightness of endoscopic image to prevent 
saturated or very dark images. This adjustment is performed by varying the CCD exposure 
time. The term "shutter control" refers to devices with a mechanical shutter regulating the 
exposure. In the DAFE camera the image brightness is measured in real-time at the centre of 
the field of view. The upper limit of the exposition time is given by the number of images 
(frames) to be acquired per unit of time. For instance, 25 fps (frames per second) are 
displayed in the PAL video standard . The frame rate might be reduced to 12.5 fps, but below 
this value, movements will be perceived as jerky. 
The automatic shutter control is sufficient to correct image intensity fluctuations during 
conventional white light illumination, but it can not correct for the low AF intensities detected 
during examination in the DAFE mode. Therefore, additional activation of the AGC is 
required. The AGC control is a 3-step (off, low, high) electronic signal amplification. In the 
DAFE mode, an activation of the AGC brightens the AF image at the level of white light 
reflectance images. However, AGC comes along with a significant increase of the image 
background. Subtracting the image background from the intensity values prior to image 
analysis compensates this effect.  
AGC is manually set, whereas the settings of the automatic shutter control cannot be tracked. 
Consequently, image analysis of the DAFE images only allows to compare intensity ratios 
between channels, but no absolute intensity levels in individual channels can be measured. 
Figure 5.2.9 Crosstalk between the green (G) 
and red (R) colour channel. The figure shows the 
distribution of the light intensity signal on the two 
colour channels for different wavelength colour 
channels in function of the wavelength. 
Figure 5.2.8 Crosstalk between the blue (B) and
green (G) colour channel. The figure shows the 
distribution of the light intensity signal on the two
colour channels for different wavelength colour 
channels in function of the wavelength. 
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5.3 Influence of the excitation wavelength bandwidth on 
the healthy-to-lesion contrast in AFB 
As already mentioned in the preceding section, all commercially available AFB systems show 
high sensitivity, but only poor specificity for the detection of early cancerous and pre-
cancerous lesions in the bronchi. A fundamental understanding of the origins of the 
mechanisms underlying the AF contrast is essential for a better differentiation between true 
and false positive results. The purpose of the present study was to investigate and understand 
the influence of the excitation wavelength bandwidth on the healthy-to-lesion AF contrasts in 
AFB.  
As discussed in Chapter 4.2, the AF contrast between (pre-)neoplastic lesions and healthy 
tissues in the bronchi results from (1) an overall decrease in AF intensity (“intensity contrast”) 
and (2) a distorsion of the spectral shape of the AF (“spectral contrast”) due to a stronger 
intensity decrease in the green (450 nm – 600 nm) wavelength region relative to the red (600 
nm – 800 nm) wavelength region. Zellweger et al. [1] demonstrated in a spectrofluorometric 
in vivo study that the excitation wavelengths producing the highest healthy-to-lesion intensity 
and spectral contrasts are between 400 nm and 430 nm with a peak around 405 nm (Figure 
4.1). The authors concluded that this wavelengths would be optimal to discriminate between 
healthy tissue and (pre-)neoplastic lesions. It should be noted, thatthis wavelength range 
corresponds to the absorption maximum of haemoglobin. This indicates that light absorption 
due to tissue haemoglobin may play a role in the AF intensity and spectral contrasts. Since, 
blue-violet light at wavelength around 405 nm does not penetrate deeply in bronchial tissue. 
The results from Zellweger et al. [1] suggest that the contrast mechanisms are located in the 
superficial layers of the bronchial walls. 
 
Figure 5.3.1 The custom-made light guide coupler. The optical quartz fibre and the endoscopic light guide 
areplugged at opposite sites. The coupling angle can be adjusted by the screws at either side of the unit. 
Consequently, the imaging study presented in this chapter aims at comparing the contrast 
obtained with a narrowband excitation around 410 nm from a laser light source (superficial 
excitation) and a broadband excitation around 430 nm (“deep” excitation) from a filtered 
lamp.  
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5.3.1 Materials and Methods 
The modified DAFE system 
The comparison between the two excitation modes was performed in a clinical study with the 
Wolf DAFE system. The system is described in detail in Chapter 5.2. The light delivery unit 
of the system was slightly modified for this study. The blue-violet excitation light (430 nm ± 
40 nm) from the DAFE light source served as the broadband excitation. 
The narrowband excitation was realised by using light from a laser instead of from the 
endoscopic light source. Light from a Krypton (Kr+) laser (Spectra Physics Type 171, Spectra 
Physics, USA) was coupled into a 400 μm optical quartz fibre (extension fibre) equipped with 
2 SMA connectors. The laser was operated in the multi-line mode at 407 nm and 413 nm and 
the maximal laser output power was 2.5 W. The light from the extension fibre was coupled 
into the endoscopic light guide using a custom made fibre coupler. A special coupling system 
was necessary to accommodate the different guide diameters and numerical apertures (NA) of 
the two devices to each other for best light transmission efficiency. While the extension fibre 
had a NA of 0.4 and a diameter of 400 μm, the liquid light guide had a NA of 0.53 and a 
diameter of 4 mm. The coupler itself consisted of a black box having a SMA plug on one side 
and custom made plug for the light guide on the other side, as shown in Figure 5.3.1. The part 
containing the SMA plug could be rotated in the x-y plane around a central axis in order to 
change the injection angle between the extension fibre and the light guide. Perpendicular 
injection resulted in a “forward peaked” light output at the distal end of the endoscopic light 
guide and the bronchoscope, thus leading to an inhomogenous illumination of the endoscopic 
site. A slight rotation of the SMA connector around the central axis of the black box resulted 
in a bell-shaped light distribution at the distal tip of the bronchoscope which fits the angular 
distribution of the illumination with the DAFE light source. 
The endoscopic procedure 
The clinical study took place at the ENT department of the CHUV University Hospital in 
Lausanne. Autofluorescence bronchoscopies with the broadband and narrowband excitations 
were performed in 3 patients with known endobronchial pre-neoplastic, but non-invasive 
lesions. All the lesions had been detected during former standard AFB examinations and had 
been confirmed by biopsy and histopathologic analysis. Bronchoscopy was performed under 
total anesthesia using rigid Hopkins optics. Typical excitation light intensities at the distal tip 
of the endoscope optics were 110 mW for the broadband excitation from the DAFE light 
source and 70 mW for the narrowband excitation from the Kr+ laser. The lesion areas were at 
first localised using conventional WLB and AFB. The light guide was then unplugged from 
the endoscopic light source and connected to the custom fibre coupler. Bronchoscopic 
examination of the lesions was repeated with the excitation light delivered from the Kr+ laser. 
The whole endoscopic procedure was recorded on a DV tape for analysis. All AF+ sites were 
biopsied and sent for histopathologic analysis. Carcinoma in situ was confirmed in 2 patients 
and moderate dysplasia was found in 1 patient. 
Image analysis 
The image analysis procedure was already described in Chapter 5.2. Still images showing 
both tumour and adjacent normal tissue were digitised in the 24-bit RGB mode using an 
IEEE1394 interface between the DV recorder and a PC. For each patient, typically two 
images obtained with the broadband excitation (“broadband images”) and two corresponding 
images obtained with the narrowband excitation (“narrowband images”), as well as a single 
WL image were digitised. Attention was paid to choose the broadband, narrowband and WL 
images showing the lesion and its normal surrounding under the same view. The intensity 
levels in the green channel of the images were computed from selected areas on the 
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autofluorescence negative (AF-) healthy tissue and areas on the fluorescence positive (AF+) 
lesions. All areas selected on the lesions showed no abnormalities under WL examination. 
Background subtraction and gamma correction were performed as described in Chapter 5.3. 
The healthy-to-lesion “contrast” was computed as the ratio (GH/GL) where GH was the 
intensity level on the healthy tissue and GL the intensity level on the lesion. 
5.3.2 Results 
Visual Results 
Figure 5.3.2,Figure 5.3.3 and Figure 5.3.4 show the WLB and the AFB images obtained with 
broad and narrowband excitation for each patient. The green channel images of the AFB 
images are shown as 8-bit greyscale images beside their corresponding RGB images. Figure 
5.3.2 represents a CIS located on the cardiac wall of the right inferior bronchus of Patient 1. 
The lesion is clearly visible in the AFB images as a well circumscribed red area. The lesion is 
distinguishable by a significant intensity decrease in the green channel AFB images. This 
decrease is more pronounced in the narrowband image compared to the broadband image. 
The images obtained from Patient 2 are shown in Figure 5.3.3. While the diseased spur is 
hardly suspicious under WL, the AFB images reveal a strong red fluorescence on the spur and 
multiple adjacent regions. Biopsy and histopathologic analysis from the AF+ spur identified a 
high grade squamous dysplasia. The green channel images exhibit a strong decrease of the AF 
intensity on the lesion. This decrease also appears to be more important in the narrowband 
image than in the broadband image. 
Figure 5.3.4 shows the WL and AFB images of the CIS in the left lower bronchus of Patient 
3. The lesion is clearly visible as a red/dark purple area on the pale normal background in 
both, the broadband and the narrowband images. The green channel images show a distinct 
intensity decrease in the lesion area compared to the healthy surrounding. Like in the first two 
patients, it is more pronounced in the narrowband image than in the broadband image. It 
should be noted, that the highest intensity contrast is observed on the dark purple area in the 
lower centre portion of the spur. However, WLB identified this area as bruished mucosa, and, 
according to the selection criteria for image analysis, this area was excluded from the image 
analysis.  
Thus, in all 3 patients the intensity decrease of the green AF was more distinct in the narrow 
band images than in the broadband images. It should be borne in mind, that the excitation 
light intensity at the distal tip of the bronchoscope optics obtained with the Kr+ laser was 
lower than the intensity obtained with the filtered endoscopic lamp. Consequently, all AFB 
images obtained with the broadband lamp excitation are less noisy and brighter than those 
obtained with the narrowband Kr+ excitation. However, this does not affect the results of our 
image analysis. 
Image Analysis 
The GH/GL ratios were computed from 10 different healthy tissue and lesion areas in the 
narrowband images and from the corresponding areas in the broadband images. 
All GH/GL ratios were superior to 1 for both excitation modes, signifying an AF intensity 
decrease on the lesion relative to the surrounding healthy bronchial wall. The column plot in 
Figure 5.3.5 shows the mean GH/GL intensity ratios for each case as well as for the ensemble 
of all cases. Striped and filled columns depict ratios from broad and narrowband excitation, 
respectively. The error bars represent the standard deviations. The number of areas from 
which the mean values were deduced is given for each patient. The mean GH/GL ratios over 
all 3 cases were 1.9 ± 0.45 for the broadband excitation, and 2.86 ± 1.3 for the narrowband 
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excitation. Thus, the mean ratios computed for the narrowband excitation exceed those for the 
broadband excitation by a factor of about 1.5.  
 
 
Figure 5.3.2: White light, DAFE and Kr+ image of a CIS located in the inferior bronchus of a 60-year old 
female patient. The lesion is clearly visible at the “11 o’clock” position on the cardiac wall of the bronchus. The 
green channel AF images obtained with DAFE and Kr+ excitation are shown in 8-bit greyscale in the lower part 
of the figure. The intensity decrease on the lesion relative to the healthy surrounding is clearly enhanced with 
the narrow band Kr+ excitation. 
 
Figure 5.3.3 White light, DAFE and Kr+ images of a lesion of high grade squamous dysplasia on the division of 
the middle lobe of a 59-year old patient. The spur exhibits strong red fluorescence in AFB. The greyscale images 
reveal a strong intensity decrease of the green AF on the lesion. This contrast is most clearly visible in the AF 
images obtained with the narrow band (Kr+) excitation. 
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Figure 5.3.4 White light, DAFE and Kr+ images of a lesion of a CIS in the left lower bronchus of a 70-year old 
patient. Hardly suspect with WLB, the spur exhibited a dark red fluorescence with both DAFE and Kr+ 
excitation. The intensity contrast on the lesion is clearly visible in the greyscale image of the green AF channel. 
 
Figure 5.3.5 The mean GH/GL ratios computed for the broadband (BB, hatched columns) and narrowband (NB, 
filled columns). The number of analysed areas is given for each column. 
 
5.3.3 Discussion 
Most of the commercially available AFB systems use the absolute or relative decrease in the 
green spectral part of the AF to distinguish neoplastic lesions and healthy bronchial wall. The 
results from our image analysis show that the green AF intensity of healthy bronchial wall is 
about twice that of lesions with our imaging system. This intensity contrast is clearly visible 
in the clinical AFB images shown above.  
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Comparison with Data from Zellweger 
In their spectrofluorometric study, Zellweger et al. [2] quantified the ratios of the green AF 
between healthy bronchial wall and neoplastic lesions for different excitation wavelengths. 
The resulting graphic showed a sharp increase in the green intensity ratios at 410 nm 
excitation wavelength. In the context of our imaging study, it is interesting to relate our 
results to those from Zellweger et al. For this purpose, we extracted GH/GL ratios from the 
data given in [2] corresponding to the wavelength range of our broad- and narrowband 
excitation. More precisely, we computed the mean ratios from Zellweger's data over (1) the 
wavelength interval between 390 nm and 470 nm (broadband excitation) and (2) for 410 nm. 
According to these data, the GH/GL ratio for a narrowband excitation corresponding to that 
used in our study should exceed that of a broadband excitation by a factor of about 1.6. In our 
imaging study the mean GH/GL intensity ratio for the broadband excitation exceeded that of 
the narrowband excitation by a factor 1.5. Thus, there is good agreement between the results 
in the two studies.  
Consequences on the AF Mechanisms 
The fact that the intensity contrast between the healthy bronchial wall and neoplastic lesions 
increases at narrowband excitation around 410 nm is very interesting for the understanding of 
the AF contrast mechanisms. As already mentioned in Chapter 4, these contrasts are likely to 
be due to (1) an angiogenesis and the associated changes in the blood content in the 
subepithelial layers of the bronchial wall, and (2) the thickening of the epithelium. First of all 
we can draw conclusions on the depth at which the contrast mechanisms are localised in the 
bronchial wall. According to the data from Qu et al. [3, 4], the main contribution of bronchial 
AF arises from the upper part of the sub-epithelial layer while no significant AF is observed 
from the superficial epithelium. 
It is interesting to note, that the uppermost sub-epithelial zone below the basement membrane, 
the lamina propria, undergoes characteristic changes in vascularisation during the 
cancerisation process. The morphometric studies from Fisseler-Eckhoff et al. [5], Fontanini et 
al. [6] and others (see Chapter 4) have shown an increase in the microvessel densities (MVD), 
resulting from angiogenesis [7, 8], in pre-neoplastic and neoplastic lesions relative to healthy 
mucosa and submucosa. This increase in the MVD preferentially occur in the vicinity of the 
basement membrane. Hence, the blood concentration is higher in this layer of the (pre-
)neoplastic bronchial lesions than in its healthy surrounding. Indeed, the increase in the sub-
epitelial blood contents is invoked by several authors as cause for the healthy-to-lesion 
intensity contrast [3, 9]. Due to the light absorption properties of blood (see Figure 4. ), the 
blue-violet excitation light used in AFB will be strongly absorbed by the vascular blood in the 
superior layers of the submucosa, hence, being no longer available for the AF excitation. This 
absorption will be stronger in the (pre-)neoplastic lesions showing an increase in the MVD 
and the blood contents close to the basement membrane than in healthy tissues. Hence, the 
results presented in this study indicate, that the tissue blood contents and angiogenesis play a 
major role in the intensity contrast observed between (pre-)neoplastic and healthy bronchial 
tissue.  
It should be noted, that the vascular blood also absorbs the AF generated in the sub-epithelial 
layers .As for the absorption of the excitation light, this effect is more important in 
(pre-)neoplastic lesions than in healthy bronchial wall and will consequently result in an 
additional amplification of the intensity contrast. However, the shielding effect will rather be 
independent of the excitation bandwidth. 
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Limited Data Set 
Though our results clearly show an increase in the intensity contrast with the line-shaped 
wavelength excitation relative to the broadband one, the data show noticeable statistical 
variations. These are mainly due to the (1) the low number of measurements, (2) the images 
available for analysis and (3) the intra-case errors. The limited number of cases in our study 
results from the very special selection criteria for the patients. Our study aimed to compare 
both broadband and narrowband excitation on early but non-invasive neoplastic lesions. The 
prevalence of second primary tumours in the lung in patients with ENT cancer is inferior to 
10% [10-13]. Within the 3-years period of our study, only 3 cases in the ENT department of 
the CHUV University Hospital fulfilled the inclusion criteria. Additionally, the endoscopic 
images recorded from the bronchoscopic examinations were not always suited for proper 
image analysis. As already mentioned above, these images had to show AF+ lesions and AF- 
healthy bronchial wall within the same view and in the same image plane. This was not 
always possible due to anatomical reasons and the location of the lesion. One example for the 
difficulties related to anatomy can be seen in the images of Patient 2 (Figure 5.3.4). The AFB 
images show the extensive moderate dysplasia on the spur with multiple AF+ satellite lesions 
all-over the field of view. Autofluorescence negative areas are small and do not always lay 
within the lesion area's image plane. Moreover, the areas classified as "AF-" in this patient 
show less contrast to the AF+ areas than their counterparts in the other two patients, resulting 
in a lower GH/GL ratio. The computed GH/GL ratio for narrowband excitation exceeds those 
for broadband excitation by only a factor 1.1 in this patient. This value is much smaller than 
the corresponding factors of 1.7 and 1.6 computed for the Patients 1 and 3, respectively. The 
example of Patient 2 illustrates the main causes for the inter-case variations in our study, 
namely (1) the differences in the overall AF intensities between individuals [2], (2) the 
differences in the GH/GL ratios between individuals [1, 14] and (3) the geometry of the 
endoscopic site, namely the distribution AF+ and AF- areas within the field of view.  
Intra-case fluctuations 
The last point is also of importance for the intra-patient variations. Within a given AF image, 
the computed intensity values are sensitive to the distance between endoscope and tissue, the 
angle of view, and the morphology of the tissue surface. Following the r-square law of the 
intensity-distance correlation, the AF signal from a tissue area close to the endoscopic optics 
will be detected with a 4 times higher intensity than that of an area located at a twice longer 
distance. Changes in the viewing angle might also induce a wavelength shift in the detected 
AF signal, thus influencing the intensity values. Consequently, the GH/GL ratios strongly 
depend on the relative distance between the selected AF+ and AF- areas. 
Morphologic structures such as the longitudinal stripe-like structure visible in the bronchial 
wall, airway crypts (invaginations in the bronchial wall) or ring-shaped convexities due to 
cartilages in the upper bronchi can, among others, influence the AF intensity values. 
Unfortunately, for technical and anatomical reasons, it is not always feasible to observe 
healthy mucosa and lesions from the same distance and avoid the aforementioned 
morphologic sources of error. However, paying attention to selecting images containing AF+ 
and AF- areas in the same or close image planes, can significantly decrease the intra-case 
variations. 
Remarks on image analysis and backscattered red light 
A short notice should be done regarding the data processing and image analysis used in this 
study. In other reports dealing with spectral image analysis [1, 14-17] we employed the 
normalised red (R) to green (G) intensity ratio (R/G), i.e. the (R/G) ratio on lesions relative to 
its value on the neighbouring healthy bronchial wall, to gain information on the spectral AF 
differences between the two tissue states. However, in this study only the green intensity 
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ratios were investigated for several reasons. First of all, the DAFE excitation source used in 
this study emitted a certain amount of red light in addition to the blue-violet AF excitation. 
During standard DAFE bronchoscopy, the backscattered portion of this red light is detected, 
increasing the lesion-to-healthy spectral contrast, as described in [16]. Though the amount of 
red light can be deliberately changed, it is not possible, to fully omit all red light from the 
DAFE images. As a consequence, the red colour intensity of the AF images not only 
corresponds to the tissue AF intensity, but also show a contribution from this red 
backscattered light. However, it should be noted that the amount of red light is much larger 
when the DAFE system is operated in standard clinical conditions. This results in an 
elimination of the healthy-to-lesion AF intensity contrast in the red part of the spectrum, as 
described in Chapter 5.1. Thus, the changes in the green spectral region reported in the 
present study not only correspond to an intensity contrast but also to the healthy-to-lesion 
chromatic contrast, when the DAFE system is used in standard conditions.  
Outlook 
In future imaging studies, attention should be paid to fully block the red light produced by the 
DAFE light source to enable comparison of the healthy-to-lesion contrast observed in the red 
part of the spectrum This approach will enable to get interesting information on the 
mechanisms responsible for the healthy-to-lesion spectral contrasts. For this purpose it might 
be necessary to use an alternative excitation filter in the DAFE light source, having the same 
blue-violet transmission properties that the actual one, but having no additional transmission 
in the red wavelengths range. Since the flip-flop filter mounted in the DAFE light source is 
designed for the sequential use of up to 3 excitation modes (2 AF excitations and 1 WL 
illumination), such a modification can easily be performed. 
Most commercially available AFB imaging system use the light from filtered halogen lamps 
for AF excitation [14, 18-21]. Endoscopic halogen light sources are available at relative high 
powers and are cost-effective. Moreover, the same light source can be used for blue-violet AF 
excitation and the WL illumination for conventional WLB. However, the use of filtered 
halogen WL sources does not allow narrowband filtering for intensity reasons. Blue-violet 
diode laser systems delivering sufficient light intensities for rigid optics or fibre based AFB, 
are not available at the present time. However, this situation will change in the near term 
future. In addition, the use of flexible videobronchoscopes dramatically increased in the last 
years and the implementation of the technology in AFB can be anticipated. Since these CCD-
tipped flexible bronchoscopes have a much higher light sensitivity than conventional 
fibreoptics, blue-violet diode lasers emitting at 405 nm are highly interesting for narrowband 
excitation AFB, as they combine small size, handiness and sufficient light power for 
videobronchoscpy. Moreover, they can easily be combined or even integrated into endoscopic 
WL sources. 
Summary 
In summary, our results presented in this clinical study demonstrate that a narrowband 
excitation around 415 nm increases the intensity contrast between healthy bronchial wall and 
neoplastic lesions in AFB. This is in good agreement with the findings reported by Zellweger 
et al. [1]. Since the excitation wavelength producing the largest intensity contrast is centred on 
the absoption peak of blood, the spatial distribution and concentration of sub-epithelial blood 
seem to play a key-role in this contrast. Thus, it is very likely that the neo-angiogenesis 
observed in the lamina propria and the submucosa of (pre-)neoplastic bronchial lesions play a 
key role in the AF intensity contrast mechanisms. 
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Abstract 
Autofluorescence (AF) imaging is a powerful tool for the detection of (pre-)neoplastic lesions 
in the bronchi. Several endoscopic imaging systems exploit the spectral and intensity contrast 
of AF between healthy and (pre-)neoplastic bronchial tissues, yet the mechanisms underlying 
these contrasts are poorly understood. In this report, the effect of formalin fixation on the 
human bronchi AF, hence on the contrast, was studied by spectrofluorometric point 
measurements and DAFE (Diagnostic AutoFluorescence Endoscopy) broad field imaging. 
Generally, formalin fixed samples have higher AF intensity than in vivo, whereas the emission 
spectral shape is similar. Additionally, the spectrofluorometric data showed a moderate 
decrease of the AF intensity on (pre-) neoplastic lesions relative to the healthy bronchial 
samples. However, this decrease was lower than that reported from in vivo measurements. 
Neither spectral measurements nor imaging revealed spectral contrast between healthy 
bronchial tissue and (pre-)neoplastic lesions in formalin. These results indicate that epithelial 
thickening and blood supply in the adjacent lamina propria are likely to play a key role in the 
generation of the AF contrast in bronchial tissues. Our results show that the AF contrast in 
bronchial tissues was significantly affected by standard, 10% buffered, formalin fixation. 
Therefore, these samples are not suited to AF contrast studies. 
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Introduction 
Bronchial squamous cell carcinoma (SCC) 
remains the leading cause of cancer related 
death in the western world and its 
incidence is currently rising in Asia and in 
developing countries [3-5]. SCC develops 
in a gradual and stepwise fashion 
according to the World Health 
Organisation (WHO) grading of pre-
neoplastic and early neoplasic lesions, 
from normal epithelium, to basal cell 
hyperplasia, squamous metaplasia, low 
grade (mild, moderate) dysplasia, high 
grade (severe) dysplasia, towards 
carcinoma in situ-(CIS) and micro-invasive 
carcinoma [6-8]. Over time, these early 
neoplastic forms progress to ultimately 
invasive squamous cell carcinoma. 
The bronchial wall has a distinctive 
layered structure involving mucosa 
(epithelium and lamina propria), 
muscularis mucosae, submucosa, cartilage 
or smooth muscle. Pre- or early neoplastic 
lesions are limited to the mucosa. Invasive 
carcinoma are characterised by an 
infiltration of the submucosa and deeper 
lying layers and are referred to as 
neoplasia. A carcinoma infiltrating the sub-
mucosal layers less than 3 mm is 
considered as microinvasive. 
Early detection of the disease can 
drastically decrease mortality and 
morbidity[9-11]. The development of 
highly sensitive, non-invasive and cost 
efficient detection methods, permitting 
detection and diagnostic of early bronchial 
lesions [12-14] has been the subject of 
much research. The application of 
diagnostic autofluorescence bronchoscopy 
(AFB) has proven to be highly sensitive to 
early, non-invasive bronchial neoplasia , 
even for occult lesions invisible during 
conventional white light bronchoscopy 
(WLB) [15, 16]. Current commercially 
available AFB systems are all based on the 
visualisation of the spectral and intensity 
contrast of the tissue autofluorescence 
(AF) between normal bronchial tissue and 
neoplastic or pre-neooplastic lesions when 
excited with light in the blue-violet 
wavelength region [17]. In several clinical 
studies AFB has shown a two fold 
improvement in sensitivity and specificity 
over WLB [15, 16, 18]. Nevertheless, the 
specificity of AFB remains limited [17-
19]. 
However, the mechanisms underlying the 
spectral and intensity lesion-healthy 
contrast are barely understood. A better 
understanding should lead to dramatic 
improvements in the spectral and technical 
design of AF based imaging systems. 
To our best knowledge, few publications 
report the fundamental optical, spectral and 
AF properties of healthy bronchial tissue 
and neoplastic and pre-neoplastic lesions in 
the bronchi. Among those, only a limited 
number rely on spectrofluorometric in vivo 
studies [2, 20, 21], while the majority of 
the reported results have been obtained 
from ex vivo tissue samples. Ex vivo 
studies are more convenient than in vivo 
studies for spectral and imaging 
measurements of the AF of bronchial 
tissue. Constraints surrounding 
measurement set-up, dynamic 
measurement conditions, accessibility, and 
ethical criteria, are much more limited with 
ex vivo studies. In addition, access to tissue 
banks gives researchers rapid access to 
many more cases, which produces 
statistically more robust results. Fixation of 
samples in 10% buffered formalin is a 
common processing used in standard 
histopathological analysis, and allow 
retrospective analysis, even after long time 
intervals. However, discrepancies between 
the in vivo and ex vivo spectofluorometric 
properties of healthy and (pre-)neoplastic 
human bronchial mucosa and submucosa 
are found in the literature [22-25]. Since it 
is not clear if similar differences exist for 
spectral condition corresponding to AFB, 
we investigated the properties of bronchial 
AF in formalin fixed human bulk bronchial 
samples. Finally, the illumination-detection 
conditions are more easily controlled 
during ex vivo measurements than under in 
vivo conditions, producing more stable 
results. 
All in vivo studies based on fluorescence 
imaging report a spectral and intensity 
Chapter 5.4 – Autofluorescence Spectroscopy and Imaging of …  Bronchial Tissue after Formalin Fixation 
107 
contrast between healthy bronchial sites, 
(pre-)neoplasia and invasive tumors. In 
contrast, spectrofluorometric 
measurements performed under in vivo 
conditions produced controversial results. 
Using a fibre bundle probe placed 3.5 mm 
from the bronchial mucosa and exciting the 
AF at blue-violet wavelengths, Zellweger 
et al. [20] observed a strong intensity 
decrease and a change in the spectral 
composition between healthy bronchial 
wall and neoplastic or (pre-)neoplastic 
lesions . In contrast, when performing 
spectrofluorometric measurements with a 
fibre bundle probe in slight contact with 
the bronchial mucosa, Qu and coworkers 
[21] reported a significant intensity 
decrease, but no spectral distortion on CIS 
and neoplastic bronchial lesions compared 
to the healthy bronchial wall. Moreover, 
AFB imaging systems, like the DAFE 
(Diagnostic AutoFluorescence Endoscopy) 
system used in this study, are based on the 
detection of the spectral and intensity 
contrast to localise bronchial neoplasia and 
pre-neoplasia. The DAFE system, 
commercialised by Richard Wolf 
Endoscopes GmbH (Germany), uses a 
switchable filtered endoscopic light source 
for WL illumination and blue-violet AF 
excitation and detects the WL and AF 
images with a filtered endoscopic camera. 
The purpose of studying the 
spectrofluorometric properties of formalin 
fixed bronchial samples was two-fold: 
first, we aimed to determine the influence 
of the formalin fixation on the tissue AF 
and the suitability of this kind of tissue 
processing for spectrofluorometric 
measurements in a spectral domain 
corresponding to that of the DAFE system. 
Secondarily, our aim was to use these 
measurements to gather information on the 
mechanisms underlying the healthy-to-
lesion contrast that can be visualised with 
the DAFE imaging systems. 
Materials and Methods 
Tissue samples and processing 
A total number of 26 formalin-fixed 
bronchial samples collected from 18 
patients who underwent surgery for their 
widely invasive bronchial cancer were 
investigated in this study. The 6 mm thick 
samples of bronchial wall were fixed at 
least 14 hours in 10% buffered formalin-. 
After fixation, each sample was divid into 
two parts; one part was paraffin-embedded, 
cut in 5 μm thick slices and stained with 
hemotoxylen and eosin (H&E) for 
morphologic control analysis. The other 
part was stored in buffered formalin 
solution at room temperature, then used for 
the spectrofluorometric measurements. 
Various lesions and regions of healthy 
bronchial mucosa were marked on the 
control HE sections. A reference mark was 
set on the slide and on the bulk sample to 
facilitate sample orientation and precise 
localisation of different lesions and healthy 
mucosa during measurements. In most 
cases, between two and three independent 
bronchial samples were obtained from a 
patient (for future reference, each case 
corresponds to an individual patient). Each 
sample exhibited at least one region of 
healthy bronchial mucosa. The lesions 
were classified according to the WHO 
classification [26] into 5 categories as 
follows: 1) reactive changes including 
basal cell hyperplasia and squamous 
metaplasia, 2) mild dysplasia, 3)moderate 
dysplasia, 4) severe dysplasia /CIS, and 
micro-invasive carcinoma, and 5) widely 
invasive squamous cell carcinoma (SCC). 
Fourteen samples were identified as 
exhibiting one or more lesions 
corresponding to the categories 1-2 and 4-
3. The number of lesions per category and 
the number of samples per case are 
summarised in Table 5.4.1. Healthy areas 
of the bronchial wall were identified in 25 
samples originating from 17 patients. 
Metaplastic lesions were found in 2 
samples from 2 patients. Mild and 
moderate dysplasia were identified in 
each1 sample from a unique case and CIS 
in 4 samples from 4 cases. Finally, 
invasive SCC was found in 10 samples 
from 6 patients. None of the samples 
showed hyperplastic or moderate 
dysplastic lesions. 
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The spectrofluorometer 
The spectrofluorometric measurements 
were performed with an optical fibre-based 
spectrofluorometer that consisted of a 
Xenon arc lamp as excitation source and 
filtered by a short pass filter. A dichroic 
mirror focused the light into a quartz 
optical fibre, which served as both 
excitation and detection fibre. The sample 
fluorescence was transmitted through a 
long pass filter and was analysed by the 
detection unit. Figure 5.4.1 illustrates this 
device in more detail. 
The light delivered by the 100 W Xe light 
source (LS) (Osram HBO 103 W/2, 
Osram, Germany) passed an electro-
mechanical shutter (Uniblitz VS25, 
Vincent Associates, USA) (S) and entered 
the filter unit of an EPI fluorescence 
microscope (Nikon Y-FL, Nikon Corp., 
Japan). The EPI fluorescence microscope 
contained a set of removable neutral 
density filters (ND) and a set of excitation-
emission filter cubes. The white light 
delivered by the light source was purified 
by an excitation band pass filter before 
being reflected by the dichroic mirror and 
focused into the 600 μm core diameter 
quartz optical fibre (Type SN EX-042, NA 
0.37, Medlight SA, Switzerland) by a 
microscope objective (Nikon Plan Fluor, 
10x, NA 0.3, Nikon Corp., Japan). The 
optical fibre was placed in gentle contact 
with the sample for the measurements. As 
already mentioned above, the same quartz 
optical fibre collected the fluorescence 
signal of the sample. The fluorescence 
signal was separated from the excitation 
light by the dichroic filter in the filter cube, 
and then filtered by a long pass filter 
installed in the filter cube. A second 
microscope objective (Nikon Plan Fuor, 
10x, NA 03, Nikon Corp.,  
Japan) focused the florescence signal into a 
600 μm round-to-slit converting fibre 
bundle (7 fibres each 200 μm, Top Sensor 
Systems, The Netherlands). The latter 
redirected the fluorescence signal to the 
spectrograph (type CP-140-104, Jobin 
Yvon SA, France) that was coupled to a 
thermoelectrically air cooled CCD head 
(Hamamatsu S7030-1006N, Hamamatsu, 
Japan). The shutter opening dwell time was 
synchronised with the read-out of the CCD 
by the CCD controller (type Spectrum One 
3500, Jobin Yvon SA, France). The 
fluorescence detection range was between 
250 nm and 850 nm (depending of the 
excitation wavelength) with a resolution of 
6 nm (FWHM). The whole set-up was 
controlled by a portable PC. 
Figure 5.4.1 Set-up of the optical fibre based spectro-fluorometer. The light from the Xenon light source 
is filtered by a band pass filter (BP) and redirected by a dicroïc mirror (DC) to the optical fibre probe.
The fluorescence signal is captured by the same fibre, passed to the DC mirror and filtered by a long pass 
filter (LP) before being analysed in a spectrograph. The two microscope objectives (MIC) focus the light
beam into the fibre and the fibre bundle. A set of neutral density filters (ND) allow attenuation of the
excitation light intensity. 
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For measurements we used a custom made 
filter cube consisting of a 405 nm ± 10 nm 
band pass filter (EX405/10), a 430 nm 
dichroic filter (DM 430, peak reflection 
45° at 415 nm) and a 435 nm long pass 
filter (BA435). A supplementary 455 nm 
long pass filter (Chroma Inc.,USA ) was 
inserted between the filter cube and the 
detection microscope objective to assure a 
100% rejection of the excitation light. With 
this spectral set-up the resolution of the 
excitation was 10 nm (FWHM) and the 
typical excitation power at the distal end of 
the quartz optical fibre was 4 μW. 
Integration time for the measurements was 
100 ms. The physical sensitivity of the set-
up yielded a signal-to-noise ratio better 
than 20 on a typical sample under these 
conditions. 
Spectrofluorometric measurements 
Before each measurement samples were 
removed from the formalin solution and 
washed with a sterile saline solution. They 
were placed on a non-fluorescing dark 
support and orientated by superposing the 
corresponding H&E stained tissue slices 
for identification of the healthy bronchial 
areas and lesions of interest. The 
fluorescence excitation light power at the 
distal tip of the measurement fibre was 
controlled with a powermeter (Field 
Master GS, Coherent Inc., USA). A dark 
spectrum was collected before each set of 
measurements by placing the distal tip of 
the fibre into a black box. This spectrum 
was used as the background spectrum for 
the system’s intrinsic fluorescence and was 
subtracted automatically from the samples’ 
spectra during data acquisition. Before and 
after each set of measurements the 
fluorescence spectrum of a stable solution 
of Rhodamine B (c=1e-6 M in ethanol) 
was collected as a reference in a 10 x 10 x 
30 mm3 quartz cuvette. For the 
measurements the distal tip of the optical 
fibre was put in slight contact with the 
epithelial (luminal) surface. 
Autofluorescence spectra were collected 
subsequently from healthy tissue and from 
the lesions. 
During the tissue AF measurements, 
particular attention was paid to ensure a 
perpendicular position of the fibre relative 
to the tissue surface was maintained. 
Whenever possible, for each type of lesion 
present in a sample, spectra were acquired 
at typically three different sites to access 
the intra-sample variations. In samples 
with more than one lesion, three 
measurements were performed on each 
lesion. 
A total of 179 spectrofluorometric 
measurements were collected: 116 from 
healthy bronchial tissue, 6 from sites with 
reactive changes, 24 from early neoplastic 
lesions and 33 from widely invasive 
cancers (Table 5.4.1). 
Data Processing 
The raw spectra, i.e. 
the acquired spectra 
after subtraction of 
the system 
background, were 
corrected for the 
peak value of the 
Rhodamine B 
reference spectrum at 
575 nm. The 
amplitude of the peak 
allows fluctuations of 
the excitation light 
intensity and 
detection sensitivity 
to be taken into 
 
Type of lesions  Cases Samples Measurements 
 Healthy tissue 17 25 116 
Basal cell hyperplasia    Reactive 
changes Squamous metaplasia 2 2 6 
Mild and moderate 
dysplasia 
1 2 7 
Pre-neoplasia 
Severe dysplasia/CIS 4 4 17 
Microinvasive carcinoma    
Neoplasia 
Invasive SCC 6 10 33 
 Total 18 26 179 
Table 5.4.1 Distribution of samples and histopathologies. The table shows the 
number of cases, samples, and measurements for the four histopathologic groups. 
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account and corrected for. These corrected 
spectra from different sets of 
measurements can be compared. The 
spectra were further corrected for the 
spectral response of the detection unit. For 
this purpose, the spectrum of a calibrated 
light source (The Eppley Laboratory, Inc., 
USA) equipped with a halogen lamp was 
collected by the spectrofluorometer. The 
resulting curve was compared with the 
specifications of the lamp’s emission and a 
correction function F(λ) was computed for 
the detection unit. Following this 
correction procedure, the spectra 
throughout this study can be compared 
between themselves and are expressed in 
relative units. All relative spectra measured 
from tissues belonging to the same 
histopathologic category were averaged 
and further normalised at their peak 
maximum. Moreover, for each sample the 
spectra corresponding to the same 
histopathologic category were averaged 
and compared with the corresponding 
spectra from other samples of the same 
patient as well with the average spectra 
from other lesions. This per patient 
comparison allowed us to directly compare 
the relative AF intensities and spectral 
shapes for the different categories of 
lesions without the bias of any interpatient 
fluctuations. 
In order to assess the spectral changes of 
the AF between the different 
histopathologic categories, we computed 
the intensity ratios between the green and 
the red spectral domains, as described by 
Zellweger et al. [20]. The spectra were 
separated in a green and a red spectral 
region, ranging from 495 nm to 570 nm 
and from 570 nm to 690 nm, respectively. 
This spectral decomposition was chosen 
according to the green and red channel 
detection ranges of the DAFE imaging 
system that is described in the following 
section. Integration of the spectra within 
these two wavelength ranges allowed us to 
compute intensity values for the green and 
the red spectral domain that can be 
compared to the green and red channel 
intensity values of the DAFE images as 
described below. 
Imaging system 
AF imaging of the samples was performed 
using the DAFE (Diagnostic 
AutoFluorescence Endsoscopy) system, 
commercialised by Richard Wolf 
Endoscopes GmbH, Germany. The system 
consisted of a filtered endoscopic light 
source (type Endo Light Projector 5137) 
and a filtered 3 CCD endoscopic video 
camera (type EndoCam 5506). The light 
source was equipped with an IR filtered 
300 W Xenon lamp. A two step flip-flop 
filter holder containing a grid and a colour 
band pass filter, respectively, allowed rapid 
changes between (i) conventional WL 
illumination and (ii) violet AF excitation at 
430 nm ± 40 nm. A liquid light guide 
delivered the light to the bronchoscope 
optics. The 3CCD camera was clipped to 
the eyepiece of the bronchoscopic optics 
and detected the WL and the AF images. 
The zoom objective of the camera had an 
integrated 475 nm long pass filter that 
rejected all violet excitation light from the 
AF images. The images were visualized on 
a monitor and were recorded by a digital 
video (DV) recorder (Sony Digital 
Videocassette Recorder DSR-11, Sony 
Corp., Japan). Three bulk samples 
exhibiting healthy bronchial wall, CIS and 
invasive SCC were examined with the 
DAFE system. For this procedure the 
samples were removed from the 5% 
buffered formalin solution, rinsed with 
sterile physiologic NaCl solution and 
placed on a black, non-fluorescing 
background. The samples were orientated 
by superposing the corresponding H&E 
stained slice. Autofluorescence imaging 
was performed with the DAFE system 
using a rigid 0° bronchoscope optics 
clipped to the camera. Excitation was 
performed with blue violet excitation with 
and without additional backscattered red 
light (BRL). The procedure was recorded 
on DV and three images per sample were 
digitised. Image analysis was performed as 
described above. After identification of the 
healthy tissue zone and the lesions zone on 
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the image, the red (R), green (G) and blue 
(B) intensity values were computed for 
both zones. All values were corrected for 
the image background and the gamma 
factor of the camera. The non-normalised 
((R/G)) and normalised red-to-green 
intensity ((R/G)norm) ratios were computed 
for the normal tissue and the tumour site 
for each image. The (R/G)norm ratio is the 
R/G on the tumour zone divided by the one 
on the normal tissue zone, i.e. (R/G)norm = 
(R/G)tumour/(R/G)normal. 
Results 
All samples had an overall pale white 
aspect with any macroscopic differences 
visible between healthy tissue and pre-
neoplastic lesions. The cross sections 
containing invasive cancer areas were well 
demarcated from adjacent structures. In 
several samples, cartilage clasps 
underlying the bronchial mucosa were 
visible in the cross section. 
Spectrofluorometric measurements 
The mean spectra for each histopathologic 
category are shown in Figure 5.4.2 with 
their standard deviations and the number of 
measurements “n”. The relative peak 
intensity decreases from metaplasia to 
healthy tissue, mild and moderate 
dysplasia, invasive SCC, and CIS or 
micro-invasive carcinoma. Standard 
variations of the mean value for the 
different types of lesions (inter-patient 
variations) were in the order of 36 % 
(range 26 % to 45 %). On a per patient 
analysis the relative standard deviations 
between samples of one patient (intra-
patient fluctuations) were found to be 36%. 
The peak intensities measured in a given 
sample (intra-sample fluctuations) showed 
a mean error of 23%. 
Figure 5.4.3 shows the same spectra 
normalised at their maximum for 
comparison of their spectral shape. Error 
bars are not shown in this graphic for 
better intelligibility. They can easily be 
deduced from Figure 5.4.2. All spectra 
corresponding to the 5 histopathologic 
categories nicely superimpose, suggesting 
no difference in the spectral shape for the 
different lesion categories. 
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Figure 5.4.2 Mean AF spectra from ex vivo 
samples. The mean AF spectra acquired from 
normal tissue (black with diamond), metaplasia 
(dotted dark grey with circle), dysplasia (light grey 
with triangle), CIS (dotted light grey with open 
square) and invasive tumour (dotted black with 
filled square) are shown with their standard 
deviations. The number of measurements used for 
computation of the mean is given for each 
histopathologic group. 
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Figure 5.4.3 Mean AF spectra from ex vivo 
samples. The mean AF spectra acquired from 
normal tissue (black with diamond), metaplasia 
(dotted dark grey with circle), dysplasia (light grey 
with triangle), CIS (dotted light grey with open 
square) and invasive tumour (dotted black with 
filled square) are shown with their standard 
deviations. The number of measurements used for 
computation of the mean is given for each 
histopathologic group. 
A per patient comparison of the relative 
AF intensities between the different types 
of lesions was possible in 7 patients with a 
total of 19 samples exhibiting both healthy 
tissue and pre- neoplastic or neoplastic 
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lesions. Fluorescence intensity ratios at 
510 nm between the AF spectra obtained 
from healthy bronchial wall and those 
obtained from invasive SCC, CIS, low 
grade dysplasia, or metaplasia, are shown 
in Figure 5.4.4 on a per patients basis. The 
mean intensity ratios between the AF from 
healthy bronchial wall and invasive SCC 
(1.7 ± 0.3) and healthy bronchial wall and 
CIS (2.0 ± 0.6), respectively, are plotted as 
dotted lines in the graphics. The other 
mean ratios, 1.2 for low grade dysplasia 
and 1.0 ± 0.3 for metaplasia, are not shown 
for clarity. While there were no differences 
in the AF intensities between healthy, 
metaplastic and low grade dysplastic 
conditions, the fluorescence intensities of 
invasive SCC and CIS were about two 
times smaller than those of the  healthy 
bronchial tissuesfor a given patient.  
The intensity ratios between the red and 
the green region of the spectra computed, 
as described above, to be (R/G) = 0.35 for 
all histopathologic categories. 
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Figure 5.4.4 Per case analysis of AF intensities. 
The figure shows the normalised R/G intensity 
ratios between normal tissue and tumour 
(diamonds), CIS (filled triangles), dysplasia (open 
triangles) and metaplasia (circles), respectively. 
The dotted lines show the mean values for the 
normal/tumour and normal/CIS ratios with the 
error bars depicting standard deviations 
Imaging 
All samples exhibited a homogenous pale 
white visual aspect when examined with 
the DAFE system. None of the neoplastic 
or pre-neoplastic sites identified by 
standard histopathologic analysis was 
visible by fluorescence imaging. One 
example of DAFE image of formalin fixed 
samples is shown in Figure 5.4.5. The 
original colour image was split into its red 
and green colour channels, and presented 
as greyscale images. Histopathologic 
analysis revealed invasive SCC and 
healthy mucosa. The tissue areas 
corresponding to the healthy mucosa and 
the neoplastic lesion are encircled in both 
images. The corresponding spectra 
obtained on the marked zones are shown 
for comparison. The image below shows a 
typical example of an AFB image obtained 
from the in vivo study reported in [1]. Once 
more the original colour image was split 
into its red and green colour channels. The 
lesion on the spur in the centre of the 
image was graded as CIS. The AF decrease 
on the lesion relative to the surrounding 
normal tissue is clearly visible in the both 
images. However, the intensity decrease is 
more marked in the green channel image 
than in the red one. 
Three images from three different samples 
were digitised and analysed according to 
the procedure described in the Materials 
and Methods section. The mean (R/G) 
ratios computed for the tumour tissue and 
the normal tissue were 0.41 ± 0.04 and 
0.43 ± 0.06, respectively. The mean 
normalised (R/G) ratio was 0.96 ± 0.17, 
signifying no visible spectral contrast 
between the healthy bronchial wall and the 
pre-neoplastic lesion in the formalin fixed 
samples with AFB. When comparing the 
mean R/G ratios of neoplastic and normal 
mucosa computed from imaging with those 
computed from the spectrofluorometric 
measurements (0.35), the relative amount 
of red AF detected with the imaging 
system is higher than that measured with 
contact point spectroscopy. It should be 
noted, that all images of the formalin fixed 
samples could be detected without 
employing the intensification function of 
the DAFE camera which must be used for 
in vivo imaging. This observation indicates 
that the AF intensity of formalin fixed 
samples is significantly larger than in the 
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in vivo conditions. This electronic signal 
intensification must be set to maximum for 
in vivo imaging in patients. 
Finally, it should be pointed out, that in all 
samples no spectral contrast between the 
healthy bronchial wall and the various 
lesions was observed with DAFE imaging, 
irrespective of the use or non use of 
additional backscattered red light in the 
DAFE excitation. 
Discussion 
Since fundamental studies on the optical 
and spectral properties of human tissue are 
encumbered by important restrictions from 
ethical and instrumental sources, few 
studies have been conducted under in vivo 
conditions [2, 20, 21, 27]. Studies on ex 
vivo tissue samples allow higher precision 
and control of measurement parameters 
than in vivo studies. For these reasons, 
most studies of human autofluorescence 
have relied on ex vivo measurements of 
fresh or fixed human samples. 
However, in the case of human bronchial 
tissue autofluorescence, in vivo and ex vivo 
studies revealed different, if not 
contradictory results. Zellweger et al. [20] 
performed non-contact spectrofluorometric 
studies of human bronchial wall in vivo 
using an endoscopic fibre bundle probe. 
They observed a constant decrease in the 
AF intensity increasing severity of the 
tumor progression from histologically 
normal mucosa to invasive SCC. The AF 
intensity measured on sites of normal 
mucosa exceeded that measured on early 
and advanced neoplastic lesions by a factor 
of 10. Moreover this group showed that the 
intensity decrease is more important for 
emission wavelengths smaller than 600 
nm, concluding that there is a significant 
spectral contrast in AF emission from 
healthy bronchial tissue and neoplastic 
lesions. In another in vivo 
spectrofluorometric study using a fibre 
bundle probe put in slight contact with the 
tissue, Qu et al. [21] found no spectral 
contrast between healthy bronchial wall 
and pre-neoplasia or invasive cancers. 
Figure 5.4.5 (a) DAFE image of one sample with healthy tissue and a zone diagnosed as invasive SCC
(depicted as “lesion”). The colour DAFE image was split into its red and green colour channels, to reveal the
visual aspect for each spectral range. The zones of normal tissue and tumour are demarcated in both images.
The mean spectra measured from the two zones are shown below. Image analysis revealed no significant
intensity differences between the two zones. (b) An example from in vivo imaging is shown (image obtained
from the study reported in [1]. The image shows a severe dysplasia on the central part of the spur and was also
split into its red and green colour channels. The intensity decrease on the lesion relative to the healthy
surrounding is more distinct in the green channel image. A blood spot showing a strong intensity decrease in
the green channel intensity is visible in the front plane of the image. 
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However, spectra from the same bronchial 
site measured in vivo and after snap frozen 
biopsy (without formalin fixation), showed 
a decrease in the fluorescence intensity for 
the ex vivo tissue.  
The spectrofluorometric study presented 
here on formalin fixed human bronchial 
samples revealed no spectral contrast 
between the healthy tissues, pre-neoplasia 
and invasive cancers. However, we 
observed a decrease of the AF intensity in 
early malignant lesions and invasive SCC. 
The illumination-detection scheme in the 
spectrofluorometric study presented here 
differed from those employed by 
Zellweger and Qu, respectively. Our 
spectrometer works with a single optical 
fibre that was put in slight contact with the 
bronchial mucosa and served for both 
fluorescence excitation and detection. 
Zellweger et al. as well as Qu et al. used 
optical fibre bundles with separated fibres 
for excitation and detection, and the probe 
was held at 3.5 mm distance from the 
epithelium [20] or put in slight contact 
with the epithelium [21], respectively. 
Several publications report a sensitivity of 
the fluorescence detected from turbid 
media such as biological tissues on the 
illumination-detection schemes [28-30]. 
Sensitive parameters are the distance 
between the illumination (or excitation) 
and detection units and the probe tissue 
distance, among others. The probe-tissue 
distance influences the detected 
fluorescence intensity primarily [31], and 
additionally the shape of the detected 
spectrum [2]. In an in vivo study of the 
human buccal mucosa AF Zellweger et al. 
[2] found changes in the relative detected 
fluorescence intensities around 540 nm and 
630 nm, i.e. the R/G ratios, with changing 
probe-tissue distances. The propagation of 
photons within the tissue is a function of 
their wavelength. Photons with longer 
wavelengths propagate further away from 
their emission spot than photons with short 
wavelengths. Consequently, 
spectrofluorometric contact measurements 
probing only a narrow field of the tissue 
are likely to miss a portion of the long 
wavelength fluorescence photons. This is 
no longer the case for broad field 
detection, i.e. distant spectrofluorometric 
measurements or imaging. This is in good 
agreement with the differences in the R/G 
ratios computed from the DAFE images 
and the fluorescence spectra in our study. 
While these differences in illumination-
detection schemes might explain the 
discrepancies between observations of the 
in vivo measurements reported by 
Zellweger and Qu, the differences between 
the in vivo and ex vivo for formalin fixed 
sample spectroscopies, can not be 
explained by the measurement geometry 
alone. Neither spectrofluorometric contact 
point measurements on the formalin fixed 
samples nor broad field imaging showed 
any spectral contrast between healthy 
bronchial wall and pre-neoplastic and 
neoplastic lesions. Since DAFE has proved 
to be highly sensitive to detecting early and 
pre-neoplastic lesions in extended clinical 
studies, we can assume that the tissue areas 
identified as pre-neoplastic or neoplastic 
by conventional histologic analysis in our 
samples would have shown a spectral AF 
contrast in in vivo DAFE bronchoscopy. 
This does not appear to be the case with 
the ex vivo measurements. However, 
imaging of the formalin fixed samples did 
not require image intensification, while in 
vivo imaging always does. This suggests a 
distinct increase of the AF intensity in the 
formalin fixed samples compared to in vivo 
conditions. 
The increase of the tissue AF intensity 
after fixation in formalin has been 
described.by Filippidis et al. [22] and 
Majumder [24]. These groups reported an 
increase of AF intensity in formalin fixed 
human abdominal aortic and breast 
samples, when compared to freshly excised 
specimens. Similarly, Xu and coworkers 
[25] found an AF intensity increase on the 
order of 1 magnitude within 2 days 
following immersion of mouse skeletal 
muscle in formalin. The phenomenon of 
AF intensity increase after formalin 
fixation is not completely understood, but 
the influence of physico-chemical 
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processes occurring during fixation, such 
as enzyme degradation and dehydration, 
along with changes in blood content are 
discussed by Xu et al. [25]. This second 
factor is likely to play the most important 
role since no change of the AF emission 
spectral shape is observed under blue-
violet light excitation between the in vivo 
and formalin fixed samples. 
In addition, the spectral properties of 
blood, one of the principal absorbers of 
visible light in biological tissues, contained 
in samples are strongly modified by the 
formalin fixation process. Haemoglobin, 
the light absorbing component in blood, 
has been shown to leak from human red 
blood cells at short time intervals 
following formaldehyde immersion [32] 
and to undergo important molecular 
modifications. Farbiszewski and coworkers 
[33] reported that the absorption of 
haemoglobin decreases significantly 
following the formaldehyde fixation 
process. There are two consequences of the 
reduced blood absorption in the formalin 
fixed samples on the fluorescence spectra 
excited with blue-violet wavelengths: on 
the one hand, more excitation light reaches 
deeper tissue layers and is available for the 
excitation of AF. On the other hand, less 
fluorescence generated in the different 
layers is reabsorbed. Both effects lead to 
an increase in the fluorescence intensity. 
Absence of contrast 
Blood content changes in the bronchial 
mucosa and sub-mucosa are also discussed 
as a potential mechanism for the spectral 
tumour-to-normal AF contrast observed in 
in vivo human bronchi [21, 34, 35]. Indeed, 
early bronchial cancers and pre-neoplasitc 
lesions are characterised by a distinct 
increase in the microvessel density, i.e. 
number of blood vessels  and by this the 
blood content in a given tissue volume, 
below the epithelial layer relative to the 
normal mucosa [36, 37]. Under in vivo 
conditions pre-neoplastic and neoplastic 
lesions show a higher absorption of the 
violet excitation light and a decrease of the 
emitted AF intensity compared to healthy 
bronchial wall. Due to the absorption 
spectrum of haemoglobin, the re-
absorption of the AF is stronger in the 
green wavelength region (490 nm to 600 
nm) than at longer wavelengths (>600 nm), 
generating the spectral AF contrast 
observed between bronchial sites with 
healthy mucosa and pre-neoplastic or 
neoplastic lesions in vivo. This can also be 
seen when comparing in vivo AF spectra 
with those from formalin fixed samples. A 
typical in vivo AF spectra from normal 
bronchial wall (adapted from [2]) is shown 
in Figure 3. The shapes of the in vivo and 
formalin spectra differ only in the 
absorption region of haemoglobin, i.e. 
between 530 nm and 600 nm. It should be 
noted that the relative increase of the tissue 
blood content in pre-neoplastic and 
neoplastic bronchial lesions might not be 
the only contrast mechanism. Spatial 
distribution of the fluorochromes in the 
bronchial wall and the thickening of the 
epithelial cell layer [17, 21, 34] may also 
contribute to this phenomenon. 
As already mentioned before, the bronchial 
wall has a distinct layered structure. It has 
been shown that the major contribution of 
AF originates from the sub-epithelial 
layers, while the epithelium is hardly 
fluorescing when excited with blue-violet 
light [21, 38, 39]. Cancerogenesis in the 
bronchi comes along with an increase in 
the cell nuclei density and nuclei size. In 
addition a thickening of the epithelium is 
frequently observed. Most of the pre-
neoplastic lesions investigated in this study 
were associated with a thickening of the 
epithelial layer relative to the healthy 
mucosa. The thickening of the epithelium 
and the modifications in size and density of 
the light scattering nuclei could act as a 
screen for the AF emitted from the sub-
epithelial layers including the lanima 
propria and the submucosa. Our results 
demonstrate that the intensity contrast is 
not totally inhibited by the formalin 
fixation process. Pre-neoplastic and 
neoplastic lesions show a decrease in the 
AF intensity relative to healthy tissues 
after formalin fixation. Since no spectral 
contrasts are observed between healthy 
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bronchial wall and neoplastic lesions, it is 
very likely that the epithelium thickening 
contributes to the normal-to-neoplasia 
intensity contrast for both in vivo and 
formalin fixed specimens. Since the 
intensity contrast after fixation is much 
smaller than in vivo [2, 20, 21, 27], the 
intensity contrast induced by the 
mechanisms mentioned above will be 
lower than that induced by changes in the 
mucosa blood content under in vivo 
conditions. Since the increase in cell nuclei 
density is more important in CIS and 
invasive carcinoma than in low grade 
dysplasia or reactive changes, the AF 
decrease in these latter lesions will be less 
important. This is in reasonable agreement 
with our results as observed in Figure 2. 
It should be noted, that apart from the 
aforementioned contrast mechanisms, 
changes in (i) the metabolic state of 
fluorochromes (especially NADH and 
flavins) [34, 40], (ii) the biochemical and 
biophysical environment (mainly pH and 
oxidation), and (iii) the concentration of 
fluorochromes, could also contribute to 
differences in the AF between bronchial 
sites with healthy mucosa and pre-
neoplastic or neoplastic lesions . However, 
recently reported fluorescence lifetime 
measurements on in vivo and ex vivo 
human bronchi [41] have not shown any 
significant differences in the fluorescence 
lifetimes, and the photonic weight of the 
AF of healthy bronchial wall and pre-
neoplastic or neoplastic lesions under in 
vivo conditions and after formalin fixation. 
This indicates that physico-chemical 
changes play a secondary role, if any in the 
discrepancies between the in vivo and 
formalin fixed sample AF spectroscopy. 
All spectrofluorometric measurements 
performed on a given type of lesion 
(healthy tissue, squamous metaplasia, mild 
dysplasia, CIS, and invasive SCC) 
exhibited fluctuations of the AF intensities 
measured in samples from different 
patients (inter-patient fluctuations). They 
also exhibited fluctuations between 
samples from a given patient (intra-patient 
fluctuations), as well as within a single 
sample (intra-sample fluctuations). The 
inter-patient and intra-patient fluctuations 
are mainly related to the anatomical origin 
of the samples. All samples in this study 
were sections collected from different 
bronchi of various sizes, within the 
bronchial tree. The normal bronchial wall 
histology undergoes changes between the 
central and peripheral portions of the 
tracheo-bronchial tree, such as decrease in 
the epithelium thickness and complexity, 
number and distribution of specific cell, 
such as Clara cells, and the spatial 
distribution of smooth muscle and cartilage 
within the bronchial wall [42]. These 
changes influence the AF signal detected 
from bronchi of different size and 
topography in a given patient, and of 
different patients. The intra-sample 
fluctuations however, are likely to result 
from heterogeneities on a sub-millimetric 
scale in the tissues. Fluctuations of the AF 
intensity on this scale might be induced by 
the discontinuities in the smooth muscle 
layer and cartilage in the bronchial wall, or 
by the presence of elastic fibres underlying 
the epithelium. The latter are organised in 
cord-like structures that run parallel to the 
longitudinal axis of the bronchi. In DAFE 
performed in vivo these “cords” are clearly 
visible as brightly fluorescing tracks in the 
bronchial wall, signifying that their AF is 
higher than that of the surrounding 
structures. Spectrofluorometric 
measurements with a single fibre probe, 
like those performed in this work, are 
highly sensitive to such heterogeneities, 
while broad field measurements (imaging) 
are “smoother” [43]. Apart from the tissue 
heterogeneities mentioned above, the shot 
noise in the spectrometer also contributes 
to the inter- and intra-patient, as well as to 
the intra-sample variations in the measured 
AF intensities. Inhomogeneities in the 
spatial distribution of the excitation light 
and anatomy based three dimensional 
image geometry are responsible for 
fluctuations in DAFE image analysis. The 
AF intensity values computed from 
different sites in a given DAFE image 
depend on the distance between the site 
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and the endoscope, as well as on the angle 
of view. However, those intra-sample 
fluctuations were reduced by comparing 
only intensity values from sites in the same 
image plane. Moreover, only intensity 
values obtained from images showing the 
samples at comparable distances from the 
endoscope were compared in this study, 
reducing inter- and intra-patient variations. 
Conclusions 
Formalin fixed bronchial samples exhibit 
no spectral contrast between histologically 
healthy tissue, squamous metaplasia, low 
grade dysplasia, CIS and invasive SCC 
with either spectrofluorometric contact 
point measurements, or the DAFE 
imaging. The AF intensity contrast 
between bronchial sites with healthy 
mucosa and neoplastic lesions is strongly 
diminished but still exists for all categories 
of early and advanced neoplasia but is 
absent for reactive changes. The overall 
AF intensity is increased compared to in 
vivo measurements.  
These observations indicate that the 
principal mechanisms responsible for the 
spectral contrast between healthy bronchial 
tissue and pre-neoplasia or neoplasia are 
destroyed or at least significantly altered 
by either tissue death and/or the formalin 
fixation process. Blood flow seems to play 
a key-role in the mechanism generating the 
spectral AF contrast between healthy tissue 
and early bronchial lesions. In contrast to 
this, the mechanisms responsible for the 
intensity contrast are altered, but not 
destroyed by tissue death and/or the 
formalin fixation process. The thickening 
of the epithelium in the measured tissue 
samples is likely to be the cause of this 
observed phenomenon. Moreover, we 
demonstrated that formalin fixed bronchial 
samples are not suited for studying the AF 
contrasts between healthy bronchial wall 
and early neoplasia and their mechanisms. 
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Abstract 
Autofluorescence bronchoscopy (AFB) is a highly sensitive tool for the detection of early 
bronchial cancers. However, its specificity remains limited due primarily to false positive 
results induced by hyperplasia, metaplasia and inflammation. We have investigated the 
potential of blue-violet backscattered light to reduce false positive results during AFB. The 
backscattering properties of normal and abnormal bronchial mucosae were investigated in a 
clinical imaging study for blue-violet wavelengths ranging between 410 nm and 490 nm with 
the DAFE (Diagnostic Auto-Fluorescence Endoscopy) system equipped with a variable 
bandpass filter. Our results showed that the detection of blue-violet light has the potential to 
significantly reduce the number of false positive results in AFB. In addition we determined 
the optimal spectral design of the emission filter dedicated to the detection of this blue-violet 
light with the DAFE system. 
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Introduction 
Bronchial carcinoma remains the most 
common cause of cancer-related death for 
both men and women in the western world 
[1, 2] and shows an increasing incidence in 
developing countries [3]. The progressive 
nature and the fact that most bronchial 
cancer cases are detected at an advanced 
stage [4], among others, contribute to the 
poor prognosis of this disease. Indeed, 
prognosis is much more favourable if the 
cancer is detected and treated at an early, 
and if possible, in situ stage [5, 6]. 
Technical advances in the chest X-ray, 
positron-emission tomography (PET) and 
the development of high-resolution spiral 
computer tomography (CT) have improved 
the detection of small peripheral bronchial 
cancers in high risk groups [7]. However, 
white light bronchoscopy (WLB) and more 
specifically autofluorescence 
bronchoscopy (AFB) remain the only 
diagnostic techniques available to detect 
and biopsy central endobronchial lesions 
locally. While the sensitivity and 
specificity of WLB remains limited, AFB 
in the tracheo-bronchial tree has been 
shown to be a powerful tool for the 
detection of early endobronchial cancers, 
with a sensitivity up to twice that of 
conventional WLB [8, 9]. Several 
autofluorescence (AF) imaging systems are 
commercially available. Their imaging 
functions are based on the detection of the 
relative or absolute difference of the AF 
intensity [9]. 
Though the sensitivity of AFB is high, its 
specificity remains limited [8, 10]. 
Conditions such as metaplasia/hyperplasia 
and inflammation of the bronchial tissue 
may produce false positive findings with 
AFB [10, 11], resulting in unnecessary 
biopsies. 
Thickening of the epithelium and increased 
vessel growth (angiogenesis) among others 
are considered to be at the origin of the AF 
contrast observed between healthy tissue 
and early neoplastic lesions during AFB 
[12]. Several authors have reported 
increased microvessel density in the sub-
epithelial layer of bronchial squamous 
dysplasia and carcinoma in situ (CIS) [13, 
14]. Vascular changes are also found in 
pre-neoplastic, i.e. inflammatory and 
metaplastic lesions, but are characterised 
by vessel sizes and distribution patterns 
different from those observed in neoplastic 
and early cancerous lesions. Inflammation 
and metaplasia exhibit a minor increase in 
the number of vessels along with increased 
vessel cross section surface, while 
angiogenesis in dysplasia and CIS is 
characterised by a significant increase in 
the number of small diameter vessels [13]. 
Moreover, in a high number of dysplastic 
lesions, the presence of capillaries being 
closely juxtaposed or even projecting into 
the bronchial epithelium [7, 15] have been 
reported. These lesions, termed angiogenic 
squamous dysplasia (ASD), are suspected 
to have a higher probability to become 
squamous cell carcinoma than dysplasia or 
CIS without the presence of the additional 
small diameter blood vessels [7]. All 
differences in the neovascularisation 
pattern are associated with differences in 
blood volume, and thereby haemoglobin 
concentration in the tissue. This is 
particularly notable for bronchial tissues, 
as described by Qu et al. [12]. Blue-violet 
light is strongly absorbed by haemoglobin. 
Thus, a tissue with a high concentration of 
haemoglobin, i.e. a high concentration of 
blood, will show higher absorption of blue 
light than tissues with a low concentration 
of blood. The method of detecting blue-
violet backscattered light with the AFB 
system in combination with the AF signal 
itself, has the advantage of both the 
different absorption characteristics of 
inflammation/metaplasia and 
dysplasia/CIS, as well as the differences in 
AF in healthy tissues and lesions which 
lead to improved specificity of the imaging 
system. 
We present two clinical studies that 
investigate the potential of backscattered 
blue-violet light to increase the specificity 
of AFB for early cancerous endobronchial 
lesion detection. Moreover we added the 
blue-violet backscattering to the AFB 
system,  which we previoudly developed in 
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collaboration with Richard Wolf 
Endoscopes (Knittlingen, Germany). The 
first study which we for convenience here 
name our "reflectance imaging study," was 
designed to identify the optimal violet 
wavelength. It was performed by 
positioning a linear variable narrow band 
pass filter (LVBF) in front of the camera of 
our imaging system while operated in the 
conventional WL mode. We measured the 
intensity contrast of the violet 
backscattered light on fluorescence 
positive lesions as compared to the 
surrounding fluorescence negative tissues 
at different backscattered blue-violet 
wavelengths.  
The second study, or “implementation 
study”, was carried out to determine the 
optimal intensity of detected backscattered 
blue light to be added to the AF signal of 
the AFB system. This was performed by 
varying the detection cut-on wavelength of  
of a linear variable high pass filter (LVHF) 
placed in front of the camera of the 
imaging system operated in the AF mode. 
In measuring the ratios between the green 
and blue channel intensities for different 
wavelengths, we estimated the optimal 
fraction of blue-violet excitation light for 
backscattering detection. 
Materials and Methods 
Reflectance imaging Study 
AFB and WLB were performed in the 
tracheo-bronchial tree using the so called 
DAFE (Diagnostic AutoFluorescence 
Endoscopy) system, commercialised by 
Richard Wolf Endoscopes GmbH, 
Germany. The system consisted of a 
filtered endoscopic light source and a 
filtered 3CCD endoscopic video camera. 
The light source (type Endo Light 
Projector 5137, Richard Wolf Endoscopes 
GmbH, Germany) () was equipped with an 
IR filtered 300W Xenon lamp (emission 
range 390 nm to 680 nm)  and a 2 step flip-
flop filter holder containing (1) a grid for 
conventional white light excitation  and (2) 
a square “top hat” profile violet colour 
band pass filter for AF excitation at 430 
nm with a FWHM of 80 nm. A foot switch 
allowed changing between white light 
illumination (WL mode) and violet 
fluorescence excitation (AFB mode). A 
liquid light guide delivered the light to the 
bronchoscope optics. The WL and AFB 
images were detected by the 3 CCD 
camera (type EndoCam 5506, Richard 
Wolf Endoscopies GmbH, Germany) that 
can be clipped to the endoscopic optics. 
The zoom objective of the camera had an 
integrated 475 nm long pass filter 
(emission filter) that rejected all violet 
excitation light. The images were 
visualized on a monitor and were recorded 
by a digital video (DV) recorder (Sony 
Digital Videocassette Recorder DSR-11, 
Sony Corp., Japan). The system was used 
with both conventional rigid optics 
(Hopkins' 0°, Storz Endoscopes, Germany) 
and bronchofiberscopes (Olympus Type 
BF, Olympus, Japan).  
Patients undergoing autofluorescence 
bronchoscopy in the ENT department of 
the CHUV University Hospital in 
Lausanne (Switzerland) and the Centre for 
Pneumology and Thoracic Surgery in 
Hemer (Germany) were included in the 
multicentric reflectance imaging study. 
Indications for AF bronchoscopy 
candidates were known or suspected 
squamous cell carcinoma in the bronchi 
(standard diagnostic workup or pre-
therapeutic bronchoscopy), and/or 
resection of lung cancer (follow up 
bronchoscopy), and/or atypia in the 
sputum, and/or abnormal X-ray findings, 
as well as complaints of dyspnea or cough 
without suspect findings in sputum or X-
ray. All bronchoscopies were performed 
according to the guidelines approved by 
the ethical committee of the CHUV 
University Hospital and the Hemer Centre 
for Pneumology and Thoracic Surgery. AF 
bronchoscopy revealed 12 fluorescence 
positive lesions in 12 patients that were 
further examined with the LVBF set-up. 
"Optical" exclusion criteria for these 
measurements were endobronchial 
bleeding or a very lateral position of the 
lesion that prohibited a frontal view during 
measurements. 
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For the reflectance imaging study the 
detection filter located in the camera 
objective comprising the emission filter, 
was replaced by the LVBF filter (Oriel 
Veril S-60, Oriel Optik GmbH, Germany). 
This filter covered a wavelength range 
from 400 to 700 nm. Full half width 
maximum (FWHM) of the transmission 
bands was 12 nm ± 1 nm and the mean 
peak transmission was 43% ± 2% for 
central wavelengths ranging from 410 to 
500 nm. To take measurements, the filter 
was placed in a custom-made endoscopic 
filter holder in which the filter could be 
moved along its longitudinal axis by a 
worm gear mechanism. The actual tuned 
central wavelength readout came from a 
calibrated scale on the filter holder. Each 
scale element was 10 nm and the 
measurement precision was ± 3 nm.  
In the case of AF positive (AF+) lesions, 
i.e. lesions exhibiting a more reddish 
fluorescence than the surrounding healthy 
tissue, the optics were positioned in a 
stable position relative to the lesion in the 
AF mode and measurements with the 
LVBF filter were performed. 
After mounting and focussing, the VBPF 
was tuned from 490 nm central wavelength 
to 410 nm central wavelength in steps of 
10 nm. The whole procedure was recorded 
with the DV recorder. All AF+ sites were 
biopsied following the measurements. 
Histopathologic analysis revealed 3 cases 
of healthy tissue, 1 inflammatory lesion, 2 
scar lesions, 1 hyperplastic lesion, 2 
metaplasia, 1 mild dysplasia and 2 invasive 
squamous cell carcinomas (SCC). For 
further analysis these pathologies were 
grouped into 5 classes, namely 1) 
neoplasia, including invasive SCC and 
dysplasia, 2) scar lesions, 3) inflammation, 
4) metaplasia, and 5) normal bronchial 
wall, including healthy mucosa and 
hyperplasia. The LVBF video sequences 
were digitised using the IEEE1394 
interface of the DV recorder and a portable 
personal computer. Still images for each 
wavelength were digitised in the 24-bit red, 
green and blue (RGB) mode. The colour 
intensity levels in the red (R), green (G) 
and blue (B) channels were computed on 
the fluorescence positive lesions and on the 
surrounding fluorescence negative tissue. 
All values were corrected for the image 
background and the gamma factor of the 
system. The latter relates the video signal 
voltage “V” and the detected illumination 
intensity “I” through the correlation V=Iγ. 
In order to quantify the relative reflectivity 
of the backscattered blue-violet light on the 
AF+ and the surrounding non-suspicious, 
i.e. AF negative (AF-) tissue sites, we 
computed the ratio of the blue intensity 
levels on these two tissues types. 
The errors related to the image analysis 
procedure were estimated by computing 
and comparing the intensity level values 
and ratios from multiple AF+ and AF- 
zones selected arbitrarily within a sample 
image. The variations between the 
computed values were in the order of 
±10% for the intensity and ± 20% for the 
intensity ratios. 
The Implementation Study 
The main goal of the implementation study 
was to determine the amount of detected 
backscattered blue-violet light intensity 
best suited for the simultaneous detection 
of the AF and the backscattered blue-violet 
light with the DAFE system. Here we 
established the position of the cut-on 
wavelength of the emission filter in order 
to detect similar green AF and 
backscattered blue-violet intensities. 
For this purpose we used the LVHF filter 
(LVF-HH, Ocean Optics BV, The 
Netherlands) to vary the amount of blue-
violet excitation light detected by the 
DAFE camera. The cut-off wavelengths of 
this filter ranged from 300 nm to 750 nm 
with a transmission of 85%. The slope of 
the cut-off edge was 20 nm from 10% to 
90% of the total transmission. For the 
endoscopic measurements the LVHF filter 
was mounted in the endoscopic filter 
holder described in our reflectance imaging 
study. The LVHF scale on the filter holder 
had a precision of ± 2 nm and an accuracy 
of 5 nm with the major scale elements 
being spaced 20 nm. The filtered DAFE 
camera objective was replaced by an 
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unfiltered objective and the LVHF filter, as 
in the first study. All measurements with 
the LVHF filter were performed on 
presumably healthy, non-fluorescing 
mucosa of the main carina. The 
bronchoscope was positioned in front of 
the carina and the WL and AF aspects of 
the tissue were recorded. After setting the 
light source to the AF mode, images were 
recorded on the DV tape for analysis while 
tuning the LVHF filter from 460 nm to 510 
nm in 5 nm increments.  
These measurements were performed in 6 
patients undergoing AF bronchoscopy in 
the ENT department of the CHUV 
University Hospital in Lausanne, 
Switzerland. Indications for AF 
bronchoscopy were the same as listed 
above. As all LVHF measurements were 
performed on fluorescence negative main 
carinae, "optical" exclusion criteria for this 
study were fluorescence positive findings 
on the main carina, bleeding of the mucosa 
as well as heavy secretion. 
The image digitisation procedure was 
identical to that described in the first study. 
In the case of the LVHF measurements, 
one zone on the fluorescence negative 
carina was selected for computation of the 
G and B intensity level values. The blue 
colour channel of our DAFE camera 
covered a wavelength band from 410 nm to 
500 nm, while the green colour channel 
detected wavelengths between 500 nm and 
570 nm. After correction for the image 
background the green to blue (G/B) 
intensity level ratios for the selected areas 
were computed. No correction for the 
system's gamma factor was applied 
because in this study we were interested 
only in our system's inherent 
characteristics, not absolute values. 
Results 
The Reflectance Imaging Study 
All measurements of the first study were 
performed for central transmission 
wavelengths ranging from 490 nm to 410 
nm in steps of 10 nm. However, in some 
cases not all images corresponding to this 
wavelength range could be used for data 
analysis. Some images recorded for the 
longer wavelengths showed extended 
zones of saturation, while in some other 
cases, the images obtained around 410 nm 
backscattered wavelength were too dark 
for image analysis. Generally, the 
brightness of the images decreased for 
shorter wavelengths, due to the decreasing 
sensitivity of the camera at those 
wavelengths. The computed healthy-to-
lesion blue-violet intensity ratios versus the 
wavelength are shown in Figure 5.5.1 for 
all cases. All symbols belonging to the 
same patient were connected by lines for 
visualisation. The error bars are shown in 
Figure 5.5.1 for selected points only to 
preserve visual clarity. 
Ratios around 1 indicate that no visible 
difference (contrast) in the backscattered 
blue light between the AF+ site and its AF- 
surrounding tissue site was detected, while 
ratios exceeding 1 signify that the 
backscattering was higher on the AF- 
surrounding tissue than on the AF+ site. 
No correlation between the histopathology 
and the computed ratios could be found. 
This is most likely due to the interpatient 
fluctuations of the AF-/AF+ ratios for a 
given histopathology and a given 
wavelength. These were in the order of 
20% for (pre-)neoplastic lesions and up to 
66% for normal bronchial wall from the 
mean values. 
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In order to compare the shape of the 
curves, all ratios were normalized at 440 
nm, the intersecting wavelength of the 
absorption spectrum of oxy- and deoxy-
haemoglobin. In addition, data were 
available for all cases at this wavelength. 
Finally, normalization at other wavelengths 
(430 nm - 460 nm) did not modify the 
results significantly (data not shown). The 
normalized ratios as a function of the 
wavelength are shown in Figure 5.5.2. All 
ratios are affected by the 20% error 
induced by image analysis as described in 
the first study. For the sake of visibility the 
values are presented in two separate 
graphs, A and B: Figure 5.5.2A presents 
the normalised ratios for neoplasia, 
inflammation and scar tissue, and Figure 
5.5.2B the normalised ratios for normal 
bronchial wall and metaplasia. 
It can be seen from Figure 5.5.2B that the 
normalised ratios for normal, metaplastic 
and hyperplastic bronchial wall, showed no 
significant wavelength dependence. Only 
one of these cases (metaplasia) showed a 
reddening of the bronchial wall under WL 
bronchoscopy (data not shown). All other 
cases were not considered suspicious under 
WL observation. In contrast, all lesions 
grouped in Figure 5.5.3A showed a 
wavelength dependence of the normalised 
ratio, its value increasing for short 
wavelengths for all sites except the 
inflammation. In the later case the 
normalised ratio exceeded 2 at 490 nm, 
and decreased rapidly with decreasing 
wavelength, reaching 1 for wavelengths 
lower than 440 nm. The spur analysed in 
this case was thickened, but not reddish 
under WL observation (data not shown). 
For the scar tissues the normalised ratios 
were about 1 for wavelengths < 440 nm, 
increasing rapidly for shorter wavelengths 
and exceeding 2 at 410 nm. In one case, 
WLB revealed a reddish zone with a 
geometry corresponding to the AF+ area. 
The other scar tissue was not considered 
suspicious under WL observation (data not 
shown). 
The three neoplastic and cancerous lesions 
showed a constant normalised ratio for 
wavelengths > 430 nm, and an increase of 
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Figure 5.5.1. Ratios of blue image intensities on AF- and AF+ sites as a function of the detected
backscattered wavelength. The mapping of the symbols is given in the legend. All ratios computed
from the same case are connected by lines for visual support. The error bars represent the 20%
error resulting from the image analysis procedure. For the sake of legibility error bars are shown
for selected data points only. 
Chapter 5.5 – Improvement of the Specificity…using backscattered Blue-Violet Light 
 
127 
these ratios for shorter wavelengths. None 
of these cases showed a reddening under 
white light observation (data not shown). 
However, both squamous cell carcinomas 
were suspicious under WL, one due to a 
spur thickening and the other due to the 
presence of a slightly exophytic mass. 
The Implementation Study 
Six patients were involved in the second 
study which was based on the use of the 
LVHF filter. In all cases the presumably 
healthy and AF- main carina was 
examined, with cut-off wavelengths 
ranging between 460 nm and 510 nm. The 
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Figure 5.5.2 A and B: Normalized ratios of the backscattered blue light from AF- and AF+ tissue sites. The data 
and the assignment of the symbols are the same than in Figure 5.5.1, but the data have been separated into two 
classes: those showing a wavelength dependence (Figure 5.5.2A) and those showing no significant wavelength 
dependence (Figure 5.5.2B). It should be noted, that the ratio scale is reduced by a factor 2 compared to Figure
5.5.1. 
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computed G/B ratios for all cases are 
shown in Figure 5.5.3 for wavelengths 
ranging between 460 nm and 495 nm. The 
ratios for wavelength > 495 nm exceeded 
10 [a.u.] and are therefore not relevant for 
the presentation of the results. The dotted 
horizontal line depicts the value of 1 for 
the G/B ratio, i.e. the ratio at which the 
blue reflectance image and the green AF 
image are detected with the same intensity. 
For G/B ratios below this threshold, the 
blue backscattered light overwhelms the 
green AF, thus overwhelming the 
sensitivity information contained in the AF 
contrast. The emission spectrum of the 
blue-violet DAFE excitation light is shown 
in the left part of both graphics for 
illustrative purposes. It can be seen from 
Figure 5.5.3 that the G/B ratio equals one 
for cut-off wavelengths located between 
475 nm and 480 nm. 
The fraction of the backscattered blue-
violet light transmitted through the 
transmission filter can be deduced from the 
product of the DAFE excitation spectrum, 
the spectral reflectance of the respiratory 
mucous membrane, deduced from[12], and 
the LVHF transmission spectrum. This 
fraction is about 0.5%. Such conditions 
will result in equal intensities of the blue-
violet backscattering image and the green 
AF image on normal mucosa with the 
DAFE system. 
Discussion 
Since the very early trial of blue light 
bronchoscopy by Hürzeler et al. in 1975 
[16], much has been learned on the 
techniques of AF imaging for the detection 
of early endobronchial lesions. Several 
studies including imaging [8] and 
spectroscopy [17, 18] have contributed to 
the significant improvement of the 
diagnostics by AF imaging systems 
available today. The commercially 
available AF bronchoscopic detection 
systems like the DAFE system (Richard 
Wolf Endoscopes GmbH, Germany), the 
D-Light system (Karl Storz Endoscopes 
GmbH, Germany), the LIFE system (Xillix 
0
1
2
3
4
5
6
460 465 470 475 480 485 490 495 500
Cut-on Wavelength [nm]
G
/B
 R
at
io
 [
a.
u
.]
0.0
0.2
0.4
0.6
0.8
1.0
E
xc
it
at
io
n
 L
ig
h
t 
In
te
n
si
ty
 [
a.
u
.]
Figure 5.5.3 Green-to-blue intensity ratios measured on the AF- normal main carina versus the
cut-on wavelength of the LVHF filter for 6 cases. The continuous line in the left part of the Figure
shows the normalised violet excitation spectrum of the DAFE light source. The dotted line depicts
the G/B=1 value, at which the green AF image and the blue reflectance image show equal
intensities. This value is reached for a wavelength located between 475 nm and 480 nm. 
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Inc., Canada) and the SAFE system 
(Pentax Corp., Japan) proved to be highly 
effective for early cancer detection and 
localisation in the tracheo-bronchial tree 
[8, 9, 11, 19]. Nevertheless, all authors 
report poor specificity with this detection 
method. In a very recent study with the 
LIFE system, Chhajed et al. [11] reported a 
sensitivity of AF imaging of 96%, while 
the specificity (23%) was inferior to that of 
conventional white light fibroscopy (53%). 
To our best knowledge only a few 
comprehensive studies aimed at improving 
the specificity of the aforementioned AF 
systems have been reported up to now 
[18]. In two independent studies published 
recently, the authors used white light 
reflectance spectroscopy to increase the 
specificity of AFB [20, 21]. The 
reflectance measurements were performed 
either with a probe inserted in the bronchi 
or with the central part of the 
bronchoscopic image projected onto the 
bronchoscope eyepiece. One advantage of 
our imaging approach is that the AF and 
the backscattering signal are detected 
simultaneously over the entire field of 
vision, while the aforementioned methods 
rely on the probing of selective and rather 
limited areas. This is of great importance 
for the development of future AF detection 
systems, namely ccd-tipped 
videoendoscopes for WL and AF 
detection, as described by [22, 23].  
The Reflectance Imaging Study 
The studies presented here exploit several 
morphometric features of angiogenesis as 
it develops in inflammatory and (pre-
)neoplastic bronchial lesions, reported by 
Fontanini et al. [14], Keith et al. [15] and 
Fisseler-Eckhoff et al. [13] among others, 
by using blue-violet backscattered light 
detection. All these authors report a 
significant increase in the microvessel 
density in the subepithelial tissue layers, 
i.e. in the lamina propria and the 
submucosa, associated with the presence of 
moderate dysplasia and in situ carcinoma. 
Fisseler-Eckhoff and Keith found 
increasing angiogenesis in the vicinity of 
the basement membrane of samples 
presenting dysplasia and CIS. Keith even 
reported the presence of capillary blood 
vessels closely juxtaposed to, or even 
projecting into the dysplastic bronchial 
epithelium, a phenomenon known as 
angiogenic squamous dysplasia (ASD). In 
an endoscopic study using a high 
magnification videobronchoscope in 
combination with narrow band imaging 
between 400 nm and 430 nm, Shibuya and 
coworkers [24] were able to differentiate 
between microvessel patterns of lesions 
with and without ASD. Thus, early 
cancerous and neoplastic lesions in the 
bronchi are characterised by an increase in 
blood content within the tissue close to the 
basement membrane. This statement is 
further supported by Bard et al. [21] who 
performed in vivo reflectance spectroscopy 
on malignant and non-malignant tissues. 
This group found a lower reflectance in the 
short wavelength region on malignant 
tissues relative to non-malignant tissues. 
All these findings correspond well to our 
observation that carcinoma shows a 
relative increase in the absorption of short 
wavelength blue-violet light, inferior to 
430 nm, compared to healthy tissue. These 
wavelengths match the absorption peak of 
oxygenated and deoxygenated 
haemoglobin, and should be absorbed 
more than average by tissue showing a 
high concentration of blood.  
Vascular conditions similar to those 
observed in early carcinomas are also 
found in newly formed scar tissue. This 
type of tissue forms following injury or 
surgery, as in the cases presented here and 
is characterised by a dense system of 
neovessels that increase the tissue blood 
content close to the tissue surface. This 
explains why the newly formed scar tissue 
in our study showed an important decrease 
in the blue violet backscattering when 
approaching the haemoglobin absorption 
wavelengths below 430 nm.  
The unique case of clearly documented 
inflammation in our study showed a 
wavelength-ratio dependence opposite to 
that of dysplasia/squamous cell carcinoma 
and scar tissues. The backscattered blue-
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violet light ratio between the AF- 
surrounding and the AF+ inflammation 
was significantly higher at wavelengths 
longer than 440 nm than for the shorter 
ones. At first this seems astonishing in the 
context of the blood absorption “theory”, 
since the absorption coefficient of 
haemoglobin at 470 nm is about one order 
of magnitude smaller than at 410 nm (data 
adapted from [25]). However, the 
decreased backscattering of this lesion of 
long wavelength blue-violet light 
compared to short wavelengths can be 
explained by a neovascularisation and 
vasodilatation rather localised deep below 
the surface in the inflammatory tissue, as 
compared to the more superficial 
neovascularisation typically present in 
carcinoma and scar tissue. Indeed, the 
penetration depth into bronchial tissue for 
wavelengths around 470 nm is about a 
factor 5 higher than for wavelengths 
around 410 nm (data adapted from [12]). If 
the neovessels are deep enough, the 
backscattering of short blue-violet 
wavelengths on the inflammatory tissue 
site will be less affected by haemoglobin 
absorption than the backscattering of long 
wavelengths. A similar effect has been 
described by Kienle et al. [26] for the 
explanation of the bluish appearance of 
veins in skin. The fact, that the 
inflammation was non-suspicious and 
without any signs of reddening when 
observed with WL, underlines the theory 
of a “deep” localisation of the 
neovascularisation. 
Hyperplastic and metaplastic tissues show 
a lower but still significant increase in the 
microvessel density compared to normal 
tissue, than it is the case for dysplasia and 
CIS [13]. Consequently, one would expect 
hyperplasia and metaplasia to show a 
wavelength dependent backscattering 
behaviour of blue-violet light. However, 
our measurements did not show any 
wavelength dependence. The depth where 
increased blood concentration occurs in the 
tissue could provide the explanation. If the 
relative increase in blood concentration in 
the sub-epithelial layers is superficial but 
not in close vicinity to the basement 
membrane, the backscattering might show 
a wavelength independent behaviour due to 
a neutralisation of the effects described 
above for the dysplasia/squamous cell 
carcinoma and the inflammation. 
Of note is that all lesions examined in this 
study showed positive fluorescence, i.e. a 
decrease in the green AF. As already 
mentioned before, epithelial thickening as 
well as changes in the haemoglobin and 
fluorochrome concentration in the sub-
epithelial layer during cancerogenesis are 
possible explanations [9, 12, 21, 27]. Since 
all tissues exhibiting positive fluorescence 
under blue-violet excitation do not show 
similar backscattering properties for the 
blue-violet light, it is likely that different 
“in depth” distributions of haemoglobin 
take place between these different tissues. 
Indeed, in microscopic ex vivo studies Qu 
et al. [12] showed that the AF of bronchial 
tissue is predominantly generated in the 
sub-epithelial tissue layers while the 
superficial epithelium exhibits very low 
fluorescence. Therefore the detected 
fluorescence signal originates from deep 
tissue layers, while the backscattering of 
light is more superficial.  
The thickness of the bronchial epithelium 
increases from 40 μm - 50 μm in normal 
tissue and to more than 120 μm in CIS 
[12]. In dysplasia and CIS the thickening is 
associated with an enlargement of the cell 
nuclei, i.e. a shift of the nucleus/cytoplasm 
ratio in favour of the nuclei, 
pleomorphism, hypercellularity and a 
continuous decomposition of the basement 
membrane [13, 28]. The optical properties 
of normal bronchial tissue and invasive 
SCC have been investigated by Qu and 
coworkers [12]. Normal epithelium shows 
only low absorption independent of the 
wavelength. The thickening of the 
epithelial layer in combination with the 
wavelength-dependent increase in the 
absorption coefficient for the sub-epithelial 
layer will positively amplify the selective 
absorption of short blue-violet wavelength 
in neoplastic and early cancerous lesions. 
This will not only decrease the intensity of 
Chapter 5.5 – Improvement of the Specificity…using backscattered Blue-Violet Light 
 
131 
the blue-violet light backscattered from the 
tissue, but also decrease the AF generated 
in and detected from the diseased tissue, 
producing an AF intensity contrast.  
It should be noted that squamous 
metaplasia and hyperplasia alike neoplastic 
changes are characterised by a thickening 
of the epithelial layer. They are therefore 
likely to show similar changes as neoplasia 
and early cancers in their AF intensity 
relative to normal tissue. 
 The reflectance imaging study was 
designed to investigate the potential of 
backscattered blue-violet light detection to 
improve the sensitivity of AFB. According 
to our preliminary findings two blue-violet 
wavelength regions below 430 nm and 
near 450 nm are well suited for this 
purpose. However, false positives resulting 
from scar tissue will not be discriminated 
from the true positive lesions. Fortunately 
scars can usually be identified as AFB 
false positives by considering their texture, 
location and the patient's clinical history, 
making them non critical false positives. 
Finally, it should be noted that only one 
properly documented inflammatory site 
exhibiting positive AF but being 
unsuspicious in WLB, has been involved in 
this study. However, most inflammations 
show a reddening of the tissue under WL 
observation due to hyperaemia, i.e. 
increased blood perfusion in the tissue near 
the surface. Therefore we do not expect 
such WL+ inflammations to exhibit blue-
violet backscattering properties similar to 
those of dysplasia, SCC and scar lesions. 
Consequently, AF+ and WL+ 
inflammatory lesions might not be rejected 
as false positives when using backscattered 
blue-violet light below 430 nm. This issue 
is the subject of further studies being 
conducted by our group. 
The clinical in vivo studies presented in 
this work are based on a limited number of 
cases, due to the restrictive inclusion 
conditions, i.e. only patients showing AF+, 
but WL- tissue sites. Moreover, for the 
sake of image analysis the respective AF+ 
areas needed to be oriented perpendicular 
to the endoscope optics, to avoid spectral 
artefacts. All images recorded had to show 
both the AF+ area and surrounding AF- 
tissue, without any sites of bleeding or 
retention of mucous. Only a few of the 
cases examined with the DAFE system 
over a one year period fulfilled these 
criteria. 
Upon image analysis, the AF-/AF+ ratios 
computed for a given wavelength showed 
large variations from one case to another, 
as seen in Figure 5.5.1. This is primarily 
due to the inter-patient changes of the 
tissue-endoscope distance and the 
bronchial anatomy. The AF-/AF+ ratios 
computed for nearby wavelengths in a 
given case showed significantly smaller 
variations. Indeed, those intra-case 
variations are due to the error induced by 
our image analysis method, as already 
described in Materials and Methods. In 
other words, the light intensity computed 
from a given image zone strongly 
correlates with the tissue-endoscope 
distance. A tissue area close to the optics 
will have a 4 times higher light intensity 
than an area situated twice as far away. For 
technical and anatomical reasons, it is not 
feasible to observe all bronchoscopic sites 
from the same distance with the same 
viewing angle. This potentially causes 
tissue areas having the same reflectivity to 
give different intensity values. To illustrate 
this problem we computed blue intensity 
level values from AF- tissue areas in the 
close and far plane of the image. The 
results showed variations of about 35% 
around the mean intensity level value (data 
not shown). Similar variations were 
observed for AF+ tissue areas. Therefore 
particular attention was paid to selecting 
AF- and AF+ analysis areas situated as 
close as possible to each other, within the 
same image plane. Moreover, images from 
a given case detected at different 
wavelengths were chosen to appear under 
similar viewing angles. This procedure 
allowed us to minimize the intra-case error 
for the intensity to about 10% (data not 
shown) and to compare the ratios 
computed from a given case at different 
wavelengths. 
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Implementation Study 
The implementation of backscattered blue-
violet light detection in the existing DAFE 
system required the replacement of the 
high pass emission filter in front of the 
camera by a similar high pass filter with an 
additional low transmission below 430 nm.  
A transmission band centred near 415 nm 
with a FWHM of 15 nm allowed us to take 
full advantage of the blood absorption. 
This value had to be about 0.25% of the 
backscattered light collected by the 
endoscope to create equal intensities of the 
blue and green images during AFB. Our 
future emission filter will be a high pass 
filter with a cut-off wavelength around 477 
nm and an additional transmission band 
ranging from 410 nm to 450 nm (square 
profile) with a transmission of 0.5%. It 
should be noted that our computations of 
the transmission value of the filter at 415 
nm from the experimental data obtained at 
480 nm were based on the assumption that 
the intensity signal detected by the blue 
CCD of the camera is independent of the 
wavelength. The sensitivity of the DAFE 
camera is wavelength dependent and 
decreases markedly for wavelengths below 
410 nm. The wavelength sensitivity S(λ) of 
the camera has to be taken into account for 
a more precise computation of the 
transmission value of the emission filter.  
In summary, we have shown in this work, 
that the detection of a blue image resulting 
from short wavelength backscattered light 
in addition to the green and red AF images 
has the potential to discriminate AF+  
neoplastic tissues that are WL- from 
benign ones, thus improving the specificity 
of AFB.  
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5.6  
Design of an endosocopic optical reference to be used for 
autofluorescence bronchoscopy with the DAFE system 
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Abstract:  
We present the design of a sterilisable optical reference to characterise and quantify the inter-
patient variations in the tissue autofluorescence (AF) during autofluorescence bronchoscopy 
(AFB) with the Richard Wolf’s DAFE system. The reference was designed to have optical 
and spectral properties similar to those of the human bronchial wall in spectral conditions 
corresponding to AFB conducted with the DAFE system (fluorescence excitation at 390 nm – 
470 nm and red illumination at 590 nm – 680 nm). The reference’s effective attenuation 
coefficient and reflectance were measured at 685 nm. In addition its fluorescence emission 
spectrum was determined under 410 nm wavelength excitation. The reference is photostable, 
reproducible, biocompatible and small enough to be easily inserted in the working channel of 
a conventional bronchofiberscope. This cylindrical (length: 2mm; diameter: 2mm) optical 
reference was validated in a clinical environment. 
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Introduction 
Autofluorescence bronchoscopy (AFB) has 
proven to be a highly sensitive tool for the 
detection and localisation of early 
bronchial cancers and pre-cancers that 
remain invisible with conventional white 
light bronchoscopy (WLB) [1-3]. Several 
AFB imaging systems are commercially 
available today [4]. They are all based on 
the visualisation of the spectral and 
intensity contrast of the tissue 
autofluorescence (AF) between healthy 
bronchial tissue and (pre-)neoplastic 
lesions when excited with light in the blue-
violet wavelength region. Most systems 
use filtered Xenon (Xe) arc lamps [1, 5, 6] 
or laser sources [7] for the AF excitation. 
The detection and imaging of the AF is 
performed with intensified or non-
intensified endoscopic colour video 
cameras. Early neoplastic or neoplastic 
bronchial lesions exhibit a significant 
decrease of the AF intensity[8-10]. The 
group in Lausanne reported a detailed 
spectral study demonstrating that this 
decrease is more marked in the green part 
of the spectrum, i.e. between 490 nm and 
600 nm [10]. Using additional red 
backscattered light as a constant 
background instead of the red (600 nm – 
800 nm) tissue AF offers one possible 
method to improve the performance of 
AFB. Such an approach will result in more 
contrasted images after the multispectral 
(red/green) image detection and processing 
procedure, because the red AF presents an 
intensity decrease on bronchial lesions. 
Using an optimised amount of red 
backscattered light, the contrast can be 
increased by a factor 2 [10]. Indeed, the 
AFB system used in Lausanne employs red 
backscattered light for contrast 
improvement. Spectrofluorometric point 
measurement studies in the human tracheo-
bronchial tree have revealed significant 
fluctuations > 50% in the AF intensities of 
healthy bronchial mucosa among different 
individuals ("inter-patient fluctuations") 
[11]. Clinical practice has shown that these 
fluctuations, in terms of brightness and 
colour aspect, are quite common between 
individuals in AFB [4]. Such inter-patient 
fluctuations can adversely affect the 
learning curve of AF bronchoscopists. 
Therefore, quantitative measurements of 
the fluctuations are important for the 
design of future AFB systems. To our best 
knowledge, no quantitative in vivo data of 
the inter-patient fluctuations of the 
bronchial AF has been reported up to now. 
Quantification of the AF intensity using 
imaging techniques is based on the 
retrospective analysis of the digitised 
intensity levels detected by the cameras in 
different colour channels. 
It demands the use of an optical/ 
fluorescence standard or reference that can 
be used in the bronchi during AF image 
acquisition. Such a reference, placed in 
such a way that it fills a small portion of 
the field of view, allows to correct the AF 
image for the settings of the AFB system at 
the time of recording and to compare the 
AF signals from different endoscopic sites 
with one another. 
The design of such a reference is not easy 
as its optical and mechanical properties 
must match a precise set of requirements. 
Its fluorescence properties should ideally 
match the AF properties of healthy 
bronchial mucosa in terms of spectroscopy 
and intensity. This latter feature is critical 
for preventing saturation of the camera. As 
the DAFE system detects backscattered red 
light around 680 nm, the reference’s 
reflectance at this wavelength must 
necessarily be similar to that of the 
bronchial mucosa. The optical properties 
of the reference must be stable and the 
physical dimensions of the reference need 
to be small enough to be inserted through 
the working channel of the bronchoscopic 
optics. Moreover, the material must be 
biocompatible and endure decontamination 
procedures. In this work we present the 
design, characterisation and first clinical 
application of an endoscopic reference for 
the Richard Wolf’s DAFE (Diagnostic 
AutoFluorescence Endoscopy) system 
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(Richard Wolf Endoscopes GmbH, 
Germany). 
Materials and Methods 
Design of the endoscopic reference 
Due to the excitation/illumination 
properties (violet excitation light and red 
backscattered light) of the DAFE system, 
the endoscopic reference must exhibit 
tissue like fluorescence between 490 and 
600 nm and backscattering properties 
around 680 nm, as mentioned above. We 
selected a white opaque polymethyl 
methacrylate (PMMA) acrylic glass 
(Perspex ® Blanc Opal 1X20, Lucite 
Solutions U.K.) for the endoscopic 
reference. This material is easy to process 
and demonstrates resistance to 
conventional sterilisation detergents used 
in the hospital. Its Rockwell hardness is 
101, according to the manufacturer’s 
specifications. Small cylinders 2 mm in 
diameter and 2 mm in length were 
machined and provided with a central 
longitudinal drilling of 0.5 mm diameter. 
The outer diameter of the cylinder was 
chosen according to the inner diameter of 
the working channel of the 
bronchofiberscopes being used for AFB in 
the local hospital. The cylinder was beaded 
on a surgical steel guide wire (Unimed, 
Switzerland) with a diameter of 0.5 mm 
and a length of 2 m. A small bead was 
formed at the distal tip of the guide wire by 
thermal heating, to prevent the cylinder 
from slipping off the wire. Biocompatible 
and non-fluorescing epoxy resin (Epo-Tek 
301, Epoxy Technology, USA, Distributor: 
Polyscience AG, Switzerland) was applied 
to the distal tip of the guide wire to keep 
the PMMA cylinder in position and to 
round up the tip. This was necessary to 
prevent damage to the patient's mucosa 
during measurement. 
A mechanical adjustable marker was set on 
the proximal end of the guide wire to 
assure a constant distance of 7 mm 
between the bronchoscope tip and the 
reference during measurements. The 
position of the marker was adjusted prior 
to each bronchoscopy for the length of the 
bronchofiberscope to be used. An image of 
the endoscopic reference is shown in 
Figure 5.6.1. 
 
 
Figure 5.6.1 Close-up look at the endoscopic 
reference protruding out of the working channel of 
the AFB bronchofiberscope. 
The imaging system 
Endoscopic procedures were performed 
according to the guidelines approved by 
the ethical committee of the CHUV 
University Hospital. The DAFE system 
used in this study has been described in 
detail elsewhere [12]. Briefly, it consisted 
of a filtered endoscopic Xenon light source 
and a filtered 3 CCD endoscopic colour 
camera. A flip-flop filter system in the 
light source controlled by a foot switch 
allowed for rapid changes between 
conventional WL illumination (WL 
mode)(390 nm - 680 nm) and blue-violet 
AF excitation (AFB mode) (430 nm ± 40 
nm). In the AFB mode, a small variable 
amount of red light around 685 nm was 
added to the blue-violet excitation. The red 
light was detected in the backscattering 
mode to create a background image and to 
improve the spectral contrast between 
healthy mucosa and lesions [13, 14]. The 
light from the light source was delivered to 
the endoscopic site via a liquid light guide 
and the bronchoscope optics. The 
endoscopic images were captured by the 
endoscopic camera that was clipped to the 
optic's eyepiece. A 475 nm long pass filter 
in the camera objective eliminated all blue-
violet AF excitation light. The spectral 
detection ranges for the three camera 
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channels were 475 nm - 490 nm (blue), 
490 nm - 580 nm (green) and 580 nm - 650 
nm (red). The system could be used with 
both rigid bronchoscopic optics and with 
bronchofiberscopes. 
Characterisation of the reference’s optical 
properties 
Determination of the optical properties of 
the endoscopic reference, namely the 
diffuse reflectance R∞, the effective 
attenuation coefficient μeff and the 
fluorescence emission spectrum and 
intensity of the reference is described in 
the following section. In addition, we 
investigate the photostability and the 
behaviour of the probe in the fluorescing 
and scattering bronchial environment. 
The diffuse reflectance Rof the reference 
material was measured by means of an 
integrating sphere (LabSphere Inc., USA) 
according to a standard procedure 
described by [15]. A thick sample (d= 14 
mm) of the reference material was put to 
one port of the sphere. A collimated light 
beam from a 675 nm diode laser (FWHM 
2nm, Spectra Diode Labs, Inc., USA) 
illuminated the sample from the opposite 
port. The reflectance signal Rreference was 
detected by a photodiode located in the 
third port of the intergrating sphere. Then 
the reference material was replaced by a 
white reflecting standard (LabSphere Inc., 
USA) with a 100% reflectivity. The total 
reflectance R∞ of the reference material at 
675 nm is derived from the ratio 
R∞=Rreference/R100%.  
For obtaining the measurements of the 
light penetration depth and the 
determination of the effective attenuation 
coefficient μeff (as depicted in Figure 
5.6.2), we used a 21 mm thick sample of 
the reference material with a central 
drilling of 1 mm diameter. The non-drilled 
side of the sample was homogenously 
irradiated with light from the 675 nm diode 
laser mentioned above using a frontal light 
distributor (Type FD, Medlight SA, 
Switzerland). The perpendicular incident 
light spot had a diameter of 40 mm on the 
sample surface. An optical fibre based 
isotropic spherical light detector with a 
diameter of 850 μm (Type IP85, Medlight 
SA, Switzerland) was inserted into the 
hole. The probed light was guided by an 
optical fibre (core diameter = 0.40 mm) 
and analysed by a photometer (Thorlabs 
Det210, Thorlabs, USA). The space 
irradiance “I” in the sample was measured 
for different surface-probe distances every 
0.5 mm steps. Plotting ln (I) versus the 
depth “d” allows determination of the 
effective attenuation coefficient μeff. 
Indeed, μeff is the slope of the straight line 
fitting the space irradiance decay. 
 
 
Figure 5.6.2. A block diagram of the experimental 
set-up used to measure the effective attenuation 
coefficient μeff. 
The fluorescence emission of the reference 
material was measured using an optical 
fibre based spectrofluorometer. The set-up 
is described in details elsewhere [16]. 
Briefly, it consisted of a 75W Xenon 
excitation light source (UXL-75XE, Ushio 
Inc., Japan) whose light was passed 
through a monochromator (Chromex 250, 
Chromex, Albuquerque, New Mexico), and 
was filtered by a short-pass filter. A 
dichroïc mirror focused the light into a 
quartz optical fibre. The fibre served as 
both excitation and detection fibre. The 
sample fluorescence was collected and 
separated from the backscattered excitation 
light by a long-pass filter. It was then 
dispersed by a spectrograph (Chromex 
250, Chromex, Albuquerque, New 
Mexico) to be detected by a Peltier-cooled 
CCD (Model TE/CCD-256, Spectroscopy 
Instruments GmbH, 82205 Gilching, 
Germany). The entire set-up was 
controlled by a 486-MHz personal 
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computer (Fast 486/50, Spectroscopy 
Instruments GmbH, 8225 Gilching, 
Germany). The excitation wavelength was 
405 nm ± 15 nm. The typical total power at 
the distal end of the fibre was 15 μW. For 
the measurements the distal tip of the 
optical fibre was put in slight contact with 
a 3 mm thick sample of the reference 
material.  
Photostability of the reference material 
According to the manufacturer's 
specifications, the selected PMMA 
material is considered to be weatherstable 
[17], i.e. stable under UV irradiation. We 
assessed the photostability of the reference 
material by longtime exposition to a high 
intensity IR-filtered WL source (Light 
Projector 5137, Richard Wolf GmbH, 
Germany). One half of the surface of a 40 
mm x 40 mm plate of the reference 
material (thickness 3 mm) was covered 
with lightproof, black aluminium foil. The 
plate's whole surface was then exposed 
homogeneously to intensive white light 
(range 390 nm – 680 nm) from the light 
source. The irradiance on the plate's 
surface was 25 mW/cm2. Irradiation was 
performed during a 7 hour period, resulting 
in a total light dose of 630 J/cm2 on the 
plate's surface. After irradiation the 
fluorescence and backscattering properties 
from the shielded and the unshielded half 
of the plate, were compared by imaging 
with the DAFE system. 
Influence of the environmental green and 
red space irradiance in the bronchi 
The behaviour of the reference in a 
fluorescing and light scattering 
environment (the "space irradiance 
modification") was investigated in one 
patient undergoing diagnostic DAFE 
bronchoscopy. This test was performed 
under local anaesthesia using an Olympus 
BF30 bronchofiberscope (Olympus Corp., 
Japan). The bronchoscope was placed in 
the right primary bronchus with the light 
source set in the DAFE mode. The 
reference was inserted into the bronchi via 
the biopsy channel of the 
bronchofiberscope. The spacer on the 
guide wire was set to allow the reference to 
extend 7 mm out of the bronchofiberscope. 
Then the bronchoscope was slowly 
redrawn towards the trachea, placing the 
reference in close contact to and at several 
different distances from the bronchial wall. 
Then the entire bronchoscope-reference 
unit was removed from the patient. The 
bronchoscope tip with the protruding 
reference was placed in a 40 cm x 50 cm 
non-fluorescing and non-reflecting black 
box with the same illumination and 
detection settings of the DAFE system. 
The whole procedure (bronchoscopy and 
black box observations) was recorded by a 
digital video (DV) recorder (Sony DSR-11, 
Sony Corp., Japan). Still images from 
different positions of the reference in the 
bronchi and in the black box were digitised 
using the IEEE 1394 interface of the DV 
recorder and a personal computer. In each 
image the red (R) and green (G) intensity 
level values were computed from an area 
on the reference and an area on the 
neighbouring healthy bronchial wall. All 
intensity level values were corrected for 
the gamma factor of the camera (gamma 
=0.62) and the image background. The 
intensity level values were computed from 
the reference as a function of the intensity 
level values of the tissue and the distance 
between reference and bronchial wall were 
compared. 
Results 
Figure 5.6.3 shows the endoscopic 
reference in the upper bronchial tree during 
bronchoscopy. The distance between the 
proximal face of the reference and the 
bronchofiberscope's tip is about 7 mm. The 
two specular reflections on the reference's 
surface result from the two illumination 
fibre bundles of the bronchofiberscope.  
The diffuse reflectance of the reference 
material at 675 nm was determined to be 
73%.  
The results from the measurements of the 
effective attenuation coefficient at the 
same wavelength are shown in Figure 
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5.6.4. In this graphic, the ln(I) is plotted 
against the measurement depth “d”. As 
mentioned above, the effective attenuation 
coefficient corresponds to the slope of the 
linear function fitting the measurements. It 
was determined to be 0.14 mm-1 ± 0.02 
mm-1. Thus, the penetration depth d =1/μeff 
is 7.1 mm for red light at 675 nm.  
Knowing the diffuse reflectance and the 
effective attenuation coefficient, the 
absorption and reduced scattering 
coefficients can be deduced according to 
[15]. 
 
 
 
Figure 5.6.3. Endoscopic view of the reference 
close to the main carina. The cylinder’s cross 
section surface is facing the observer. The two red 
specular reflections observed on the right side of 
the reference are due to the reflection of the red 
light delivered by the DAFE light source through 
the two illumination fibre bundles of the 
bronchofiberscope. 
 
For the reference material the absorption 
coefficient was computed to be μa = 0.001 
mm-1 and the reduced scattering 
coefficient, μ's = 6 mm-1. A compilation of 
the principal optical properties of the 
PMMA material and healthy human 
bronchial tissue for light at 675 nm is 
presented in Table 5.6.1.  
The reference fluorescence emission 
spectrum measured with the optical fibre 
based spectrofluorometer is shown in 
Figure 5.6.5. For illustrative purposes, the 
same graphic shows a typical in vivo AF 
spectrum of healthy human mucosa, 
measured with the same set-up (adapted 
from [11]). 
 
-2.5
-2
-1.5
-1
-0.5
0
0.5
0 5 10 15
Depth [mm]
ln
 (
I)
 
Figure 5.6.4. The graphic shows the decrease of 
the space irradiance versus the depth of the 
isotropic probe within the sample for a broad (40 
mm in diameter), collimated and perpendicular 
illumination at 675 nm. The effective attenuation 
coefficient μeff of the reference material is given by 
the slope of the straight line fitting the data. 
 
 
R∞ [%] 
μeff  
[mm-1] 
μa  
[mm-1] 
μ’s  
[mm-1] 
d  
[mm] 
PMMA material 
73a 
(human mucosa: 74) 
0.14a 0.001 6 7.1 
Table 5.6.1 Optical properties of the reference material for light at 675 nm. The table shows the 
diffuse reflectance R∞, the effective attenuation coefficient μeff, the absorption coefficient μa, the 
reduced scattering coefficient μ’s, and the penetration depth “d”. Values superscripted with (a) 
were measured in the study presented here. The diffuse reflectance value for the human mucosa 
was taken from [18]. All other values were deduced as shown in [15]. 
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Figure 5.6.5. Fluorescence emission spectra of the 
reference material. Excitation was performed at 
405 nm ± 15 nm (FWHM). A typical in vivo AF 
spectrum from healthy bronchial tissue measured 
with the same set-up, is shown for comparison. The 
spectrum was adapted from [11]. 
The long-term exposure to a white light 
dose of 630 J/cm2 did not affect the 
fluorescence and backscattering behaviour. 
Imaging of the exposed plate of the 
reference material with the DAFE system 
did not reveal any measurable difference of 
the fluorescence and backscattering signal 
between the exposed and the unexposed 
areas (data not shown).  
Imaging of the reference in the tracheo-
bronchial tree showed no correlation 
between the AF intensity levels of the 
bronchial wall and that of the reference 
when it was not in direct contract with the 
wall. However, when the reference 
cylinder was put in direct contact with high 
fluorescing bronchial tissue areas, the red 
and green intensity levels computed from 
the reference increased by a factor of 2 
(data not shown). 
Discussion: 
The aim of this work was to design a stable 
fluorescence and reflectance standard for 
the quantification of inter-patient 
variations in the AF intensity during AFB 
imaging. The chosen PMMA material, 
Perspex Blanc Opal/White 1X20 is a 
commercially available white semi- 
opaque plexi glass. The material complies 
with the European regulations for food 
contact and can easily be sterilised after 
use. 
The dimensions of the reference were 
limited by the inner diameter of the biopsy 
channel (2.2 mm) of the diagnostic 
bronchofiberscopes in use at the CHUV 
University Hospital in Lausanne. 
Image acquisition and analysis is most 
reliable and reproducible when performed 
on the even, homogenous surfaces of the 
reference perpendicular to the optical axis. 
The cylinder cross cut-section was 
localised perpendicularly to the optical axis 
of the bronchoscope and allowed unbiased 
read out of the intensity levels. Due to its 
size the reference is also compatible to 
with most other bronchofiberscopes and 
the more recent chip-on-tip 
videobronchoscopes equipped with a 
standard working channel. 
One drawback of the set-up was the 
slightly inhomogenous illumination of the 
reference due to the asymmetrically 
arranged illumination fibrebundles of the 
bronchofiberscopes. The resulting specular 
reflections are visible as bright red spots on 
the reference's cut section in some 
endoscopic images. Those spots might bias 
the reference measurement if they are not 
excluded in the retrospective image 
analysis. 
The shape of the Perspex's fluorescence 
spectrum is similar to the in vivo AF 
spectrum of human bronchial mucosa 
excited at 405 nm. However, it should be 
noted that the relative contribution of 
wavelength > 590 nm is slightly higher in 
the reference fluorescence spectrum than in 
the in vivo spectrum. However, this 
difference in the spectral shape of the 
reference material fluorescence and the 
tissue AF do not adversely affect the 
material’s functionality as an endoscopic 
reference since most (about 65 %) of the 
red light emitted by the reference during 
AFB originates from the red backscattered 
light. 
A comparison of the relative fluorescence 
intensities was not possible with our set-
up. However, a preliminary clinical study 
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with the endoscopic reference showed that 
the green (490 nm – 580 nm) fluorescence 
intensity of the reference is about 55% of 
the typical green AF intensity of the 
bronchial wall [19]. The latter is in the 
order of 4.2 pW/(μW · nm) [11]. Since the 
DAFE camera uses automatic shutter and 
gain control functions based on central 
image measurements to optimise its image 
brightness during AFB, the lower 
fluorescence of the reference might be 
affected by a poor signal-to-noise ratio 
when used in a high 
fluorescing/backscattering environment. In 
addition, the low luminescence of the 
reference increases the distortion of the 
measurements by the space irradiance due 
to the AF of the bronchial wall. Indeed, as 
described above, the endoscopic 
measurements on the reference are 
modified in a high light irradiating 
surrounding. Using a material with a 
fluorescence intensity equal to or slightly 
higher than the tissue AF intensities will 
reduce the relative contribution of the 
space irradiance to the detected reference 
signal. However, this reference 
luminescence yield has to be kept at a 
value comparable to that of the bronchial 
wall due to the limited dynamic range of 
the camera. 
The reference material has a relatively high 
(73%) reflectance at 675 nm. The diffuse 
reflectance of normal bronchial mucosa 
was measured by Tecelj [18] using 
reflectance spectroscopy. This group 
reported a diffuse reflectance of about 75% 
at 675 nm wavelength. Thus the 
reflectance of the reference can be 
considered identical to that of the bronchial 
mucosa.  
The effective absorption coefficient of the 
reference material is in the order of 0.14 
mm-1. Unfortunately there is a lack of 
knowledge on the values of μeff of human 
bronchial mucosa in vivo. However, Bays 
et al. [20] reported a value of 0.24 mm-1 
for μeff for the human esophageal mucosa 
at 630 nm. Since the reflectance of the 
bronchial mucosa is higher than that of the 
esophageal mucosa, the absorption and by 
this μeff is likely to smaller than the value 
given by Bays et al. Moreover, μeff 
decreases with increasing wavelengths. 
Thus the effective absorption coefficient of 
the reference can be considered identical to 
that of the human bronchial mucosa. 
Conclusions: 
We have designed an endoscopic reference 
to characterise and quantify the AF 
intensity and spectral composition of 
bronchial tissue in vivo using imaging 
techniques. The reference has optical 
properties simulating that of the bronchial 
mucosa. It can easily be inserted into the 
biopsy channel of conventional 
bronchofiberscopes and can be used during 
routine AF bronchoscopy. The main 
interest of this reference is to enable a 
reliable assessment of the inter-patient 
fluctuations of bronchial tissue AF. This is 
of importance for the spectral and optical 
design of AFB systems. Optimisation of 
the spectral design of the endoscopic 
reference can be achieved by the use of a 
material having a slightly green shifted and 
stronger (by a factor 2) fluorescence 
emission relative to the Perspex 1X20 one. 
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5.7  
Autofluorescence bronchoscopy: Quantification of inter-
patient tissue remitted light intensity variations 
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Abstract 
Autofluorescence (AF) from bronchial tissue is widely used for the endoscopic detection of 
early bronchial neoplasia. Several imaging systems are commercially available, all detecting 
the absolute or relative AF intensity and/or spectral contrasts between normal tissue and early 
neoplastic lesions. These devices have a high sensitivity for flat neoplasia, but the specificity 
remains limited. Variations in the AF intensity between individuals (inter-patient variations), 
is considered one of the most limiting factors. In the clinical study presented here, we 
quantified those variations using a non-invasive optical reference positioned in situ during AF 
bronchoscopy. The inter-patient intensity variations were in the order of 25%- 30%. The 
results of this study are quite useful for improving and defining the design of the optical 
features (dynamic range, physical sensitivity) of AF detection systems.  
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Introduction 
Autofluorescence bronchoscopy (AFB) 
using blue-violet excitation light is a 
powerful tool for the detection and 
localisation of early cancers and pre-
cancers in the tracheo-bronchial tract [1, 
2]. Its sensitivity exceeds that of 
conventional white light bronchoscopy 
(WLB) by a factor of 2 [3-6]. AFB is based 
on the visualisation of the intensity and 
spectral contrasts of the autofluorescence 
(AF) of healthy bronchial mucosa and 
neoplastic or early cancerous lesions. 
Several AFB imaging systems are 
commercially available [3]. These systems 
use filtered arc lamps [5, 7, 8] or laser 
sources [9] for the AF excitation whereas 
AF imaging is performed with endoscopic 
colour cameras. One limitation of AFB 
contributing to the limited specificity of 
this approach is due to the fluctuation of 
the AF intensity [5, 10, 11].  
Spectrofluorometric in vivo studies have 
shown significant variations in the AF 
intensities of healthy bronchial mucosa 
among patients ("inter-patient variations") 
[12]. Those inter-patient variations can 
adversely affect the image quality in AFB 
and the learning curve of bronchoscopists. 
The unique complex morphology and 
anatomy of the tracheo-bronchia tree 
makes AFB imaging highly sensitive to 
inter-patient as well as intra-patient 
variations. One example of the inter-
patient variations affecting AFB is the 
regular stripe-like structure on the 
bronchial wall that is mainly present on the 
dorsal wall of the primary and secondary 
bronchi. The size and structure of the 
stripes can vary between patients 
depending on anatomical variations and 
bronchial pathology, mainly chronic 
inflammation and bronchitis. In AFB the 
structures appear as white stripes 
alternating with red stripes, running along 
the longitudinal axis of the bronchi. These 
white stripes are formed by longitudinal 
bundles of elastic fibres situated just below 
the epithelium in the lamina propria of the 
bronchial wall. These bundles are less 
pronounced on the red stripes.  Disruption 
and mutation of this stripe structure is an 
important diagnostic criterion in AFB. 
Knowledge of the inter-patient variations 
of the bronchial AF intensity is extremely 
important for the design and development 
of improved future AF imaging systems. 
However, the determination of the inter-
patient variations using imaging systems is 
not easy. Indeed, clinical AFB imaging 
systems generally employ features like 
camera gain control, frame integration or 
adjustment of the shutter time to react to 
the dynamic imaging conditions during 
endoscopy. These adjustments are 
performed automatically by the system and 
can generally not be tracked either in real 
time, or retrospectively. Quantification of 
tissue optical properties by means of an 
AFB system therefore demands the use of 
an optical/ fluorescence standard or 
reference that can be used at the 
endoscopical site during AF image 
recording. Such a reference, placed where 
it fills a small portion of the field of view, 
allows to correct the tissue AF image for 
the settings of the AFB system at the time 
of recording, and to compare AF signals 
from different endoscopic sites among 
each other. The design and the 
characterisation of an endoscopic reference 
for use with the Richard Wolf DAFE 
(Diagnostic AutoFluorescence Endoscopy) 
system has recently been reported by 
Gabrecht et al. [13, 14]. In these reports we 
present a detailed optical and spectral 
characterisation of this reference sample. 
To our best knowledge, no quantitative in 
vivo data of the inter-patient variations of 
AF intensity and reflectivity of 
endobronchial tissues have previously been 
reported.  
Materials and Methods 
The imaging system 
AF imaging was performed using the 
DAFE (Diagnostic AutoFluorescence 
Endoscopy) system commercialised by 
Richard Wolf Endoscopes GmbH, 
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Germany. Very briefly, the system 
consisted of an IR filtered endoscopic 
Xenon arc lamp light source and a filtered 
3 CCD endoscopic colour camera. A two 
step flip-flop filter holder containing a grid 
and a colour band pass filter allowed for 
rapid changes between (i) violet AF 
excitation at 430 nm ± 40 nm and (ii) a 
conventional white light (WL) illumination 
(wavelength range 390 nm - 680 nm). For 
AF detection, a variable amount of red 
light around 680 nm was added to the blue-
violet AF excitation. This light was 
detected to create a background image 
[Gabrecht, JBO submitted]. In this study 
the system was used with Olympus 
bronchofiberscopes (Type BF30, Olympus 
Inc., Japan). The excitation light power at 
the distal tip of the bronchofibroscope was 
130 mW. The endoscopic images were 
captured by the endoscopic camera and 
recorded on a digital video (DV) tape. A 
475 nm high pass filter placed in the 
camera objective cut off all blue-violet 
excitation light. The spectral detection 
ranges for the three camera channels were 
475 nm - 490 nm (blue), 490 nm - 580 nm 
(green), and 580 nm - 650 nm (red). 
The endoscopic optical reference 
The endoscopic reference was described in 
detail elsewhere [13, 14]. Briefly, it was 
based on a white opaque polymethyl 
methacrylate (PMMA) acrylic glass 
(Perspex® Blanc Opal 1X20, Lucite 
Solutions U.K.). A small cylinder (size 2 
mm in diameter and 2 mm in length) was 
machined, provided with a central 
longitudinal drilling of 0.5 mm diameter 
and beaded on a 0.5 mm surgical stainless 
steel guide wire (Unimed SA, 
Switzerland). The outer diameter of the 
cylinder was limited by the inner diameter 
of the bronchofiberscope's biopsy channel 
(2.2 mm). The optical properties of this 
PMMA resemble those of human bronchial 
tissues. More precisely, the fluoresence 
emission of the material and its reflectance 
are similar to that of bronchial mucosa in 
the spectral conditions of the DAFE 
system. A detailed description of the 
optical properties can be found in [13, 14]. 
An adjustable marker positioned at the 
proximal end of the guide wire assured a 
constant distance of 7 mm between the 
bronchoscope tip and the reference during 
measurements.  
Patients 
All eleven patients involved in this study 
underwent diagnostic DAFE bronchoscopy 
in the ENT department of CHUV 
University Hospital in Lausanne, 
Switzerland. The bronchoscopies were 
performed under general anaesthesia. The 
measurements were performed on the 
optically healthy, i.e. with WL and AF 
bronchoscopy non-suspicious, main carina. 
"Optical" exclusion criteria were: areas 
suspicious with WL or AF bronchoscopy 
in the proximity of the carina, and bleeding 
or mucous on the bronchoscopic site. All 
exams were performed according to the 
guidelines approved by the ethics 
committee of CHUV University Hospital. 
Protocol 
Folllowing examination of the entire 
bronchial tree with both AF and 
conventional WL bronchoscopy, the 
flexible bronchofibroscope was positioned 
in front of the main carina. The visual 
aspect of the site was assessed for 
normality by both AFB and WLB. Then 
the endoscopic reference was inserted into 
the biopsy channel of the 
bronchofiberscope and positioned beside 
the main carina. As reported by Gabrecht 
et al. [Gabrecht, submitted], the reference 
was positioned at a minimal distance from 
the bronchial wall to avoid a modification 
of the reference signal by the spatial 
irradiance coming from the bronchial wall. 
Images of the reference positioned close to 
the main carina were recorded in the AFB 
mode. The whole procedure took less than 
2 min and did not interfere with the 
bronchoscopy. All AF bronchoscopies 
were performed according to the guidelines 
approved by the ethical committee of 
CHUV University Hospital.  
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Image analysis 
Typically 3 images per patient were 
digitised in a 24-bit RGB mode from the 
DV recordings using the IEEE1394 
interface of the DV recorder and a portable 
PC. In each image 4 areas were selected 
and analysed for their red (R) and green 
(G) intensity level values: (i) the face side 
of the reference, i.e. the surface facing the 
observer, (ii) a tissue area on the main 
carina, (iii) and (iv) an area on a red and a 
white stripe, respectively. The position of 
the reference close to the carina and the 
selection of the analysed areas are 
illustrated in Figure 5.7.1. Saturated image 
areas as well as those showing specular 
reflections and surface abnormalities 
(secretion, airway crypts etc.) were 
excluded from the analysis. All computed 
R and G intensity level values were 
corrected for the image background and 
the gamma factor of the camera system.  
 
 
Figure 5.7.1 DAFE image of the main carina 
showing the endoscopic reference. The brightness 
and the chromatic aspect of the reference are 
similar to that of the bronchial wall. The stripe like 
structures on the dorsal wall (bottom) of the 
primary bronchi are clearly visible. 
 
In order to quantify the inter-patient 
intensity variations of the AF, we 
computed three green intensity ratios 
between (i) the reference area and the area 
on the carina, (ii) the reference area and the 
area on the red stripes, and (iii) the 
reference area and the area on the white 
stripes. In the following sections, these 
ratios will be referred to as the (Gref/Gtis) 
ratios. 
Moreover, we computed the so-called 
normalised red-to-green ratio ((R/G)norm), 
which is defined as the ratio between the 
red and the green intensity levels of the 
reference (Rref/Gref) divided by the ratio 
between the red and the green intensity 
levels from the bronchial wall, (Rtis/Gtis). 
In other word, (R/G)norm= 
(Rref/Gref)/(Rtis/Gtis). The (R/G)norm ratio is 
of interest as it is a monotonic function of 
the chromatic aspects of the image 
obtained with the DAFE system. It should 
be kept in mind that the green signal 
results from the AF while the red signal is 
composed of both the AF and the 
backscattering signal. 
Typically 3 different images per patient 
were digitised, analysed, and averaged. 
Our image analysis procedure was based 
on the selection of zones within an 
endoscopic image. To determine at which 
point the values of the computed (Gref/Gtis) 
and (R/G)norm ratios depend on the 
selections performed, the standard 
deviations were deduced from these 
measurements.  
Results 
The results from the image analysis are 
shown in Figure 5.7.2 and Figure 5.7.3 for 
(Gref/Gtis) and (R/G)norm, respectively. 
Figure 5.7.2 shows the (Gref/Gtis) ratios 
between the reference and (i) the carina 
(triangles), (ii) the red stripes (diamonds) 
and (iii) the white stripes (squares) for all 
11 patients. Each point represents the mean 
of three ratios computed from the three 
different images of a given patient and the 
error bars depict the standard deviations. 
The mean (Gref/Gtis) ratios between the 
reference and the tissue over all cases are 
0.55 ± 0.14 for the carina, 1.13 ± 0.52 for 
the red stripes, and 0.38 ± 0.12 for the 
white stripes. The mean ratios for each 
zone are depicted as dashed horizontal 
lines in Figure 5.7.2. It should be noted, 
that the (Gref/Gtis) ratios between the 
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reference and the carina, as well as those 
between the reference and the white stripes 
are all smaller than 1, while most of the 
corresponding ratios for the red stripes 
exceed 1.  
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Figure 5.7.2 Green intensity ratios of the 
reference and the bronchial tissues measured in 11 
patients. The ratios are presented for the carina, 
the red stripes and the white stripes. The horizontal 
lines depict the mean ratios for the carina (dashed 
line), the red stripes (continuous line) and the white 
stripes (large dashed line). The error bars depict 
the standard deviations. 
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Figure 5.7.3 Normalised (R/G) intensity ratios 
between the reference and the bronchial carina, the 
red stripes, and the white stripes measured in 11 
patients. The error bars depict the standard 
deviation. 
 The (R/G)norm ratios for the carina are 
shown in Figure 5.7.3 for all 11 cases. As 
in Figure 5.7.2 each data point represents 
the mean of typically 3 ratios and the error 
bars depict the standard deviations. The 
dotted horizontal line shows the mean 
(R/G)norm ratio. The mean (R/G)norm ratios 
were 1.46 +/- 0.38 (26%) for the carina, 
1.19 +/- 0.45 (38%) for the red tracks and 
1.76 +/- 0.65 (37%) for the white tracks.  
We deduced from multiple measurements 
performed on the same site that the errors 
resulting from our image analysis 
procedure were about 15% for the 
(Gref/Gtis) intensity level ratios and about 
11% for the (R/G)norm ratios. 
Discussion 
The autofluorescence spectra of human 
bronchial tissue have been studied by 
several groups [12, 15-17]. However, the 
inter-patient variations of the AF intensity 
and spectral composition have hardly been 
studied quantitatively in vivo. Zellweger 
and coworkers [12] reported significant 
inter-patient variations of about 50% 
within the 67% confidence interval using 
405 nm as excitation wavelength. 
Compared to these values, the inter-patient 
variations found in the study presented 
here are surprisingly small. The inter-
patient variations measured on the healthy 
carina were about 25% for the AF intensity 
in the green part of the spectrum (490 nm - 
580 nm) and about 26% for the relative 
ratio between the green and the red spectral 
part of the AF. These values are nearly two 
times that of the error related to the image 
analysis method in this study. The 
differences between the inter-patient 
variations found by Zellweger et al. and 
those presented in this report most likely 
result from the measurement geometry 
used in the two studies. Zellweger et al. 
performed spectrofluorometric 
measurements using a fibre bundle and a 
spacer to keep a tissue-bundle distance of 
3.5 mm [18]. This set-up offers a relatively 
small probing area for a given 
measurement. Consequently, local non 
homogeneities of the tissue AF in the 
millimeter range in all probability 
dramatically influenced the AF signals 
measured from different spots in a given 
patient or between patients. Moreover, the 
AF intensities measured with this set-up 
are highly sensitive to slight changes in the 
tissue-probe distance. The results presented 
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in this work were obtained using a broad 
field imaging technique. This measurement 
geometry is much less sensitive to tissue 
AF non homogeneities in the millimetric 
range and to slight variations in the tissue-
probe distance, since the tissue-endoscope 
distance is about 10 mm. 
In this context, it is worth noting that the 
inter-patient variations observed in this 
imaging study are significantly higher 
(31% to 46%) on the white and red stripes 
of the dorsal bronchial wall than on the 
carina (25%). As already pointed out in the 
introduction, the white stripes are formed 
by dense bundles of highly fluorescent 
elastic fibres that are closely juxtaposed to 
the epithelium. On the red stripes the fibre 
bundles are missing, resulting in a much 
lower AF intensity. Thus the signal from 
the red stripes is dominated by the red 
backscattered light. The higher variations 
observed on the stripes are most likely due 
to the small size of both types of stripes 
(and consequently the small size of the 
analysed areas) making image analysis 
more sensitive to heterogeneities in the 
tissue’s emission. 
Though the inter-patient variations in the 
bronchial tissue AF observed in the this 
study were small, it is known from clinical 
practise with AFB that autofluorescence 
images obtained from different patients can 
show clear differences in their chromatic 
composition and intensity [3]. This is 
likely to be partly due to variations in the 
system's performance from one 
bronchoscopy to another, including 
variations of the excitation light intensity 
at the tip of the bronchoscope optics, the 
transmission quality of the imaging optics, 
and colour settings of the camera-display 
unit, among others. Calibration charts or 
references used prior to the bronchoscopic 
exam can reduce these instrumental 
variations. Surprisingly, virtually no such 
test reference samples are provided by 
manufactures producing AFB systems. 
This pioneering clinical study conducted 
with the endoscopic reference shows that 
its optical and fluorescence properties 
differ slightly from that of human 
bronchial tissue. As reported by Gabrecht 
et al. [13, 14] the diffuse reflectance of the 
endoscopic reference is slightly higher than 
that of human bronchial mucosa at 675 nm. 
However, the AF emission spectrum of the 
reference was found to be slightly blue 
shifted relative to the tissue AF, resulting 
in a higher R/G ratio for the reference. This 
is confirmed by the fact that all (R/G)norm 
ratios computed for the carina in the study 
presented here were larger than one. 
Moreover, the mean (Gref/Gtis) ratios 
computed for the main carina were 0.55. 
This indicates that the AF intensity emitted 
by the endoscopic reference in the green 
spectral part, i.e. between 490 nm and 580 
nm, is about half the AF intensity typically 
emitted by healthy bronchial tissues. 
Although the tissue AF and that of the 
reference sample are about the same, this 
relative low AF of the Perspex material is 
indeed not ideal in the sense that the 
reference emission is more affected by the 
environmental space irradiance induced by 
the tissues. Most reliable results will 
therefore be obtained with a brighter 
reference. Thus for further clinical studies 
the choice of a higher fluorescing reference 
material than the current one should be 
considered. It should be kept in mind that 
the procurement of material presenting 
similar optical and spectral properties than 
the bronchial wall, while being suited fro 
this clinical use is very challenging. In 
addition it is crucial to prevent a saturation 
of the image which will occur if the 
reference is too bright. 
Apart from the inter-patient variations, the 
differences in the AF intensity and spectral 
composition within the bronchial tree of a 
given patient (the so called "intra-patient 
variations") are also very likely to 
influence the performance of AFB. Intra-
patient variations result from morphologic 
changes of the bronchial wall observed 
between the lower and the higher level 
bronchi [3, 19]. These changes are at least 
in part due to variations in: the epithelium 
thickness and complexity, the number and 
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distribution of specific cells and the spatial 
distribution of smooth muscle and cartilage 
in the bronchial wall. A clinical study by 
our group aiming to quantify these intra-
patient variations using the endoscopic 
reference at different levels of the tracheo-
bronchial tree is currently in progress. 
Conclusions: 
In this study we present the use of an 
endoscopic reference for the determination 
and quantification of inter-patient 
variations in the AF and reflectance of 
human bronchial tissue using AFB 
imaging. The inter-patient variations in the 
bronchial AF intensity and spectral 
composition found on the carina with the 
AFB imaging system are small and 
therefore probably do not significantly 
affect the performance of AFB. The 
endoscopic reference described here 
presents a rapid and minimally invasive 
method to determine and quantify the 
intensity and spectral composition of the 
bronchial AF during AFB.  
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Chapter 6  
Conclusions and 
Future Prospects 
The main aims of the first part of this thesis were to improve our understanding of the 
mechanisms playing a role in AFB, and to optimize this approach for the detection of early 
endobronchial carcinoma. Several clinical and ex vivo imaging and spectrofluorometry studies 
were performed to gain insight on the origins of the lesion/healthy tissue AF contrast and, 
consequently, define further possibilities to increase the sensitivity and specificity of AFB. 
These studies led to the identification of two main factors that are likely to be at the origin of 
these contrast mechanisms: (1) A lesions-specific neovascularisation, located inside these 
dysplasia/CIS as well as in their underlying lamina propria and submucosa, plays a key role in 
the AF intensity and chromatic contrasts; (2) the epithelium thickening, at locations 
corresponding to these lesions, seems to be responsible for an intensity contrast only. The 
increase of haemoglobin concentration associated with the neovascularisation mentioned in 
"1" absorbs both the excitation light and the AF it induces, whereas the epithelium thickening 
(point "2") essentially prevents the excitation light to reach the lamina propria and the 
submucosa, the latter containing much more endogenous fluorochromes than the epithelium. 
These statements already had, and will have, a high impact on the optical and spectral design 
of future AFB systems. 
The first clinical imaging study reported in Chapter 5.1 demonstrated that the use of 
additional red backscattered light as a background reference, instead of the red AF image, 
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increases the spectral contrast by a factor of about two. Thus, detection of the red background 
image increases the sensitivity of the system, even if this novel approach generates specular 
reflections that are not present in the red AF images. Although the quantification of this 
increase of sensitivity is very difficult to assess, the novel approach proposed here can be seen 
as a significant improvement. Indeed, according to [1, 2] an improvement of contrast by a 
factor two enables to detect twice-smaller lesions. It should be noted that this improvement is 
probably more important since the S/N ratio is much better for images generated with red 
backscattering light than with red AF. It is also not clear to determine if the use of infrared 
(IR) light, as suggested by the group of Vancouver [ref], gives better results than the use of 
ref light. However, since all medical light sources for endoscopy are equipped with IR cut-off 
filter, the instrumental implementation of the red light-based approach seems to be a sensible 
choice. This study eventually let to the development and commercialisation of the DAFE 
(Diagnostic AutoFluorescence Endoscopy) system by our industrial partner, as described in 
details in chapter 5.2.  
Considering the role played by blood in the contrast mechanisms, the use of blue-violet light 
at wavelengths corresponding to the blood absorption is useful to enhance the lesion-healthy 
intensity and spectral contrast as described in chapter 5.3. Consequently, this approach is also 
likely to improve the sensitivity of AFB. One approach to exploit this concept can be based 
on the use of a narrowband blue-violet excitation instead of the current broad band one, as 
suggested in this Chapter. However, sufficiently powerful and cost effective light sources that 
are compatible with a clinical use are not available at the present time. Indeed, solid-state 
lasers and gas lasers provide high power, but they are generally cumbersome, costly and not 
well suited for routine clinical application. Blue diode lasers at 410 nm with output powers in 
the range of 100 mW have become available recently. Their small size allows an integration 
into standard endoscopic light source. It should be noted that the use of videobronchoscopes, 
which were recently implemented in AFB, will require less excitation light intensity for 
satisfactory image quality than the conventional fibre-based bronchofibroscopes. In addition, 
the move from bronchofiberscopes to videobronchoscope is fortunate since the later have 
higher resolution. It should be noted, that all suggestions resulting from the studies reported in 
this thesis manuscript to improve the performance of AFB can be implemented in 
videobronchoscopy systems. 
Another approach to improve the performances of AFB is the combination of AFB and 
imaging reflectometry, as described in the chapter 5.5. This approach can improve the 
specificity of AFB since the detection of background images generated by blue-violet 
backscattered light presents a good approach to discriminate between true and false positives. 
Since the main source of false positives comes from inflammation, the idea behind this 
approach consists to exploit the differences of subepithelial vascularisation between inflamed 
tissues and dysplasia/CIS. The main limitation of this approach is probably due to the fact that 
dysplasia/CIS are frequently associated with the presence of inflammation. This problems 
seem to be one of the main ultimate challenges of AFB and it definitively needs further 
investigations. Nevertheless, blue-violet backscattered light detected around 430 nm showed 
the most promising results for this purpose. The implementation of this method in the Richard 
Wolf's DAFE system is based on the modification of the camera's detection filter. However, 
the optimal conditions still remain to be refined before this method can definitively be 
integrated in the DAFE system. It should be noted, that the close vicinity of the wavelengths 
used for the narrowband excitation and the blue backscattered light detection facilitates the 
integration of both approaches in the next generation of DAFE systems. Since the differences 
of spectral reflectance between dysplasia/CIS and inflammation are quite small, one approach 
could be to characterise AFB positives areas using a spectroscopic system. If this reflectance 
spectroscopy is performed after the use of the AFB system, it will enable to investigate the 
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information located in the green part of the spectrum. Since light around 550 nm penetrates 
deeper in the respiratory mucosa than blue-violet light and since it corresponds to secondary 
absorption peak of haemoglobin, the use of green light will probe vascular structures deeper 
in the submucosa. However, the integration of these combined imaging and spectral 
approaches in one cost-effective commercial system seems to be very difficult. This approach 
was recently reported by Chiyo et al. [3]. This group found an increased specificity with this 
spectral set-up compared to "LIFE" AFB.  
A very similar endoscopic approach based on a narrowband excitation and detection of both 
backscattered light and tissue AF is the so-called narrow band imaging (NBI). Sano and 
coworkers at the National Cancer Center Hospital East, Chiba, Japan, recently developed this 
technique in collaboration with Olympus Corporation. Current NBI systems illuminate the 
endocopic site with a narrow wavelength band (FWHM = 30) around 415 nm and detect the 
signal emitted by the tissue around 415 nm, 445 nm and 500 nm. Each corresponding image is 
assigned to a R, G, or B channel. The first wavelength band is comparable to the wavelength 
range of the blue backscattered light in AFB (first absorption maximum of haemoglobin). A 
very interesting aspect of NBI is its potential to emphasise the surface structure and vascular 
patterns in the GI tract [4, 5] and in the bronchi [6] when combined with high magnification 
endoscopy. However, the absence of a red backscattered image of this NBI system may 
negatively affect the orientation in the ramified tube-like structure of the bronchi. 
Unfortunatly, nothing has been reported up to now according to our knowledge on the 
performance of NBI for the detection of (pre-)neoplastic lesions in the tracheo-bronchial tree. 
High magnification bronchoscopy may reveal features of the vascular pattern, emphasised by 
blue backscattered light AFB, thus allowing discrimination between (pre-)neoplastic lesions 
and non-malignant changes. However, high magnification bronchoscopy is a recent tool that 
is still under development. Nevertheless, its combination with AFB in a single instrument 
should be considered for future developments. 
The use of exogenous agents for the detection of early carcinoma in the tracheo-bronchial tree 
should be avoided due to the complexity of their use as well as for regulatory and cost 
effectiveness reasons. However, their use can be envisaged if they prove to provide a robust 
and specific contrast between the lesions and their surrounding tissues. A very promising way 
of detecting early neoplastic and pre-neoplastic epithelial lesions is to rely on the selective 
induction of PpIX by 5-ALA or its derivatives. First experimental uses of 5-ALA induced 
PpIX for the imaging fluorescence detection in the tracheo-bronchial tree have proven 
disappointing [7, 8]. However, ALA hexylester (h-ALA) demonstrated superior performances 
than 5-ALA for the fluorescence detection of neoplasia in the bladder [9-11]. Thus, 
comparable results may be expected in the bronchi. Testing this approach with the DAFE 
system is of particular interest since its spectral design is well adapted to that of PpIX. 
However, since one of the main limitation of this approach seems to be the homogenous 
application of the PpIX precursor in the tracheo-bronchial tree, attention should be paid to the 
optimisation of the administration procedure. Although an administration under the form of 
the inhalation of an aerosol seems to be the most appropriate application method for the 
tracheo-bronchial tree, significant efforts still need to be performed in this field.. This is why 
the exploration of PpIX based fluorescence bronchosocopy following inhalation of h-ALA is 
currently under investigation in the Lausanne's Photomedicine group. 
Endobronchial ultrasonography (EBUS) like optical coherence tomography (OCT) can 
visualise some distinct layers of the bronchial wall. It is successfully used to define tumour 
invasion in the bronchial wall. The use of EBUS in combination with AFB has recently been 
reviewed [12]. Unfortunately, currently available EBUS systems have resolutions below the 
thickness of the bronchial epithelium. However, systems with resolutions higher than the 
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epithelium thickness are undergoing clinical evaluation. It should also be kept in mind that the 
main limitation faced by EBUS is its difficulty to establish a contrast between early 
carcinoma and the non-neoplastic epithelium. Therefore, its main interest is related to the 
determination of the epithelium thickness. This may provide supplementary information on 
the staging of the lesions discovered by AFB. Since the EBUS probe is inserted through the 
working channel of the bronchoscope, it may easily be used with AFB 
(video-)bronchoscopes. 
It should be noted, that the studies presented in this part of the thesis aimed to improve the 
lesion-to-healthy contrast in terms of spectroscopy. However, the way colours and contrasts 
between colours are perceived by the human eye are not addressed in this thesis. It appears 
clearly that an optimisation of the display of the AF contrast may significantly improve the 
sensitivity and specificity of AFB. This may be realised by modifying the standard 
assignment of the three primary RGB signals delivered by the camera, as reported by [13] and 
[3]. A thorough selection of the colour space and colour balance used for the camera signal 
conversion dramatically influences the perceived colour contrast. Human colour vision and its 
correlation to physics and spectroscopy is a highly complex subject. The optimisation of the 
AFB system in terms of colour contrast perception is beyond the scope of this work, but may 
be the subject of another PhD thesis. 
Finally, it should be noted, that a new AFB system is currently under development at the 
Richard Wolf's R&D department in close collaboration with the Lausanne's Photomedicine 
group. This last generation system will be based on a videobronchoscope. Its first clinical 
evaluation will start within several months. 
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PART II 
CLINICAL 
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UTERINE BLEEDING 
DISORDERS  
BY PHOTODYNAMIC 
THERAPY 
 
The second part of this thesis presents a clinical pharmacokinetics study of topically 5-ALA 
induced PpIX in the endometrium for the optimisation of photodynamic endometrial ablation 
to treat abnormal menstrual bleedings. Light induced fluorescence spectroscopy (LIFS) was 
performed in the human uterus with a specially designed intrauterine optical probe between 
20 min and 345 min after topical application of 5-ALA. This work was performed in 
collaboration with the Obstetrics and Gynaecology department of the University Hospital in 
Zurich (Switzerland). Parts of this study have been published in Lasers in Surgery and 
Medicine [1, 2].  
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Chapter 7  
Uterine bleeding 
disorders 
7.1 Anatomy and Histology of the Uterus 
The human uterus is a pear-shaped hollow organ located between the urinary bladder and the 
rectum. A ventral view of the uterus anatomy is depicted in Figure 7.1. The dome shaped 
sector at the “end” of the organ is called fundus uteri. The corpus uteri is located between the 
fundus uteri and the cervix, which connects the uterine cavity with the vagina. The wall of the 
uterus is built up by a serous membrane called perimetrium, a thick muscle layer called 
myometrium, and a mucous membrane lining the uterus called the endometrium. The thick 
myometrium essentially consists of smooth muscle fibres and plays an important role during 
pregnancy and delivery. The average length of the uterus in a mature woman is 7-9 cm. It 
should be noted that the uterine cavity does not form a hollow as might be wrongly derived 
from FF. The lateral view of the female pelvis (Figure 7.2) reveals that the cavity almost 
collapses due to the ventral inclination of the corpus uteri. The ventral and dorsal walls of the 
uterus almost lay on each other.  
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Figure 7.1 Anatomy of the human uterus. 
(adapted from [1]) 
 
Figure 7.2 Transvaginal ultrasound image of the 
uterus. The anatomical structures were traced for 
clearity. The opposite endometrial surfaces lay on 
each other. The white line in the centre delineates 
their contact surface. (adapted from [3]) 
The endometrium can be subdivided in the permanent basalis and the non-permanent 
functionalis (Figure 7.3). The latter undergoes permanent cyclic changes and is entirely 
renewed during the menstrual cycle of a woman. Within a cycle period, its thickness varies 
from 1- 7 mm. The endometrium is the only human tissue, which bleeds periodically while 
undergoing a regular cycle of proliferation, necrosis and desquamation.  
 
Figure 7.3 Histology of the uterus. The slide shows a transversal cut through the uterus. The thick smooth 
muscle layer of the myometrium is well visible. The endometrium is in the proliferative state. The interfaces 
between the myometrium, the basalis and the functionalis are illustrated by dashed lines. (adapted from [4]) 
As shown schematically in Figure 7.4, this cycle is controlled by a complex system of varying 
hormonal concentrations. Oestrogen and progesterone are the main hormones regulating the 
thickness and pathological state of the uterine tissue. In a woman of fertile age, a complete 
cycle, during which endometrium undergoes rejection and renewal, lasts about 25 - 31 days. 
The uterine endometrial cycle can be divided into three phases: the follicular or proliferative 
phase (typically day 4-14), the luteal or secretory phase (typically 14-28), and the menstrual 
phase (typically day 1-4).  
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The proliferative phase, spans from the end of the menstruation until ovulation. The luteal, or 
secretory phase, begins at ovulation and lasts until the menstrual phase of the next cycle. The 
menstrual phase is accompanied by uterine bleeding, called menstruation, lasting for 4-5 days. 
Cycle starts on the first day of bleeding.  
Average blood loss during menstruation ranges from 30 ml to 50 ml [1], whereas a menstrual 
blood loss of 80 ml is generally considered as the upper acceptable limit [2]. However, it is 
often difficult to measure the effective blood loss during a patient’s menstruation [3, 4].  
 
Figure 7.4 The endometrial cycle (adapted from [1]). 
7.2 Abnormal Uterine Bleeding 
Abnormal uterine bleedings are pathologic bleeding patterns that occur in most cases because 
of hormonal and organic disorders, but may also originate from psychogenic factors. Frequent 
organic factors are benign or malign uterine tumours and pelvic infections, but also 
complications in pregnancy. Hormone-related abnormal bleedings are often associated with 
systemic diseases or disorders of the ovarian function (ovarial insufficiency). If neither 
organic nor hormonal causes can be identified, the abnormal bleedings are referred to as 
dysfunctional uterine bleeding (DUB). It is estimated that 19% of all women in the fertile age 
are touched by DUB [5].  
Abnormalities can influence bleeding frequency and/or amount of blood loss. Bleeding 
abnormalities related to bleeding frequency are poly- (more frequent), oligo- (less frequent), 
and amenorrhoea (absence of menstrual bleeding), as well as metrorrhagia (acyclic bleeding). 
Hypomenorrhoea is regular menstrual bleeding associated with an extremely low blood loss, 
whereas hypermenorrhoea is associated with an extremely high, but regular menstrual 
bleeding. Menorrhagia is characterised by a regular, but excessive and long lasting (more than 
one week) menstrual bleeding. The normal and abnormal bleeding patterns are illustrated in 
Figure 7.5). Dysmenorrhea describes menstrual bleeding associated with crampy abdominal 
pain. Menorrhagia, hypermenorrhea and metrorrhagia are frequently associated with 
dysmenorrhea and may present a high physical, psychological and also social burden for the 
patient. Moreover, an excessive blood loss can lead to serious clinical conditions. Strong 
repetitive menorrhagia and hypermenorrhea with a blood loss of more than 80 ml can cause 
an iron deficiency (anaemia) and require treatment. Indeed, menorrhagia is one of the major 
clinical indications for hysterectomy in premenopausal women [5, 6]. 
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Figure 7.5 Normal and abnormal bleeding patterns. The menstrual blood loss is plotted vs. the number of days. 
Each column corresponds to 7 days period. (adapted from [2]) 
7.3 Treatment of Menorrhagia and Hypermenorrhea 
The most common treatments against menorrhagia and hypermenorrhea are pharmacological 
treatment, hysterectomy, and ablation of the endometrium [7]. Pharmacological treatments 
(hormonal or non-hormonal) are often unsuccessful or associated with side effects, ultimately 
requiring surgery. A definitive treatment option would be total hysterectomy, i.e. the surgical 
removal of the uterus [8]. However, hysterectomy is a major operation, which may be 
associated with severe complications and comorbidities. Hysterectomy might be associated 
with urinary incontinence, ovarian failure [9] and multiple psycho-social problems [10]. 
The treatment of menorrhagia and hypermenorrhea with endometrial ablation is based on the 
concept that destruction of the basal layer of the endometrium leads to a strong reduction in 
the endometrial thickness and eventually to amenorrhea. Numerous studies have demonstrated 
that endometrial ablation preserving the uterus is effective in reducing menstrual blood loss in 
women [11]. Endometrial ablations techniques can be divided into two groups: 1) first-
generation hysteroscopic procedures, which are performed under direct vision (e.g. dilation 
and curettage (D&C) and transcervical resection using rollerball or resectoscope) and 2) 
second-generation non-hysteroscopic procedures. All the hysteroscopic techniques require 
general or local anaesthesia and involve the risk of perforation, haemorrhage, fluid overload 
and infection [12, 13]. The efficiency of these techniques for menorrhagia is only limited and 
short-term [14]. Nd:YAG laser ablation has shown promising results when combined with 
rollerball resection. The reported success rates vary between 65 and 85% [15, 16]. Non-
hysteroscopic ablation techniques are designed to ablate the full thickness of the endometrium 
by the controlled application of heat, light, radio- or microwaves. General anaesthesia and 
hospitalisation is usually not required and treatment related complications are less frequent 
than with the hysteroscopic techniques [17]. Non-hysteroscopic endometrial ablation 
techniques include uterine thermal balloon devices, hydrothermablation, low-power Nd:YAG 
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laser, microwave ablation, and radio-frequency induced hyperthermia [7]. These methods are 
based on a non-selective thermal destruction of the inner uterine tissue layers. Reported 
amenorrhea rates after treatment vary from 35% for hydrothermablation to 68% for the 
thermal balloon devices and 90% for low power Nd:YAG laser ablation [18]  
7.4 Photodynamic Endometrial Ablation 
In contrast to endometrial damaging by hyperthermia, photodynamic endometrial ablation 
(PEA) provides a selective endometrial destruction based on phototoxic reactions. The 
photosensitiser or its precursor is applied either systemically or topically to the uterus. After a 
time delay, the uterine cavity is irradiated with light of appropriate wavelength using a 
dedicated light applicator. One form of light applicator was designed as a diffusing elastic 
balloon with a shape and a size similar to the uterine cavity [19]. The deflated balloon 
diameter is smaller than 6 mm to pass the cervix with minimal dilation. First clinical studies 
have shown that PEA can be performed without extensive anaesthesia [20]. The success of 
PEA critically depends on the complete destruction of the endometrium, as well as the 
proliferating stem cells at the endo-myometrial junction [21-24]. A photosensitiser for PEA 
should therefore be highly selective for the endometrium. Topically applied 5-ALA induced 
PpIX has shown promising results for PEA in several preclinical and clinical studies. The 
basics of 5-ALA induced PpIX based PDT have already been discussed in the first chapter of 
this thesis. The fluorescence emission spectra of PpIX are shown in Figure 7.6. The 
fluorescence intensity emitted by PpIX with blue (410 nm) or green (504 nm) excitation light 
is dependent on the photosensitiser's concentration in biological cells or tissues [25]. 
Spectrofluorometric measurements of the PpIX fluorescence intensity can therefore be used to 
monitor the pharmacokinetics of PpIX in biological tissues. 
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Figure 7.6 Fluorescence excitation and emission spectra of PpIX in ethanol. 
5-ALA-related photodynamic therapy (PDT) and fluorescence detection (FD) of neoplastic 
lesions have been widely developed within the past years [26, 27]. Its major application fields 
and have been reviewed in Chapter 1.3.3 of this thesis.are dermatology and urology. The high 
vascularisation and oxygenation of the endometrium compared with the surrounding 
myometrium makes it a potential good target for photodynamic ablation. Photodynamic 
endometrial ablation using topically applied 5-ALA induced PpIX as a photosensitiser has 
been investigated since the 1990’s. Several preclinical studies in rats, rabbits and non-human 
primates showed that PpIX localises selectively in the endometrium after systemic or topical 
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application of 5-ALA [21-24, 28]. One major advantage of the intrauterine application of 5-
ALA compared to a systemic application is the absence of skin photosensitisation [29]. 
Generation of PpIX after intrauterine application of 5-ALA in humans was investigated by 
Gannon et al. [30] and Fehr et al.[28]. Gannon et al. quantified the concentration of PpIX 
after intrauterine administration of 5-ALA using fluorescence microscopy. They analysed 
human endometrium and myometrium samples after hysterectomy. They found a 9 to 10 
times higher concentration of PpIX in the functional and basal layers of the endometrium than 
in the adjacent myometrium. Similar results were reported by Fehr et al.. who demonstrated 
that 5-ALA induced PpIX accumulates selectively in endometrial glands compared to the 
adjacent myometrium in human hysterectomy samples.  
The outcome of PDT strongly depends on the concentration of the photosensitiser in the tissue 
at the time of irradiation. Thus, the determination of the pharmacokinetics of PpIX 
concentration in the endometrium is the basis for effective PEA. However, no in vivo 
pharmacokinetic measurements in the human uterus were reported until now to our best 
knowledge. Wyss et al. [22] reported a fluorescence peak 3 hours after intrauterine instillation 
of 5-ALA in the endometrium of rats and rabbits. In a clinical hysterectomy study including 
26 patients, Fehr et al. [28] showed that a maximal PpIX fluorescence in the human 
endometrium can be observed 4-8 hours after intrauterine application of 5-ALA. In both 
studies, the fluorescence was measured by fluorescence microscopy of frozen sections from 
hysterectomy preparations. The measurements obtained by ex vivo fluorescence microscopy 
may be subject to errors, related to environmental factors (changes in pH, bleaching) that may 
affect the photosensitiser's fluorescence yield. Moreover, theses studies did not take into 
account the inter-individual fluctuations in the pharmacokinetics of 5-ALA induced PpIX. 
The inter-patient variation may result, among others, from the patient's menopausal status 
and/or the phase of the menstrual cycle at the time of drug instillation [28, 31]. 
The clinical study presented in this thesis aimed to (1) determine the optimal time interval 
between application of the precursor and treatment, (2) assess the inter-patient variations in 
terms of pharmacokinetics and maximal PpIX concentration, and (3) investigate the 
correlation between the PpIX pharmacokinetics and the patient's menopausal status and/or 
phase of menstrual cycle at the time of 5-ALA instillation. Considering a linear relation 
between the fluorescence intensity and the PpIX concentration in the endometrium [32, 33], 
the results from the LIFS measurements allow prediction of the tissue damage induced by 
PEA [25]. PpIX fluorescence intensity in the endometrium was measured with a specially 
designed optical probe attached to a fibre-based spectrofluorometer. 
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Chapter 8  
The clinical 
pharmacokinetics 
study 
8.1 Materials and Methods 
8.1.1 The spectrofluorometer 
The optical fibre-based spectrofluorometer is shown in Figure 8.1. Excitation light is provided 
by a filtered Xenon (Xe) arc lamp. A dicroic mirror focuses the light into a quartz optical 
fibre, which serves as both excitation and detection fibre. The fluorescence is collected by the 
fibre, then filtered by a longpass filter and analysed with the help of a CCD-based detection 
unit.  
The light delivered by the 100 W Xe light source (Osram HBO 103 W/2, Osram) passes 
through an electro-mechanical shutter (Uniblitz VS25, Vincent Associates, USA) (S) and 
enters the filter unit of an EPI fluorescence microscope (Nikon Y-FL, Nikon Corp., Japan). 
The said unit contains a set of removable neutral density filters (ND) and a set of 
interchangeable filter cubes. Each filter cube consists of an excitation bandpass filter (BP), a 
dichroic filter (DC), and a longpass filter (LP). The white light from the light source is filtered  
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Figure 8.1 The optical fiber-based spectrofluorometer. The light from the Xenon light source passes through an 
electronic shutter, is filtered by a band-pass filter (BP), reflected by a dichroic mirror (DIC) and focused by a 
microscope objective (MIC 1) into a quartz optical fibre. The fibre delivers excitation and collects emission 
light. The backscattered excitation light is rejected by a long-pass filter (LP). The filtered fluorescence signal is 
focussed into a round-to-slit quartz optical fibre bundle by a second microscope objective (MIC 2), dispersed in 
a spectrograph and projected on a cooled CCD. A set of 3 neutral density filters (ND) allows attenuation of the 
excitation light if necessary. An additional LP filter (LP(opt.)) can be inserted into the detection pathway to select 
a spectral portion of the fluorescence . 
by the excitation band-pass filter before being reflected by the dichroic mirror and focused 
into a 600 μm optical quartz fibre (Medlight SN EX-042, NA 0.37, Medlight SA, 
Switzerland) by a microscope objective (Nikon Plan Fluor, 10x, NA 0.3, Nikon Corp., Japan). 
The optical fibre delivers the excitation light to the sample and it is equipped by a SMA 
connector for easy plugging of clinical probes. The fluorescence signal is then first separated 
from the excitation light by the dichroic filter and filtered by the longpass filter in the filter 
cube. A second microscope objective focuses the fluorescence light into a 600 μm fibre 
bundle, which contains 7 fibres of each 200 μm (Top Sensor Systems, The Netherlands). 
Additionally, a round-to-slit conversion occurs in the fibre bundle. The bundle guides the 
fluorescence signal to the entrance of the detection spectrograph (type CP-140-104, Jobin 
Yvon SA, France). A thermoelectrically air cooled CCD head (1024 x 80 active pixels, type 
Hamamatsu D70301006N, Hamamatsu, Japan) is attached to the spectrograph. Opening of the 
mechanical shutter is synchronised with the CCD exposure by the CCD controller (type 
Spectrum One 3500, Jobin Yvon SA, France). The whole set up is controlled by a portable PC 
using a PCMCIA-GPIB interface (National Instruments Corp., USA) and LabVIEW (Version 
5.1, National Instruments Corp., USA) software. The interchangeable filter cubes allows a 
rapid switching between different excitation/detection modes. Up to 4 different filter cubes 
can be mounted in parallel on a dove tail in the EPI fluorescence microscope unit. Three 
independent ND filters (Nikon Corp., Japan) with transmissions of 25% (filter ND4), 12.5% 
(filter ND8), and 6.25% (filter ND16) can be slid into the illumination optical pathway to 
adjust the excitation light intensity. A supplementary longpass filter can by inserted in the 
detection optical pathway between the filter cube and the second microscope objective to 
reject all residual excitation light from the fluorescence signal. The whole setup was mounted 
on a compact trolley to allow easy transport to the medical facilities. 
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8.1.2 Characterisation of the spectrofluorometer 
The detection range of the spectrofluorometer is 250 nm to 850 nm, whereas its spectral 
resolution is 6 nm (FWHM). Wavelength calibration of the detection unit was performed with 
a calibrated mercury argon (Hg Ar) lamp (Type HG-1, Ocean Optics, The Netherlands) with 
well-defined spectral lines. The lamp spectrum was measured with the described 
spectrofluorometer setup. The pixel position of the detected emission peaks on the CCD was 
compared with their emission wavelengths given by the lamp's manufacturer. The pixel-to-
wavelength transfer function was implemented into the LabView routine controlling the 
setup. This conversion allows data to be displayed vs. real wavelengths instead of pixel 
positions. 
Spectral response of the spectrofluorometer was determined using a calibrated light source 
(Type EPLAP EH-117, The Eppley Laboratory Inc., USA). The lamp (operated at 6.5 mA) 
was positioned according to the manufacturer specifications at a 50 cm distance from the 
distal tip of the spectrometer's quartz optical fibre. The lamp spectrum was acquired with the 
spectrofluorometer without any filter cube. A correction factor was computed from the 
measured spectrum. Figure 8.2 shows the calibrated lamp emission spectrum supplied by the 
manufacturer, the spectrum acquired with the spectrofluorometer, and the correction function. 
For the PpIX pharmacokinetics study, the wavelength region of interest ranges from 500 to 
650 nm (PpIX emission maxima at 635 nm). The mean correction factor within this 
wavelength region is 1.02 +/- 0.08. Thus the fluorescence data presented in this chapter did 
not require correction for the spectrometer's spectral response. 
8.1.3 Configuration for the clinical measurements 
The pharmacokinetics measurements were performed with a filter cube optimised for the 
excitation and emission characteristics of PpIX (maximal excitation peak at 405 nm, maximal 
emission peak at 635 nm). It consisted of a 405 nm ± 10 nm band pass filter (type EX405/10), 
a 430 nm dichroic filter (type DM 430, peak reflection at 45° at 415 nm) and a 435 nm 
longpass filter (BA435). All three filters were purchased from Nikon Corp, Japan. A 
supplementary 455 nm longpass filter (Chroma Inc., USA) was inserted between the filter 
cube and the detection microscope to assure 100% rejection of the excitation light. The 
spectral resolution with this setup was 10 nm. Exposure time was typically 100 ms. This 
exposure time allowed us to detect low PpIX fluorescence signals, whereas the measurements 
are less sensitive to position variations of the probe during data acquisition.  
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Figure 8.2 Spectral response of the detection unit. The correction factor is about one (dashed line) within the 
PpIX fluorescence emission. 
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Below this value, the shutter dwell time significantly differs from the value set by the control 
software and was not reliable. In the case of high intensity fluorescence signals, the excitation 
light intensity was reduced with the help of neutral density (ND) filters. Measurements were 
often performed with the excitation light attenuated by the ND 4 filter. Signal-to-noise ratio 
was better than 30:1 under these conditions. 
8.1.4 The intrauterine optical probe 
A dedicated intrauterine optical probe was developed for the in vivo pharmacokinetics 
measurements. This probe had to fulfil the following requirements: (1) excitation and 
detection of the PpIX fluorescence, (2) stable position in the uterine cavity during several 
hours, (3) small size to be inserted into the uterine cavity through the cervix without sedation 
or anaesthesia, and (4) biocompatibility. 
The probe was based on a commercial silicone balloon catheter (Willy Ruesch GmbH, 
Germany) with an outer diameter of 1.67 mm (Figure 8.3). The spherical silicone balloon 
located at 10 mm from the catheter distal tip was about 13 mm in diameter when inflated with 
1.5 ml of sterile saline. The catheter had a working channel and a balloon inflation channel. 
The distal tip of the catheter was drilled. A 600 μm quartz optical fibre with NA 0.4  was 
inserted through the working channel from the proximal end of the catheter. The polished 
fibre tip protruded 2 mm out of the distal tip. The fibre was glued and the probe distal tip was 
rounded up using non-fluorescing, biocompatible epoxy resin (type Epo-Tek 301, Epoxy 
Technology, USA). A SMA connector was mounted on the proximal end of the fibre to 
connect the probe to the spectrometer's optical fibre. The overall length of the intrauterine 
probe was 1.2 m. The entire probe could be sterilised by ethylene-oxide cold gas sterilisation. 
 
Figure 8.3 The intrauterine optical probe. 
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8.1.5 Patients 
Patients undergoing diagnostic or therapeutic hysteroscopy for dysfunctional bleeding (dys- 
or hypermenorrhoea, as well as postmenopausal bleeding) were asked to participate in the 
study. Exclusion criteria were pregnancy, vaginal bleeding, sterility examination, women 
younger than 30 years, and a history of porphyria. The study was approved by the local 
ethical committee of the Zurich University Hospital. Eleven patients gave written informed 
consent to the pharmacokinetics measurements in the uterine cavity. 
Several problems occurred during the study. In one case, the measurement probe broke during 
the measurements. In another case, the instillation of the precursor solution failed due to a 
caesarean scar. Thus, only 9 patients were included in the data analysis. The average age of 
the patients was 52.1 years, ranging from 36 to 85 years. Five patients were premenopausal, 3 
postmenopausal and 1 perimenopausal. Histopathologic analysis of the endometrial biopsies 
revealed the following states: 3 atrophy, 1 proliferation, 3 secretory phase and 2 hyperplasia 
(Table 8.1). 
Pharmacokinetics Interval 
[min] 
 Patient 
Endomaterial 
Histology 
Menopausal 
status Patient's 
room 
Operation 
Theatre 
Time of 
Imax(PpIX) [min] 
Fluorescence 
Hysteroscopy 
P1 Atrophy premp  225 N.A. F- 
P2 Atrophy postmp  345 N.A. F- 
P3 Atrophy postmp 50 - 190  190a) N.A. 
P4 Proliferation premp 20 - 170 220 180 F- 
P5 Secretion premp 30 - 240 280 260 F+ 
P6 Secretion premp 40 - 180 310 310a) F- 
P7 Secretion premp 40 - 140 200 200a) F±c) 
P8 Hyperplasia perimp 20 - 140 270 80 F+ 
P9 Hyperplasia postmp 40 - 210 270 180b) F- 
a) end of measurements b) constant fluorescence over long time period (80 - 270 min) c) highly inhomogeneous 
fluorescence 
Table 8.1 Histology and pharmacokinetics conditions for all patients. The table shows the endometrial histology 
and menopausal status (premenopausal = premp, postmenopausal =postmp, perimenopausal= perimp), the time 
interval of the pharmacokinetics measurements in the patient’s room and in the operation theatre, and the time 
interval between the instillation and the maximal in PpIX fluorescence intensity. Moreover, the table shows the 
observations during fluorescence hysteroscopy (F+ = visible PpIX fluorescence, F- = no PpIX fluorescence 
visible, F± = inhomogenous PpIX fluorescence). 
8.1.6 Protocol 
100 mg diclofenac were given 30 min before ALA-instillation to prevent uterine cramps and 
pain during instillation. 2 ml of a 2% aqueous solution of 5-ALA (ASAT AG, Zug, 
Switzerland) was administered through a sterile 0.22 μm filter unit (Millex-GS, Milipore 
Products Division, Bedford, MA) into the uterine cavity using a hysterosalpingography 
catheter (Sholkoff Balloon Catheter, COOK, USA). The acidic ALA-solution was buffered to 
pH 4.0. After instillation of the precursor, the catheter was carefully removed. The sterile 
intrauterine optical probe was inserted into the uterine cavity. The balloon was inflated with 
1.5 ml sterile saline and blocked in the cervix in order to prevent backflow of the 5-ALA 
solution out of the uterus and to keep the probe in place. The patient was sent back to her 
room and the probe remained in place until the surgical intervention. The procedure was 
generally well tolerated. Slight pain and discomfort related to the drug instillation were only 
reported in 2 cases. 
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The system background spectrum was measured inside a black box before each 
pharmacokinetics measurement session. It was subtracted in real-time during the 
pharmacokinetics measurements. The fluorescence spectrum of a stable solution of 
Rhodamine B (c= 1 E-6 mol/l) in a 10 mm quartz cuvette was measured as reference 
spectrum. Fluctuations in the excitation light intensity was corrected using the intensity of the 
Rhodamine B fluorescence peak at 575 nm. The excitation light power at the distal tip of the 
spectrometer's optical fibre was monitored with an optical powermeter (Spectra Physics 404, 
Laser Power Meter). Typical values were 0.14 mW with the ND 4 filter. Background, 
reference and power measurements, referred to as calibration procedure, were repeated 3 to 5 
times during the pharmacokinetics session at the distal tip of the spectrometer fibre. Since the 
intrauterine probe had to be kept sterile upon insertion into the uterus, the calibration 
procedure at the probe distal tip could only be performed after completion of the 
pharmacokinetics measurements. Typical excitation light power at the distal tip of the 
intrauterine probe was 0.1 mW. 
Spectrofluorometric measurements started about 20-30 minutes after instillation depending on 
the clinical conditions. There were no significant alterations between fluorescence spectra 
acquired within 1 min (data not shown). Therefore, measurements were performed in 10 min 
intervals until the patient was transferred to the operation theatre. The measurement protocol 
was the following: spectra were continuously acquired during 15 s, displayed on a monitor 
and visually checked for stability. After this delay, one spectrum was stored for analysis. 
During a session of pharmacokinetics measurements, all special events like pain and physical 
activities (sitting/standing up, position in bed) were documented. 
The patient stayed in her room until the scheduled operation. In the operation theatre, the 
clinician controlled the position of the intrauterine probe. Then, the balloon was deflated and 
the intrauterine probe was carefully withdrawn from the uterus. The probe distal tip was 
checked for blood contamination or mechanical damage. Then the intrauterine probe was re-
inserted into the uterus and put in slight contact with the uterine wall by the surgeon. Several 
measurements were performed at different locations in the uterine cavity. Upon completion of 
the fluorescence measurements, the intrauterine probe was withdrawn from the uterus and re-
calibrated as described above. Blue-violet light fluorescence hysteroscopy was performed 
using a STORZ D-light system. The procedure is described in details in [1, 2]. Endometrial 
biopsies were taken from different locations in the uterus to assess the histopathology and the 
patient's cycle state. 
8.1.7 Data Processing 
The background corrected spectra were normalised with the 575 nm peak intensity value of 
the corresponding Rhodamine B reference spectrum. The resulting fluorescence spectra (FL) 
can be decomposed in two main components: 1) endometrial autofluorescence (A) and 2) the 
PpIX fluorescence (P). Assuming that the spectral shape of autofluorescence spectrum is 
constant over time, a scaling factor can be derived from the ratio between AF intensity at 590 
nm (k*A0) and at 635 nm (A0), as illustrated in Figure 8.4. Hence, the PpIX fluorescence (P) at 
635 nm was derived with P=(FL-At) with k*At, the fluorescence value measured at 590 nm, 
and k, the known scaling factor. Additionally, P can be further normalized with k*At to 
account for geometry artefacts. The k factor was computed individually for each patient at the 
time when contribution of the PpIX fluorescence was still negligible.  
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Figure 8.4 PpIX fluorescence spectra in the endometrium and relevant factors for data post-processing 
 
8.2 Results 
In 6 of the 9 patients included in the study PpIX fluorescence measurements were performed 
in the patient room as well as in the operation theatre, as described above. For one patient 
(Patient 3) measurements were only performed in the patient room because the scheduled 
surgical intervention was cancelled for medical reasons. In the two other patients (Patient 1 
and Patient 2), PpIX fluorescence measurements could only be performed in the operation 
theatre at 225 min and 345 min after instillation. The mean time interval between 5-ALA 
instillation and transfer to the operation theatre was 180 min (range 140 min - 240 min), and 
between 5-ALA instillation and surgery 260 min (range 195 min - 345 min). The time 
intervals for every patient are summarised in Table 8.1. 
Figure 8.5 shows the corrected and normalised PpIX fluorescence intensity values as a 
function of time after instillation for all 9 patients. The data presented without error bars were 
obtained from the measurements in the patients room, whereas the data points presented with 
error bars show the mean values and the standard deviations of the measurements performed 
in the operation theatre. The curves were drawn for visual support. It can easily be seen that 
the shape of the pharmacokinetics vary significantly from one patient to another. Inter-patient 
variations of the PpIX fluorescence intensities at a given post instillation time were about one 
order of magnitude. The highest PpIX fluorescence intensities were measured in P5 in the 
secretory phase and in P8 with endometrial hyperplasia. The lowest PpIX fluorescence was 
observed in P3 with atrophic endometrium. The PpIX fluorescence intensities measured with 
LIFS showed good correlation with the fluorescence observed during the subsequent 
fluorescence hysteroscopies. Endometrium with low PpIX fluorescence intensities measured 
with LIFS generally exhibited no or extremely low PpIX fluorescence (F-) with fluorescence 
hysteroscopy, while patients with high LIFS PpIX fluorescence intensities in the endometrium 
exhibited a clear PpIX fluorescence (F+). 
Moreover, significant inter-patient variations were observed in the time intervals between 
instillation and maximal measured PpIX fluorescence. The mean time interval between 
instillation and PpIX fluorescence maximum was 200 min (range 80 min - 310 min). The 
shortest time interval (80 min) was observed in P8 with endometrial hyperplasia. There were 
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no significant correlations between the PpIX pharmacokinetics parameters (instillation-
fluorescence maximum interval, maximal fluorescence intensity value) and the patient  
menopausal status or endometrial histology. The variations in the PpIX fluorescence 
intensities measured in a patient at a given time post instillation can be estimated from the 
measurements performed in the operation theatre. Those "intra-patient" variations were in the 
order of 47% (range 16% - 73 %). In P4, important fluctuations of 160% were observed due 
to very low Pp IX fluorescence values in the corpus uteri and one high value obtained in 
contact with the fundus uteri. The fluorescence diagnostic hysteroscopy performed after the 
spectrofluorometric measurements revealed a non-fluorescing endometrium in this case. 
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Figure 8.5 Pharmacokinetics of 5-ALA induced PpIX in the endometrium for all 9 patients. The error bars 
depict the standard deviations. The curves were drawn for visual support. 
Significant relative decrease or increase of the PpIX fluorescence intensity at two successive 
times post instillation occurred principally following a patient's change of position in the bed 
(data not shown). Eleven of such changes were documented. The mean fluctuations resulting 
from the changes of position were 37% (range 5% - 75%). In two patients, the change of 
position resulted in fluctuations of 300%. Fluorescence hysteroscopy revealed an endometrial 
polyp in one patient and a hardly fluorescing endometrium in the other. 
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Chapter 9  
Discussion and 
Future Prospects 
9.1 Discussion 
Photodynamic endometrial ablation for the treatment of menorrhagia and hypermenorrhea is 
under investigation since more than one decade. PEA following topical application of 5-ALA 
into the uterine cavity has shown promising results in preclinical studies in rodents [1-3] and 
non-human primates [4, 5]. However, first clinical trials reported only limited therapeutic 
effect of PEA due to an incomplete and/or inhomogenous destruction of the functional and 
basal layers of the endometrium [6, 7]. In both studies, the PEA parameters (amount of 
instilled 5-ALA, drug-light time interval, and irradiation light dose) were determined 
according to the results of ex vivo fluorescence microscopy studies. These results might have 
been biased by several artefacts, as already mentioned above. However, it seems likely that 
the variable and limited success for clinical PEA is due to the variations observed in this study 
here. Indeed, these ljThey may have a severe negative impact on the outcome of PEA. In a 
morphological clinical study, Wyss et al. [7] found incomplete or absent destruction of the 
endometrium after 5-ALA based PEA resulting from inhomogeneities in the PpIX 
distribution, among others. The results presented here strongly suggest that the outcome of 
PEA may strongly vary from one patient to another, even if a well-defined protocol is applied 
to all patients.  
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To our best knowledge, the study presented here is the first report of an in vivo 
pharmacokinetics study of 5-ALA induced PpIX in the human endometrium. The main results 
of the study may be summarised as follows:  
(1) we demonstrated that in vivo pharmacokinetics measurements of 5-ALA induced PpIX 
using LIFS are feasible and well tolerated by the patient.  
(2) The in vivo pharmacokinetics of PpIX following intrauterine instillation of 5-ALA show 
strong in intra-patient and inter-patient variations: a) in the time corresponding to the 
maximum of the PpIX fluorescence and b) the PpIX fluorescence intensity. Indeed, in 3 of 9 
patients, the maximal PpIX fluorescence intensity was measured earlier than 3 h after 
instillation. In addition, the maximal PpIX fluorescence intensity fluctuated by more than one 
order of magnitude between the patients. Moreover, the measurements revealed significant 
intra-patient variations of the PpIX fluorescence, these variations being in the order of 50%.  
(3) No correlation between the inter- and intra-patient variations in the PpIX 
pharmacokinetics and the menopausal status and/or endometrial histology was observed. 
These three types of results are not in complete agreement with those reported by other 
groups as described below. 
LIFS measurements 
LIFS artefacts can be due to the following reasons: variations in the tissue-probe contact, 
difference in the uterus length and width, anatomical variations in the uterus position, and 
contamination, and contamination of the probe tip (blood, secretions), among others. We 
observed a good correlation between the PpIX fluorescence intensities measured with LIFS 
and the observations by fluorescence hysteroscopy. This validates the LIFS measurements 
and rejects the possibility that the inter-patient variations in the PpIX intensity are due to 
LIFS artefacts. 
Time of maximal PpIX fluorescence 
In their fluorescence microscopy study on human hysterectomy samples, Fehr et al. [8] found 
maximal PpIX fluorescence in the endometrium at 4-8 hours after intrauterine instillation of 
5-ALA. Clinical PEA was typically performed at this time interval [7, 9, 10]. Similar time 
intervals between topical 5-ALA application and PpIX fluorescence maximum have been 
reported for other organs [11, 12]. However, our results indicated that this time interval might 
be too long or too short for a significant portion of patients. Performing PEA at this drug-light 
interval may lead to a reduced photodynamic reaction in the endometrium, thus negatively 
affecting the outcome of PEA. Fluorescence studies in non-human primates showed maximal 
5-ALA induced PpIX fluorescence 3-5 hours after instillation [5]. However, the 
pharmacokinetics was based on a single animal only. 
It should be noted that not all patients involved this study allowed the determination of the 
time interval between 5-ALA instillation and the PpIX fluorescence maximum. This is 
principally due to two reasons. 1) the pharmacokinetics measurements were interrupted 
during the patient's transfer to the operation theatre. Consequently, no data are available for 
the corresponding time interval. 2) Measurements were stopped at the time of hysteroscopy 
and no data are available for times longer than typically 4 hours.  
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Intra-patient variations 
The intra-patient variations observed in our pharmacokinetics study are likely to be due to (1) 
changes in the tissue-probe contact/distance related to movements of the patient ,and (2) 
inhomogeneous spatial distribution of the PpIX fluorescence in the endometrium. While the 
first factor may play a role in the measurements performed in the patient's room (in the 
following “room measurements”), the second will be dominant in the measurements 
performed in the operation theatre with the intrauterine optical probe put in slight contact with 
the uterine wall ("guided measurements"). The intra-patient variations observed in the in situ 
measurements (about 40%) are comparable to those observed in the guided measurements 
(about 50%). This suggests that the intra-patient variations associated to patient movements 
may related to inhomogeneous spatial distribution of PpIX fluorescence across the 
endometrium rather than to the fluctuations of the tissue-probe contact. Unfortunatly, the 
relative contribution of both factors to intra-patient variations of in situ measurements is 
difficult to determine, since these measurements were performed without any visual and 
tactile control. 
Inhomogeneous spatial distribution of PpIX fluorescence across the endometrium has also 
been reported in literature. Gannon et al. reported significant inhomogeneities of topically 5-
ALA induced PpIX fluorescence in a fluorescence microscopy study on human hysterectomy 
samples [13]. Unfortunately, no the authors gave only a qualitative description of the 
variations but did not quantify these inhomogeneities. 
Not much is known on the origins of the inhomogeneous distribution of PpIX fluorescence 
observed in tissues after topical application of 5-ALA. Two principal mechanisms should be 
considered [14]: (1) inhomogeneities in the spatial distribution of the 5-ALA solution across 
the uterine cavity upon instillation, and (2) local variations in the cellular ALA metabolism. It 
should be noted that about half of all patients in our study, who showed high (> 50%) intra-
patient variations, showed endometrial polyps, myomas or foci of hyperplasia during 
fluorescence hysteroscopy (data not shown). It has been reported that neoplastic endometrial 
cells show a higher PpIX fluorescence than normal endometrial cells [15]. Thus, it is very 
likely that measurements on polyps or myomas result in higher PpIX fluorescence than 
measurements performed in contact with the normal endometrium. However, significant intra-
patient variations have also been observed in normal uteri. In these cases, it is possible that 
these inhomogeneities result from the intrauterine distribution of the 5-ALA solution after 
instillation.  
Maximal PpIX fluorescence intensity 
Significant inter-patient variations in the PpIX fluorescence in the endometrium were also 
reported in other human studies. Fehr et al. reported variations of the PpIX fluorescence 
measured at a given time after instillation in the order of 50% [8]. The authors attributed these 
variations to the menopausal status and the phase of cycle of the patients at the time of 
instillation. Indeed, human endometrium undergoes rapid cycles of rejection and renewal, 
associated with significant changes in its histology, under the influence of sex hormones, 
principally oestrogen and progesterone. Thus, it seems likely that the phase of menstrual cycle 
and the endometrial histology may influence the pharmacokinetics of PpIX. Indeed, oestrogen 
stimulation has been reported to increase the fluorescence of dihematoporphyrin ether in rat 
endometrial cells [16]. Not much is known about the mechanism by which oestrogen and 
progesterone may influence PpIX metabolism in the human endometrium. Animal studies in 
rats [17] and non-human primates [4] showed that oestrogen is not required for the PpIX 
generation from 5-ALA. Similar results have been reported from in vitro studies on prostate 
cancer cell lines [18]. Cells treated with androgens prior to application of 5-ALA showed a 
significant increase in PpIX accumulation, while a pre-treatment with oestrogen had no effect 
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on the PpIX accumulation. Butowska et al. [19] reported an increased 5-ALA induced PpIX 
fluoresecence in normal human endometrial epithelial cells stimulated with estradiol and 
progesterone. In a qualitative fluorescence hysteroscopy study including more than 60 
patients Wyss et al. observed strong inter-patient variations in the endometrial PpIX 
fluorescence 4 hours following intrauterine instillation of 5-ALA [20]. PpIX-related 
fluorescence was observed in only 50% of all patients. PpIX fluorescence was correlated to 
the phase of cycle and endometrial histology. Indeed, less than 17% of patients with atrophic 
and proliferating endometrium showd fluorescence, whereas more than 80% of patients in the 
secretory phase and hyperplasia showed PpIX fluorescence. These observations may be 
indeed related to the inter-patient variations in the PpIX pharmacokinetics observed in the 
study presented Here. Since the fluorescence hysteroscopy system used by Wyss et al. is less 
sensitive to PpIX fluorescence than the spectrofluorometer, patients with low fluorescence at 
the time of hysteroscopy might have been identified as "fluorescence negative" in the 
hysteroscopy study. However, the data obtained in our in vivo pharmacokinetics study did not 
reveal any correlation between the pharmacokinetics and the patient's menopausal status 
and/or endometrial histology. It should be noted that the number of patients and the data set in 
this first clinical study are limited compared to the data set of the study by Wyss.  
Not much is known on the origins of the inhomogeneous distribution of PpIX fluorescence 
observed in tissues after topical application of 5-ALA. Two principal mechanisms should be 
considered [14]: (1) inhomogeneities in the spatial distribution of the 5-ALA solution across 
the uterine cavity upon instillation, and (2) local variations in the cellular ALA metabolism. It 
should be noted that about half of all patients in our study, who showed high (> 50%) intra-
patient variations, showed endometrial polyps, myomas or foci of hyperplasia during 
fluorescence hysteroscopy (data not shown). It has been reported that neoplastic endometrial 
cells show a higher PpIX fluorescence than normal endometrial cells [15]. Thus, it is very 
likely that measurements on polyps or myomas result in higher PpIX fluorescence than 
measurements performed in contact with the normal endometrium. However, significant intra-
patient variations have also been observed in normal uteri. In these cases, it is possible that 
these inhomogeneities result from the intrauterine distribution of the 5-ALA solution after 
instillation.  
They may have a severe negative impact on the outcome of PEA. In a morphological clinical 
study, Wyss et al. [7] found incomplete or absent destruction of the endometrium after 5-ALA 
based PEA resulting from inhomogeneities in the PpIX distribution, among others. The results 
presented here strongly suggest that the outcome of PEA may strongly vary from one patient 
to another, even if a well-defined protocol is applied to all patients. Monitoring of the PpIX 
concentration and its spatial distribution across the endometrium prior to PDT may reduce the 
failure rate of PEA. In vivo drug concentration monitoring for the optimisation of PDT was 
reported for other sensitisers [21]. In the case of 5-ALA based PEA, such monitoring could be 
performed by measuring the endometrial PpIX fluorescence by hysteroscopy or LIFS 
measurements. 
In this study, we demonstrated that in vivo LIFS measurements using an intrauterine optical 
probe are feasible even over long time periods. In contrast to hysteroscpy, LIFS does not 
require anaesthesia and is not associated with the typical side effects related to hysteroscopy. 
On the other hand, fluorescence hysteroscopy allows visualisation of the spatial distribution 
of the PpIX fluorescence across the uterine cavity. Both methods use blue-violet light around 
the PpIX absorption maximum for fluorescence excitation. Since blue-violet wavelengths do 
not penetrate deep into biological tissue, no information is obtained on the in-depth 
distribution of the PpIX fluorescence in the endometrium. The use of green excitation 
wavelength around 540 nm may provide more information on non-superficial PpIX 
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fluorescence [14]. Green wavelengths (500 nm – 550 nm) have higher penetrations depths 
than blue-violet light, thus exciting also PpIX in deeper endometrial layers.  
9.2 Conclusions  
We presented a low invasive spectroscopic method to assess the PpIX build-up in the human 
endometrium. The pharmacokinetics of 5-ALA induced PpIX in the human endometrium 
showed strong inter-patient variations in both the time interval between instillation and the 
PpIX fluorescence maximum, and the PpIX fluorescence intensity. The 4 hours drug-light 
interval currently used in 5-ALA based PEA should thus be revised and individualised. These 
intra-patient variations potentially result from inhomogeneous distribution of PpIX across the 
endometrium. Our study did not reveal a correlation between the cycle phase/ menopausal 
status of the patient and the PpIX build-up. However, it cannot be excluded that the PpIX 
pharmacokinetics is influenced by sex hormones.  
9.3 Future Prospects 
PpIX based PDT for the ablation of the endometrium to treat menorrhagia and/or 
hypermenorrhea may be optimized following different strategies. 
PpIX build-up improvements may be achieved by changing the precursor formulation and 
derivation. Indeed, no systematic studies of the PpIX precursor concentration and formulation 
have been reported for this application according to our knowledge. This situation is 
surprising considering the critical rule played by these parameters in the bladder[12], and in 
dermatology [22]. LIFS is clearly a useful tool for this purpose. The study reported in this 
manuscript provides interesting informations in this context. ALA derivatives, particularly its 
esters, induce a more rapid build-up of PpIX than 5-ALA in several epithelia. PDT would be 
possible with significantly lower doses and shorter instillation time (typically < 2h) relative to 
ALA if the same effect is induced in the endometrium. Iron chelators, such as deferoxamine 
mesylate (DFO), decrease the quantity of PpIX that is transformed into haem. Therefore the 
administration of PpIX precursor in combination with DFO may significantly increase the 
PpIX concentration while reducing the instillation time. 
A shorter drug-light interval is of high interest for PEA, in particular if it is used as an 
adjuvant treatment for other endometrial ablation techniques. PEA could easily be performed 
following the precursor instillation after a standard ablation within a short time. This approach 
is of interest since hyperthermal ablation techniques (thermal balloon devices, microwaves, 
Nd:YAG laser, rollerball, etc.) induce inflammatory reactions in the endometrium. Since 
inflammatory tissues are known to exhibit a high PpIX build-up, such a combined treatment is 
likely to provide optimal conditions for photodynamic destruction of the ablation margins. 
This might significantly improve the outcome of the standard therapies. One of the main 
advantages of PEA is that it can be performed without extensive anaesthesia. Thus, the 
additional physiological stress for the patient would remain minimal. 
Hormone modulation of the endometrium may be another possibility to increase the PpIX 
build-up in the endometrium. This approach is relevant since it is well established that the 
metabolic activity strongly influence the PpXI built-up.  One supplementary potential interest 
of this approach my be to significantly reduce the hormone-related inter-patient variations of 
the PpIX pharmacokinetics. However, as mentioned above, it is still unclear whether and how 
sexual hormones influence the pharmacokinetics of PpIX in the endometrium.  
Further studies are needed in this field. It would be ideal to investigate the PpIX 
pharmacokinetics under different hormonal conditions in the same patient, e.g. over the 
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period of a menstrual cycle. However, repetitive instillation and intrauterine fluorescence 
measurements cause a physical stress to the patient that is medically hardly acceptable. 
Pharmacokinetics studies in patient groups with comparable hormonal conditions (hormonal 
contraceptives, same day of cycle and menopausal status) may be an alternative approach. 
Monitoring the PpIX fluorescence build-up and getting information on its spatial distribution 
in the endometrium prior to PDT is likely to be crucial for the outcome of PEA. Light-
induced fluorescence spectroscopy provides a minimal invasive method for monitoring the 
PpIX fluorescence in the uterus. A routine monitoring of the PpIX build-up requires a small, 
easy-to-use spectrofluorometer system. Such a system might be based on a small size USB 
spectrometer, combined with a small diode laser source. 
For this study, we developped an optical probe with straight cut optical fibre, resulting in a 
point like measurement geometry. Using a spherical isotropic probe instead of the straight cut 
fibre will reduce the influence of the tissue-probe contact on the fluorescence measurements. 
Moreover, an isotropic detector will be less sensitive to small inhomogeneities of the 
endometrial PpIX distribution. Finally, small size isotropic optical probes are commercially 
available and may easily be integrated in a balloon-based catheter. 
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Appendix A  
Clinical cases with 
the DAFE system 
he Richard Wolf’s DAFE system was designed following the results of the clinical 
study presented in Chapter 5.1. The system is described in detail in Chapter 5.2. The 
system has been widely used in the Endoscopy Department of the CHUV University 
Hospital. 151 pneumology and ENT patients of the departement of the CHUV University 
Hospital in the period underwent AFB with the DAFE system in the between January 2002 
and September 2005. Five typical examples of fluorescence positive lesions are shown here. 
The diameter of the endoscopic view is between 15 mm and 20 mm. For each case, the DAFE 
images on the left hand side is presented with its corresponding white light (WL) image. The 
location of the lesion within the tracheo-bronchial tree is illustrated in the attached graphics. 
Further images as well as short video sequences showing DAFE exams in the bronchi can be 
found on the Lausanne Photomedicine group’s website on 
http://lpas.epfl.ch/PDT/pdt_images.html. 
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Clinical Case #1:RR4 69-year old male 
 
 
 
 
Fluorescence positive spurs in the upper left 
bronchus of a 69-year old male patient 
known for recurring multiple dysplasia in the 
bronchi. Although white light bronchoscopy 
revealed a thickening of the spurs, the DAFE 
images revealed well circumscribed positive 
zones. Multiple biopsies were taken from the 
fluoresence positive zones. The 
histopathologic analysis of these biopsies 
confirmed the presence of moderate 
dysplasia. 
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Clinical Case #2:SR2 46-year old male 
 
 
 
 
Fluorescence positive spur in the 
intermediate bronchi of a 46-year old male 
patient with history of mulitple recurring 
bronchial dysplasia. The left part of the spur 
was described as "scar tissue" during white 
light bronchoscopy. A biopsy taken from the 
fluorescence positive zone showed a mild 
dysplasia in the histopathologic analysis. 
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Clinical Case #3:RR6: 69-year old male 
 
 
 
 
The 69-year old male patient underwent 
panendoscopy and AFB for recurring 
multiple bronchial squamous dysplasia. 
Some of these dysplasia had been treated by 
PDT 12 month prior to this exam. AFB 
revealed a prolate red zone centered on the 
spur that had not been described in former 
bronchoscopies. The spur was classified as 
non-suspect with WL bronchoscopy. Two 
biopsies were taken from the fluoresence 
positive zone. The histopathologic analysis 
of these biopsies showed a mild squamous 
dysplasia.  
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Clinical Case #4: SR1 45-year old male 
 
 
 
 
Fluorescence positive spur in the 
intermediate bronchi of a 45-year old male 
patient with a history of multiple recurring 
bronchial dysplasia. The left, thickened part 
of the spur was described as "scar tissue" 
during white light endoscopy. DAFE 
revealed a larger fluorescence positive zone 
on the spur than the zone looking suspicious 
in white light bronchoscopy. A biopsy taken 
from the fluorescence positive zone showed a 
mild dysplasia in the histopathologic 
analysis. 
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Clinical Case #5: MJM1:60-year old male 
 
 
 
 
This 60-year old patient underwent a 
panendoscopy for a squamous cell carcinoma 
in the buccal cavity. The trachea and the 
bronchi were non-suspect with WL 
bronchoscopy. DAFE bronchoscopy 
immediately revealed an extended red zone 
on the interior wall of the right upper 
bronchus. The lesion had not been identified 
during 1st look WL bronchoscopy, due to its 
tangential localisation. Biopsies were taken 
from the fluorescence red zone. 
Histopathologic analysis showed a squamous 
metaplasia. It should be noted, that the tissue 
sampling in cases like this is often difficult 
due to the tangential position or the tissue 
area, the rigidity of the bronchial wall and 
the smoothness of the mucosa. 
This example nicely illustrates one drawback 
of bronchofibroscopy: in this Olympus BF-
40 several imaging fibers are broken and 
appear as black spots on the image. Damage 
to the optical fibers might occur due to 
mechanical stress, but also due to 
sterilisation processes. This drawback is 
biased by the recent videobronchoscopes. 
These flexible bronchoscopes have the 
camera for image acquisition at their distal 
tip. Thus no imaging fiber bundle is needed 
for imaging. 
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Appendix B  
Camera Basics 
he image formed by the camera objective is projected onto an optical prism separator 
where the incoming optical signal is split according to its wavelength and directed to 
the 3 CCD detectors. The three primary images red, green, and blue (Figure B.1) are 
captured. 
 
 
Figure B.1 Setup and colour detection in a 3CCD video camera. 
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After the objective, the light beam goes through a λ/4 filter and an infrared (IR) filter. Since 
the response of the optical separator is sensitive to the horizontal or vertical polarization of 
the incoming light, the λ/4 filter converts the incoming light waves to a circular polarisation 
to avoid bias from light polarisation. The infrared filter cuts off all IR wavelengths in order to 
limit the image information to the visible spectrum. The optical prism separator is an 
assembly of three optical prisms with dicroic optical coatings that selectively reflect or 
transmit light depending on its wavelength. 
The light from the camera objective enters the first prism, where the blue component of the 
beam is reflected by the dichroic filter. Its coating reflects blue light, but transmits longer 
wavelengths. The blue beam is totally reflected on the front face of the prism and exits it 
through a side face, where it is detected by the first (blue) CCD. The transmitted beam enters 
the second prism and is split by a second dichroic filter that reflects green light but transmits 
longer wavelengths. The green beam is also totally internally reflected due to a small air gap 
between the first and the second prism and is detected by the second (green) CCD. The 
remaining red light travels through the last prism and is detected by the third (red) CCD. A 
colour band pass filter is placed in front of each CCD detector to eliminate all spurious 
wavelengths. The transmission bands of the blue, green and red filters overlap at their 
boundaries. This overlap is referred to as the spectral crosstalk of the camera's colour 
channels. It is essential for a natural reproduction of colour. The position and width of the 
crosstalk regions are specific for each video camera. Figure B.2 schematically shows a typical 
crosstalk situation in commercial video cameras. 
 
Figure B.2 Illustration of the spectral crosstalk in video cameras, with the overlap of the wavelength detection 
ranges of the 3 colour channels. 
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Fluorescence in history 
1500 B.C. Phenomenon corresponding to fluorescence and phosphorescence were 
described in Chinese literature. 
1565 Nicolas Monardes (1493-1588) observed luminescence in extracts from 
Lignum nephriticum, a wood from a South American plant, used for the 
treatment of kidney stones. 
1671 Athanasius Kirchner (1602-1680) described the luminescence 
phenomenon of extracts from Lignum nephriticum in water in his book 
"Ars Magna Lucis et Umbrae", Kirchner observed and described 
fluorescence for the first time in history. 
1808 - 1810 Johann Wolfgang von Goethe (1749 - 1832) described fluorescence in 
his "Farbenlehre" (Theory of Colours), encouraging the reader to 
observe the fluorescence from horsechestnut (Aesculus hippocastanum) 
bark in water. 
1833 Sir David Brewster described the red emission from chlorophyll. 
1845  Sir John Frederick William Herschel discovered the phenomenon of 
fluorescence in an aqueous quinine solution. 
1852  Sir Georges Gabriel Stokes named the luminescence phenomenon 
occurring from the mineral fluorite (calcium fluoride) "fluorescence". 
Stokes was the first to interpret the light-emitting phenomenon and 
formulated the "Stokes Law". 
1911 Max Haitinger (1868 - 1946) introduced the term "fluorochrome" for 
fluorescence emitting molecules. 
1911/13 Otto Heimstaedt and Heinrich Lehmann developed the first fluorescence 
microscope to investigate the autofluorescence of bacteria, protozoa, 
plant and animal tissues. 
1935 Alexander Jablonski (1898 - 1980) established his model (Jablonski 
diagram) explaining the molecular and electronic origins of 
fluorescence. 
1950 Albert Hewett Coons and Melvin Kaplan developed the 
immunofluorescence technique in biology. 
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Appendix D  
Bronchoscopy 
ronchoscopy is the visualisation of the upper airways using flexible or rigid 
endoscopes that are introduced through the mouth or the nose. The first bronchoscopy 
was performed in 1897. The German ENT physician G. Kilian successfully examined 
the trachea with an optical device for the eventual removal of a foreign body. The 
introduction of the rigid bronchoscopy techniques constituted and important event in the 
development of pneumology, since it allowed for the direct exploration of the tracheo-
bronchial tree. The advent of the flexible bronchoscope (“bronchofibroscope”), designed by 
S. Ikeda in 1968, expanded the applications of bronchoscopy. Bronchofibroscopic 
explorations are much easier, faster and more comfortable for the patient than rigid 
bronchoscopy. 
Rigid bronchoscopy is performed with a rigid, straight, hollow stainless steel tube called the 
bronchoscope that is inserted into the trachea through the patient's mouth. The bronchoscope's 
diameter can vary, but most bronchoscopes for adult patients have diameters between 8 mm 
and 14 mm. Visual inspection of the tracheo-bronchial tree is performed with a rod telescope 
that is inserted into the bronchoscope. Since most endoscopic rod-telescopes contain a lens 
optical system invented by Hopkins, they are often referred to as Hopkins optics. A fibre optic 
or liquid light guide delivers the light from an external endoscopic cold light source to the 
telescope where it illuminates the endoscopic site. Rigid bronchoscopy requires general 
anaesthesia, whereas local anaesthesia and sedation is often sufficient for bronchofibroscopy.  
B
Appendix D - Bronchoscopy 
202 
The bronchofibroscope is a tube-like, flexible device containing typically 2 optical fibre 
bundles for light delivery to the endoscopic site and an oriented optical fibre bundle for 
mapping the endocopic site. Moreover, most bronchofibroscopes have a working channel for 
suction or introduction of tools like biopsy forceps, optical fibres, and so on. Typical outer 
diameters of bronchofibroscopes for adults are 5 mm - 6 mm. Intubation is performed either 
via the patient's mouth or nostril. A sketch of flexible bronchoscopy is illustrated in Figure 
D.1.  
Both, rigid and flexible bronchoscopy, allow direct visualisation of the endoscopic site 
through the optic eyepiece. More frequently, small, endoscopic video cameras are clipped to 
the eyepiece. They capture the endoscopic images and display them on a monitor or screen. 
Recently, videobronchoscopy has become a new standard in bronchoscopy. In 
videobronchoscopes and videobronchofibroscopes the imaging CCD chip is integrated on 
their distal tip. This so-called chip-on-tip technology provides bright, high-resolution images, 
since the artifacts and limitations resulting from the imaging fibre bundle are bypassed. 
Moreover, videobronchoscopes are more light weight and handy than the fibre-based models.  
 
 
 
Figure D.1: Bronchoscopy with a flexible bronchofibroscope. 
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Appendix E  
Glossary 
24-bit RGB : Additive model in which three primary colours, namely red, green and blue, are 
combined in various ways to reproduce other colours. In numeric 24-bit RGB each primary is 
encoded in 8-bit, i.e. in integers from 0 to 255. 
Accuracy : (1) freedom from mistake or error (correctness). (2) conformity to truth or to a standard 
model (exactness). (3) the degree of conformity of a measured/calculated quantity to its 
actual (true) value. 
adjuvant : additional; completing. 
AF : Autofluorescence; the tissue intrinsic fluorescence. 
AFB : Autofluorescence Bronchoscopy 
AGC : Automatic gain control. 
Airway crypt : Invagination of the bronchial wall, often occurring in chronic inflammatory bronchi, 
and chronic bronchitis. 
ALA : Aminolaevulinic acid. 
Albedo : The ratio between the scattering and the total attenuation coefficient A=(μs)/(μt)= (μs)/(μa + 
μs), for A=0 the attenuation is exclusively due to absorption, whereas in the case of A=1 only 
scattering occurs. 
AMD : Age-related macula dgeneration. 
Aniline : Aniline, phenylamine or aminobenzene (C6H5NH2) is an organic chemical compound which 
is a primary aromatic amine consisting of a benzene ring and an amino group. 
Apoptosis : One of the main types of programmed cell death. As such, it is a process of deliberate life 
relinquishment by an unwanted cell in a multi-cellular organism. In contrast to necrosis, 
which is a form of cell death that results from acute cellular injury, apoptosis is carried out in 
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an ordered process that generally confers advantages during an organism's life cycle. [source 
http://www.wikipedia.org] 
Atelectasis : Collapse of the expanded lung. 
Basement lamina : See: basement membrane 
Basement membrane : A thin, delicate membranous layer of connective tissue underlying the 
epithelium of many organs. The basement membrane is also called basement lamina. 
Benzidine : Benzidine is the trival name for 4,4'-diaminobiphenyl, this is a carcinogenic aromatic 
amine which has been used as part of a test for cyanide and also in the synthesis of dyes. It 
has been linked to bladder cancer. [source http://www.wikipedia.org] 
Bronchoscope : Tubular illumination instrument used for inspecting or  passing instruments into the 
bronchi; in rigid bronchoscopy, the telescope (Hopkins optics) is sometimes wrongly referred 
to a bronchoscope.  
Carcinogene : In pathology, a carcinogen is any substance or agent that promotes cancer. Carcinogens 
are also often, but not necessarily, mutagens or teratogens. [source http://www.wikipedia.org] 
Carcinogenesis : Carcinogenesis (meaning literally, the creation of cancer) is the process by which 
normal cells are transformed into cancer cells. [source http://www.wikipedia.org] 
CCD : Chage-coupled device. 
cervical :of or relating to a neck or a cervix 
Chromosome : A threadlike linear strand of DNA and associated proteins in the nucleus of eukaryotic 
cells that carries the genes and functions in the transmission of hereditary information. 
CIS : Carcinoma in situ. 
Clavicle : Bone of the pectoral girdle that links the scapula and sternum. It is situated just above the 
first rib on either side of the neck, and has the form of a narrow elongated S; also called 
collarbone 
Comorbidity : The presence of coexisting or additional diseases with reference to an initial diagnosis 
or with reference to the index condition that is the subject of study. Comorbidity may affect 
the ability of affected individuals to function and also their survival; it may be used as a 
prognostic indicator for length of hospital stay, cost factors, and outcome or survival. 
Computed tomography : Radiography in which a three dimensional image of a body structure is 
constructed by computer from a series of plane cross-sectional image made along an axis 
contralateral : the opposite side 
Crisis : (1) Turning point or decisive moment in events. (2) A stage of the in vitro transformation of 
cells. It is characterized by reduced proliferation of the culture, abnormal mitotic figures, 
detachment of cells from the culture substrate, and the formation of multinucleated or giant 
cells. During this massive cultural degeneration, a small number of colonies usually, but not 
always, survive and give rise to a culture with an apparent unlimited in vitro lifespan.  
CRT : Cathode Ray Tube; the traditional form of video and computer monitors 
CT : See: Computed tomography 
CXR : Chest X-ray. 
DAFE : Diagnostic AutoFluorescence Endoscopy 
Detection : (1) to discover the true character of. (2) to discover or determine the existence, presence, 
or fact of. 
Diagnosis : (1) The process of identifying a disease by its signs, symptoms and results of various 
diagnostic procedures. (2) The decision reached by diagnosis. 
Diagnostic testing : Evaluation of patients with signs or symptoms associated with cancer (blood in 
stool, fatigue, breast lump, weight loss). 
Disorder : Abnormal physical or mental condition. 
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DV : Digital video. 
Endoscope: Instrument for visualising the interior of a hollow organ 
ENT: Abbreviation for ear, nose, and throat. 
Epidemiology: Study of frequency of the disease in populations living under different conditions. 
ERTS: Environmental tobacco smoke. 
Erythrocytes: Red blood cells (RBCs). 
Erythrocytes consist mainly of hemoglobin, a complex molecule containing heme groups 
whose iron molecules temporarily link to oxygen molecules in the lungs or gills and release 
them throughout the body. Hemoglobin also carries some of the waste product carbon dioxide 
back from the tissues. (In humans, less than 2% of the total oxygen, and most of the carbon 
dioxide, are held in solution in the blood plasma). A related compound, myoglobin, acts to 
store oxygen in muscle cells. [source: http://www.wikipedia.org] 
FAD : Flavin adenine dinucleotide (oxidised form). 
FD : Fluorescence detection. 
Fibroblast : A cell that gives rise to connective tissue. 
fps :Frames per second; a measure for the frame rate in video. 
Franck-Condon principle : Classically, the approximation that an electronic transition is most likely 
to occur without changes in the positions of the nuclei in a molecular entity and its 
environment. The resulting state is called a Franck-Condon state, and the transition involved 
is called a vertical transition. The quantum mechanical formulation of this principle is that the 
intensity of a vibronic transition is proportional to the square of the overlap integral between 
the vibrational wavefunctions of the two states involved in the transition. [IUPAC 
PHOTOCHEMICAL GLOSSARY (1988)]. 
FWHM : Full width half-maximum; expression of the extent of a function, given by the difference 
between the two extreme values of the independent variable at which the dependent variable 
is equal to half of its maximum value. FWHM is applied to such phenomena as the duration 
of pulse waveforms and the spectral width of sources. 
Gamma : Here: gamma correction in video. A power-law relationship that approximates the 
relationship between the encoded luminance in a television system and the actual desired 
image brightness. 
Genomics : The study of an organism's genome and the use of the genes. It deals with the systematic 
use of genome information, associated with other data, to provide answers in biology, 
medicine, and industry. 
GI : gastro-intestinal (tract). 
h-ALA : 5-hexylester-aminolaevulinic acid. 
hilar : Relating to, affecting, or located near a hilum. 
Hilum : A depression or fissure where vessels or nerves or ducts enter a bodily organ. 
Hilus : See: hilum. 
HPD : Haematoprophyrin dervative; a first generation photosensitiser. 
Ipsilateral : the same side 
Lamina Propria : A thin vascular layer of connective tissue beneath the epithelium of an organ; 
underlying covering epithelial tissues is a layer of connective tissue called lamina propria, 
which is bound to the epithelium by the basal lamina. The lamina propria not only serves to 
support the epithelium but also binds it to neighboring structures. The contact between 
epithelium and lamina propria is increased by irregularities in the surface in the form of 
evaginations called papillae. 
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Laser : Light Amplification by Stimulated Emission of Radiation; an optical source that emits photons 
in a coherent beam. Laser light is typically near-monochromatic, i.e. consisting of a single 
wavelength or hue, and emitted in a narrow beam. [source: http://www.wikipedia.org] 
Lesion : An abnormal change in structure of an organ or part due to injury or disease 
Lifetime probability : A statistical estimate of being diagnosed with a specified cancer during an 
individual’s lifetime, expressed as percent. 
Lobe :  (1) a more or less rounded projection of a body organ or part. (2) a division of a body organ 
(as the brain, lungs, or liver) marked off by a fissure on the surface 
Magnetic resonance imaging : A non-invasive diagnostic technique that produces computerized 
images of internal body tissues and is based on nuclear magnetic resonance of atoms within 
the body induced by the application of radio waves  
metachronous : occurring at different times 
MRI : See: magnetic resonance imaging 
Mucosa : (pl. mucosae) Linings of ectodermic origin, covered in epithelium, and are involved in 
absorption and secretion. They line various body cavities that are exposed to the external 
environment and internal organs. It is at several places continuous with skin: at the nostrils, 
the lips, the ears, the genital area, and the anus. Body cavities featuring mucous membrane 
include most of the respiratory tract, the entire gastrointestinal tract, including the rectum, the 
urethra, and various other organs. In addition, the vagina, cervix, the clitoris, the covering of 
the glans penis (head of the penis) and the inside of the prepuce (foreskin) is mucous 
membrane, not skin. [source: http://www.wikipedia.org] 
Multiple Primary Cancers : (1) Two or more distinct tumors in the same organ, opposite side of 
paired organs, or different organs, regardless of time (sitespecific issues need to be addressed, 
clinical input is needed). (2) Two or more abnormal growths of tissue occurring 
simultaneously. The neoplasms are histologically different and may be found in the same or 
different sites. [source: http://www.dictionarybarn.com]  
NADH : Nicotinamide adenine dinucleotide (reduced form). 
NADPH : Nicotinamide adenine dinucleotide phosphate (reduced form). 
Necrosis : Cell death resulting from acute cellular injury; comp. apoptosis 
Negative predictive value : The probability that the patient will not have the disease when restricted 
to all patients who test negative. [source: http://www.wikipedia.org] 
neoadjuvant : added before 
neoadjuvant therapy : Treatment such as chemotherapy, radiation therapy, or hormone therapy 
which is given before the primary treatment. 
Neoplasia : Abnormal, disorganized growth in a tissue or organ, usually forming a distinct mass. 
Neoplasm : A new growth of tissue serving no physiological function 
Non-small cell lung cancer : Non-small cell lung cancer (NSCLC) is a heterogeneous aggregate of at 
least 3 distinct histologies of lung cancer including epidermoid or squamous carcinoma, 
adenocarcinoma, and large cell carcinoma. 
[source: http://www.meds.com/pdq/nonsmallcell_pro.html#22] 
Noxae : plural of noxa; see: noxa. 
Noxa : Something that exerts a harmful effect on the body 
NPV : See: negative predicitve value 
NSCLC : See: Non-small cell lung cancer 
Oestrogen : Any of several steroid hormones produced chiefly by the ovaries and responsible for 
promoting oestrus and the development and maintenance of female secondary sex 
characteristics. 
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Oncogene : A gene having the potential to cause a normal cell to become cancerous; An oncogene is a 
modified gene that increases the malignancy of a tumor cell. Some oncogenes, usually 
involved in early stages of cancer development, increase the chance that a normal cell 
develops into a tumor cell, possibly resulting in cancer. [source: http://wikipedia.org] 
pack-years : Number of cigarette packs smoked per day multiplied with number of years of smoking. 
PAL : Phase Altenating Line; the principal European video norm, based on 25 fps (or 50 fields) with 
625 rows. 
PDT : Photodynamic therapy. 
PET : See: Positron emission tomography. 
Pleomorphism : The quality or state of existing in or assuming different forms. 
Pneumonitis : Disease characterised by the inflammation of the lung. 
Positive predictive value : The positive predictive value (sometimes abbreviated as PPV) of a test is 
the probability that the patient has the disease when restricted to those patients who test 
positive. [source: http://www.wikipedia.org] 
Positron emission tomography : Tomography in which an in vivo, non-invasive, cross-sectional 
image of regional metabolism is obtained by and susal colour-coded CRT representation of 
the distribution of gamma radiation given off in the collision of electrons in cells with 
positrons by radionuclides incorporated into metabolic substances. 
PPV : See: positive predictive value. 
Pp IX : Protoporphyrin IX; an endogenously induced photosensitiser and fluorochrome. 
Precision : (1) The quality or state of being precise (exactness). (2) The degree of refinement with 
which an operation is performed or a measurement stated. 
Precision in engineering and science, is the degree to which further measurements or 
calculations will show the same or similar results. See also: accuracy 
Progesteron : A steroid hormone secreted by the corpus luteum of the ovary and by the placenta, that 
acts to prepare the uterus for implantation of the fertilized ovum, to maintain pregnancy, and 
to promote development of the mammary glands. 
Proliferation : Rapid and repeated production of new parts or of offspring (as in a mass of cells by a 
rapid succession of cell divisions 
Proteomics : The large-scale study of proteins, particularly their structures and functions. This term 
was coined to make an analogy with genomics.[wiki] 
Proto-oncogene : A normal gene that can become an oncogene, either after mutation or increased 
expression. 
PS : Photosensitiser. 
Radioluminescence : Luminescence caused by nuclear radiation. Older "glow-in-the-dark" watches 
used paint with radioactive and radioluminescent material. 
RGB : Red-Green-Blue; the RGB colour model is an additive (light) model in which red, green and 
blue are combined in various ways to reproduce other colours. 
SAM : Smoking-attributable mortality. 
SCC : Squamous cell carcinoma. 
Scalene : (1) of, relating to, or being a scalenus muscle. (2) See: scalenus 
Scalenus : Any of usally three deeply situated muscles on each side of the neck of which each extends 
from the transverse processes of two or more cervical vertebrae too the first or second rib. 
Screening : (1) Early detection of cancer/ premalignant disease in asymptomatic persons/ persons of 
risk. (2) Screening, in medicine, is a strategy used to identify disease in an unsuspecting 
population. 
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Secretory phase : The second half of the menstrual cycle after ovulation; the corpus luteum secretes 
progesterone which prepares the endometrium for the implantation of an embryo; if 
fertilization does not occur then menstrual flow begins 
Sensitivity : The proportion of those cases having a positive test result of all positive cases (e.g., 
people with the disease) tested. 
Shot noise : The noise that results from statistical fluctuations of current carrying particles across a 
junction or interface. 
Specificity : The proportion of true negatives of all the negative samples tested 
Specular reflection : Specular reflection is the perfect, mirror-like reflection of light from a surface, 
in which light from a single incoming direction is reflected onto a single outgoing direction. 
Such behaviour is described by the law of reflection, which states that the direction of 
outgoing reflected light and the direction of incoming light make the same angle with respect 
to the surface normal; this is commonly stated as θi= θr. This is in contrast to diffuse 
reflection, where incoming light is reflected in all directions equally. [source: 
http://www.wikipedia.org] 
Squamous epithelium : Epithelium consisting of one or more cell layers, the most superficial of 
which is composed of flat, scalelike or platelike cells. These surface cells are irregularly 
shaped and very flat; so flat that the cell nucleus sometimes creates a bump in the surface of 
the cell. 
Staging :T he determinationof the extent of disease for the purpose of grouping patinets with similare 
levels of disease for therapeutic and prognostic guidance. 
Submucosa : Supporting layer of loose connective tissue directily under a mucous membrane. 
supraclavicular : situated or occuring above the clavicle. 
Surveillance : Follow-up screening for new evidence of cancer in patients who have already been 
diagnosed with/ treated for cancer/premalignant disease 
synchronous : occurring at the same time 
Telomere : Either end of a chromosome; a terminal chromosome. 
Thermoluminescence : Luminescence triggert by heat; it should be noted, that heat is not the primary 
source of excitation, only the trigger for the release of the excitation energy from another 
source 
TIFF : Tagged image file format 
Triboluminescence : Luminescence triggert by mechanical action; also refers to electroluminescence 
excited by electricity generated by mechanical action. Triboluminescenc can be observed in 
several minerals. 
Tumor markers : Substances produced by malignant tumours that can be found in the blood, proteins 
(proteomics), antigens (genomics), enzymes. Ideally: tumour markers should always be 
produced by same tumour type, indication of presence of tumour and sometimes its size. 
Tumour : An abnormal mass of tissue that is not inflammatrory, arises from cells of preexistent 
tissue, and serves no useful purpose 
Tunica Propria : See: lamina propria 
Ultrasonography : Ultrasound-based diagnostic imaging technique used to visualize muscles and 
internal organs, their size, structure and any pathological lesions, making them useful for 
scanning the organs. The choice of frequency is a trade-off between the image spatial 
resolution and the penetration depth into the patient. Typical diagnostic sonography scanners 
operate in the frequency range of 2 to 13 megahertz 
UPA : Units Per Anno, i.e. units per year; the number of cigarette packs (units) smoked per year 
US : See: utrasonography 
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Xenon lamp : Artificial source of light that use ionized xenon gas to produce a bright white light that 
closely mimics natural daylight. 
Xenon short arc lamp : See: Xenon lamp 
YPLL : Years of potential life lost 
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